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  In memoriam: Hamid Ghodse 
 
 
 After graduating as a Doctor of Medicine (M.D.) in the Islamic Republic of Iran (1965), 
Professor Ghodse specialized in psychology and psychiatry in the United Kingdom, where  
he was awarded a Diploma in Psychological Medicine (D.P.M.), United Kingdom (1974),  
Doctor of Philosophy (Ph.D.), University of London (1976), and Doctor of Science (D.Sc.), 
University of London (2002). 
 Professor Ghodse devoted his professional life to treatment, research and teaching in the 
field of drug addiction, becoming Professor of Psychiatry and of International Drug Policy, 
University of London, in 1987 and Director of the International Centre for Drug Policy at  
St. George’s, University of London in 2003.  
 In addition to an extensive teaching career, Professor Ghodse was extremely active in 
research in fields of drug addiction, public health, psychiatry and drug policy. He was the 
author or editor of over 350 scientific books and papers on drug-related issues and addiction, 
including a number of highly regarded reference books. He was rapporteur, chairman and 
convener of various World Health Organization and European Community expert 
committees, review groups and other working groups on drugs and alcohol dependence. 
 Professor Ghodse’s academic and professional achievements were recognized through 
numerous awards and recognitions, including: Honorary Fellowship, Faculty of Forensic and 
Legal Medicine (FFFLM) (2012); International Distinguished Fellow, American Psychiatric 
Association (2009); Fellow (1985) and Honorary Fellow (2006), Royal College of Psychiatrists 
(R.C.Psych.), United Kingdom; Honorary Fellow, World Psychiatric Association (FWPA) 
(2008); Honorary Professor, Peking University (since 1997); Honorary Fellow, St. George’s, 
University of London (2011) and Lifetime Achievement Award, Royal College of Psychiatrists, 
United Kingdom (2011). He was a Fellow of the Royal College of Psychiatrists (F.R.C.Psych.), 
United Kingdom (1985); Fellow of the Royal College of Physicians (F.R.C.P.), London (1992); 
Fellow of the Royal College of Physicians of Edinburgh (F.R.C.P.E.), Edinburgh (1997); Fellow 
of the Faculty of Public Health Medicine (F.F.P.H.), United Kingdom (1997); Fellow of the 
Higher Education Academy (F.H.E.A.), United Kingdom (2005). 
 Professor Ghodse made major contributions to policymaking at the highest 
international level. He became a member of the International Narcotics Control Board in 
1992 and served as its President in 1993, 1994, 1997, 1998, 2000, 2001, 2004, 2005, 2008, 2010 
and 2011.  
 In recognition of his unparalleled contribution to international drug control, the Board 
dedicates this report to the memory of Professor Hamid Ghodse. He will be remembered for 
his unique and outstanding academic and scientific knowledge, his remarkable leadership, 
wisdom and elegant diplomacy and, above all, for his deepest compassion for the suffering of 
people affected by drug abuse, his passionate work to bring about changes to reduce such 
suffering worldwide and his warmth and kindness. Professor Ghodse’s legacy and vision  
in the field of international drug control will provide guidance and inspiration to generations 
to come. 
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  Foreword 
 
 
 Each year, the International Narcotics Control Board (INCB) reports on the functioning 
of the international drug control system and developments in international drug control. 
Based on its findings, the Board makes recommendations to Governments and regional and 
international organizations to improve various aspects of drug control. Often, a cross-cutting 
aspect of the Board’s recommendations is international or regional cooperation.  
 International cooperation to address the global drug problem is founded upon the 
principle of shared responsibility, a mutual commitment to common goals and a commitment 
to complementary policy and joint action. The overwhelming majority of States have 
developed and acceded to the three international drug control conventions that make up the 
international drug control system, which in turn is built upon the principle of shared 
responsibility. Those conventions are the best available tools for addressing the global drug 
problem and for protecting humanity from drug abuse and the impact of trafficking in and 
illicit cultivation and production of drugs. The conventions are based upon the fact that drugs 
can flow across borders and between continents, from producer to trafficker, from one society 
to another, and from trafficking to abuse. In signing the conventions, Governments agreed 
that this global problem requires a global solution and committed themselves to meeting their 
individual obligations under those conventions.  
 Given the importance of shared responsibility in drug control efforts, INCB has decided 
to highlight that principle in chapter I of the present report. That chapter describes the 
evolution and achievements of shared responsibility in drug control and presents examples of 
good practice in applying the principle of shared responsibility to drug control efforts in areas 
such as demand reduction, supply reduction, judicial cooperation and the control of licit 
trade in drugs. In the context of shared responsibility, all levels of government, civil society, 
local communities and the private sector must work together to ensure that the health and 
well-being of citizens are not undermined by drug abuse or by the impact of trafficking in or 
illicit cultivation and production of drugs, such as drug-related crime and violence. The 
Board’s recommendations in this regard include, inter alia, the need to maintain the delicate 
balance between supply and demand reduction efforts; the necessity of establishing 
comprehensive programmes for the prevention and treatment of drug abuse, as well as for 
reintegration; and the importance of coordination between the authorities responsible for 
health, education, justice, economic development and law enforcement, together with civil 
society and the private sector.  
 The principle of shared responsibility for the global drug problem is also reflected in the 
global debate on drug policy that is under way between Governments at the regional level and 
also within Governments. INCB welcomes and supports initiatives of Governments aimed at 
further strengthening international drug control within the framework of the international 
drug control conventions. We note with concern, however, that in this debate, some 
declarations and initiatives have included proposals for the legalization of the possession of 
drugs for non-medical and non-scientific use, that is, for “recreational” use, that would allow 
the cultivation and consumption of cannabis for non-medical purposes. Any such initiatives, 
if implemented, would violate the international drug control conventions and could 
undermine the noble objectives of the entire drug control system, which are to ensure the 
availability of drugs for medical purposes while preventing their abuse. Proponents of such 
initiatives ignore the commitment that all Governments have made to promote the health and 
well-being of their communities, and such initiatives run counter to the growing body of 
scientific evidence documenting the harm associated with drug abuse, including occasional 
use, particularly among young people during their formative years. Furthermore, such 
initiatives would create a false sense of security and would send a false message to the public, 
in particular children, regarding the health impact of abuse of drugs. Some have argued that 
these proposals would eliminate the illicit markets and organized crime associated with drugs 
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of abuse. Yet, even if such initiatives were implemented, organized criminal groups would get 
even more deeply involved, for instance by creating a black market for the illicit supply of 
newly legalized drugs to young people. To target the organized crime and violence associated 
with the illicit trade in drugs, the most effective tool is primary prevention of drug abuse, 
coupled with treatment and rehabilitation, and complemented by supply reduction measures, 
as provided for in the conventions.  
 Primary prevention is also the key means of preventing the abuse of new psychoactive 
substances, which the Board addresses as a special topic in chapter II of the report. Controls 
are being circumvented by the manufacture and sale of substances that have been designed to 
be chemically different from controlled substances but have similar psychoactive effects. 
National controls, including generic controls, of such substances can help to address this 
growing phenomenon, as can monitoring and the exchange of information on trends of 
abuse. But ultimately, demand reduction is the most effective approach. A similar challenge is 
seen in the control of precursor chemicals, with the increasing use of non-scheduled 
chemicals as “pre-precursors” in the illicit manufacture of drugs. Illegal sales of controlled 
substances, as well as non-controlled substances of abuse, through Internet pharmacies is 
another growing problem. The present report outlines how this issue can be remedied 
through proper registration, licensing and supervision of such pharmacies at the national 
level, as well as international cooperation between Internet registrars and national regulatory 
authorities.  
 Strengthening the capacity of the competent authorities is essential to achieve the key 
objective of the international drug control conventions: ensure the availability of controlled 
medicines for the treatment of pain and suffering associated with illness, including mental 
disorders, and prevent their abuse. While the medical use of cannabis is permitted by the 
treaties under specific conditions, it poses a major challenge in some countries. If not 
adequately regulated, such “medical cannabis” schemes can contribute to increasing levels of 
abuse of the substance. That issue is elaborated on in this report. 
 While shared responsibility in international drug control is essential to addressing the 
global drug problem, so too is the responsibility of States to fulfil their obligations at the 
national level, as set out in the conventions. A prerequisite to effectively fulfilling these 
obligations at the national level is the adequate capacity of national drug regulatory 
authorities. Governments must ensure that their competent authorities have the appropriate 
resources and staff, and INCB calls on Governments and the international community, as 
appropriate, to provide technical assistance in this area so as to promote effective and 
sustainable national regulatory control of drugs for licit purposes. 
 Ultimately, we all have a shared responsibility to address the global drug problem, 
whether it be at the individual, community, governmental or international level. We must 
continue to strive to prevent and minimize the suffering and loss of potential caused by drug 
abuse and drug-related crime and violence. 
 
Raymond Yans 
President 
International Narcotics Control Board 
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Explanatory notes 
 
 Data reported later than 1 November 2012 could not be taken into consideration in preparing 
this report. 
 The designations employed and the presentation of the material in this publication do not 
imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations 
concerning the legal status of any country, territory, city or area or of its authorities, or concerning 
the delimitation of its frontiers or boundaries.  
 Countries and areas are referred to by the names that were in official use at the time the 
relevant data were collected. 
 All references to Kosovo in the present publication should be understood to be in compliance 
with Security Council resolution 1244 (1999). 
 References to dollars ($) are to United States dollars, unless otherwise stated. 
 The following abbreviations have been used in this report: 
ADHD attention deficit hyperactivity disorder
AIRCOP Airport Communication Project
ASEAN Association of Southeast Asian Nations
BZP N-benzylpiperazine
CARICOM Caribbean Community
CICAD Inter-American Drug Abuse Control Commission (Organization 
of American States) 
ECOWAS Economic Community of West African States
EMCDDA European Monitoring Centre for Drugs and Drug Addiction 
Europol European Police Office
FATF Financial Action Task Force
GHB gamma-hydroxybutyric acid
ha hectare
INTERPOL International Criminal Police Organization
ISAF International Security Assistance Force
LSD lysergic acid diethylamide
MDMA methylenedioxymethamphetamine
3,4-MDP-2-P 3,4-methylenedioxyphenyl-2-propanone
OAS Organization of American States
P-2-P 1-phenyl-2-propanone
PEN Online Pre-Export Notification Online
PICS Precursors Incident Communication System
REFCO Central American Network of Organized Crime Prosecutors 
SMART Synthetics Monitoring: Analysis, Reporting and Trends 
THC tetrahydrocannabinol
UNODC United Nations Office on Drugs and Crime
WHO World Health Organization
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 I. Shared responsibility in international drug control 
 
 
  Introduction 
 
1. Common and shared responsibility is a principle of 
international law and is applied in many fields of 
cooperation. It is thus not specific to drug control. Whereas 
international treaties establish a set of rules creating 
individual obligations for States parties, the principle of 
common and shared responsibility goes much further. It 
provides the framework for a cooperative partnership 
among a community of parties, based on a common 
understanding of a shared problem, a common goal and 
the necessity of reaching that goal through common and 
coordinated action. Thus, the principle of shared 
responsibility can be seen as a joint undertaking involving 
government institutions, the private sector, civil society, 
local communities and individuals who have agreed to 
work together as partners and who have a shared mutual 
obligation for concerted action at different levels in 
response to the drug challenge. Consequently, the principle 
of common and shared responsibility commits parties to 
strengthening their cooperation not only to pursue their 
own interests but also to take into account the interests of 
others and to assist those parties that need help. However, 
shared responsibility in drug control at the international 
level will be effective when States fully meet their 
obligations at the national level.  
2. This principle has evolved over the years from the 
concept of collective responsibility in drug control in the 
1980s, shared responsibility in the 1990s and common and 
shared responsibility since the turn of the century. 
Addressing the elements of shared responsibility calls for 
the recognition of key criteria and principles, including 
how to apportion responsibility between multiple actors, 
the notion of mutual accountability and liability, the 
dimensions of capability and capacity, and role and 
resources of each partner.  
3. The effective implementation of this principle today 
is all the more important since almost every country suffers 
from drug abuse and illicit production, trafficking or  
drug-related corruption and violence. 
 
  Background 
 
4. In the late nineteenth century and the early twentieth 
century, a number of countries faced economic and social 
problems associated with increasing use of opium, 
morphine and other addictive substances. In the absence of 
effective controls, significant addiction problems were 
affecting China, as well as other parts of the world. In 
response, representatives of 13 Governments gathered in 
Shanghai, China, in February 1909 to address the world’s 
narcotics problem. This first international forum, known as 
the International Opium Commission, collected a large 
amount of data on the cultivation, production and 
consumption of narcotics. The Commission also adopted a 
number of recommendations urging the gradual 
suppression of opium smoking and controls on opium 
smuggling. The resolutions adopted by the Commission at 
Shanghai were historic. For the first time, a considerable 
number of leading nations agreed that the non-medical use 
of opium should be a matter for careful international 
regulation. Those resolutions marked the international 
community’s first commitment to act together and share 
responsibility for countering the growing drug problem. 
Although the Commission had not been empowered to 
establish binding legal obligations, its work accelerated 
efforts that led to the first codified example of shared 
responsibility in drug control: the International Opium 
Convention signed at The Hague on 23 January 1912.  
5. Like many new concepts, the framework for 
international drug control was implemented only gradually, 
over a long period of time. After the conferences at 
Shanghai and The Hague, a series of multilateral 
agreements were crafted to address the cultivation and 
production of, trafficking in and abuse of opium and other 
narcotic drugs. Those efforts culminated in 1961 with the 
first of the international drug control treaties that form 
today’s framework for action. 
 
 
 A. A legal and institutional framework for 
shared responsibility 
 
 
 1. The international drug control conventions 
 
6. The key purposes of the Single Convention on 
Narcotic Drugs of 19611 were to reorganize the 
international drug control regime, within the framework of 
the United Nations, and to extend the existing control  
to include the plant materials for narcotic drugs.  
The 1972 Protocol amending the Single Convention on 
Narcotic Drugs of 19612 further strengthened controls on 
the illicit production, use and distribution of narcotics. The 
Single Convention on Narcotic Drugs of 1961 as amended 
by the 1972 Protocol3 constitutes a break from previous 
conventions in that it contains international commitments 
on treatment and rehabilitation of drug abuse.  
__________________ 
 1  United Nations, Treaty Series, vol. 520, No. 7515. 
 2  Ibid., vol. 976, No. 14151. 
 3  Ibid., vol. 976, No. 14152. 
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7. The Convention on Psychotropic Substances of 19714 
extended international control to include a number of 
synthetic psychotropic substances liable to be abused, 
namely stimulants, depressants and hallucinogens. Both the 
1961 Convention as amended by the 1972 Protocol and the 
1971 Convention also called for coordinated, universal 
action to implement effective measures to prevent the 
diversion and abuse of narcotic drugs and psychotropic 
substances. 
8. The United Nations Convention against Illicit Traffic 
in Narcotic Drugs and Psychotropic Substances of 19885 
complements the other two conventions by addressing the 
illicit traffic in drugs under international control. Its key 
goals are to improve international law enforcement 
cooperation and to harmonize and strengthen domestic 
criminal legislation. The 1988 Convention contains 
provisions on money-laundering, the freezing of financial 
and commercial records, the extradition of drug traffickers, 
the transfer of criminal proceedings, mutual legal 
assistance and monitoring of chemicals often used in the 
illicit manufacture of drugs. 
9. While States parties have an individual responsibility 
to comply with the provisions of the international drug 
control conventions, those conventions also contain 
elements of shared responsibility, as evidenced in the 
preamble of the 1988 Convention, in which the parties to 
the Convention recognize that eradication of the illicit 
traffic is a collective responsibility of all States. In fact, 
many articles of the 1988 Convention require international 
cooperation and coordination if they are to be effectively 
and fully implemented.  
10. Many of the achievements of the international drug 
control system in its first 100 years occurred because the 
parties to the conventions agreed — despite different 
geopolitical, commercial, moral and humanitarian interests 
— to work together, act collectively and cooperate to 
reduce the illicit production of, trafficking in and abuse of 
drugs and address the health, social and criminal aspects of 
the illicit drug trade. In line with the spirit and the letter of 
the conventions, many Governments have set up at the 
national level drug regulatory authorities or central 
coordinating bodies to guide the development and 
implementation of national multisectoral drug control 
policies and control the licit use of drugs. These bodies 
coordinate the efforts of agencies in the health, social, 
economic development, law enforcement, foreign affairs 
and judicial sectors and, in some instances, embrace the 
private sector, as well as civil society. States parties have 
__________________ 
 4  Ibid., vol. 1019, No. 14956. 
 5  Ibid., vol. 1582, No. 27627. 
also concluded bilateral and multilateral agreements that 
include the principle of shared responsibility.  
11. Today, well over 95 per cent of all States are parties to 
the three international drug control conventions. These 
States have on various occasions reiterated their firm 
commitment to fully implementing the conventions and to 
taking all measures necessary to safeguard the integrity of 
the international drug control regime. The diversion of 
narcotic drugs and psychotropic substances from licit 
international trade has been greatly reduced, and a well-
functioning system is effectively monitoring international 
trade in chemicals that can be used in the illicit 
manufacture of drugs. 
 
 2. An international agenda for shared 
responsibility 
 
12. The 1960s and 1970s witnessed major economic and 
social changes worldwide. In the international system, the 
birth of new States stemming from decolonization resulted 
in the growth of the membership of the United Nations 
from 51 founding Members in 1945 to 127 Members in 
1970 and 193 Members today. During those two decades, 
which saw the adoption of the 1961 Convention and 1971 
Convention, the drug control system was primarily 
anchored in the individual responsibility of States to 
comply with the provisions of the conventions. At the 
international level, those two decades were also 
characterized by drug control policies focusing on law 
enforcement and illicit crop eradication and crop 
substitution. A clear political line of demarcation evolved, 
persisting until the mid-1990s, distinguishing the so-called 
“drug-producing countries” of the “South” from the “drug-
consuming countries” of the “North”. Within the normative 
framework of that time, the reduction of illicit demand for 
drugs and the public health consequences of drug abuse 
were treated more as exclusively domestic issues than as 
issues requiring shared international responsibility. For 
example, the 1961 Convention left to individual States the 
responsibility to reduce illicit demand for narcotic drugs 
through prevention, treatment, aftercare, rehabilitation and 
social reintegration. With respect to international 
cooperation in drug control, evidence of that practice can 
be found, for example, in the amount of voluntary 
contributions made to the former United Nations Fund for 
Drug Abuse Control by Member States, mainly for 
capacity-building in law enforcement and illicit crop 
substitution. 
13. Levels of illicit production, trafficking and abuse 
continued to rise during the 1980s and 1990s, decades  
that also saw the emerging global influence of  
organized criminal groups. In addition, the illicit 
manufacture and abuse of psychotropic substances, notably 
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amphetamine-type stimulants, increased in Europe, North 
America and South-East Asia. Drug abuse, particularly by 
injection, also emerged as a serious social issue in many 
countries, posing new public health challenges such as the 
spread of HIV and hepatitis C. That period also coincided 
with the unprecedented opening up of global trade, the 
expansion of media and the movement of people, as well as 
the explosive growth of modern information and 
communications technology.  
14. In 1981, in response to growing worldwide drug 
challenges, the General Assembly adopted, as its first such 
measure, the International Drug Abuse Control Strategy,6 
recognizing the urgent need for an effective, comprehensive 
and coordinated global approach to the drug problem. 
With its adoption of the Declaration on the Control of 
Drug Trafficking and Drug Abuse7 in 1984, the Assembly 
also underlined the collective responsibility of all States 
while acknowledging the links between the drug issue and 
social and economic development. 
15. The principle of shared responsibility in drug control 
was affirmed during the seventeenth special session of the 
General Assembly, devoted to the question of international 
cooperation against illicit production, supply, demand, 
trafficking and distribution of narcotic drugs and 
psychotropic substances, held in 1990. At that special 
session, the Assembly adopted a political declaration and 
global programme of action8 in which Member States 
agreed to increase their efforts to intensify international 
cooperation and concerted action, based upon the principle 
of shared responsibility.  
16. The concept of shared responsibility was central to 
the twentieth special session of the General Assembly, 
devoted to countering the world drug problem together, 
held in 1998. By that time, the sharp distinction between 
so-called “producing countries” and “consuming countries” 
no longer applied because many countries suffered from 
illicit drug production, trafficking and abuse 
simultaneously. Producing countries had become 
consumers and consuming countries had become 
producers. Recognition of this fact was reflected in the 
Political Declaration adopted by the General Assembly at 
its twentieth special session,9 in which Member States 
recognized that action against the world drug problem was 
a common and shared responsibility. At that special session, 
the Assembly also adopted measures to enhance 
international cooperation to counter the world drug 
__________________ 
 6  Official Records of the Economic and Social Council, 
1981, Supplement No. 4 (E/1981/24), annex II. 
 7  General Assembly resolution 39/142, annex. 
 8  General Assembly resolution S-17/2, annex. 
 9  General Assembly resolution S-20/2, annex. 
problem10 and the Declaration on the Guiding Principles of 
Drug Demand Reduction.11 
17. In all of the above-mentioned declarations, 
programmes of action and resolutions, the principle of 
shared responsibility in drug control has always been 
mentioned in a specific context, namely (a) the need for 
international cooperation and concerted action; (b) the 
requirement of a comprehensive, balanced and mutually 
reinforcing approach to drug supply and demand 
reduction; and (c) respect for the principles of the Charter 
of the United Nations and international law, including 
respect for the sovereignty and territorial integrity of States, 
the principle of non-intervention in internal affairs, and 
human rights and fundamental freedoms. 
18. Authoritative statements by the governing bodies of 
many United Nations institutions dealing with global 
challenges such as sustainable development, population 
growth, climate change, food security and counter-
terrorism have shown a similar evolution of principles: 
from that of collective responsibility to shared 
responsibility, and then both common and shared 
responsibility. In recent years, this principle as used in drug 
control has also evolved to encompass security because of 
the increasing threat to international peace and security 
posed by drug-fuelled organized crime. Since 2008, the 
Security Council, which in the past had addressed the drug 
problem only in a specific context (such as the situation in 
Afghanistan), has devoted several meetings to drug control 
and matters related to organized crime. Those meetings 
have reaffirmed the principle of shared responsibility in 
dealing with the smuggling of precursors into and within 
Afghanistan and the trafficking of cocaine through West 
Africa. 
19. The International Narcotics Control Board has been 
attentive to the measures taken by Member States over the 
past few decades to promote joint and collaborative efforts 
to reduce the magnitude and consequences of the global 
drug problem, its transnational ramifications and the huge 
criminal proceeds derived from illicit drug markets. On 
various occasions, in its annual reports and presidential 
statements, INCB has urged Governments to strengthen 
cooperation within the framework of shared responsibility. 
The Board, noting that the drug problem cannot be dealt 
with in isolation, without addressing other global concerns 
such as social justice, economic development, corruption, 
organized crime and human rights, encourages 
Governments to embrace a comprehensive approach to 
those challenges based on shared responsibility. 
__________________ 
 10  General Assembly resolution S-20/4 A to E. 
 11  General Assembly resolution S-20/3, annex. 
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20. In its capacity as the central policymaking body of 
the United Nations drug control system, the Commission 
on Narcotic Drugs has also taken up the principle of shared 
responsibility, especially in the framework of its reviews in 
2003 and 2009 of the measures taken to implement the 
commitments made by all Governments at the twentieth 
special session of the General Assembly, held in 1998. 
Shared responsibility is a principle that has remained at the 
core of the current 10-year strategy, as reflected in the 
Political Declaration and Plan of Action on International 
Cooperation towards an Integrated and Balanced Strategy 
to Counter the World Drug Problem,12 adopted during the 
high-level segment of the fifty-second session of the 
Commission on Narcotic Drugs, in 2009. In 2011, the 
Commission adopted a resolution (resolution 54/12) to 
revitalize the notion that the principle of common and 
shared responsibility is one of the pillars of the 
international drug control system. 
21. There are numerous examples of institutions, at the 
regional and international levels, that have placed shared 
responsibility in drug control at the centre of their own 
strategies and activities, including the following: 
 (a) The United Nations Office on Drugs and 
Crime (UNODC), which is promoting collaborative efforts 
under the Paris Pact initiative and the Triangular Initiative, 
involving Afghanistan, Iran (Islamic Republic of) and 
Pakistan; 
 (b) The Organization of American States (OAS), 
which in 1986 created the Inter-American Drug Abuse 
Control Commission (CICAD) and, in 1999, established 
the Multilateral Evaluation Mechanism to review progress 
in the individual and collective efforts of Governments in 
the region; 
 (c) The African Union Commission, which 
oversees implementation of the revised African Union  
Plan of Action on Drug Control and Crime Prevention 
(2007-2012), with the support of some of the African 
regional economic communities; 
 (d) The European Union, which is acting on the 
principle of shared responsibility, with the support of the 
European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA), to provide a well-coordinated and 
balanced response to the drug problem in the region. 
22. While States assume a major responsibility under the 
provisions of the drug control conventions, civil society and 
the private sector also play an important role in 
implementing the principle of shared responsibility 
__________________ 
 12  See Official Records of the Economic and Social Council, 
2009, Supplement No. 8 (E/2009/28), chap. I, sect. C. 
through their daily activities, on-the-ground work and 
advocacy. The Board recalls, for instance, the outcome of 
the global forum entitled “Beyond 2008”, which concluded 
with three key themes: first, shared responsibility, 
accountability and commitment whereby Governments at 
all levels were encouraged to leverage the experience, reach, 
professionalism and passion of NGOs; secondly, giving a 
voice to the most affected (i.e. individuals and their families 
and communities); and thirdly, a call for strong action. 
 
 
 B. Examples of good practices of shared 
responsibility at all levels 
 
 
23. The clearest indication of the commitment of 
Governments worldwide to address the drug problem in a 
coordinated concerted and shared manner is the fact that 
almost all States have acceded to the international drug 
control conventions.  
24. Some examples of good practices embodying the 
principle of shared responsibility that have been developed 
and implemented worldwide are presented below. 
 
 1. Licit control 
 
25. One area of best practice in shared responsibility is 
the current system for regulating licit international trade in 
narcotic drugs and psychotropic substances. The strict 
control exercised by States parties, combined with the 
efficient administration of regulatory systems and 
voluntary controls — today applied almost universally — 
have substantially reduced diversion of these drugs. That 
would not have been achieved without the concerted and 
coordinated efforts of Governments and INCB. 
26. Another good example of shared responsibility is the 
voluntary agreement among Governments, and 
administered by INCB, to ensure adequate availability of 
opiate raw materials for medical and scientific purposes 
while preventing excessive accumulation of stocks, which 
could lead to diversion. This has involved (a) action by all 
parties to prevent the proliferation of sources of production 
of opiate raw materials; and (b) agreement that opiate raw 
materials, and the opiates derived from them, are not 
ordinary commodities that can be left unregulated. 
 
 2. Demand reduction measures 
 
27. Some countries have promoted specific initiatives to 
reduce drug demand that embody the principle of shared 
responsibility. For example, in 2008 Colombia launched an 
international campaign known as the “Shared 
Responsibility” project. Intended to send a clear signal to 
the population of countries where drugs are abused, the 
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campaign raised awareness, particularly in Europe and 
North America, of the social and environmental damage 
caused by cocaine manufacture and abuse. 
28. Another example of joint and concerted efforts to 
reduce drug demand — and supply — is the partnership 
model involving the Coordination and Cooperation 
Mechanism on Drugs between the Community of Latin 
American and Caribbean States and the European Union. 
The mechanism supports, inter alia, the coordination of 
common positions for the two regions in international 
forums, facilitates cooperation and the exchange of 
information and good practices among national drug 
control agencies and promotes joint initiatives on key 
policy topics such as the social reintegration of drug users. 
29. National drug observatories play a critical role in 
providing a more accurate picture of the drug situation by 
identifying emerging trends at an early stage and providing 
planners and decision makers with the evidence needed to 
design national and regional drug control strategies, 
particularly in the areas of prevention, treatment and social 
reintegration. These challenges are increasingly being 
addressed cooperatively, at the national, regional and global 
levels. Building a National Drugs Observatory: A Joint 
Handbook13 by EMCDDA and CICAD serves as a 
noteworthy example of the shared responsibility of regional 
organizations to strengthen national institutions 
responsible for collecting drug-related data. 
 
 3. Supply reduction and interdiction measures 
 
30. A variety of good practices in shared responsibility 
can also be found in efforts to counter drug trafficking. A 
crucial issue is improving cooperation and the exchange of 
intelligence between law enforcement agencies with regard 
to the use of techniques such as controlled delivery 
operations, as described in the 1988 Convention. In the 
view of drug law enforcement authorities, controlled 
delivery can be an effective technique requiring, however, 
trust and confidence among law enforcement and judicial 
authorities.  
31. Effective regional drug law enforcement cooperation 
has been strengthened in recent years with initiatives such 
as the establishment in Almaty, Kazakhstan, of the Central 
Asian Regional Information and Coordination Centre. The 
Centre, modelled after the European Police Office 
(Europol) and supported by UNODC, acts as a focal point 
__________________ 
 13  European Monitoring Centre for Drugs and Drug 
Addiction and Inter-American Drug Abuse Control 
Commission, Building a National Drugs Observatory:  
A Joint Handbook (Luxembourg, Office for Official 
Publications of the European Communities, 2010). 
for information exchange and operational cooperation 
among drug law enforcement agencies in Central Asia.  
32. Examples of successful regional concerted efforts by 
Governments include international initiatives against the 
diversion of chemicals used in the illicit manufacture of 
heroin, cocaine and amphetamine-type stimulants. 
Undertakings such as Project Prism and Project Cohesion 
have involved many Governments, organizations and INCB 
sharing responsibility for information exchange, 
implementation of an international programme for 
tracking individual shipments, and cooperation and 
investigations among law enforcement authorities at the 
national and international levels. 
33. Many examples of concerted and collaborative efforts 
can be found in programmes to develop alternative 
livelihoods, which, complemented by interdiction 
measures, are implemented in rural areas of developing 
countries where narcotic plants, mainly opium poppy and 
coca bush, are illicitly cultivated. 
 
 4. Judicial cooperation 
 
34. In the decades since the adoption of the  
1988 Convention, there has been a growing realization  
that judicial cooperation between countries is essential  
to fighting money-laundering and promoting legal 
assistance and facilitating extradition. The United Nations 
Convention against Transnational Organized Crime and  
its three Protocols14 provide opportunities for State  
parties formally to cooperate on judicial assistance issues. 
In particular, the Convention provides the framework  
for extradition requests, which is especially important  
for States without bilateral treaties. 
35. The Financial Action Task Force (FATF) has 
successfully encouraged countries to bring their national 
legislation in line with the international conventions and 
recommendations and to strengthen financial systems 
against money-laundering. A particular feature of shared 
responsibility in the context of FATF is that Governments 
allow for the periodic monitoring of progress made in 
implementing FATF recommendations. This mechanism, 
known as multilateral peer review, reflects the strong 
commitment of Governments to shared responsibility in 
countering money-laundering and in preserving the 
integrity of the international financial system. 
36. The establishment of financial intelligence units in 
various parts of the world is another example of increased 
partnership and collaboration. These units exchange 
operational and other information on suspicious 
__________________ 
 14  United Nations, Treaty Series, vols. 2225, 2237, 2241 and 
2326, No. 39574. 
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transactions reported in the financial sector, which can 
then be forwarded to law enforcement agencies for further 
investigation.  
37. The European arrest warrant is a good example of 
shared responsibility in judicial cooperation in, inter alia, 
drug control. Use of the warrant increases the speed and 
ease of extradition within the European Union by removing 
the political and administrative steps required in the 
previous system of extradition in Europe. Use of the 
European arrest warrant has steadily risen since it was first 
implemented in 2004. Similarly, cooperation on judicial 
matters, such as extradition requests, among countries in 
Latin America and the Caribbean has increased over recent 
years. 
 
 
 C. Achievements and challenges in 
shared responsibility in drug control 
 
 
38. Dividing countries into the categories of  
“drug-producing”, “drug-consuming” or “transit countries” 
has long ceased to be realistic. To varying degrees, all 
countries are drug-producers and drug-consumers and 
have drugs transiting through them. The problem of 
synthetic drugs exemplifies that evolution. In recent years, 
the principle of shared responsibility has been reinforced 
through recognition that the drug problem in its multiple 
aspects affects almost all countries and cannot be tackled 
without strong political will, international cooperation and 
enhanced coordination between State and non-State actors 
at all levels. 
39. Effectively applying the principle of shared 
responsibility at the national level is also key to the success 
of drug control policies. States must implement an 
approach that is comprehensive, balanced, long-term and 
multidisciplinary and that combines social policies, health, 
education, law enforcement and the judiciary, with the 
active participation of the private sector and civil society. 
40. As evidenced by the reviews undertaken by the 
Commission on Narcotic Drugs and the findings of the 
Board, countries worldwide have achieved considerable 
results in many areas of drug control by strengthening 
national drug control capacity and domestic legislation, 
establishing and improving mechanisms and procedures 
for data collection, assessing drug abuse, monitoring 
trends, exchanging information and implementing specific 
programmes to reduce illicit drug supply and demand and 
counter drug trafficking.  
41. The full potential of the principle of shared 
responsibility cannot be fully realized unless each country 
accepts responsibility for reducing its own specific illicit 
supply of and demand for drugs. Governments of countries 
with large illicit drug markets need to develop more 
effective drug abuse prevention policies and, in partnership 
with donors, developing countries and countries with 
emerging economies should devote greater resources to 
address their own drug abuse problems. Given that drug 
abuse, especially in wealthy countries — even though the 
problem exists in less wealthy countries — remains one of 
the important factors of the drug problem, Governments 
should fully exploit the education and health institutions in 
their countries to provide drug abuse prevention, treatment 
and rehabilitation services. That also means that countries 
need to have adequate national legislation and services in 
the area of drug abuse prevention that are aligned with the 
requirements of the international drug control treaties. 
Such measures should send clear messages to young people 
and society as a whole.  
42. The Board has pointed out in its previous annual 
reports that alternative development is feasible only in 
those areas where there is adequate security and stability as 
provided under the rule of law. Unless Governments are 
able to establish their authority and provide a safe 
environment, alternative development efforts cannot be 
effective. INCB has also called on Governments to address 
more effectively the issue of marginalized communities that 
are vulnerable to drug-related problems, including crime 
and violence. Governments need to extend the services of 
national institutions to marginalized communities, 
especially in the areas of citizen security, governance, 
health and education. 
43. In the context of shared responsibility, the Board has 
over the past years drawn the attention of Governments to 
new issues related to drug control that require a more 
vigorous coordinated and concerted response from 
Member States, regional and international organizations, 
the private sector and civil society. These issues include 
new forms and the scope of organized criminal groups, 
unregulated drug markets, the abuse of prescription drugs, 
inadequate availability of opioid medication in many 
countries, the spread of unregulated Internet pharmacies, 
drug advertisements, counterfeit medicines, limited access 
to health-care facilities and the lack of capacity and 
resources to effectively reduce illicit drug supply and 
demand.  
44. International cooperation is of particular importance 
to stop illegal sales of internationally controlled substances 
by Internet pharmacies, due to the global and dynamic 
nature of the medium. Activities of illegal Internet 
pharmacies operating in any one country have global 
implications, and the closing down of such illegal activities 
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in one country often leads to relocation of the illegal 
activity to another country. Therefore, taking action against 
illegal sales by Internet pharmacies is a shared 
responsibility of all countries, and international 
cooperation of governmental authorities, as well as 
collaboration with other stakeholders such as 
pharmaceutical associations, the pharmaceutical industry, 
Internet service providers and financial services, is required 
to successfully counter these activities.  
45. Challenges in the control of precursors require the 
continuing, concerted attention of the international 
community. There is a need for all Governments to 
recognize that precursor control is a shared responsibility 
requiring the special attention of national drug control 
authorities. Political will is also needed to address problems 
such as the use of non-scheduled substances as substitutes 
for controlled precursors, the diversion of precursors from 
domestic distribution channels and the continuing 
vulnerability of countries that do not have the resources to 
develop the capacity and technical skills needed or the 
institutions required to control precursors. 
46. While almost all States have acceded to all of the 
international drug control conventions, the integrity of the 
entire drug control system can also be undermined by 
actions of States or their failure to act. The Board has 
drawn the attention of Governments to the need for treaty 
obligations to be implemented consistently at all levels of 
government. The Board has noted that in some countries, 
while there is full compliance with the conventions at the 
national level, policies and measures at the state, provincial 
or municipal level are not in line with the provisions of the 
conventions.  
47. In addition, the Board has called upon Governments 
to increase their national capacity for drug control and 
address the basic prerequisites for effective measures and 
international assistance, namely adequate domestic drug 
control legislation, a functioning national drug control 
body and an up-to-date, integrated and balanced drug 
control strategy that addresses illicit drug supply and 
demand, as well as transit trafficking.  
48. The challenges identified point to the need to use the 
principle of shared responsibility to more effectively 
develop and implement national drug control policies that 
are consistent with the spirit and the letter of the 
conventions. Institutional ties at the national, regional and 
international levels must also be strengthened, particularly 
between drug law enforcement authorities, in order to 
build trust and promote closer cooperation in targeting, 
investigating and dismantling drug trafficking groups. 
 D. Conclusions and recommendations 
 
 
49. Support for the principle of shared responsibility in 
drug control must go beyond rhetoric. As a cross-cutting 
issue, drug control and its legal framework — the 
international drug control system — have the power to 
effectively mobilize many actors in government 
departments, non-governmental organizations, the private 
sector, professional health-care and consumer 
organizations and regional and international organizations.  
50. Governments have come to recognize that the drug 
problem affects almost every community in every country. 
Applying the principle of shared responsibility means that 
there should be realistic and practical measures in which all 
State and non-State actors may move in concert to achieve 
the aims of the international drug control conventions. 
Indeed, shared responsibility in drug control is a concept 
that should be used to measure how countries work 
together at the international level, as well as domestically.  
51. As the year 2012 marks the centenary of the adoption 
of the first international drug control treaty, it is critically 
important that Member States embrace shared 
responsibility as a foundation of international drug control 
efforts, along with the three international drug control 
conventions, in order to safeguard public health and reduce 
the risks that drug problems will pose to future generations. 
In addition, the lessons learned in the area of drug control 
could serve as an example in addressing other current 
global challenges. 
52. Shared responsibility is not always an easy principle 
to guide action worldwide, but it will be the most effective 
one. Governments, civil society, local communities and the 
private sector need to work together to secure healthy lives 
for their citizens and respect for the rule of law.  
53. In order to improve the concerted actions by the 
international community to advance shared responsibilities 
in drug control, the Board recommends the following:  
 (a) Governments should comply with the 
provisions of the international drug control conventions. 
They should develop more effective practices in reducing 
illicit drug demand, focusing on education, prevention, 
treatment and rehabilitation, and should devote greater 
attention to the basic requirement of preventing first use of 
drugs; 
 (b) Governments, the United Nations system, 
regional organizations, civil society and the private sector 
should develop a renewed sense of shared responsibility in 
drug control. This should be based on the fundamental 
values of inclusiveness, a clear definition of purpose and 
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roles, and an integrated, balanced and multisectoral 
approach aimed at achieving sustainable results and 
promoting accountability among all actors. In addition, 
Governments and public institutions should seek greater 
common purpose among the policies and strategies for 
drug control and those promoting social justice, economic 
development and human rights and addressing corruption 
and organized crime; 
 (c) Governments, in concerted and collaborative 
efforts, should promote the health and welfare of mankind 
by ensuring the use of internationally controlled substances 
solely for medical and scientific purposes; 
 (d) Governments should fully integrate drug 
control as a well-established priority in national economic 
and social development plans, including providing their 
drug control programmes with needed resources. Action at 
the national level must be supported by full 
implementation of the conventions at a subnational level 
and a strong commitment to regional, international and 
development cooperation among drug control partners; 
 (e) As a commitment to shared responsibility, 
Governments should take full advantage of the  
1988 Convention, in particular its article 5, to contribute 
the value of seized assets and property for social and 
economic development programmes and support, where 
appropriate, bilateral and multilateral drug control 
agreements; 
 (f) Better recognition by Governments of the 
importance of drug control under the Millennium 
Development Goals for 2015 would also promote a stronger 
commitment by States, international organizations and 
international financial institutions to fully integrating 
marginalized communities affected by illicit drug 
production, trafficking and use, within social and 
economic development programmes; 
 (g) Governments and the organizations concerned 
should establish efficient mechanisms for exchanging 
information on their actions, experiences and good 
practices in drug control. Greater synergy and coordination 
of action among the regional and international 
organizations concerned should be encouraged in order to 
avoid duplication of efforts and promote collaboration. 
Those organizations should be encouraged to be more 
actively involved in joint efforts, especially efforts aimed at 
reducing illicit drug demand. At the same time, States in 
the various regions should provide their regional 
organizations with the capacity and resources necessary to 
implement regional drug control strategies; 
 (h) At the national level, Governments should 
reinforce shared responsibility by making greater efforts to 
integrate supply and demand reduction activities under a 
unified central drug control authority that coordinates the 
work of government departments and agencies responsible 
for law enforcement, health, education, justice and 
economic development, together with representatives of 
civil society and the private sector;  
 (i) Governments should promote greater 
involvement of local citizens, non-governmental 
organizations and other members of civil society, as well as 
the private sector, to develop new avenues for 
strengthening shared responsibility in drug control efforts. 
This would enable Governments to secure a higher level of 
cooperation and coordination among all relevant actors, 
distribute tasks and responsibilities among them and 
promote the allocation of the necessary financial and other 
resources among those services and agencies; 
 (j) UNODC and regional organizations should 
continue to support shared responsibility through 
multilateral collaborative schemes such as the Paris Pact 
initiative and the Triangular Initiative. They should also 
provide assistance to States through the design and 
implementation of integrated programmes that address all 
aspects of drug control and related crime at the national 
and regional levels. Programmes that have a steering 
committee composed of States and funding partners 
provide an excellent framework for shared responsibility, 
allowing them to jointly review progress, achievements and 
challenges and carry out joint activities. 
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 II. Functioning of the international drug control system 
 
 
 A. Promoting the consistent application 
of the international drug control 
treaties 
 
 
54. In discharging its mandate under the international 
drug control treaties, the Board maintains an ongoing 
dialogue with Governments by various means, such as 
regular consultations and country missions. That dialogue 
has been instrumental to the Board’s efforts to assist 
Governments in complying with the provisions of the 
treaties. 
 
 1. Status of adherence to the international 
drug control treaties 
 
55. As at 1 November 2012, the number of States parties 
to the 1961 Convention or that Convention as amended by 
the 1972 Protocol stood at 185. Of those States, 183 were 
parties to the 1961 Convention as amended by the  
1972 Protocol. A total of 11 States have yet to accede to the 
1961 Convention: 2 States in Africa (Equatorial Guinea and 
South Sudan), 1 in the Americas (Plurinational State  
of Bolivia), 1 in Asia (Timor-Leste) and 7 in Oceania  
(Cook Islands, Kiribati, Nauru, Niue, Samoa, Tuvalu  
and Vanuatu). 
56. The number of States parties to the 1971 Convention 
remained at 183. A total of 13 States have yet to become 
parties to that Convention: 3 States in Africa (Equatorial 
Guinea, Liberia and South Sudan), 1 in the Americas 
(Haiti), 1 in Asia (Timor-Leste) and 8 in Oceania (Cook 
Islands, Kiribati, Nauru, Niue, Samoa, Solomon Islands, 
Tuvalu and Vanuatu). 
57. With the accession by the Holy See in January 2012 
and Nauru and Niue in July 2012, the number of States 
parties to the 1988 Convention increased to 187. A total of 
9 States have yet to become parties to that Convention:  
3 States in Africa (Equatorial Guinea, Somalia and  
South Sudan), 1 in Asia (Timor-Leste) and 5 in Oceania 
(Kiribati, Palau, Papua New Guinea, Solomon Islands  
and Tuvalu). 
58. The Board welcomes the accession by the Holy See, 
Nauru and Niue to the 1988 Convention and urges those 
States that have not done so, particularly those in Oceania, 
the region with the largest number of non-parties, to take 
the steps necessary to accede to all the international drug 
control treaties without further delay. 
 2. Evaluation of overall treaty compliance in 
selected countries 
 
59. The Board reviews on a regular basis the drug control 
situation in various countries and overall compliance by 
Governments with the provisions of the international drug 
control treaties. The Board’s review covers various aspects 
of drug control, including the functioning of national drug 
control administrations, the adequacy of national drug 
control legislation and policy measures taken by 
Governments to combat drug trafficking and abuse and 
Governments’ fulfilment of their reporting obligations 
under the treaties.  
60. The findings of the review, as well as the Board’s 
recommendations for remedial action, are conveyed to the 
Governments concerned as part of the ongoing dialogue 
between the Board and Governments to ensure that the 
international drug control treaties are fully implemented. 
61. In 2012, the Board reviewed the drug control 
situation in Benin, Canada, Mozambique, Myanmar and 
the United States of America, as well as measures taken by 
the Governments of those countries to implement the 
international drug control treaties. In doing so, the Board 
took into account all information available to it, paying 
particular attention to new developments in drug control in 
those countries. 
 
 (a) Benin 
 
62. Benin is faced with a serious level of transit trafficking 
in drugs. While the volume of drugs transiting Benin is 
unclear, there are indications that large cocaine shipments 
originating in South America and heroin from South-West 
Asia enter Benin on maritime vessels and in cargo 
containers for distribution in West Africa and Europe. 
Methamphetamine coming from Cotonou has been seized 
in Belgium, Japan, Malaysia, Thailand and Viet Nam.  
63. The Government of Benin has stepped up its efforts 
to counter illicit drug trafficking. A specialized police unit 
for drug trafficking (OCERTID) was established to 
investigate all drug-related cases in Benin, including 
trafficking in psychotropic substances and precursors. In 
2010, the global Container Programme jointly carried out 
by UNODC and the World Customs Organization was 
extended to the port of Cotonou, Benin, and international 
cooperation with the International Criminal Police 
Organization (INTERPOL) in fighting drug abuse and 
drug trafficking has been strengthened. While the Board 
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welcomes those measures, the capacity of the Government 
to face those challenges needs to be increased. The Board 
calls upon the international community to provide the 
necessary technical support to the Government of Benin, as 
appropriate.  
64. The Board notes that Benin, a party to all three 
international drug control treaties, is committed to the 
objectives of the drug control treaties. The Government has 
adopted a national drug control policy to address drug 
abuse and drug trafficking and has established an 
interministerial committee for the control of narcotic drugs 
and psychotropic substances (CILAS). The country’s 
national drug control legislation appears to be adequate. 
Illicit drug manufacture and trafficking are criminalized, as 
is the laundering of the proceeds of drug trafficking. The 
law authorizes the use of certain special investigative 
techniques and provides for the freezing, seizure and 
confiscation of proceeds of crime. 
65. Laws and decrees govern the pharmaceutical sector 
and the importation and distribution of precursor 
chemicals and pharmaceuticals, establishing penalties for 
the diversion of these substances. Benin has functional 
administrative structures in place for control over the licit 
movement of narcotic drugs, psychotropic substances and 
precursor chemicals and for fulfilling its reporting 
obligations to the Board. Overall, reporting performance 
has been satisfactory. The Board encourages the 
Government to continue its efforts to ensure that further 
progress is made in these areas.  
66. The Board notes that the Government’s capacity to 
reduce illicit drug demand remains limited. While the 
Government continues to address drug abuse and 
trafficking through education and enforcement of  
anti-drug legislation, no reliable data are available on the 
extent of drug abuse in the country. 
 
 (b) Canada 
 
67. The Board notes that, following its continuous 
dialogue with the Government of Canada over the past few 
years, the Government has significantly improved its level 
of cooperation with the Board and intensified its efforts to 
curb illicit drug manufacture, trafficking and abuse. The 
Government is committed to taking an integrated approach 
to ensure that controlled substances are handled effectively 
and that their diversion from licit distribution channels is 
countered through effective control measures. 
68. The Government announced in June 2011 that it was 
considering amendments to the Marihuana Medical Access 
programme. The amendments would be implemented in 
line with new regulations to become operational in late 
2012. The Board remains concerned that the control 
measures presently in force in Canada are not fully in 
compliance with the provisions of the 1961 Convention, in 
particular articles 23 and 28 of the Convention. The Board 
has, on several occasions requested the competent 
authorities to provide the Board with detailed clarifications. 
69. Efforts have been made by the Government of 
Canada to address prescription drug abuse: initial steps 
have been taken to identify problematic use of 
pharmaceuticals and to develop strategies to detect, prevent 
and treat the abuse of prescription drugs and over-the-
counter drugs. Furthermore, an ongoing general 
population survey, the Canadian Alcohol and Drug Use 
Monitoring Survey, was developed to track trends in the 
abuse of drugs, including prescription drugs. The Board 
encourages the Government to continue its efforts in this 
area, particularly with regard to the setting-up of a national 
standardized monitoring system for systematic reporting 
on the prevalence and nature of drug abuse nationwide. 
70. The Board notes that, as part of the National  
Anti-Drug Strategy, the Government of Canada will 
enhance its law enforcement efforts to combat illicit use of 
drugs and increase the capacity of the criminal justice 
system to investigate, interdict and prosecute offenders. 
The Government is also planning to implement a national 
campaign for the prevention of drug abuse aimed at young 
people and their parents, to provide treatment services for 
drug abusers and to support referral and treatment 
programmes for young people. 
71. The Board, while taking note of the recent decision of 
the Supreme Court and the Government’s views on the 
drug injection room in Vancouver, wishes to reiterate its 
position on that issue as expressed on numerous occasions, 
namely that the provision of such facilities for the abuse of 
drugs is contrary to the international drug control treaties, 
particularly article 4 of the 1961 Convention, under which 
States parties are obligated to ensure that the production, 
manufacture, import, export and distribution of, trade in 
and use and possession of drugs are limited exclusively to 
medical and scientific purposes. 
 
 (c) Mozambique 
 
72. After a protracted civil war, Mozambique has made 
some progress in the implementation of the three 
international drug control treaties, to which it is a party. 
However, more efforts need to be made to address the drug 
control problems of the country. The Government’s focal 
point for drug control has the overall responsibility for 
coordinating measures against drug trafficking and abuse 
and works closely with law enforcement bodies. The 
Government has adopted a strategic plan for the prevention 
of drug abuse and combating drug trafficking for the 
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period 2010-2014. While the comprehensive strategy 
addresses all aspects of drug control, it lacks a sufficiently 
detailed implementation plan. 
73. National controls over the licit movement of narcotic 
drugs, psychotropic substances and precursor chemicals, as 
well as the Government’s compliance with its reporting 
obligations under the drug control treaties, need to be 
improved. The availability of opioids for pain management 
remains very limited, and supplies do not cover the 
country’s basic needs. With limited abuse and treatment 
options and no treatment programmes specifically 
designed for drug abusers, those seeking assistance are 
often referred to the psychiatric wards of general hospitals. 
74. Mozambique has emerged as a major transit hub for 
illegal drugs such as cannabis resin and cannabis herb, 
cocaine and heroin destined primarily for Europe, and for 
methaqualone (Mandrax) that is abused primarily in South 
Africa. The Government is increasingly aware of the 
challenge posed by drug trafficking but lacks the capacity 
and resources to tackle it. Government seizure figures are 
at variance with seizure data of other countries suggesting 
that in 2010, multi-ton shipments of cocaine, heroin and 
cannabis resin were landed in Mozambique for 
transportation onward to illicit markets in Europe and 
North America. Furthermore, illicit consignments of 
amphetamine-type stimulants have been seized while en 
route from Mozambique to South Africa.  
75. The Board will continue its dialogue with the 
Government of Mozambique with a view to promoting the 
country’s compliance with the international drug control 
treaties. The Board urges the Government to consider 
requesting UNODC and other international bodies to 
provide the necessary technical assistance in this regard. 
 
 (d) Myanmar 
 
76. Myanmar lies in a region that for many years was the 
world’s main area of illicit cultivation of opium poppy. 
Since 1999, the Government of Myanmar has been 
implementing a 15-year drug control plan aimed at 
eliminating all illicit drug production and trafficking by 
2014, and sustained efforts of the Government to ensure 
the eradication of opium poppy have, over the years, 
achieved significant results in the first half of the 15-year 
period covered by the drug control plan.  
77. The Board is concerned, however, that illicit opium 
poppy cultivation in Myanmar has increased constantly 
since 2007. In 2011 the illicit crop survey jointly carried out 
by the Government and UNODC revealed that for the fifth 
year in a row, the area of opium poppy cultivation 
increased to a new record amount. In addition, production 
of opium increased by 5 per cent from 2010 to 2011, 
reaching an estimated 610 tons. With illicit opium poppy 
cultivation on the rise, Myanmar appears not to be on track 
to meet its goal of becoming drug-free by 2014.  
78. The Board notes that in Myanmar there continue to 
be challenges in providing legitimate alternative livelihoods 
for farming communities engaged in illicit opium poppy 
cultivation. While acknowledging the efforts of the 
Government of Myanmar to eradicate illicit opium poppy 
cultivation, the Board encourages the Government to work 
with the international community to address that problem 
and to take adequate measures to provide legitimate 
alternative livelihoods for those farming communities. 
79. There has been an increase in illicit manufacture, 
consumption and export of synthetic drugs, especially 
amphetamine-type stimulants, since 2006. 
Methamphetamine production, which takes place on a 
large scale in Myanmar, fuels the abuse of that substance in 
many countries in East and South-East Asia. While 
recognizing the difficulties that the Government of 
Myanmar has faced in expanding its control over areas in 
the country where illicit drug-related activities take place, 
the Board urges the Government to continue strengthening 
its efforts to address the illicit manufacture of 
methamphetamine, in cooperation with the Governments 
of neighbouring countries. 
 
 (e) United States of America 
 
80. The Board notes with serious concern the ongoing 
move towards the legalization of cannabis for non-medical 
purposes in some parts of the United States of America 
and, in particular, the outcomes of recent ballot initiatives 
that took place in the states of Colorado and Washington in 
November 2012.  
81. Following these developments, the two states would 
legalize the non-medical use of cannabis for persons  
21 years and older, impose state-level taxes on the drug and 
allow its sale at special stores. This constitutes a significant 
challenge to the objective of the international drug control 
treaties to which the United States is a party.  
82. The Board underlines that the Single Convention on 
Narcotic Drugs of 1961 establishes, in its article 4 (“General 
obligations”), that the parties to the Convention shall take 
such legislative and administrative measures as may be 
necessary to give effect to and carry out the provisions of 
this Convention within their own territories and to limit 
exclusively to medical and scientific purposes the 
production, manufacture, export, import, distribution of, 
trade in, use and possession of drugs. 
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83. The Board stresses the importance of universal 
implementation of the international drug control treaties 
by all States parties and urges the Government of the 
United States to take necessary measures to ensure full 
compliance with the international drug control treaties in 
its entire territory. 
 
 3. Country missions 
 
84. In pursuing its mandate under the international drug 
control treaties and as part of its ongoing dialogue with 
Governments, the Board undertakes a number of country 
missions every year to discuss with competent national 
authorities measures taken and progress made in various 
areas of drug control. The missions provide the Board with 
an opportunity to obtain not only first-hand information 
but also a better understanding of the drug control 
situation in each country it visits, thereby enabling the 
Board to provide Governments with relevant 
recommendations and to promote treaty compliance. 
85. Since the previous report of the Board, the Board has 
sent missions to the following countries: Bangladesh, 
Bolivia (Plurinational State of), Brazil, Cuba, Dominican 
Republic, Ecuador, Nigeria, Pakistan, Peru, Portugal, 
Republic of Korea, Saudi Arabia and Turkey. 
 
 (a) Bangladesh 
 
86. A mission of the Board visited Bangladesh in  
January 2012. The primary focus of the mission was to 
discuss with relevant authorities issues related to precursors 
control, specifically precursors in the form of 
pharmaceutical preparations, and to engage in dialogue on 
the Government’s compliance with the three international 
drug control conventions, to which the country is party. 
The Board’s last mission to Bangladesh took place in 2005. 
87. Several developments have taken place since the 
Board’s last mission to the country in 2005. The control of 
precursor chemicals, specifically pseudoephedrine in the 
form of pharmaceutical preparations, remains problematic, 
with inconsistent use of the Pre-Export Notification Online 
(PEN Online) system. Intragovernmental and 
intergovernmental communication related to activities to 
counter the smuggling of precursors and related law 
enforcement efforts are inadequate, particularly with 
regard to the quality of information disseminated from the 
highest organizational levels to rank-and-file staff. Staffing 
levels are inadequate, and there is a lack of basic materials, 
equipment and training, particularly in the area of 
precursor control. The Board has previously reported on a 
significant number of smuggling cases originating in 
Bangladesh beginning in 2009. 
88. Progress to address issues related to drug abuse raised 
during the 2005 mission has been limited. There are 
indications that drug abuse is increasing and spreading to 
rural areas. Tablets containing methamphetamine are 
increasingly being abused, as is Phensidyl, a cough syrup 
containing codeine. The availability of treatment services in 
the country is low compared with the estimated number of 
injecting drug abusers — primarily abusers of 
buprenorphine — as evidenced by the open abuse of drugs 
by injecting drug users on the densely populated streets of 
old Dhaka. 
 
 (b) Bolivia (Plurinational State of) 
 
89. A high-level mission of the Board, led by the 
President of the Board, visited the Plurinational State of 
Bolivia in December 2011. The mission met and exchanged 
views with the President of the Plurinational State of 
Bolivia and the highest national authorities on matters 
relating to the implementation of the provisions of the 
international drug control treaties. Discussions 
concentrated on the denunciation by the Plurinational  
State of Bolivia of the 1961 Convention as amended by the 
1972 Protocol in June 2011 with the intention of  
re-acceding to that Convention with a reservation 
regarding coca leaf, and on the serious implications of that 
course of action for international drug control. 
90. The Board regrets that the Government of the 
Plurinational State of Bolivia has not reconsidered its 
decision to withdraw from the 1961 Convention as 
amended by the 1972 Protocol. The decision of the 
Government became effective on 1 January 2012. The 
Board also notes that shortly after the Board’s mission to 
the country, the Government on 29 December 2011 
submitted to the Secretary-General of the United Nations 
an instrument of accession to the 1961 Convention as 
amended by the 1972 Protocol containing a reservation 
with respect to coca leaf. The reservation was submitted  
in accordance with article 50, paragraph 3, of the  
1961 Convention as amended by the 1972 Protocol.  
The Government confirmed that its accession was subject 
to the acceptance of the reservation by States parties to  
the Convention.  
91. Should the proposed reservation be deemed to be 
permitted (that is, if less than one third of States parties 
have objected to it by the end of 12 months after the date of 
notification by the Secretary-General, i.e. by 10 January 
2013), the Plurinational State of Bolivia will be authorized 
to accede to the Convention with the reservation. In that 
case, in accordance with article 50, paragraph 3, of the 
Convention, States which have objected to the reservation 
need not assume towards the reserving State any legal 
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obligation under this Convention which is affected by the 
reservation. The accession of the Plurinational State of 
Bolivia will enter into force, and the State will once again be 
a party to the Convention on the thirtieth day after the 
deposit of its instrument of accession. 
92. The Board, while welcoming the country’s intention 
of rejoining the 1961 Convention, is disappointed at the 
Government’s decision to make its re-accession to that 
Convention dependent on the acceptance of its proposed 
reservation with respect to coca leaf. The Board wishes to 
point out that irrespective of the denunciation of the 
Convention by the Government, and the proposed  
re-accession to the Convention with a reservation, coca  
leaf remains a narcotic drug under the provisions of the 
1961 Convention, and all aspects of national and 
international control upon its cultivation, production, 
import, export and use will continue to remain in force.  
93. The Board reiterates that universal adherence to the 
1961 Convention and the other international drug control 
conventions, which together form the basis for the 
international drug control regime, is an indispensable 
requirement for the effective functioning of international 
drug control. Therefore, in the Board’s opinion, the 
reservation proposed by the Plurinational State of Bolivia is 
contrary to the fundamental object and spirit of the  
1961 Convention. The Board believes that the approach 
taken by the Government — of denunciation of the 
Convention and re-accession with a reservation with 
respect to coca leaf — might create a dangerous precedent 
with incalculable consequences that could jeopardize the 
very fundament of the international drug control regime in 
the long run. If the international community were to accept 
an approach whereby States parties used the mechanism of 
denunciation and re-accession with reservations to 
overcome problems in the implementation of certain treaty 
provisions, the integrity of the international drug control 
system would be undermined. 
94. The Board calls upon the Government of the 
Plurinational State of Bolivia to very seriously consider all 
the implications of its actions in this regard, and invites it 
to do so in the context of the shared responsibility of all 
countries in dealing with the universal drug problem.  
The Board hopes that the Government will take 
appropriate action to resolve any existing problems related 
to the issue of coca leaf in a manner that is consistent with 
the 1961 Convention. 
 
 (c) Brazil 
 
95. In August 2012, a mission of the Board visited Brazil. 
The Board’s last mission to Brazil was carried out in 2006. 
Brazil is a party to all three international drug control 
treaties, and the Government is committed to the 
implementation of the treaties. Brazil’s geographic location 
bordering all but two countries in South America, long land 
borders and coastline constitute major challenges to law 
enforcement efforts against drug trafficking. Although 
Brazil continues to be a major transit country for cocaine 
produced in neighbouring countries, INCB notes that the 
Government of Brazil has taken important measures to 
bolster its law enforcement capacity, in particular through 
the deployment of surveillance drones, container scanners 
and body scanners and through the establishment of a drug 
laboratory. 
96. The Board also notes that substantial resources have 
been invested in drug prevention programmes, as well as in 
the establishment of an extensive community-based 
treatment and rehabilitation network. The mission of the 
Board encouraged the competent authorities of Brazil to 
consider extending treatment and rehabilitation 
programmes to prison populations. The mission also 
discussed the growing problem of “crack” cocaine abuse 
with the Brazilian authorities, as well as the work being 
done in the country to identify treatment strategies for 
“crack” addiction. Among the issues discussed were the 
availability of analgesics for medical use, which remains 
low; and the need to adopt measures to address that 
important issue. 
 
 (d) Cuba 
 
97. In July 2012, a mission of the Board visited Cuba, its 
first mission to the country since 1999. The Board notes 
that the Government of Cuba, a party to all three 
international drug control conventions, is firmly 
committed to the goals and objectives of those treaties.  
The national drug control policy is primarily focused on 
the prevention of drug abuse, and health services are 
provided free of charge to the entire population. Active 
counter-narcotics efforts have prevented drug trafficking 
from having a significant impact on the country. There is 
no evidence of any major illicit cultivation of drug crops or 
illicit manufacture of drugs in the country.  
98. The controls applied to the licit movement of narcotic 
drugs and psychotropic substances are satisfactory. The 
Government regularly provides to the Board the 
information required under the international drug control 
treaties, although with some delay and minor 
discrepancies. The mission discussed with the Government, 
among other things, the availability of narcotic drugs for 
the treatment of pain, which is lower in Cuba than in some 
other countries in the Caribbean. According to the latest 
survey, conducted in 2006, the prevalence of drug abuse in 
the country is low. The mission also discussed with the 
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Government the need for a new survey on drug abuse to 
enable a comparison of drug abuse data and identify any 
new trends in drug abuse in the country. 
 
 (e) Dominican Republic 
 
99. In October 2012, a mission of the Board was sent to 
the Dominican Republic. A previous mission had visited 
the country in 2001. The Dominican Republic is a party to 
the three drug control conventions and is committed to 
fully implementing the provisions of the conventions. The 
Dominican Republic continues to be used significantly as a 
transit country for the smuggling of drugs from South 
America to consumer markets in North America. However, 
the Government has increased its interdiction efforts, in 
particular through increased international cooperation 
with the law enforcement authorities of other countries in 
the region, leading to a decline in trafficking through the 
country. 
100. The mission discussed with the Government the legal 
framework applicable to drug control in the country and 
measures to prevent and punish drug trafficking and 
related criminal activities such as money-laundering. In 
particular, the Board welcomed the adoption since its last 
mission of a special law on money-laundering. The mission 
noted, however, that enforcement of the law may need to be 
strengthened, in particular with respect to the use of 
casinos to launder the proceeds of illegal activities. The 
mission also discussed the need to ensure adequate 
availability of analgesics used for the treatment of pain in 
the Dominican Republic and noted that more work was 
needed on the development of treatment and rehabilitation 
for persons suffering from drug dependency. 
 
 (f) Ecuador 
 
101. A mission of the Board visited Ecuador in June 2012. 
The Board’s previous mission to the country took place  
in 2003. Ecuador is a party to all three international drug 
control treaties. The competent authorities expressed their 
commitment to complying with the provisions of the 
international drug control conventions. Because of its 
strategic location, Ecuador continues to be used by 
traffickers as a transit country for illicit consignments of 
cocaine being transported from neighbouring countries to 
more distant countries. Furthermore, coca paste produced 
in Colombia and Peru is smuggled into Ecuador for 
processing into cocaine and then shipped onward, and the 
country is a source of chemicals used in the illicit 
manufacture of cocaine and heroin. The prevalence of drug 
abuse in Ecuador appears to be low but increasing, and 
current facilities for treatment, rehabilitation and social 
reintegration of drug abusers are inadequate. 
102. The Government is undertaking a reform of the 
legislative basis for drug control and of the structure of the 
police service to enable the police and the judiciary to 
better respond to trafficking in drugs and precursors. 
Preventive alternative development programmes have been 
initiated in vulnerable areas bordering areas of illicit 
cultivation of drug crops, with a view to providing the 
population in those areas with licit sources of income. 
Further initiatives are assessing the extent and types of 
drug abuse in the country. The Board’s mission examined 
with the authorities their efforts to expand demand 
reduction activities, the administrative mechanisms for the 
control of narcotic drugs, psychotropic substances and 
precursor chemicals with a view to preventing their 
diversion and the measures taken against the abuse of 
pharmaceutical preparations containing narcotic drugs or 
psychotropic substances. Also examined were measures to 
ensure the rational use of controlled substances, including 
opioid analgesics, and their availability for medical 
purposes. The Board communicated to the Government 
comprehensive recommendations aimed at strengthening 
the drug control situation in Ecuador. 
 
 (g) Republic of Korea 
 
103. A mission of the Board visited the Republic of Korea 
in June 2012. The Republic of Korea is a party to the three 
international drug control treaties, and the Government 
remains fully committed to the implementation of the 
provisions of those treaties. The Board welcomes the 
progress that has been made by the Government in 
implementing the Board’s recommendations following its 
last mission to the country in 2007. Particular progress has 
been achieved in strengthening the control and monitoring 
of licit activities involving narcotic drugs and psychotropic 
substances, as well as of precursor chemicals in the form of 
raw material. Furthermore, the Government has increased 
its efforts in strengthening the capacity of drug law 
enforcement and enhancing international and regional 
cooperation in drug control.  
104. The Board notes, however, that significant challenges 
remain. Evidence shows that the Republic of Korea has 
become an important source for traffickers of ephedrine 
and pseudoephedrine contained in pharmaceutical 
preparations, which are used for the illicit manufacture of 
amphetamine-type stimulants. The Board considers that 
the Government of the Republic of Korea should 
strengthen controls over the international trade in and 
domestic distribution of pharmaceutical preparations 
containing ephedrine and pseudoephedrine in order to 
prevent trafficking in these substances. Furthermore, 
although the Republic of Korea has made notable progress 
in providing treatment and rehabilitation services to drug 
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abusers, the full extent of the overall drug abuse situation in 
the country is unknown, due to the lack of comprehensive 
assessments of drug abuse among the general population. 
 
 (h) Nigeria 
 
105. A mission of the Board visited Nigeria in  
October 2012. The Board notes that since its last mission to 
Nigeria in 1997, the Government has made some progress 
in certain areas of drug control. The Board notes the 
commitment of the country’s National Drug Law 
Enforcement Agency and the National Agency for Food 
and Drug Administration and Control to ensuring 
compliance with the provisions of the international drug 
control treaties to which Nigeria is a party. In particular, 
the Government has taken some steps to address the 
emerging problems of drug abuse and drug trafficking in 
the country, as well as the transit of illicit drugs, for 
example by strengthening border control, enhancing law 
enforcement capacity and carrying out drug abuse 
prevention programmes targeting young persons. 
106. However, significant challenges remain. Nigeria 
continues to be used as a transit country for illicit drug 
consignments, particularly cocaine from countries in South 
America, which is transported onward to Europe.  
107. Although drug abuse, particularly of cannabis, 
appears to be significant in the country, no recent 
epidemiological studies of the drug abuse situation have 
been carried out, and therefore precise information on the 
extent of drug abuse in the country is not available. 
Furthermore, the availability of narcotic drugs and 
psychotropic substances for medical and scientific 
purposes remains low. There is a need for the Government 
to take the necessary measures to address those problems. 
 
 (i) Pakistan 
 
108. A mission of the Board visited Pakistan in  
September 2012 to review the Government’s compliance 
with the international drug control treaties and progress 
made in the implementation of the recommendations made 
by the Board following its previous mission in 2004. 
Pakistan is a party to all international drug control  
treaties. The Government of Pakistan is endeavouring to 
implement its national drug control master plan for  
the period 2010-2014 and has made advances in some 
areas, most notably in the field of supply reduction and  
law enforcement. Through the establishment of an  
inter-agency task force on narcotics control and other 
mechanisms, the Government has improved the 
coordination of various law enforcement agencies in 
combating drug trafficking. The Government has also 
made increased efforts to counter drug abuse at various 
levels. Institutional changes, as well as legislative and 
administrative measures and policies, have also been 
adopted at the federal and provincial levels to address the 
emerging challenges in drug control in the country. 
However, the devolution of responsibilities from the federal 
to the provincial level, foreseen under the eighteenth 
amendment to the Constitution in 2010, has yet to  
fully materialize. 
109. The Board, while noting those positive developments, 
remains concerned over the continued weaknesses in the 
Government’s capacity to monitor licit activities related to 
narcotic drugs and psychotropic substances and, at the 
same time, to ensure their adequate availability for medical 
and scientific purposes. In particular, inadequacies in the 
control of pharmaceutical preparations containing 
psychotropic substances at the retail level have led to 
increased abuse of such substances, causing additional 
health problems. The lack of a monitoring mechanism for 
precursor chemicals has increased the risk of their 
diversion into illicit channels. The Board welcomes the 
establishment of the Drug Regulatory Agency, as well as 
additional measures for the control of precursor chemicals. 
The Board trusts that the Government will take necessary 
steps to ensure that the Drug Regulatory Agency becomes 
fully functional, that the country’s provinces assume the 
responsibilities recently devolved to them by the 
Constitution, particularly in the field of demand reduction, 
and that the provisions of the international drug control 
treaties are fully implemented. 
 
 (j) Peru 
 
110. A high-level mission of the Board, led by the 
President of the Board, visited Peru in May 2012. The 
purpose of the mission was to examine developments that 
had taken place since its previous mission to that country 
in 2006, in particular, the increasing illicit cultivation of 
coca bush and manufacture of cocaine in Peru, and to 
discuss with the competent national authorities measures 
for countering such cultivation and manufacture and 
trafficking and abuse of drugs.  
111. The Board notes with appreciation that the 
Government has launched a comprehensive national drug 
strategy for the period 2012-2016 that places emphasis on 
alternative development, the fight against illicit coca bush 
cultivation and drug trafficking and the prevention and 
treatment of drug abuse. Implementation of the national 
drug strategy is efficiently coordinated by an 
interministerial coordinating mechanism. Control over the 
licit movement of narcotic drugs, psychotropic substances 
and precursor chemicals continues to function well. The 
Board welcomes the measures taken by the Government to 
strengthen its drug interdiction capacities, and invites the 
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international community to support, as appropriate, Peru’s 
alternative development efforts, including the improvement 
of market access for products coming from such 
programmes.  
112. However, Peru remains one of the two largest  
coca-growing countries of the world. There is a danger that 
illicit coca bush cultivation may increase even further 
unless vigorous action is taken against such cultivation. In 
that connection, the Board notes that the Government 
continues to permit cultivation of coca bush for traditional 
domestic uses (chewing of coca leaf) and for certain 
industrial purposes that are in contravention to the  
1961 Convention. Yet the Government does not even seem 
to be in a position to take effective control over the  
9,000 tons of coca leaf that are used annually for such 
purposes. The Board calls upon the Government to take 
appropriate measures to enable the National Coca 
Company to fully comply with its mandates in conformity 
with articles 23 and 26 of the 1961 Convention as amended 
by the 1972 Protocol. 
 
 (k) Portugal 
 
113. A mission of the Board visited Portugal in June 2012. 
The previous mission took place in 2004. The Board notes 
that the Government of Portugal, a party to all three 
international drug control conventions, is fully committed 
to the objectives of those treaties. The drug control strategy 
is clearly defined and is implemented through a 
comprehensive national plan. The Government regularly 
evaluates the effectiveness of its drug control efforts. The 
available data indicate an increase in drug abuse in 
Portugal in the past decade. Drug abuse by injection 
continues to be associated with a significant number of new 
cases of diagnosis of HIV infection. Cannabis abuse among 
youth is of a major concern. Drug traffickers continue to 
use Portugal as a transit country, in particular for the 
smuggling of cocaine and cannabis resin. The Board notes 
with appreciation that the Government is committed to 
strengthening the primary prevention of drug abuse, with a 
special emphasis on cannabis. The Board trusts that the 
Government will provide adequate resources for the 
implementation of measures against trafficking in and 
abuse of drugs, in spite of the present economic constraints. 
114. The mission discussed with the Government 
cooperation in maintaining a global balance between the 
licit supply of and demand for opiate raw materials. Other 
issues discussed by the mission included the experience 
gained through the work of the commissions for the 
dissuasion from drug addiction and their contribution 
towards preventing drug abuse. Also discussed were 
measures to ensure rational use of controlled substances, 
including opioid analgesics and benzodiazepine anxiolytics, 
for medical purposes. 
 
 (l) Saudi Arabia 
 
115. A mission of the Board visited Saudi Arabia in 
September 2012 to review the progress achieved in the 
country to implement the provisions of the international 
drug control treaties since the Board’s last visit to the 
country in 2005. The Board notes the commitment of the 
Government of Saudi Arabia to comply with its obligations 
under the three international drug control conventions to 
which it is a party and commends the country’s 
government agencies involved in drug control for their 
commitment and efforts in the fight against drug abuse and 
drug trafficking. 
116. The Board takes note that although the Government 
has developed a comprehensive national drug control 
strategy, further coordination efforts among all 
implementing institutions involved may facilitate greater 
achievements in drug control. Control mechanisms on the 
licit movement of narcotic drugs and psychotropic 
substances under international control are efficient. The 
Board also discussed with the Government of Saudi Arabia 
further measures to strengthen precursor control 
mechanisms and to enhance information exchange among 
all authorities involved in drug control.  
117. Trafficking in and abuse of counterfeit amphetamine 
sold as Captagon and cannabis continue to be the major 
drug problems in Saudi Arabia although there are signs of 
growing trafficking in and abuse of heroin in the country. 
The Board calls upon the Government to develop the 
appropriate mechanisms to accurately assess the extent of 
drug abuse in the country in order to better evaluate and 
adapt the efficiency of the drug control policies. The Board 
commends the Government of Saudi Arabia for the 
multifaceted and comprehensive care system developed for 
the treatment of drug abuse. The mission included a visit to 
the Al Amal mental health complex, which provides 
treatment, counselling and aftercare for drug-dependent 
patients. 
 
 (m) Turkey 
 
118. A mission of the Board visited Turkey in  
November 2011. Turkey is a party to all three international 
drug control conventions and has demonstrated its 
commitment to complying with the provisions of the 
Conventions. The Board notes the comprehensive activities 
of the Government in supply reduction law enforcement 
and the extensive capacity of the authorities in that regard. 
Effective cooperation between the various law enforcement 
agencies in the country was evident. Turkey is a transit 
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country through which large amounts of heroin are 
trafficked to Western Europe, although the quantity of 
heroin seized over the previous two years had decreased 
due to the increasing importance of trafficking via North 
Africa and by sea container and cargo shipments. The 
quantity of cocaine seized in the country more than 
doubled from 2009 to 2010.  
119. The Board noted some positive developments in 
demand reduction since the previous mission of the Board 
in 2003, and encourages the Government to strengthen its 
efforts in this area, including in the evaluation of the extent 
of drug abuse and in prevention and treatment. The 
mission took note of activities being initiated with the aim 
of ensuring the adequate availability of internationally 
controlled substances for medical purposes. Turkey is a licit 
producer of opium poppy, and the mission was of the view 
that control measures in the licit cultivation of opium 
poppy and production of alkaloids were adequate. 
 
 4. Evaluation of the implementation by 
Governments of recommendations made by 
the Board following its country missions 
 
120. As part of its ongoing dialogue with Governments, 
the Board also conducts, on a yearly basis, an evaluation of 
Governments’ implementation of the Board’s 
recommendations pursuant to its country missions. In 
2012, the Board invited the Governments of the following 
six countries, to which it had sent missions in 2009, to 
provide information on progress made in the 
implementation of its recommendations: Angola, Australia, 
Hungary, Jordan, Morocco and Sudan. 
121. The Board wishes to express its appreciation to the 
Governments of Hungary, Jordan and Morocco for 
submitting the information requested. Their cooperation 
facilitated the Board’s assessment of the drug control 
situation in those countries and the compliance of the 
Governments with the international drug control treaties. 
Information from the Government of Australia was 
received too late to be reviewed by the Board, and the 
outcome of its review will be included in the annual report 
for 2013.  
122. In addition, the Board reviewed the implementation 
of the recommendations it made following its 2008 mission 
to Ethiopia, which did not provide the requested 
information in time for review in 2011. The Board notes 
with appreciation additional information provided by the 
Government of Argentina with regard to the 
implementation of the Board’s recommendations following 
its 2006 mission to that country. 
 (a) Argentina 
 
123. The Board notes with appreciation that the 
Government of Argentina has taken comprehensive 
measures to extend prevention programmes and treatment 
and rehabilitation facilities to all sectors of the population, 
including at the provincial level. Those measures include 
integrated drug-abuse prevention programmes in 
educational institutions, for families, in the workplace and 
in prisons; community drug abuse prevention programmes; 
the organization of awareness-raising events and 
promotional activities; the provision of assistance and 
training for technical teams and health-care professionals 
providing prevention and treatment services. Through 
registers of service-providing institutions and agencies, the 
Government provides public access to welfare and 
treatment services. Specialized programmes cater to the 
needs of specific population groups, such as the treatment 
programme for low-income patients, support programmes 
for families and friends of drug-dependent persons, 
programmes for care after discharge from hospital and for 
social and occupational rehabilitation, and provincial care 
network programmes.  
124. According to the Government, there has been an 
increase in the number of illicit laboratories processing 
coca base detected in Argentina in recent years. Most of 
those laboratories were intended for processing coca paste 
for domestic abuse. In response, the Government has 
undertaken a number of measures to strengthen 
Argentina’s law enforcement capacities in the area of drug 
control, notably through the provision throughout the 
country of specialized training courses on countering drug 
trafficking and related crime and on preventing the 
diversion of precursor chemicals, for law enforcement 
personnel and officials of the judicial system and the public 
prosecution service. Other measures include the 
preparation of a voluntary code of conduct for the chemical 
industry; implementation of the federal inspection plan for 
entities working with controlled substances, with an 
emphasis on precursors used in the illicit manufacture of 
cocaine; and the maintenance of a 24-hour hotline to reply 
to queries from security and police officers regarding 
checkpoint procedures. The Board welcomes such 
initiatives and encourages the Government to continue 
expanding its activities in that area. 
 
 (b) Ethiopia 
 
125. The Government of Ethiopia has acted on the Board’s 
recommendations following its mission to the country in 
2008, and progress has been made in a number of areas of 
drug control. The Board notes with appreciation that a 
comprehensive national drug control master plan that 
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addresses most of the recommendations of the Board has 
been elaborated and adopted, and an interministerial 
committee has been established to monitor and guide the 
implementation of that master plan.  
126. The Board welcomes the measures taken against the 
illegal cultivation of cannabis plant and against drug 
trafficking. The drug control division of the national police 
has stepped up its eradication efforts in collaboration  
with the local communities in the areas most affected by 
illicit cannabis plant cultivation, and drug interdiction 
capacities at the Addis Ababa international airport have 
been significantly strengthened. Measures taken include 
the establishment of an inter-agency coordination team  
to improve operational cooperation at the airport among 
the relevant drug law enforcement entities, as well as  
capacity-building training sessions for law enforcement 
personnel such as police staff, airport administration 
personnel, regional police supervisors and customs 
officials.  
127. The Board notes that in 2009, legislation to counter 
money-laundering was adopted and a financial  
intelligence centre was established to investigate cases of 
money-laundering and to enhance public awareness and 
understanding of matters related to money-laundering.  
128. The Government has made progress in demand 
reduction and the prevention and treatment of drug abuse. 
Under the country’s national drug control master plan, 
programmes have been adopted and measures have been 
taken by national and regional institutions to counter 
substance abuse. To address the low availability of opioids 
for medical use in Ethiopia, including for palliative care, 
the authorities have provided capacity-building sessions, 
and training sessions for raising awareness have been  
given to health-care providers and medical practitioners  
to manage effectively the rational use of opioids for  
medical purposes.  
129. The Board invites the Government to further 
strengthen cooperation with it in the control of precursors 
and to provide prompt responses to the Board’s inquiries 
on the legitimacy of orders for export of precursors to 
Ethiopia, in particular, by using the PEN Online system. 
The Board encourages the Government to continue its 
efforts in the area of drug control and to keep the Board 
informed of the drug control situation in Ethiopia and 
further measures taken against drug trafficking and abuse 
in the country. 
 
 (c) Hungary 
 
130. The Board notes that efforts have been made by the 
Government of Hungary in the implementation of the 
Board’s recommendations following its mission to that 
country in 2009. The Government has taken measures to 
strengthen the control of licit activities related to precursor 
chemicals, particularly with regard to the distribution and 
use of acetic anhydride. Additional steps have been taken 
with a view to identifying the diversion of acetic anhydride 
from licit trade into illicit channels. The Government 
appears committed to fulfilling the requirements of 
Economic and Social Council resolution 1999/32, entitled 
“International regulation and control of trade in poppy 
seeds”, and has expressed its intention to nominate an 
authority empowered to certify the origin of poppy seeds 
produced in Hungary, as recommended by the Board.  
131. Progress has also been made in the rational use of 
narcotic drugs and psychotropic substances. Legislative 
amendments adopted in July 2011 provide for stricter 
controls on medicinal products containing narcotic drugs 
and psychotropic substances. The control of retail 
pharmacies and storage of controlled substances by  
health-care providers has also been strengthened, and new 
regulations in respect of the prescription of narcotic drugs 
and psychotropic substances for medical purposes have 
entered into force. The Board trusts that the Government 
of Hungary will continue strengthening its efforts to ensure 
adequate availability of narcotic drugs and psychotropic 
substances for medical and scientific purposes and, at the 
same time, prevent their diversion into illicit channels.  
132. While welcoming those measures, the Board notes 
that continued efforts need to be made in the area of drug 
abuse prevention and treatment. Although Hungary has 
established a comprehensive system for the treatment and 
rehabilitation of drug abusers, further development of the 
system is required to fully respond to needs. The Board 
encourages the Government to increase its efforts in the 
primary prevention of drug abuse among youth and to 
ensure that activities in this area address all commonly 
abused controlled substances, including pharmaceutical 
preparations containing such substances.  
 
 (d) Jordan 
 
133. The Board notes that some progress in drug control 
has been made by the Government of Jordan since the 
mission of the Board to that country in 2009. The 
Government has introduced a number of measures to 
strengthen coordination among the relevant Government 
agencies under the coordination of the Food and Drug 
Administration of Jordan, the main coordinating body for 
drug control in the country. The Government has also 
strengthened its cooperation in the exchange of 
information on precursor chemicals with the neighbouring 
countries participating in several international initiatives. 
The Board remains concerned that only limited 
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information on drug trafficking and seizures in Jordan 
continues to be available. 
134. Since 2009, the National Narcotics Control Council 
launched a new national strategy to combat abuse of 
narcotic substances. A new centre for the treatment of 
addicts with 250 beds has been opened. The Board 
welcomes the measures taken by the Government to reduce 
drug demand through programmes to raise awareness 
about drug prevention and programmes for the treatment 
of addiction, rehabilitation and social reintegration. 
135. The Board notes that little progress has been made in 
ensuring the availability of narcotic drugs for medical 
purposes in Jordan. The availability of opioids for the 
treatment of pain in medical institutions continues to be 
inadequate. The Board requests the Government to 
examine the current situation and take the steps necessary 
to ensure that narcotic drugs, particularly opioids, are 
made available for medical purposes.  
 
 (e) Morocco 
 
136. The Board notes with appreciation that the 
Government of Morocco has implemented the 
recommendations of the Board following its mission to that 
country in 2009. Specifically, controls over the licit 
movement of narcotic drugs, psychotropic substances and 
precursor chemicals have been further improved through 
the introduction in January 2011 of harmonized 
administrative procedures and the use of standardized 
forms. The national commission on narcotic drugs of 
Morocco has taken steps to improve dissemination of 
information on demand reduction. Furthermore, the Board 
was provided with a compilation of studies carried out in 
Morocco on the extent and pattern of drug abuse in the 
country.  
137. Morocco is one of the major producers of cannabis 
resin. According to the Government, the area under illicit 
cannabis plant cultivation stood at 47,400 hectares (ha) in 
2010. The Government employs a multifaceted strategy 
that encompasses law enforcement efforts, eradication of 
illicit drug crops, alternative development programmes and 
demand reduction and treatment efforts to overcome the 
cannabis plant-growing culture that has historically existed 
in northern Morocco. The Board notes the steps taken by 
the Government to share its experience and good practices 
in the field of combating illicit cannabis plant cultivation. 
The Board encourages the Government to continue its 
efforts against illicit cannabis cultivation and trafficking, to 
continue to collect and analyse pertinent statistical data on 
the extent of cannabis cultivation in the country, and to 
share its experiences with the international community.  
138. Action against international drug trafficking 
networks is a priority of Morocco’s national drug strategy. 
The Board notes that in order to counter the use of the 
national territory as a transit area for international drug 
trafficking, the Government has taken a number of 
measures such as operational capacity-building for various 
security sectors, the introduction of a policy for border and 
coastal control, the provision of continuous training 
programmes for law enforcement officers, the utilization of 
new detection technologies in seaports and airports, the 
development of strategies to prevent and combat the use of 
light aircraft in drug trafficking and improved international 
cooperation activities with other countries, in particular 
through INTERPOL.  
139. The Board notes that the issue of accessibility of 
medicines, including opioids, has been included in the plan 
of action for the period 2012-2017 of the Ministry of 
Health of Morocco, with a view to addressing regulatory 
constraints at the national level. The Board welcomes this 
measure and encourages the Government to make further 
progress in improving the availability of licit drugs for 
medical purposes. 
 
 
 B. Action taken by the Board to ensure 
the implementation of the 
international drug control treaties 
 
 
 1. Action taken by the Board pursuant to  
article 14 of the 1961 Convention and  
article 19 of the 1971 Convention 
 
140. Article 14 of the 1961 Convention (and that 
Convention as amended by the 1972 Protocol), article 19 of 
the 1971 Convention and article 22 of the 1988 Convention 
set out measures that the Board may take to ensure the 
execution of the provisions of those Conventions. Such 
measures, which consist of increasingly severe steps, are 
taken into consideration when the Board has reason to 
believe that the aims of the Conventions are being seriously 
endangered by the failure of a State to carry out the 
provisions of those Conventions. 
141. The Board has invoked article 14 of the  
1961 Convention and/or article 19 of the 1971 Convention 
with respect to a limited number of States. The Board’s 
objective has been to encourage compliance with those 
Conventions when other means failed. The States 
concerned are not named until the Board decides to bring 
the situation to the attention of the parties, the Economic 
and Social Council and the Commission on Narcotic Drugs 
(as in the case of Afghanistan). Following continuous 
dialogue with the Board pursuant to the above-mentioned 
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articles, most of the States concerned have taken remedial 
measures, resulting in the Board’s decision to terminate 
action taken under those articles vis-à-vis those States. 
142. Afghanistan is currently the only State for which 
action is being taken pursuant to article 14 of the  
1961 Convention as amended by the 1972 Protocol. 
 
 2. Consultation with the Government of 
Afghanistan pursuant to article 14 of the  
1961 Convention 
 
143. At the invitation of the Board, a high-level 
Government delegation, headed by the Minister of 
Counter-Narcotics of Afghanistan, attended the  
103rd session of the Board in February 2012. The 
delegation was composed of Government officials from 
various ministries responsible for drug control in 
Afghanistan.  
144. The Board heard a report presented by the delegation 
on the drug control situation in Afghanistan and measures 
taken by the Government to address the drug problem, 
particularly with regard to the illicit cultivation of opium 
poppy and related illicit activities. The delegation expressed 
the commitment of the Government of Afghanistan to drug 
control and continued cooperation with the Board in the 
implementation of the international drug control treaties. 
Pursuant to the meeting, the Board communicated its 
recommendations to the Government and requested a 
progress report on the implementation of those 
recommendations.  
145. The Afghan delegation attended the Board’s session 
as part of the continuing consultations under article 14 of 
the 1961 Convention. The information provided by the 
delegation and subsequent follow-up has facilitated an 
adequate assessment by the Board of the current drug 
control situation in Afghanistan and the progress made by 
the Government in complying with its treaty obligations.  
146. Pursuant to the decision made by the Board at its 
104th session held in May 2012, the Board has proposed to 
the Government that a high-level mission of the Board to 
Afghanistan be scheduled as a matter of priority in order to 
continue consultations with the highest authorities of the 
country under article 14 of the 1961 Convention. 
 
 (a) Current drug control situation in Afghanistan  
 
147. In 2012, the total area under illicit opium poppy 
cultivation reached 154,000 ha, an increase of 18 per cent 
compared with 2011 (131,000 ha). The southern and 
western regions continued to be the centre of illicit opium 
poppy cultivation, accounting for 95 per cent of the total 
cultivation in the country. Potential illicit production of 
opium decreased by 36 per cent, from 5,800 tons in 2011 to 
3,700 tons in 2012, due to the lower yield caused by plant 
disease and adverse weather conditions in the main opium 
poppy-growing areas. 
148. The Governor-led eradication force is estimated to 
have eradicated 9,672 ha of opium poppy in 2012,  
a 154-per-cent increase compared with the area eradicated 
in 2011 (3,810 ha). However, illicit opium poppy cultivation 
remained widespread in Afghanistan, being present in half 
of the country’s 34 provinces. The increase in the area 
eradicated in 2012 was much less than the increase in the 
area of opium poppy cultivation that same year and also 
much less than the area eradicated in 2003 (21,430 ha) and 
2007 (19,047 ha). The Board urges the Government to 
address all impediments to the goal of its national drug 
control strategy and take effective measures to ensure that 
sustained progress is made in reducing and preventing 
illicit opium poppy cultivation in the country.  
149. Illicit cultivation of cannabis plant and production of 
cannabis resin continue to pose a significant challenge to 
drug control in Afghanistan. Cannabis cultivation has 
become increasingly lucrative, with revenues similar to or 
even surpassing those earned from the cultivation of opium 
poppy. In 2011, the number of Afghan households growing 
cannabis plant as a cash crop leapt by more than a third, to 
about 65,000 compared with 47,000 in 2010. Fifty-eight per 
cent of households cultivating cannabis plants also reported 
having cultivated opium poppy in the previous growing 
season, with three quarters of farmers surveyed citing high 
sale prices as the reason for cultivating cannabis plant. 
Afghanistan’s importance as a source of cannabis resin for 
world markets has been growing due to the continued high 
level of cannabis plant cultivation and the high yield 
obtained. The Board notes that little has been done in this 
regard and urges the Government to take the necessary 
measures to address the problem in accordance with the 
international drug control treaties. 
150. In 2012, the Government of Afghanistan updated its 
national drug control strategy, placing a particular 
emphasis on adopting a partnership approach in order to 
ensure joint, effective implementation and coordination; 
capacity-building of law enforcement bodies at all levels of 
government; and support for a functioning system to 
monitor progress using measurable, time-bound targets. 
Furthermore, the Government developed three national 
drug control policies: on alternative livelihoods, countering 
drug trafficking and drug demand reduction. The Board 
welcomes those positive developments and expects the 
Government to translate those policies into specific actions 
and make continuous progress towards achieving the goals 
set out in those policies.  
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 (b) Ensure full compliance with treaty obligations  
 
151. The Government of Afghanistan informed the Board 
that it was considering undertaking a pilot project, entitled 
“Poppy for Medicine”, under a scheme referred to as 
“controlled cultivation under licence”. The Board is 
seriously concerned about that proposal to legalize opium 
poppy cultivation in Afghanistan, where illicit opium 
poppy cultivation remains widespread and continues to 
pose a significant challenge to Afghanistan’s compliance 
with the international drug control treaties, and requests 
the Government to attend to the Board’s concern about this 
matter at its highest level.  
152. The Board underlines that the licit cultivation of 
opium poppy and the production of opiate raw materials 
are subject to control measures pursuant to the provisions 
of the 1961 Convention and that Convention as amended 
by the 1972 Protocol. The Board believes that, until such 
time as the Government is able to put in place credible and 
sustainable control measures and to effectively exercise 
control over narcotic drugs, psychotropic substances and 
precursors, an enforceable ban on opium poppy cultivation 
in Afghanistan is the most suitable and realistic measure to 
address the drug problem in the country.  
153. In that context, the Board recalls the Government’s 
prior rejection in 2007 of a proposal to legalize illicit opium 
cultivation in the country, as well as its commitment to 
fulfilling its obligations under the international drug 
control treaties, in particular its obligations under article 22 
of the 1961 Convention. The Board trusts that the 
Government will take adequate measures to address the 
drug problem in accordance with the provisions of the 
international drug control treaties.  
 
 (c) Cooperation by the international community  
 
154. In 2012, the international community demonstrated 
its continued commitment to assisting Afghanistan in 
addressing the drug problem, as evidenced by the ongoing 
efforts of the international community in various areas of 
drug control, as well as in the areas of security, governance 
and reconstruction and development. The convening of the 
Third Ministerial Conference of the Paris Pact Partners in 
Combating Illicit Traffic in Opiates Originating in 
Afghanistan, held in February 2012, and the Vienna 
Declaration at the Conference further demonstrated the 
spirit of common and shared responsibility in curbing the 
menace of illicit Afghan opiates. That commitment was 
reaffirmed at the Tokyo Conference on Afghanistan held in 
July 2012, as evidenced by the number of high-level 
representatives in attendance and the scale of financial 
pledges made at the Conference.  
155. The drug control problem in Afghanistan and the 
neighbouring region remains of grave concern and requires 
the consolidated effort and the long-term commitment of 
all stakeholders. While the focus remains on combating 
illicit production and trafficking in opiates, the emerging 
situation of illicit cultivation of and trafficking in cannabis 
should not be overlooked. More also needs to be done to 
prevent the diversion of precursor chemicals from licit 
sources into illicit channels in the region. The Board calls 
upon the Government of Afghanistan and the international 
community to pursue a balanced approach among supply 
and demand reduction measures in accordance with the 
international drug control treaties and the relevant 
resolutions on drug control of the General Assembly and 
the Economic and Social Council. 
 
 (d) Conclusions 
 
156. Afghanistan remains the centre of illicit cultivation of 
opium poppy worldwide, seriously endangering the aims of 
the international drug control treaties. The emerging 
situation of illicit cultivation of cannabis plant requires 
urgent action by the Government of Afghanistan with the 
assistance of the international community. The Board, 
while noting the political will and commitment expressed 
by the Government, remains concerned over the lack of 
progress and urges the Government to step up its efforts 
and take a sustained approach to implementation of its 
national drug control strategy and policies and to ensure 
ongoing progress in alternative development, efforts 
against drug trafficking and drug demand reduction. The 
Government of Afghanistan should also strengthen its 
capacity to monitor licit activities related to narcotic drugs, 
psychotropic substances and precursors in the country and 
to prevent their diversion and abuse. 
 
 
 C. Governments’ cooperation with the 
Board 
 
 
 1. Provision of information by Governments to 
the Board 
 
157. The Board is mandated to publish each year two 
reports (the annual report and the report of the Board on 
the implementation of article 12 of the 1988 Convention) 
and also publishes technical reports based on information 
that parties to the international drug control treaties are 
obligated to submit. These publications give Governments 
detailed analyses on estimates and assessments of 
requirements, manufacture, trade, consumption, utilization 
and stocks of internationally controlled substances. 
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158. The analysis of the data provided is crucial in order 
for the Board to monitor and evaluate treaty compliance 
and the overall functioning of the international drug 
control system. If issues or problems are identified, 
measures can be recommended by the Board to help 
prevent the diversion of narcotic drugs and psychotropic 
substances into illicit markets. The provision of data also 
helps account for the legitimate use of narcotic drugs and 
psychotropic substances for medical and scientific 
purposes.  
 
 2. Submission of statistical reports 
 
159. Governments are obliged to furnish to the Board 
each year, in a timely manner, statistical reports containing 
information required under the international drug control 
conventions.  
160. As at 1 November 2012, annual statistical reports on 
narcotic drugs (form C) for 2011 had been furnished by 
159 States and territories (representing 75 per cent of the 
States and territories requested to submit such reports), 
although more Governments are expected to submit their 
reports for 2011 in due course. In total, 180 States and 
territories provided quarterly statistics on their imports 
and exports of narcotic drugs in 2011, amounting to 85 per 
cent of the States and territories required to provide such 
statistics. A large number of Governments in Africa, the 
Caribbean and Oceania do not submit their statistics 
regularly, despite repeated requests by the Board to do so. 
161. In 2012, several Governments either did not submit 
their annual statistical reports on narcotic drugs to the 
Board on time or submitted incomplete reports, including 
countries that are major manufacturers, exporters, 
importers and users of narcotic drugs, such as Brazil, Israel, 
Pakistan, Romania and the United Kingdom of Great 
Britain and Northern Ireland. This delays the Board’s 
analysis of global trends and makes it difficult for the 
Board to prepare its annual report and the technical 
publication on narcotic drugs. The Board has contacted the 
Governments concerned and have requested them to 
improve their reporting. 
162. As at 1 November 2012, annual statistical reports on 
psychotropic substances (form P) for 2011, in conformity 
with the provisions of article 16 of the 1971 Convention, 
had been submitted to the Board by a total of 146 States 
and territories, amounting to 69 per cent of the States and 
territories required to provide such statistics. In addition, 
97 Governments voluntarily submitted all four quarterly 
statistical reports on imports and exports of substances 
listed in Schedule II, in conformity with Economic  
and Social Council resolution 1981/7, and a further  
65 Governments submitted some of the quarterly reports. 
The Board notes that the Governments of three countries 
that trade in such substances failed to submit any quarterly 
form for 2011.  
163. As in previous years, up to 50 per cent of countries 
and territories in Africa, the Caribbean and Oceania did 
not submit the required statistical forms on psychotropic 
substances, which might be an indication that those 
Governments have yet to establish the necessary legal or 
administrative structures to enable their competent 
authorities to collect and compile the required information. 
It is also an indication that those Governments may not be 
fully aware of the specific reporting requirements on 
psychotropic substances as they relate to their territories 
and that they require capacity-building in that regard.  
164. Among the countries that did not submit the 
required information for 2011 or were not able to submit 
the annual statistical report on psychotropic substances 
before the deadline of 30 June 2012 were major 
manufacturing, importing and exporting countries, such as 
Argentina, Brazil, India, Israel, Pakistan and the United 
Kingdom. The Board understands that those shortcomings 
were mainly due to changes in the Government structure 
responsible for reporting to the Board or to changes of staff 
within the competent authorities. However, some 
Governments continued to experience difficulties in 
collecting the required information from their national 
stakeholders due to legislative or administrative 
shortcomings. 
165. The Board notes that, in 2012, a total of 43 countries 
and territories submitted data on consumption of some or 
all psychotropic substances in accordance with 
Commission on Narcotic Drugs resolution 54/6, which is 
12 per cent more submitting countries and territories than 
in 2011, the first year when such data were requested. The 
Board appreciates the cooperation of the concerned 
Governments and calls upon all other Governments to take 
the necessary steps allowing them to furnish information 
on the consumption of psychotropic substances with a view 
to promoting their adequate availability for medical and 
scientific purposes while preventing their diversion and 
abuse. 
166. Pursuant to article 12 of the 1988 Convention, parties 
are obliged to report information on substances frequently 
used in the illicit manufacture of narcotic drugs and 
psychotropic substances. As at 1 November 2012, such 
information had been submitted by a total of 129 States and 
territories, which was an improvement on last year’s 
submission rate. However, some Governments continue to 
submit blank or incomplete forms, fail to report or miss the 
reporting deadline of 30 June of each calendar year. The 
Board reminds all States parties that reporting, as outlined 
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in the 1988 Convention, is an obligation and urges them to 
submit a single completed form D, using the latest version 
available, in a timely manner. The latest version of form D 
is available in all six official languages of the United 
Nations from the Board’s website (www.incb.org). The 
Board stands ready to assist any Government in meeting 
their reporting obligations.  
167. According to data provided on form D for 2011,  
59 Governments effected seizures of substances in Tables I 
and II of the 1988 Convention. However, details regarding 
the seizures, other than the amounts seized, are not 
provided by a majority of Governments. Parties to the 
Convention are required to provide qualitative data about 
seizures, the provision of which is essential to develop a 
greater understanding of the modus operandi used by drug 
traffickers. The Board reminds Governments effecting 
seizures of their obligation to provide comprehensive 
information on methods of diversion, stopped shipments 
and illicit manufacture. 
168. In March 2012, the Board launched the Precursors 
Incident Communication System (PICS) during the  
fifty-fifth session of the Commission on Narcotic Drugs. 
The system was developed by the Board as a response  
to the rapidly changing trends seen in drug development 
(e.g. the emergence of non-scheduled substances and 
“designer drugs”) with a view to complementing traditional 
reporting mechanisms on individual precursor seizures. 
Registered users of PICS have access to secure, real-time 
data on incidents and can use the system to communicate 
with relevant counterparts in order to help launch 
bilateral/regional investigations into seizures and identified 
cases of diversion of chemicals. The system is helping the 
Board and users to quickly identify emerging patterns of 
diversion of precursors. As at 1 November 2012, there were 
237 users representing 58 Governments and 8 international 
and regional agencies registered with PICS. The Board 
encourages all Governments to register their law 
enforcement, regulatory and intelligence authorities 
involved in the control and monitoring of chemicals used 
in illicit drug manufacture with PICS and to use the system 
without delay.  
 
 3. Submission of estimates and assessments  
 
169. Pursuant to the 1961 Convention, States parties are 
obliged to provide the Board each year with estimates of 
their requirements for narcotic drugs for the following year. 
As at 1 November 2012, a total of 162 States and territories 
had submitted estimates of their requirements for narcotic 
drugs for 2013, representing 76 per cent of the States and 
territories required to furnish annual estimates for 
confirmation by the Board. As was the case in previous 
years, the Board had to establish estimates for those States 
and territories that had not submitted their estimates on 
time, in accordance with article 12 of the 1961 Convention.  
170. Failure to submit adequate estimates or assessments 
for narcotic drugs and psychotropic substances may 
undermine drug control efforts. If estimates or assessments 
are lower than the legitimate requirements, the importation 
or use of narcotic drugs or psychotropic substances needed 
for medical or scientific purposes may be impeded or 
delayed. Submission of estimates or assessments 
significantly higher than legitimately required increases the 
risk that imported narcotic drugs and psychotropic 
substances will be diverted into illicit channels. The Board 
calls upon all Governments to ensure that their estimates 
and assessments are adequate but not excessive. When 
necessary, Governments should submit to the Board 
supplementary estimates for narcotic drugs or inform the 
Board of modifications to their assessments for 
psychotropic substances. INCB invites all Governments, in 
particular those of countries and territories with low  
levels of consumption of controlled substances, to use the 
Guide on Estimating Requirements for Substances under 
International Control, developed by the Board and  
the World Health Organization (WHO) for use by 
competent national authorities, which was published in  
February 2012.  
171. In recent years, several countries have requested the 
Board to clarify certain parts of the estimates and 
assessments systems. In particular, Governments have 
indicated that the adjustment to stocks procedure, which is 
an important component of the system of estimates for 
narcotic drugs, was difficult to fully comprehend due to its 
complexity. Therefore, in September 2012, the Board 
organized training sessions for interested countries in order 
to explain the estimates system in general and the 
adjustment to stocks procedure in particular. The Board 
trusts that on the basis of information provided during the 
training, countries will be able to submit adequate 
supplementary estimates and prevent stocks of narcotic 
drugs from dropping to levels below actual requirements. 
The training also focused on assessments for psychotropic 
substances and on how to avoid having imports and 
exports exceed the quantities set out in the estimates and 
assessments. Future training sessions will be organized for 
those countries expressing an interest in them.  
172. Similar to the situation with the control of narcotic 
drugs, pursuant to Economic and Social Council 
resolutions 1981/7 and 1991/44, Governments are 
requested to provide the Board with annual assessments of 
requirements for psychotropic substances contained in 
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Schedules II, III and IV of the 1971 Convention for medical 
and scientific use.  
173. As at 1 November 2012, Governments of all countries 
and territories, except for the Government of South Sudan, 
had submitted to the Board at least one assessment of their 
annual medical and scientific requirements for 
psychotropic substances. The assessments of requirements 
for psychotropic substances for South Sudan were 
established by the Board in 2011, in accordance with 
Economic and Social Council resolution 1996/30, in order 
to allow that country to import such substances for medical 
purposes without undue delay.  
174.  Assessments for psychotropic substances remain in 
force until Governments modify them to reflect changes in 
national requirements. The Board recommends that 
Governments review and update the assessments of their 
annual medical and scientific requirements for 
psychotropic substances at least every three years.  
Since 1 November 2011, a total of 101 countries and  
8 territories fully revised assessments of their requirements 
for psychotropic substances, and a further 93 Governments 
submitted modifications to assessments for one or more 
substances as at 1 November 2012. Governments of  
13 countries and one territory have not submitted any 
revision of their legitimate requirements for psychotropic 
substances for at least three years.  
175. In accordance with Economic and Social Council 
resolution 1995/20, Governments provide data on their licit 
trade in, uses of and requirements for substances in Tables I 
and II of the 1988 Convention, which enables the Board to 
identify trends in the international trade in precursors  
as well as unusual or suspicious trade patterns. As at  
1 November 2012, 109 States and territories had provided 
information on licit trade and 101 had provided data on 
licit uses of and requirements for precursors. 
176. In its resolution 49/3, the Commission on Narcotic 
Drugs requested that Member States provide the Board 
with estimates of their annual legitimate requirements for 
the import of four substances frequently used in  
the manufacture of amphetamine-type stimulants  
(3,4-methylenedioxyphenyl-2-propanone (3,4-MDP-2-P), 
pseudoephedrine, ephedrine and 1-phenyl-2-propanone 
(P-2-P)) and to the extent possible, estimated requirements 
for imports of preparations containing those substances. 
The information on legitimate trade for precursor 
chemicals for amphetamine-type stimulants assists the 
competent authorities of exporting countries in preventing 
exports of substances in quantities exceeding the legitimate 
requirements of the importing countries, which could 
potentially be diverted to illicit channels.  
177. The number of Governments and the number of 
substances in Tables I and II for which estimates of annual 
legitimate requirements are provided have steadily 
increased. As at 1 November 2012, 150 Governments had 
provided those estimates for at least one substance.  
First-time submissions were provided by Bolivia 
(Plurinational State of), Brunei Darussalam, Curaçao, 
Eritrea, Faroe Islands, France, Greenland, Japan, Maldives, 
Norfolk Island, Qatar and Tunisia.  
178. The Board wishes to remind all Governments that the 
totals of estimates of annual medical and scientific 
requirements for narcotic drugs, as well as assessments for 
psychotropic substances, are published in yearly and 
quarterly publications and that monthly updates are 
available on the Board’s website (www.incb.org). Updated 
information on annual estimates of legitimate requirements 
for precursors of amphetamine-type stimulants is also 
available on the website. 
 
 4. Data examination and identified reporting 
deficiencies 
 
179. The provision of statistical data by Governments 
allows the Board to overview the functioning of the drug 
control systems. This in turn helps to address concerns 
about possible diversion and illegitimate use of substances.  
180. Countries that provide accurate statistical data to the 
Board in a timely manner typically have well-established 
national drug control agencies with the adequate human 
and technical resources required to carry out their 
responsibilities that are operating on the basis of 
appropriate legislation and administrative regulations. 
Those agencies are also given the necessary authority to 
fulfil their role under the international drug control 
treaties. Further, they provide clear guidance at the national 
level on the requirements for engaging in the manufacture 
and trade of internationally controlled substances, which 
improves cooperation between national drug control 
authorities and industry. Such national drug control 
systems contribute significantly to the effective functioning 
of international drug control.  
181. Late submission and the submission of incomplete or 
inaccurate data required under the international drug 
control treaties and resolutions of the Economic and Social 
Council and the Commission on Narcotic Drugs may 
significantly obstruct examination and overall analysis of 
the data by the Board. Some Governments, among them 
major manufacturing countries, experience difficulties in 
reporting accurately and in a timely manner after changes 
of staff, or after restructuring of the competent authorities. 
To avoid such difficulties, the Board encourages all 
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Governments to take the necessary steps to establish 
mechanisms that allow competent authorities to maintain 
the knowledge base of the staff with regard to reporting 
requirements under the drug control convention at times of 
change. In particular, training of new staff should be 
envisaged.  
182. Many Governments are making use of new 
developments, in particular in the area of information 
technology, to enhance established drug control systems. In 
particular, electronic systems are used to collect and 
compile data required under the Conventions in order to 
facilitate timely and accurate processing of the large 
volumes of data related to internationally controlled drugs. 
However, the Board notes that, in some countries, the 
quality of information collected from national stakeholders 
using electronic tools is low. One possible reason for this 
might be that the companies or other national stakeholders 
are not sufficiently familiar with the tools in question or are 
not sufficiently aware of which information should be 
submitted, and therefore may not furnish the required data. 
The Board reminds Governments that it is their 
responsibility to ensure that all national stakeholders are 
fully aware of the reporting requirements and that any 
electronic system used at the national level for collecting 
data and reporting to the Board is used in a way that is 
compatible with the provisions of relevant international 
treaties. The Board notes that Governments that provide 
regular training sessions for all national stakeholders on the 
use of these tools, as well as on the reporting requirements 
under the international drug control conventions, submit 
accurate data. The Board invites all Governments of major 
manufacturing and trading countries to establish regular 
training events at the national level and stands ready to 
assist Governments in this endeavour in accordance with 
its mandate.  
183. The Board reviews the reports received from 
Governments to identify any systematic shortcomings in 
those reports that may be the result of inadequate 
implementation of the provisions of the drug control 
treaties, and can recommend appropriate action. It is also 
an obligation of Governments and their competent 
authorities to rectify errors in the collection and processing 
of data. In that regard, the Board recommends that 
competent authorities use screening mechanisms to check 
the validity of the data they receive prior to sending it to 
the Board. By implementing such measures, inconsistencies 
and gaps can be identified more easily, clarifications can be 
sought and Governments will be able to compile and 
submit accurate national reports to the Board. 
Furthermore, it appears that, due to gaps in national 
legislation, national stakeholders are not required to report 
on all or some of their activities involving controlled 
substances, or are not required to do so in time for the 
authorities to furnish comprehensive reports to the Board. 
The Board is concerned about those gaps in national 
legislation as they may also prevent adequate monitoring 
by competent authorities.  
184. The Board notes the development by UNODC of  
the project “Building national capacity in regulatory 
control of internationally controlled substances”. As part  
of the project, the Board’s Secretariat and UNODC  
will provide regional workshops and electronic learning 
tools with the aim of improving drug control 
administration at the national level. The Board invites 
Governments to support UNODC in carrying out  
that project. 
 
 
 D. Ensuring the implementation of the 
provisions of the international drug 
control treaties 
 
 
185. The international drug control regime was 
established with two equally important aims: first, to 
ensure the availability of narcotic drugs and psychotropic 
substances for medical and scientific purposes; and second, 
to prevent the diversion of controlled substances into illicit 
channels for subsequent sale to drug abusers or, in the case 
of precursor chemicals, for use in the illicit manufacture of 
narcotic drugs and psychotropic substances. The drug 
control regime comprises the international drug control 
conventions and additional control measures, adopted by 
the Economic and Social Council and the Commission on 
Narcotic Drugs to enhance the effectiveness of the 
provisions contained in the drug control conventions to 
achieve the two main goals. Pursuant to its mandate, the 
Board regularly examines action taken by Governments to 
implement the treaty provisions and related resolutions of 
the Council and the Commission, points out problems that 
continue to exist in this area and provides specific 
recommendations on how to deal with such problems. 
 
 1. Preventing the diversion of controlled 
substances 
 
 (a) Legislative and administrative basis 
 
186. Parties to the conventions need to adopt and enforce 
national legislation that is in line with the provisions of the 
international drug control treaties. They also need to 
amend the lists of substances controlled at the national 
level when a substance is included in a schedule of an 
international drug control treaty or transferred from  
one schedule to another. Inadequate legislation or 
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implementation mechanisms at the national level or delays 
in bringing lists of substances controlled at the national 
level into line with the schedules of the international drug 
control treaties result in inadequate national controls being 
applied to substances under international control. In some 
cases such deficiencies have led to the diversion of 
substances into illicit channels. 
187. The Board notes that some Governments appear to 
have difficulties in reflecting changes that have been 
introduced in the scope of control of the international 
treaties in their national legislation. For example, although 
in 2001 zolpidem and gamma-hydroxybutyric acid (GHB) 
were added to Schedule IV of the 1971 Convention, even in 
2012 some Governments of countries where those 
substances are used for medical purposes have not yet 
amended their national lists of controlled substances 
accordingly, although the 1971 Convention stipulates that 
such amendments should be enforced 180 days after receipt 
of the appropriate notification of the Secretary-General. 
188. As stated in paragraphs 159-168 above, when 
reviewing the statistical reports the Board determined that 
in some countries the control measures foreseen in the 
international drug control conventions were not adequately 
reflected in the national laws or regulations, which resulted 
in an absence of data or incomplete data. In the countries 
concerned, some stakeholders, or some geographical areas, 
are not monitored by the competent authorities. In some 
other countries with federal structures, weak federal laws 
prevent the national competent authorities from enforcing 
at the state level the control measures foreseen at the 
national level. In all the examples cited above, entities that 
are not monitored adequately could unintentionally or 
intentionally contribute to the diversion and abuse of 
controlled substances. 
189. The Board notes that such deficiencies seem to be 
particularly common with regard to provisions of the  
1971 Convention, which are already weaker than the 
control mechanisms of the 1961 Convention. The Board is 
concerned that some Governments seem to neglect the 
monitoring of psychotropic substances, possibly under the 
misconception that the consequences of diversion and 
abuse of psychotropic substances are less serious than those 
of diversion and abuse of narcotic drugs. 
190. The Board requests all Governments to review their 
laws and regulations to verify that they are in line with all 
the relevant provisions of the drug control treaties and with 
the current schedules and tables of the international drug 
control treaties, and to amend their laws as necessary. 
191. More action is also needed with regard to precursor 
control. The Board is aware that Governments maintained 
measures to strengthen their controls over the import and 
export of precursors. In view of the continued 
identification of cases of diversion of pharmaceutical 
preparations containing ephedrine or pseudoephedrine, the 
Board welcomes the fact that many countries, including 
most recently China, the Republic of Korea and Thailand, 
have broadened their legislation to address particularly 
such diversion. 
192. Despite the foregoing, the Board is concerned that 
the controls applied to domestic distribution and end-use 
of precursors are still inadequate in many countries, which 
facilitates their continued diversion. Such controls should 
have, as a minimum: a system of end-user registration and 
declarations of end use; knowledge of legitimate 
requirements in order to set realistic limits to importation, 
particularly for chemicals with little or no legitimate use; 
and notification of all exports prior to their departure. To 
help stop the efforts of illicit trafficking organizations, the 
Board urges Governments to review existing domestic 
control systems, determine whether weaknesses exist and 
work to close existing gaps. 
193. In this context, the Board wishes to remind all 
Governments that the ability to monitor the international 
trade of precursors is fundamentally linked to effective 
monitoring of manufacture and distribution at the 
domestic level. The Board is concerned that without 
information about the domestic market and stakeholders, 
Governments are at risk of not being in a position to 
comply with their obligations related to preventing 
diversion. 
194. With a view to strengthening the monitoring of the 
international trade in precursors, in March 2012 the Board 
signed a memorandum of understanding with the World 
Customs Organization, which institutionalizes its 
constructive, long-standing cooperation with that 
Organization. One point of such cooperation is to establish 
unique Harmonized System codes for pharmaceutical 
preparations containing ephedrine and pseudoephedrine. 
 
 (b) Prevention of diversion from international trade 
 
  Estimates and assessments of annual 
requirements for controlled substances 
 
195. One of the main control measures used to prevent the 
diversion of controlled substances from international trade 
is the system of estimates or assessments of legitimate 
annual requirements for controlled substances, since this 
enables exporting and importing countries alike to ensure 
that the trade stays within the limits determined by the 
importing Governments. For narcotic drugs, such a system 
is mandatory under the 1961 Convention, and the 
estimates furnished by Governments need to be confirmed 
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by the Board before becoming the basis for the limits of 
manufacture or import. The system of assessments of 
annual requirements for psychotropic substances and the 
system of estimates of annual requirements for selected 
precursors were adopted by the Economic and Social 
Council and the Commission on Narcotic Drugs, 
respectively, to help Governments to identify unusual 
transactions that might reflect attempts by traffickers to 
divert controlled substances into illicit channels. 
196. The system of estimates or assessments can be 
effective only if both exporting and importing countries 
adhere to it: Governments of importing countries should 
ensure that their estimates and assessments are in line with 
their actual requirements and that no import of controlled 
substances in quantities exceeding those requirements is 
taking place. If the actual requirements are found to have 
increased beyond the requirements submitted previously to 
the Board or to have decreased substantially from those 
requirements, importing countries should inform the 
Board immediately of such changes. Governments of 
exporting countries should set up a mechanism to check all 
export orders involving controlled substances against the 
estimates and assessments of importing countries and allow 
exports only when they are in line with legitimate 
requirements in the importing countries. 
197. In accordance with its mandate to identify loopholes 
in the implementation of the control systems that could 
lead to diversion, the Board regularly investigates cases 
involving possible non-compliance by Governments with 
the system of estimates or assessments. In this connection, 
the Board provides advice to Governments on the details of 
the estimates and assessments systems, as necessary. For 
example, during the consultations organized by the Board 
in September 2012, the components of the international 
drug control system relating to observance of import  
and export limits were discussed (see para. 171 above). 
Participants were informed about the procedures to 
identify import and export excesses and about the rules 
that should be observed to avoid such excesses. In this 
respect, the Board would like to remind Governments to 
utilize the training material on narcotic drugs and 
psychotropic substances whenever clarifications on the 
international drug control system are needed. The Board is 
also at the disposal of Governments to respond to specific 
questions on the matter. 
198. As in previous years, the Board has found in 2012 
that the system of estimates for narcotic drugs continues to 
be respected by most countries. Through its analysis, the 
Board determined that in 2011 six countries authorized 
imports or exports of narcotic drugs in excess of the 
respective estimates. The Board contacted the 
Governments concerned and requested them to ensure full 
compliance with the relevant treaty provisions.  
199. For psychotropic substances, too, the system is well 
respected and the assessments of annual requirements have 
become more accurate, showing that Governments are 
increasingly aware of the actual requirements for 
psychotropic substances. In 2011 the authorities of  
14 countries issued authorizations for substances for which 
they had not established any assessments or in quantities 
that significantly exceeded their assessments, and most 
exporting countries paid attention to the assessments 
established in importing countries and did not knowingly 
export psychotropic substances in quantities exceeding 
those assessments. A frequent cause of excess imports was 
imports destined for re-export, which are difficult to assess 
in advance. The system of assessments for psychotropic 
substances has therefore been amended slightly: as of 2013, 
Governments will no longer be requested to include 
estimates for exports or re-exports in the annual 
requirements for psychotropic substances. The Board trusts 
that the change will make the system of assessments for 
psychotropic substances even more transparent and 
effective. 
200. The estimates of annual licit requirements for the 
four substances used in the illicit manufacture of 
amphetamine-type stimulants,15 which have been 
published by the Board since 2006, have proved to be a very 
useful tool to assist Governments in verifying the 
legitimacy of shipments of precursors. They have also 
allowed the Board to identify emerging regional trends in 
the diversion of precursors, and several major 
investigations into cases of diversion have been launched as 
a result. The positive momentum generated in such a short 
period by this new tool needs to be maintained. 
Methodologies employed by some Governments when 
estimating their requirements must be improved, since 
some Governments made estimates far in excess of their 
actual legitimate annual requirements (see para. 223 
below). The regular review of annual licit requirements for 
precursors and the submission of updated figures, as 
necessary, reflecting changing market conditions, as well as 
the participation of Governments that have not yet 
submitted such estimates, would improve this system. 
 
  Requirement of import and export authorizations 
 
201. The requirement for import and export 
authorizations is another main control measure to prevent 
the diversion of controlled substances from international 
__________________ 
 15  3,4-MDP-2-P, pseudoephedrine, ephedrine and P-2-P 
and preparations containing those substances. 
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trade, since it allows the competent national authorities to 
check the legitimacy of individual transactions prior to 
shipment. Import and export authorizations are mandatory 
for a transaction involving any of the substances controlled 
under the 1961 Convention or listed in Schedule I or II of 
the 1971 Convention. The competent national authorities 
are obliged to issue import authorizations for transactions 
involving the importation of such substances into their 
country. The authorities of exporting countries must verify 
the authenticity of the import authorizations before issuing 
the export authorizations required to allow the shipments 
containing the substances to leave their territory. Moreover, 
upon receipt of the consignments, the authorities in 
importing countries must inform the authorities of 
exporting countries of the actual quantities received. 
202. The 1971 Convention does not require import and 
export authorizations for trade in psychotropic substances 
listed in Schedule III or IV of the Convention. However, in 
view of widespread diversion of those substances from 
international trade in the 1970s and 1980s, the Economic 
and Social Council, in its resolutions 1985/15, 1987/30 and 
1993/38, requested Governments to extend the system of 
import and export authorizations to cover all psychotropic 
substances. In 2012 the Board has been informed by the 
Governments of Azerbaijan, Chile, the Russian Federation, 
Tajikistan and Ukraine that they recently imposed import 
authorization requirements for international trade 
involving some or all of the substances in Schedules III  
and IV. In addition, the Governments of Christmas Island, 
the Cocos (Keeling) Islands, French Polynesia, Norfolk 
Island, Saint Helena and Sint Maarten informed the Board 
that they implement the same regulations as their sovereign 
Governments. 
203. The Board notes that most countries and territories 
now require import and export authorizations for most of 
the psychotropic substances in Schedules III and IV of the 
1971 Convention, in accordance with the Economic and 
Social Council resolutions mentioned above. All 
Governments that do not yet require import and export 
authorizations for all psychotropic substances are invited to 
extend such controls to all substances in Schedules III and 
IV as soon as possible and to inform the Board accordingly. 
204. Some Governments, although in principle they 
require import and export authorizations for substances 
included in Schedules III and IV, have exempted certain 
specific preparations containing those psychotropic 
substances from the import/export authorization 
requirements otherwise in place in their countries, without 
informing other Governments or the Board accordingly. 
This has sometimes created confusion among trading 
partners and resulted in undue delays of transactions. The 
Board therefore requests all Governments that have 
exempted from the import authorization requirements that 
are normally enforced in their country certain preparations 
containing psychotropic substances included in  
Schedule III or IV to inform the Board of such exemptions 
without delay, so that other Governments can be advised 
accordingly. The Board further wishes to remind all 
Governments that exempt certain preparations containing 
psychotropic substances in accordance with the provisions 
of article 3 of the 1971 Convention that they should inform 
the Secretary-General of such exemptions, as applicable. 
205. The Board shares with the competent authorities 
information on the import authorization requirements for 
substances listed in Schedules III and IV of the  
1971 Convention that are applied in countries and 
territories, as well as of the exemptions, as applicable, to 
assist in monitoring international trade in psychotropic 
substances while preventing traffickers from targeting 
countries in which controls are less strict. For instance, this 
information can be reviewed on the secure area of the 
Board’s website, which is accessible only to specifically 
authorized Government officials. 
206. The Board is increasingly informed about import and 
export authorization requirements applied to precursors. 
According to the most recent information, about  
70 Governments now require individual export 
authorizations for all precursors included in Tables I and II 
of the 1988 Convention. Those Governments that have 
either no controls or require only general permits for  
the export of Table I and Table II substances may not be  
in a position to comply with their treaty obligations.  
The Board therefore urges all Governments to ensure that 
they are able to provide pre-export notifications, 
particularly to the importing countries that have officially 
requested such notifications. 
 
  Verifying the legitimacy of individual 
transactions, particularly those involving import 
authorizations 
 
207. Individual import authorizations are sometimes 
falsified by traffickers to obtain substances from legitimate 
international trade. The Board therefore reiterates its 
request to the authorities of exporting countries to verify 
the authenticity of all import authorizations using new or 
unknown formats, bearing unknown stamps or signatures, 
or that were issued by an unrecognized national authority, 
as well as of authorizations for consignments containing 
substances known to be frequently abused in the region of 
the importing country. The Board notes with appreciation 
that many Governments of exporting countries, including 
those of Belgium, Denmark, France, Germany, Hungary, 
India, Switzerland, the United Kingdom and the United 
States, are verifying the legitimacy of import authorizations 
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directly with the competent national authorities of 
importing countries or with the assistance of the Board. In 
this regard, the Board assists in such verifications, 
particularly in cases where the authorities of exporting 
countries did not receive feedback from the authorities of 
the importing countries, or when there is a concern that 
transactions might not fully comply with the requirements 
set out in the international drug control system. 
208. The Board wishes to remind the Governments of 
importing countries that it is in their interest to respond in 
a timely manner to all queries regarding the legitimacy of 
transactions that they receive from competent authorities 
or from the Board. Failure to respond quickly in such cases 
may hinder the investigation of diversion attempts and/or 
cause delays in legitimate trade in controlled substances, 
thus adversely affecting the availability of those substances 
for legitimate purposes.  
 
  Developing an international electronic import 
and export authorization system for narcotic 
drugs and psychotropic substances 
 
209. Governments will recall that in the report of  
the International Narcotics Control Board for 2011  
(paras. 212-219), the Board informed Governments of the 
initiative of developing an international electronic import 
and export authorization system for narcotic drugs and 
psychotropic substances. In that report, the Board also 
highlighted the joint efforts of the international community 
since 2009 to identify how the proposed system could assist 
national drug control authorities in their daily work, while 
at the same time ensuring that the system functions in a 
way that fully complies with the requirements set out in the 
international drug control conventions. 
210. The proposed electronic system is aimed at 
facilitating the exchange of electronic import and export 
authorizations between the competent national authorities 
of importing and exporting countries. The system would be 
able to check the quantity of a shipment against the latest 
estimate or assessment for the narcotic drug or 
psychotropic substance in question. Online endorsement 
would also be an important feature of the electronic system. 
All of those important features would be designed to help 
Governments to meet their obligations under the 
international drug control treaties and would enhance the 
monitoring of international trade in narcotic drugs and 
psychotropic substances and the prevention of their 
diversion. 
211. Since the end of 2011, that initiative has gained great 
momentum. On the basis of extensive consultations with 
interested Governments and the Board, UNODC presented 
a system-design document and the cost estimate for 
developing and maintaining the electronic system. 
212. In March 2012, Governments further strengthened 
their support for that initiative by adopting the 
Commission on Narcotic Drugs resolution 55/6. The 
resolution encourages Member States to provide the fullest 
possible financial and political support for developing, 
maintaining and administering an international electronic 
import and export authorization system for narcotic drugs 
and psychotropic substances. It also requests UNODC to 
undertake the development and maintenance of the system 
and invites the INCB secretariat to administer the 
international system during the start-up phase in the 
biennium 2012-2013. Furthermore, the resolution invites 
Member States and other donors to provide extrabudgetary 
contributions for those purposes. 
213. The Board, which has regularly reviewed the progress 
achieved in that initiative, notes with appreciation that a 
number of Governments have pledged, contributed to or 
are considering contributing to the funding required for 
developing and maintaining the electronic system. Thanks 
to such contributions, the initial development of the system 
by UNODC is assured, and UNODC has commenced the 
development work. The Board invites all Governments to 
continue providing voluntary contributions to UNODC in 
order to ensure the continued maintenance of the 
electronic system after the first, development phase. The 
Board wishes to stress that the administration of such a 
system implies the monitoring of Governments’ compliance 
with the control provisions for international trade in 
narcotic drugs and psychotropic substances. As reflected in 
Commission on Narcotic Drugs resolution 55/6, the Board 
is best placed to administer the system, once developed. 
 
  Pre-export notifications for precursor chemicals 
 
214. Only 81 countries have made use of article 12, 
paragraph 10 (a), of the 1988 Convention, which makes it 
mandatory for exporting countries to inform the 
competent authorities of those countries of a planned 
export of precursors to their territory prior to actual 
shipment. Without this control measure, the more than  
100 other parties to the 1988 Convention, in particular 
countries in parts of Africa, Central America and the 
Caribbean, Central Asia, South-East Asia and  
South-Eastern Europe, are at risk of being targeted by 
traffickers. The Board wishes to remind all Governments 
that the provisions of article 12, paragraph 10 (a), if used 
and implemented by all, would create a robust and practical 
mechanism for control of international trade in scheduled 
chemicals. Governments that have not yet invoked  
article 12, paragraph 10 (a), of the 1988 Convention should 
do so without delay, since it would oblige exporting 
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countries to issue notifications of all shipments of 
precursors destined to their country. 
215. The Board notes with satisfaction that the number of 
registered users of the Board’s PEN Online system now 
stands at 136, with an average of 1,800 pre-export 
notifications sent per month. Since the Board’s last report, 
10 additional States and territories — Armenia, Benin, the 
British Virgin Islands, Chad, Ethiopia, Kazakhstan, Nepal, 
Qatar, Senegal and Serbia — have registered with the PEN 
Online system. The information that is shared through 
PEN Online assists national competent authorities, and the 
Board, in identifying and confirming the legitimacy of 
individual shipments of precursors and in suspending or 
stopping suspicious shipments in an efficient and timely 
manner. As such, it is an important tool for the 
international community to help to monitor international 
trade in scheduled chemicals in order to help to prevent 
diversion. The Board reminds all Governments exporting 
scheduled chemicals to countries that have invoked  
article 12, paragraph 10 (a), of their obligation to issue 
notifications of such shipments prior to departure and 
recommends that they use the PEN Online system for such 
notifications, pursuant to Security Council resolution 1817 
(2008). The Board also encourages all Governments to 
actively review pre-export notifications sent to their 
country and to communicate via the PEN Online system so 
that an unbroken chain of monitoring trade in chemicals 
can be maintained. 
216. The Board launched Operation Ephedrine and 
Pseudoephedrine Intelligence Gaps in Africa (Operation 
EPIG) in June 2012, to gather strategic information on the 
licit trade, trafficking and illicit use of ephedrine and 
pseudoephedrine, including in their pharmaceutical 
preparation forms, in countries of Africa. The Operation, 
which lasted for three months and in which the 
Governments of 51 countries either in Africa or trading 
with countries in Africa participated, brought about a more 
active use of PEN Online by the authorities of participating 
countries. The Operation also showed the extent of  
trade in ephedrines to African countries. However, since 
pre-notification of exports of pharmaceutical preparations 
containing those substances, while recommended, is not 
mandatory, there is likely to be unaccounted trade in such 
preparations through and to African countries. 
 
 (c) Effectiveness of the control measures aimed at 
preventing the diversion of controlled 
substances from international trade 
 
217. The control measures described in paragraphs 195-216 
above continue to be effective. Very few cases involving 
diversion of narcotic drugs or psychotropic substances 
from international trade into illicit channels have been 
identified in recent years. From time to time, attempts to 
divert narcotic drugs and psychotropic substances from 
international trade are detected by vigilant competent 
national authorities, which often work in close cooperation 
with the Board. In such cases traffickers seem to be fully 
aware of the control measures that are applied by most 
Governments and circumvent them whenever possible. For 
example, falsified import authorizations continue to be 
used by traffickers in attempts to divert controlled 
substances. The Board recommends that Governments 
remain vigilant and scrutinize the import and export 
orders involving controlled substances to ensure that they 
are destined for legitimate purposes. 
218. Diversion from international trade appears to 
continue to occur when the substances involved do not 
require import and export authorizations, as is the case in 
some countries for substances listed in Schedules III and IV 
of the 1971 Convention, including most of the commonly 
diverted benzodiazepines, and for the preparations 
included in Schedule III of the 1961 Convention. For 
example, diversion from international trade was the 
primary method noted by the Government of Indonesia for 
the diversion of benzodiazepines. The Board therefore 
reiterates its call to all Governments that do not yet require 
import and export authorizations for all psychotropic 
substances to extend the import and export authorization 
requirement to all psychotropic substances as soon as 
possible. The Board also urges the countries that have in 
principle introduced such authorization requirements for 
all psychotropic substances, but that have subsequently 
exempted some preparations from the import and export 
authorization requirements, to consider revoking the 
exemptions with regard to international trade, where 
appropriate. 
219. With regard to the diversion of precursor chemicals, 
preparations containing precursor chemicals such as 
ephedrine and pseudoephedrine continue to be diverted 
from international trade to be used in the illicit 
manufacture of amphetamine-type stimulants, as reported 
by the Governments of Australia and New Zealand, among 
others. 
 
 (d) Prevention of diversion from domestic 
distribution channels  
 
220. The diversion of narcotic drugs, psychotropic 
substances and precursors from licit domestic distribution 
channels has become a main source for supplying illicit 
markets. For narcotic drugs and psychotropic substances, 
the substances involved are diverted mainly in the form of 
pharmaceutical preparations. The problems associated with 
the diversion of preparations containing narcotic drugs or 
psychotropic substances, which are predominantly diverted 
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for subsequent abuse, and the actions to be taken to tackle 
those problems are described in paragraphs 303-315 below. 
221. The availability of “medical cannabis” in California 
and other states in the United States constitutes a major 
challenge to compliance by the Government of the United 
States with the international drug control treaties, in 
particular the 1961 Convention. The Board notes that the 
so-called “medical cannabis” scheme in California has 
contributed to an increase in cannabis abuse, due to a lack 
of the required institutional framework for regulating the 
sale of cannabis for “medical” use. In particular, the 
number of “medical cannabis” dispensaries, selling 
cannabis and drug paraphernalia, has increased 
exponentially in California in recent years. There has also 
been an increased number of unregulated cannabis retailers 
in some parts of that state. Furthermore, it has been noted 
that more than 90 per cent of “patients” registered with 
“medical cannabis” dispensaries do not present medical 
histories associated with such dispensing and 70 per cent of 
the users of such dispensaries are under 40 years of age. 
The real outcome of such a scheme has been to make 
cannabis more readily available for recreational purposes. 
The Board urges the Government of the United States to 
take necessary steps to ensure that internationally 
controlled substances are used only for medical and 
scientific purposes and to prevent their diversion and 
abuse, in accordance with the international drug control 
treaties. 
222. The diversion of precursors from domestic 
distribution channels increasingly involves pharmaceutical 
preparations containing those precursors. Most 
prominently, preparations containing ephedrine and 
pseudoephedrine have often been targeted by traffickers for 
use in the illicit manufacture of amphetamine-type 
stimulants. For instance, such preparations have been 
diverted from domestic distribution channels in China and 
the Republic of Korea, where there are a significant number 
of legitimate manufacturers of those preparations, and 
smuggled to Australia and New Zealand for the illicit 
manufacture of amphetamine-type stimulants. The Board 
invites the Governments concerned to attend to the 
recommendations in paragraphs 313 and 314 below, such 
as prohibiting the sale of such preparations by Internet 
pharmacies, ascertaining the points in the domestic supply 
chain that are most vulnerable to being exploited by 
traffickers, investigating the origin of seized preparations to 
identify their sources and points of diversion, and the 
sharing of information by law enforcement authorities of 
the countries concerned, and to apply those 
recommendations, as appropriate. 
223. In this connection, the Board previously raised its 
concern regarding the relatively high annual legitimate 
requirements for imports of ephedrine and 
pseudoephedrine in some countries in Asia,16 since those 
high levels of requirements put those countries at risk of 
being targeted by traffickers seeking to divert the 
substances for use in the illicit manufacture of 
amphetamine-type stimulants. Recent multiple seizures 
have borne out the concerns of the Board in this regard. 
Following large-scale disappearances of tablets containing 
pseudoephedrine from hospitals in Thailand, the annual 
legitimate requirement for the import of the substance was 
reduced considerably and investigations were launched. 
The Government of Pakistan started investigations into 
allegations that companies imported excessive quantities of 
ephedrines. The Board encourages all countries that 
identify significant diversions of precursors for 
amphetamine-type stimulants to re-evaluate their 
requirements for those substances and to inform the Board 
about changes without delay. 
224. When trying to obtain acetic anhydride, trafficking 
organizations rely nowadays on diversion from domestic 
distribution channels. In order to address this situation,  
the establishment and maintenance of an effective  
domestic regulatory control system, as described in 
paragraphs 191-193 above, is essential. 
225. The control measures applied to international trade 
in potassium permanganate have been effective and  
have forced the trafficking organizations to obtain 
potassium permanganate for use in the illicit manufacture 
of cocaine from other sources. There is evidence of that 
substance, as well as other chemicals, being illicitly 
manufactured. As laboratories illicitly manufacturing 
cocaine are increasingly being dismantled outside the  
three coca-producing countries along cocaine trafficking 
routes, all Governments, particularly those along known 
trafficking routes, should remain vigilant so as to prevent 
chemical trafficking organizations from establishing their 
activities in locations that were previously free from illicit 
manufacture. 
 
 2. Ensuring the availability of internationally 
controlled substances for medical and 
scientific purposes 
 
226. In line with its mandate to ensure the availability of 
internationally controlled substances for medical and 
__________________ 
 16  See, for example the report Precursors and Chemicals 
Frequently Used in the Illicit Manufacture of Narcotic 
Drugs and Psychotropic Substances: Report of the 
International Narcotics Control Board for 2011 on the 
Implementation of Article 12 of the United Nations 
Convention against Illicit Traffic in Narcotic Drugs and 
Psychotropic Substances of 1988 (United Nations 
publication, Sales No. E.12.XI.4), paras. 22-24. 
REPORT OF THE INTERNATIONAL NARCOTICS CONTROL BOARD  
 
32 
scientific purposes, the Board carries out various activities 
related to narcotic drugs and psychotropic substances. The 
Board monitors action taken by Governments, 
international organizations and other bodies to support the 
rational use of controlled substances for medical and 
scientific purposes and their availability for those purposes. 
 
 (a) Supply of and demand for opiate raw materials  
 
227. The Board has an important role to play in the supply 
of raw materials required for the manufacture of all 
medications containing opiates. Pursuant to the  
1961 Convention and relevant resolutions of the 
Commission on Narcotic Drugs and the Economic and 
Social Council, the Board examines on a regular basis 
developments affecting the supply of and demand for 
opiate raw materials. The Board strives, in cooperation 
with Governments, to maintain a lasting balance between 
supply and demand for those materials. In order to analyse 
the situation regarding supply of and demand for opiate 
raw materials, the Board uses information from 
Governments of countries producing opiate raw materials, 
as well as from countries where those materials are utilized 
for the manufacture of opiates or substances not controlled 
under the 1961 Convention. A detailed analysis of the 
current situation with regard to the supply of and demand 
for opiate raw materials is contained in the 2012 technical 
report of the Board on narcotic drugs.17 The following 
paragraphs are a summary of that analysis.  
228. The Board recommends that global stocks of opiate 
raw materials be maintained at a level sufficient to cover 
global demand for approximately one year, in order to 
ensure the availability of opiates for medical needs in case of 
an unexpected shortfall of production, for example, caused 
by adverse weather conditions in producing countries.  
229. In 2012, according to the information available to the 
Board, global production of opiate raw materials rich in 
morphine, as well as opiate raw materials rich in thebaine, 
was above the levels required to satisfy global demand. For 
2013, Governments of producing countries are envisaging a 
further increase in the production of those materials. 
Global stocks of opiate raw materials rich in morphine are 
expected to reach a level covering global demand for a 
period of almost two years, and global stocks of opiate raw 
materials rich in thebaine are expected to reach a level 
covering global demand for a period of more than one year.  
230. The Board has been in contact with the major 
producing countries of opiate raw materials to request them 
to ensure that their future production is maintained at a 
__________________ 
 17  Narcotic Drugs: Estimated World Requirements for 2013 
— Statistics for 2011 (United Nations publication,  
Sales No. T.13.XI.2). 
level that conforms to the actual requirements for those 
materials worldwide, in order to prevent the accumulation 
of excessive stocks. All producing countries should carefully 
attend to this important issue and prevent the accumulation 
of excessive stocks that might be a source of diversion. 
231. Global demand for opiate raw materials rich in 
morphine and opiate raw materials rich in thebaine is 
expected to rise in the future, in line with the trend of 
previous decades. It is expected that the worldwide efforts 
to ensure the adequate availability of opioid analgesics, 
which are encouraged and supported by the Board and 
WHO, will contribute to the continuing rise in global 
demand for opiates and opiate raw materials.  
 
 (b) Consumption of narcotic drugs and 
psychotropic substances 
 
232. Disparities in consumption levels of narcotic drugs 
between countries and regions remain as described in the 
2010 Report of the International Narcotics Control Board on 
the Availability of Internationally Controlled Drugs: 
Ensuring Adequate Access for Medical and Scientific 
Purposes.18 The availability of opioids for pain management 
is still inadequate in a large number of countries. While 
global consumption has significantly increased during the 
last 10 years, it remains concentrated in a limited number 
of countries. For example, consumption of fentanyl grew by 
more than 280 per cent between 2002 and 2011, but the 
major part of that increase was reported by high-income 
countries in North America and Europe. The increase in 
consumption of hydrocodone is almost exclusively, and the 
increase in consumption of oxycodone mostly, attributable 
to the high consumption rates in the United States. 
Although a large part of the growth in consumption of 
morphine is also due to elevated consumption rates in the 
United States and some European countries, increasing 
consumption has also been noted in many other countries 
of the world. In many regions, much remains to be done to 
ensure availability of opioids at levels adequate for medical 
requirements.  
233. With regard to the consumption levels of 
psychotropic substances, it is more difficult to come to 
reliable conclusions than in the case of narcotic drugs. 
Nevertheless, it appears that more action is needed to assess 
the current adequacy of the availability of psychotropic 
substances and to promote changes, as necessary.  
234. The analysis of the consumption levels of 
psychotropic substances is still hindered by the lack of 
adequate data, since the 1971 Convention does not require 
Governments to submit data on the consumption of such 
__________________ 
 18  United Nations publication, Sales No. E.11.XI.7. 
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substances to the Board. The Commission on Narcotic 
Drugs, in its resolution 54/6, encouraged all Governments 
to furnish such data to INCB. In accordance with that 
resolution, over 50 Governments have started to furnish 
consumption data for 2010 or 2011 to the Board. INCB 
welcomes this development, which will enable it to analyse 
more accurately the consumption levels of those substances 
in the countries and territories concerned. However, most 
Governments, including those of some manufacturing 
countries for which the calculated consumption levels 
appear to be very high and for which those levels might be 
overestimated in the absence of better data, have yet to 
follow suit. The Board wishes to remind those 
Governments that it is in their interest to collect such data, 
following the definition of consumption of narcotic drugs 
contained in the 1961 Convention,19 and to provide them 
to national and international bodies, including INCB, to 
enable the monitoring of consumption trends and the 
identification of unusual or unwanted developments. 
235. On the basis of the limited data available, it would 
appear that there are no major changes with regard to the 
consumption levels of psychotropic substances. If anything, 
the disparities in consumption levels of psychotropic 
substances between countries and regions, as described in 
the 2010 Report of the International Narcotics Control Board 
on the Availability of Internationally Controlled Drugs: 
Ensuring Adequate Access for Medical and Scientific 
Purposes, appear to be increasing, with most of the 
consumption of all psychotropic substances taking place in 
a limited number of countries. The Board has requested the 
countries concerned to determine whether there are 
problems of oversupply and possible misuse and to 
promote the rational use of the substances in question.  
 
 (c) Guide on Estimating Requirements for 
Substances under International Control, 
developed by the International Narcotics Control 
Board and the World Health Organization 
 
236. The Board has for a number of years noted with 
concern the global disparities in the availability of narcotic 
drugs and psychotropic substances. As impediments to 
adequate availability of internationally controlled 
substances vary, national authorities need to recognize 
country-specific impediments and take appropriate action. 
As a first step, countries should identify their actual 
requirements for internationally controlled substances in 
__________________ 
 19  See article 1, paragraph 2, of the 1961 Convention:  
“For the purposes of this Convention a drug shall be 
regarded as ‘consumed’ when it has been supplied to  
any person or enterprise for retail distribution, medical 
use or scientific research; and ‘consumption’ shall be 
construed accordingly.” 
order to overcome underconsumption and at the same time 
prevent overconsumption.  
237. In order to support countries in estimating their 
requirements, the Board and WHO have developed the 
Guide on Estimating Requirements for Substances under 
International Control, which was launched during the  
fifty-fifth session of the Commission on Narcotic Drugs, in 
March 2012, and was brought to the attention of all 
Governments through a letter of the Board.20 The Guide is 
intended to assist competent national authorities in 
identifying methods for calculating the quantities of 
controlled substances required for medical and scientific 
purposes. Furthermore, the Guide provides assistance to 
national authorities in preparing the estimates and 
assessments of annual requirements for controlled 
substances that countries are required to furnish to  
the Board. 
238. The Board hopes that the Guide will help 
Governments in their efforts to ensure appropriate 
consumption levels of internationally controlled substances 
for their countries. The Board is at the disposal of 
competent national authorities to support them in the use 
of the Guide and to provide any clarification required. 
 
 (d) Activities of intergovernmental and  
non-governmental organizations 
 
239. A number of international organizations, 
intergovernmental bodies and non-governmental 
organizations are undertaking activities focusing on the 
uneven accessibility of opioids for pain management. 
240. UNODC, WHO and the Union for International 
Cancer Control have developed plans for a joint initiative 
to enhance access to internationally controlled drugs for 
the relief of pain while preventing diversion and abuse. The 
aim of the initiative is to coordinate activities at the 
international level and to contribute to in-country progress, 
beginning with three pilot countries in different regions, 
with the intention of scaling up the initiative in the years 
ahead. The initiative will cover various areas of activity, 
including data collection; regulatory revision and reform; 
training on estimates and statistics for narcotic drugs; 
awareness-raising and public education; procurement and 
distribution; community-based health care; and standards 
of care in health-care facilities. The objective is to 
contribute to the implementation of Commission on 
Narcotic Drugs resolutions 53/4 and 54/6 and the 
recommendations contained in the 2010 Report of the 
__________________ 
 20  The Guide is available, in all six official languages of the 
United Nations, on the website of the Board 
(www.incb.org/incb/en/publications/guidelines-for-use-
by-competent-national-authorities.html). 
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International Narcotics Control Board on the Availability of 
Internationally Controlled Drugs: Ensuring Adequate Access 
for Medical and Scientific Purposes. The Board welcomes 
the initiative and invites Governments to support it. 
 
 (e) National activities 
 
241. The Board notes that action has been taken in several 
countries to increase the level of consumption of 
internationally controlled substances, in particular opioid 
analgesics.  
242. In Georgia, the National Programme for Palliative 
Care for 2011-2015 was adopted by the parliament. The 
Ministry of Labour, Health and Social Affairs seeks to 
improve the availability of opioid analgesics for outpatients. 
In the spring of 2012, the parliament of Georgia adopted an 
amended law on narcotic drugs, psychotropic substances 
and precursors that takes into account current medical and 
scientific knowledge. The amendments included the 
addition of a paragraph concerning the indispensability of 
opioid use for medical reasons, which reflects the principle 
of ensuring adequate availability of narcotic drugs for 
medical purposes. To facilitate the rational use of opioid 
analgesics, the Ministry has agreed to support the 
organization of training courses for physicians who care for 
patients with chronic pain. At the request of the Ministry, 
guidelines on chronic pain management were developed, 
along with recommendations for patients. Those guidelines 
were adopted by the Ministry in July 2012 and all  
medical facilities were requested to create corresponding 
treatment protocols. 
243. In Guatemala, there have been recent improvements 
in the availability of low-cost opioids. Previously, 
inexpensive morphine was available only in injectable form 
and only for patients who were hospitalized. In  
January 2012, a local pharmaceutical company obtained a 
licence to manufacture immediate-release oral morphine, 
which became available at the national reference hospital 
for cancer beginning in February 2012. As new opioid 
analgesic formulations are being made available in 
Guatemala, the important process of educating and 
training physicians about how to safely prescribe opioids to 
treat pain was initiated in February 2012, with the 
implementation of a new postgraduate course in palliative 
care at the university level, which consists of over 300 hours 
of training over nine months. 
244. In 2011, the Ministry of Health of Jamaica 
administered a survey to measure access to and availability 
of opioids at all Government hospitals and to identify the 
storage and handling capabilities of those facilities. A need 
was identified for immediate-release oral morphine tablets, 
which became available in April 2012 in the public-health 
sector in Jamaica for the first time. In May 2012 the 
Ministry held a meeting on the National Strategic Plan for 
the Prevention and Control of Non-Communicable 
Diseases in Jamaica for the period 2012-2017. As a result of 
that meeting, the Ministry agreed to include palliative care 
services in the strategic plan, as well as to work towards 
developing a separate, comprehensive cancer control plan, 
which will consist of policies for palliative care, including 
the use of opioids to treat cancer pain. 
245. In Nepal, health-care practitioners’ efforts to work 
with government and industry to address the availability of 
all necessary formulations of opioid analgesics have 
continued, with support from international experts. The 
production of sustained-release morphine tablets has been 
under way since August 2012. The local production of an 
additional formulation of morphine will ensure a more 
continuous availability of all essential morphine 
formulations for patients in Nepal than was possible in the 
past. These advances in opioid availability have been 
coupled with ongoing efforts to educate health-care 
professionals about pain relief and the rational use and safe 
handling of essential controlled medicines.  
246. In the Russian Federation, the Ministry of Health has 
been working with pain-relief experts to evaluate the 
mechanism governing the medical use of preparations 
containing narcotic drugs in order to improve the 
treatment of pain in the country. The lack of knowledge on 
the part of health-care professionals regarding the 
treatment of pain has been identified as one of the main 
impediments to the use of opioid analgesics. Health-care 
professionals are also wary of the consequences of errors in 
complying with administrative requirements for the use of 
narcotic drugs. The Ministry is preparing a full range of 
programmes at both the pre- and postgraduation stages of 
training to provide health-care professionals with the 
knowledge and skills for using such medicines. The 
Ministry is also drawing up legislation to simplify 
requirements for the prescription and administration of 
medical preparations containing narcotic drugs and 
psychotropic substances. The new legislation would extend 
the validity of prescriptions for controlled substances and 
facilitate access to opioid analgesics for patients released 
from hospitals. In 2011, the issue of palliative medical care 
was introduced in the federal legislation regulating the 
health system of the Russian Federation (art. 36 of Act  
No. 323 of 21 November 2011 on Federal Health Protection 
in the Russian Federation). In 2012, new methodological 
recommendations for oncologists and general practitioners 
regarding palliative treatment with narcotic drugs for 
outpatients were issued by the Herzen Oncological 
Research Institute. 
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247. In Serbia, following the enactment of the new Law on 
Psychoactive Controlled Substances in early 2011, a 
governmental commission was established to monitor the 
implementation of the new Law and to draft implementing 
regulations. As new opioid formulations such as 
immediate-release morphine are being made increasingly 
available in Serbia, palliative-care experts have consulted 
with Government officials to clarify modern medical and 
scientific pain management prescribing standards. For 
example, in early 2012, the Serbian Republic Institute for 
Health Insurance published an explanation allowing 
physicians to prescribe transdermal fentanyl along with 
immediate-release morphine for the treatment of 
breakthrough pain and issued a new list of prescription 
medicines allowed to be prescribed. In 2012, the 
prescription of methadone for the treatment of severe 
cancer pain was also allowed for the first time.  
248. The Board acknowledges these national efforts to 
improve the availability of controlled substances for 
medical and scientific purposes. Countries where health 
administrations face similar problems may use them as 
examples of possible remedial measures. The descriptions 
above of positive developments in some countries should 
not obscure the fact that enormous discrepancies exist 
between countries with regard to the accessibility of 
internationally controlled substances. INCB underlines 
once again the need for WHO and the international 
community to support efforts of countries concerned  
to improve availability. At the same time, countries need  
to raise awareness of the risk of abuse of those  
substances and to ensure the prevention of their  
diversion into illicit markets. 
 
 (f) Need for targeted action for psychotropic 
substances 
 
249. The Board is not aware of any intergovernmental, 
regional or national initiatives in the countries and regions 
where access to psychotropic substances is low to promote 
adequate availability and accessibility of medications 
containing psychotropic substances. Most actions taken to 
improve the availability of controlled substances have 
focused heavily or exclusively on opioid analgesics.  
250. Similarly, among countries where consumption of 
psychotropic substances has been very high, some 
Governments showing high consumption levels have not 
yet taken the necessary actions to address their apparent 
excessive use and to promote rational use of those 
substances. In addition, even when the Board has been 
informed of action taken by Governments to prevent 
inappropriate use of psychotropic substances, it would 
appear that such action has been effective in only a few 
countries; in most other countries, the action has been 
effective only for a short time, if at all, and excessive 
consumption of the substances concerned continues to be 
noted. 
251. The use of psychotropic substances for medical 
purposes is indispensable, as stated in the preamble to the 
1971 Convention. They are useful in the treatment of a 
variety of mental and other diseases and, if properly 
prescribed and dispensed in line with the provisions of the 
1971 Convention, will reduce human suffering and 
improve the quality of life of patients and their families.  
252. The Board trusts that the lessons learned from the 
activities to improve the availability of medications that are 
used in the treatment of pain will help to support rational 
use of psychotropic substances in all countries and regions. 
In addition, the Board recommends that Governments 
continue to (a) collect reliable data on the consumption of 
psychotropic substances and share them with the Board to 
allow accurate analysis of their consumption levels;  
(b) investigate whether there are other medications 
containing substances that are not internationally 
controlled that are used in their territories to treat mental 
and other diseases commonly treated with psychotropic 
substances, and determine whether their use might have an 
impact on the consumption of internationally controlled 
substances; (c) taking into account those findings to the 
extent possible, compare their consumption levels with 
those in other countries and regions with a view to 
identifying inadequate or excessive consumption; and  
(d) take the appropriate actions to promote the rational use 
of psychotropic substances in their country. 
 
 (g) Replenishment of medical kits on board ships 
docked in foreign territorial waters 
 
253. The Board was asked by the competent authorities of 
some countries to clarify the legal rules applicable to the 
replenishment of medical kits on board ships docked in 
foreign territorial waters under the international drug 
control conventions. Ships are, in principle, expected to 
restock their medical kits in the country in which they are 
registered. However, in some situations, it may be necessary 
to use the narcotic drugs or psychotropic substances 
contained within the medical kits during the journey to 
treat members of the crew or passengers. This would 
require the replenishment of the ship’s medical kit prior to 
its return to its country of registry and possibly while it is 
docked in territorial waters of a foreign State. 
254. When the ship is docked in foreign territorial waters, 
given that the resupply of the controlled substance would 
take place entirely within the jurisdiction of the foreign 
port in which the ship is docked, the conditions under 
which it would be undertaken would be those set forth in 
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the national legislation of that State. For the replenishment 
of first-aid kits, the crew of the ship would have to comply 
with regulations related to the purchase or acquisition of 
narcotic drugs and psychotropic substances valid in the 
territory in which such a purchase or acquisition takes 
place. Once these substances have been obtained and 
placed in the ship’s medical kit, article 32, paragraph 1,  
of the 1961 Convention and article 14 of the  
1971 Convention, which allow for the carriage of controlled 
substances in medical kits across territorial waters, would 
apply, allowing the ship to continue its onward journey, 
while it would be the responsibility of the country of 
registry to prevent the improper use of those substances. 
255. The Board trusts that all countries will facilitate the 
replenishment with narcotic drugs and psychotropic 
substances of medical kits of ships docked in their 
territorial waters to ensure the availability of those drugs 
and substances on those ships in case of their need for 
medical use. Adequate control measures should be applied 
to prevent any misuse of that procedure for the diversion of 
controlled substances. 
 
 
 E. Special topics 
 
 
 1. Global drug policy debate 
 
256. The Board takes note of recent calls by some 
Governments for a review, by States Members of the United 
Nations, of the approach to the global drug problem 
hitherto adopted by the international community, with the 
aim of adopting a balanced approach in enhancing the 
effectiveness of the strategies and instruments used by the 
world community in confronting the challenge of the drug 
problem and its effects. The Board welcomes and supports 
initiatives by Governments aimed at further enhancing 
international drug control, undertaken in conformity with 
the international drug control conventions.  
257. At the same time, the Board notes with concern 
recent declarations and initiatives reported from some 
countries in the Western hemisphere proposing the 
legalization of the possession of narcotic drugs and 
psychotropic substances for purposes other than medical or 
scientific use, and the decriminalization of the cultivation 
of cannabis plant for non-medical use. In this regard, the 
Board notes with deep concern a proposal by the 
Government of Uruguay before the Parliament of Uruguay 
that would allow the State to assume control over and 
regulation of activities related to the importation, 
production, acquisition of any title, storage, sale and 
distribution of cannabis or its derivatives, under terms and 
conditions to be determined by a regulation, for the 
purpose of non-medical use.  
258. The Board wishes to point out that such an initiative, 
if it were to be implemented, would be contrary to the 
provisions of the international drug control conventions. 
The 1961 Convention and the 1988 Convention require all 
States parties to limit the use of narcotic drugs, including 
cannabis, exclusively to medical and scientific purposes. 
Non-compliance by any party with the provisions of the 
international drug control treaties could have far-reaching 
negative consequences for the functioning of the entire 
international drug control system. 
259. The Governments of those States, which are parties 
to the international drug control treaties, have 
demonstrated over many years their commitment to the 
aims and object of the international drug control 
conventions, extending their valuable cooperation to the 
Board in the implementation of the treaties. The Board 
stands ready, in line with its mandate, to continue a 
dialogue with all Governments in order to promote 
universal compliance with the provisions of the 
international drug control treaties. 
 
 2. New psychoactive substances 
 
260. The term “new psychoactive substances” denotes 
substances of abuse that are not subject to international 
control measures but that have effects similar to those of 
controlled drugs. It is a generic term that includes 
emerging drugs of abuse sometimes referred to as “designer 
drugs”, “herbal highs”, “research chemicals” and “legal 
highs”. It also includes substances that are not necessarily 
new but which have recently been increasingly abused.  
261. In the past several years, the warnings about the 
dangers posed by new psychoactive substances have 
multiplied. Public health officials and drug control 
stakeholders have been raising awareness of the emergence 
of new psychoactive substances which are outside the scope 
of international control for some time. In its annual report 
for 2010, the Board warned Governments of this growing 
threat and recommended that they take concrete steps to 
monitor the emergence of new psychoactive substances 
with a view to adopting national control measures intended 
to stem the manufacturing, export, import, distribution 
and sale of these substances.  
262. The Board notes that the international community 
has taken notice of the problem and has turned its attention 
to identifying ways to address it effectively. The Board also 
reminds Governments that pursuant to the international 
drug control conventions, States parties are explicitly 
authorized to adopt whatever national control measures 
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they deem necessary in addition to those existing at the 
international level. In this regard, the Board acknowledges 
the adoption in many States of legislative and regulatory 
measures aimed at establishing mechanisms to address the 
public health dangers caused by the emergence of new 
psychoactive substances. 
263. In March 2012, the Commission on Narcotic Drugs 
adopted resolution 55/1, entitled “Promoting international 
cooperation in responding to the challenges posed by new 
psychoactive substances”, in which the Commission 
encouraged States to take various decisive individual and 
collective actions to deal with the threat posed by new 
psychoactive substances. Through that resolution, the 
Commission recognized that the capacity of States to 
effectively deal with new psychoactive substances is a 
function of their ability to identify those substances in a 
timely manner, allowing for preventive measures to be 
taken, and, given the global nature of the problem, to share 
that information with other States and relevant 
stakeholders in order to make concerted action possible. 
264. In recent years, there has been an unprecedented 
increase in the emergence of new psychoactive substances 
not within the purview of the international drug control 
conventions. The most common categories of these drugs 
have been synthetic cannabinoids, synthetic cathinones, 
piperazines and phenethylamines. According to EMCDDA, 
the number of notifications of new psychoactive substances 
received by the Centre averaged five per year from 2000 to 
2005. In 2011, the figure had increased to 49, meaning that 
a new psychoactive substance was put on the market almost 
every week on average. Although it is impossible to know 
the exact number of new psychoactive substances on the 
market, experts have advanced estimates running well into 
the thousands. As abuse of these substances has increased, 
so too has the number of users who have experienced grave 
health consequences or even suffered death due to 
exposure to them. In many countries, use of such 
substances has manifested itself in marked increases in 
emergency room visits for adverse health reactions caused 
by the ingestion of new psychoactive substances, as well as 
in significant increases in calls to poison treatment centres. 
265. The Board encourages all Governments to establish 
formal mechanisms aimed at collecting information 
regarding new psychoactive substances, including 
information regarding their chemical make-up, patterns of 
abuse, marketing techniques, trade names, distribution and 
diversion methods and countries of origin. There is 
mounting evidence suggesting that many new psychoactive 
substances are being manufactured in China and India. The 
Board urges the Governments of China and India to 
investigate this matter and to take decisive action to 
prevent the manufacturing of new psychoactive substances 
on their territory. 
266. The Board notes that several States have established 
early warning systems for new psychoactive substances, 
which have been pivotal in national efforts to identify and 
move to control new psychoactive substances. With respect 
to the regional level, the Board acknowledges the leading 
role taken by EMCDDA on the question of new 
psychoactive substances, particularly through its 
establishment of a European early warning system. The 
Board encourages those States that have not yet done so to 
consider establishing early warning systems and to 
establish mechanisms for the sharing of obtained 
information with other States and with multilateral 
stakeholders, including WHO, INTERPOL, UNODC and 
INCB. The Board urges those multilateral stakeholders to 
continue to examine specific aspects of the problem of new 
psychoactive substances and to disclose their findings to 
the international community. The Board also acknowledges 
the particularly important role of WHO in monitoring the 
emerging abuse of uncontrolled substances and 
recommending scheduling when it deems appropriate. 
267. The Board particularly welcomes efforts made by 
UNODC in response to Commission on Narcotic Drugs 
resolution 55/1 aimed at collecting information about new 
psychoactive substances, including through the elaboration 
and distribution to national laboratories of a questionnaire 
on the topic. The Board encourages UNODC to act as a 
focal point on the question of new psychoactive substances 
and to gather information from States regarding new 
substances of abuse and measures adopted to address the 
problem. The Board also encourages States to continue to 
support ongoing UNODC activities regarding new 
psychoactive substances such as the global Synthetics 
Monitoring: Analysis, Reporting and Trends (SMART) 
programme.21 
268. A particular challenge to Government efforts to place 
new psychoactive substances under national control is the 
difficulty of identifying those substances in a timely 
manner, given the rapid succession of new substances 
entering the market, their inconsistent chemical 
composition and the lack of technical and pharmacological 
data and reference material, as well as insufficient forensic 
and toxicological capacity on the part of some States. The 
Board acknowledges the recommendation contained in 
Commission on Narcotic Drugs resolution 55/1 that 
UNODC should continue to provide technical assistance to 
States, upon request, in order to assist them in bolstering 
the capacity of their institutions to deal with the problem of 
__________________ 
 21  Available from 
www.unodc.org/unodc/en/scientists/smart.html. 
REPORT OF THE INTERNATIONAL NARCOTICS CONTROL BOARD  
 
38 
new psychoactive substances. The Board also encourages 
closer cooperation between States on a bilateral and 
multilateral level, as well the provision of technical 
assistance where required. 
269. In order to raise awareness of the public health 
dangers associated with many new psychoactive substances 
and, in particular, to dispel the misconception that those 
substances are safe since they are not controlled, the Board 
invites all Governments to include new psychoactive 
substances in the scope of all existing prevention 
programmes, and, if deemed necessary, to design specific 
prevention initiatives targeting this phenomenon. The 
Board reminds States that it is impossible to gauge the 
extent of the abuse of new psychoactive substances without 
comprehensive data on prevalence of abuse, populations 
specifically at risk and patterns of abuse, and encourages 
Governments to include new psychoactive substances in 
their national drug abuse surveys and to effectively 
disseminate the findings of those studies to all 
stakeholders, as well as to the public, as an additional 
means of awareness-raising. 
270. The Board also encourages States to cooperate in the 
development of chemical reference standards aimed at 
identifying new psychoactive substances and to make those 
standards available to drug-testing laboratories as 
necessary. Where such reference samples are not available, 
the Board encourages States to share analytical data. The 
Board is aware that in many cases, the work of forensic 
laboratories in identifying new substances is hampered by 
obstacles to the availability of test and reference samples of 
internationally controlled substances. INCB encourages 
States to consider the recommendations made by the Board 
in its Guidelines for the Import and Export of Drug and 
Precursor Reference Standards for Use by National Drug 
Testing Laboratories and Competent National Authorities22 
and the “Additional courses of action in support of the 
implementation of the 2007 INCB Guidelines for the 
import and export of drug and precursor reference 
standards for use by national drug testing laboratories and 
competent national authorities”,23 which are available on 
the Board’s website. 
271. A further obstacle has been the distribution of new 
psychoactive substances through the Internet. The Board 
encourages Governments to monitor the activities of 
websites selling new psychoactive substances and products 
__________________ 
 22  United Nations publication, Sales No. M.08.XI.6 
(available from www.incb.org/documents/Narcotic-
Drugs/Guidelines/reference_standards/NAR_Guidelines
_reference-standards_en.pdf ). 
 23  Available from www.incb.org/documents/Narcotic-
Drugs/Guidelines/reference_standards/Additional_ 
courses_of_action_ref_standards_EN.pdf. 
containing those substances that are based in their 
territory, as well as such websites based in other countries, 
and to share information in that regard with the competent 
authorities of countries used as a base for such websites. 
The Board invites Governments to apply the 
recommendations contained in its Guidelines for 
Governments on Preventing the Illegal Sale of Internationally 
Controlled Substances through the Internet24 to the extent to 
which they are relevant to addressing the sale of new 
psychoactive substances on the Internet. 
272. In addition to the measures listed above, States have 
taken various legislative and regulatory action to reduce the 
supply of new psychoactive substances on their territory.  
273. Traditionally, national attempts to address new 
psychoactive substances have been primarily concentrated 
within the ambit of drug control legislation. Given the 
speed with which new substances are designed, 
manufactured and put on the market, drug syndicates are 
often able to outpace existing controls by staying one step 
ahead of national legislative and regulatory norms. Further 
exacerbating this problem is the fact that the onus of 
identifying and evaluating the potential for harm of new 
psychoactive substances generally falls upon States, and in 
many cases no action can be taken to control the substance 
until that process has been concluded. 
274. The adoption of traditional national control 
measures is often a lengthy and onerous process which, in 
many cases, has shown itself to be ill-suited for use in 
addressing such a dynamic phenomenon. In recognition of 
this fact, States have increasingly developed novel 
approaches to combating the problem of new psychoactive 
substances by supplementing traditional drug control 
measures through an innovative combination of emergency 
control powers, consumer protection measures and food 
and drug safety mechanisms in order to expedite the 
application of control measures to new substances.  
275. Among the methods used by States to address the 
emergence of new psychoactive substances have been the 
use of “generic” and “analogue” scheduling. In the case of 
analogue scheduling, a substance that is both structurally 
similar and has a similar or greater psychoactive effect as a 
substance already controlled is deemed to be a controlled 
substance analogue and as such is also considered to be 
controlled. Under generic scheduling measures, particular 
variations of a core molecular structure are to be 
controlled. Thus, each substance does not have to be dealt 
with individually, and new types of substances can be 
controlled through these approaches. However, the 
__________________ 
 24  United Nations publication, Sales No. E.09.XI.6. 
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analogue approach requires the availability of 
pharmacological data to be able to demonstrate the 
similarity of psychoactive effects. 
276. In seeking to protect the public from potentially 
harmful substances, States have also made increasing use of 
“emergency scheduling” procedures that allow them to take 
swift action to remove a substance from the market while a 
decision is pending on whether permanent control 
measures are to be applied to that substance. The adoption 
of such emergency measures has been highly effective in 
ensuring that the public is not unnecessarily put at risk 
before a comprehensive evaluation of the substance can be 
undertaken by national authorities.  
277. Another approach taken by States to limit the public 
health dangers posed by some new psychoactive substances 
has been to subject such substances to requirements similar 
to those imposed upon manufacturers of medications. This 
has meant that in order for a new psychoactive substance to 
be deemed to be legal and obtain market authorization, it 
must have gone through a rigorous approval process 
backed up by toxicological data, medical trials etc. States 
having resorted to this type of control measure have 
reported that the costs associated with the approval process 
have acted as an effective deterrent for manufacturers of 
new psychoactive substances. 
278. In many countries, recourse has been made to 
provisions under consumer and health protection laws with 
respect to requirements for clear disclosure of ingredients, 
labelling and instructions for use, leading to the 
confiscation of contravening products, as well as the 
closure of retail outlets selling them. 
279. As noted above, the legal framework established by 
the international drug control conventions provides the 
possibility for States to adopt national control measures 
beyond those mandated at the international level. The 
choice by each State of what type of measures to apply is 
informed by the real situation on the ground that such 
measures are meant to address, and is also governed by the 
legal and regulatory norms and structures in place. While 
the Board acknowledges that each State must pursue the 
adoption of measures tailored to its specific situation, it 
remains convinced that in identifying appropriate 
responses to the emergence of new psychoactive 
substances, States may benefit from an exchange of best 
practices on the matter.  
280. A global problem such as the proliferation of new 
psychoactive substances requires global solutions. The 
Board notes the efforts that have been undertaken at the 
national, regional and international levels to find effective 
ways to deal with this imposing problem, and encourages 
States and international organizations to continue to work 
together in sharing information, developing common 
strategies and exchanging best practices. In the pursuit of 
its mandate, the Board stands ready to assist Governments. 
 
 3. Abuse of pharmaceutical preparations 
containing narcotic drugs or psychotropic 
substances 
 
281. Over the years, the Board has repeatedly drawn the 
attention of Governments to the increasing abuse of 
prescription drugs containing controlled substances. In its 
annual report for 2009, in particular, the Board devoted a 
special topic to this problem to highlight the need for 
Governments to give it increased attention and to 
introduce countermeasures. Since 2009, the abuse of 
prescription drugs has continued to spread in all regions of 
the world, and is posing serious health and social 
challenges in some countries. In North America and South 
and South-East Asia, as well as some countries in Europe 
and South America, prescription drug abuse has increased 
substantially in recent years. In the United States, for 
example, prescription drug abuse is more prevalent than 
the abuse of any other internationally controlled substance 
except cannabis. In Germany and the Russian Federation, 
sedatives and tranquillizers containing benzodiazepines 
ranked the second most commonly abused substance 
group. The most abused substances that have been reported 
include opioids containing buprenorphine, codeine, 
hydrocodone, methadone and oxycodone, sedatives and 
tranquillizers containing benzodiazepines, barbiturates or 
GHB, and stimulants.  
282. The abuse of prescription drugs by injection, which 
increases the risk of HIV, hepatitis B and hepatitis C 
infection, has also been reported by many Governments. 
This problem is noted particularly in South Asia, where the 
most commonly injected prescription drugs include a 
variety of benzodiazepines and buprenorphine. Health-care 
coverage among injection drug users in the region is low; 
this increases the likelihood of drug abusers sharing their 
injection equipment.  
283. One particular concern of the Board is the increase in 
recent years in the reported abuse of prescription drugs 
containing psychotropic substances. According to a recent 
CICAD report on drug abuse in the Americas, the past year 
prevalence of the abuse of tranquillizers obtained without a 
prescription among secondary school students was higher 
than 6 per cent in Bolivia (Plurinational State of), Paraguay 
and Colombia. In Singapore, the Government has reported 
a large increase in the abuse of sedatives and tranquillizers 
containing benzodiazepines. Increased deaths related to the 
REPORT OF THE INTERNATIONAL NARCOTICS CONTROL BOARD  
 
40 
abuse of psychotropic substances have been reported by a 
number of countries. 
284. While more and more Governments have become 
aware of the increased abuse of prescription drugs 
containing psychotropic substances, the problem remains 
largely underreported worldwide, compared to the abuse of 
prescription drugs containing narcotic drugs. Furthermore, 
the Board is concerned that the general public, in particular 
youth, are not adequately informed about the damaging 
effects of such abuse. 
285. As with the abuse of prescription drugs in general, 
the abuse of prescription drugs containing psychotropic 
substances has gained popularity, owing mainly to the fact 
that such abuse is less stigmatized than the abuse of illicitly 
manufactured drugs, the perception that such medications 
can be obtained legally (for example, from health-care 
professionals) and the mistaken belief that the abuse of 
such substances is not damaging to health.  
286. Another concern of the Board relates to the role of 
health-care professionals: they may intentionally or 
unintentionally contribute to the problem of prescription 
drug abuse in different ways. According to the latest United 
States National Survey on Drug Use and Health, the 
majority of prescription drug abusers who obtained such 
preparations from a friend or relative indicated that the 
friend or relative had obtained them using a legitimate 
prescription. Research has indicated that the training that 
health-care professionals have received in prescribing and 
dispensing controlled substances and identifying substance 
abuse was insufficient in many countries. In addition, the 
dispensing of prescription drugs by pharmacists without 
the required prescriptions is a factor in sustaining the illicit 
use of prescription drugs in some regions, such as  
South Asia.  
287. In response to the challenges posed by prescription 
drug abuse, many Governments have taken action to 
address this growing problem. For instance, the 
Government of Singapore requires medical practitioners to 
report information such as the duration of treatment 
periods and the dosage and quantities of prescription drugs 
that are prescribed to suspected drug addicts. The 
Governments of Germany and the United States have 
formulated targeted action plans to monitor and reduce 
prescription drug abuse. However, more needs to be done.  
288. The crucial first step is to improve knowledge about 
the nature and extent of the abuse of prescription drugs, so 
as to devise a targeted response. Although a number of 
studies and research papers regarding prescription drug 
abuse have become available recently, knowledge about this 
problem in most countries remains extremely limited. The 
lack of information on the extent of abuse is a particular 
concern in Africa, where the availability of prescription 
drugs on unregulated markets outside the control of the 
health authorities appears to be a serious problem. As the 
Board outlined in its annual report for 2009, Governments 
should include prescription drugs containing controlled 
substances in national drug abuse surveys to obtain 
information on the nature and extent of the abuse. In some 
countries where this has already been done, the questions 
on the abuse of prescription drugs in the surveys tend to be 
unspecific and do not lead to sound conclusions. In some 
other countries, queries about the abuse of psychotropic 
substances have been omitted in such surveys, perhaps 
owing to the perception that the high abuse of opioid 
analgesics is a greater concern. In all such cases, national 
surveys should be improved by making the questions 
comprehensive as well as specific regarding the type of 
substance abused.  
289. Secondly, although there has been significant 
improvement in some countries in raising awareness about 
the harmful effects of prescription drug abuse, many 
people, including from the medical profession, are still not 
aware that the abuse of prescription drugs containing 
controlled substances can be as dangerous as the illicit use 
of other drugs such as heroin and cocaine. Therefore, it is 
necessary for Governments to formulate and implement 
effective prevention strategies; such strategies should target 
the general public and medical professionals, who need to 
be better educated about the dangers associated with 
prescription drug abuse. Health authorities and 
professional organizations should develop guidelines and 
codes of conduct and enhance training programmes for 
health-care professions, with the aim of promoting rational 
prescription and dispensation and reducing abuse of 
prescription drugs. 
290. In some countries, prescription drugs that have high 
rates of abuse have been removed from the market or 
replaced with variants less prone to abuse. While such 
approaches can be part of an effective strategy to tackle the 
abuse of certain prescription drugs over the longer term, 
care needs to be taken when applying such approaches 
because they might limit the availability of those substances 
on the licit market. In addition, dependent abusers can 
switch to other forms of abuse to substitute for the 
substance or substances they were abusing previously, and 
the substitutes may be even more harmful. Therefore, a 
balanced approach is needed to prevent abuse while at the 
same time ensuring the availability of prescription drugs 
for licit purposes.  
291. Last but not least, to tackle the problem of 
prescription drug abuse, measures need to be taken to 
prevent the illicit supply of prescription drugs. In addition 
to diversion from licit channels, the clandestine 
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manufacture of pharmaceutical preparations containing 
controlled substances has been uncovered in some 
countries. This suggests that the abuse of certain 
prescription drugs has become so widespread that 
traffickers are seeking new methods to meet the demand. 
Therefore, the Board urges all Governments to take 
measures to prevent the diversion and illicit manufacture of 
prescription drugs, as an effective way to prevent abuse.  
292. Some psychotropic substances, all of them central 
nervous system stimulants, are used mainly in the 
treatment of attention deficit hyperactivity disorder 
(ADHD), a mental and behavioural disorder that usually 
results in learning problems, among many others. 
Methylphenidate is the most widely known and prescribed 
substance, and in some countries the only substance, used 
for such treatment. Dexmethylphenidate, the more potent 
stereoisomeric form of methylphenidate (which is 
controlled under the 1971 Convention), is now increasingly 
imported and used in some countries. Furthermore, 
amphetamine and dexamphetamine, alone or in 
combination products, are used for the treatment of 
ADHD. All three substances mentioned above are included 
in Schedule II of the 1971 Convention, since they are 
considered to be of little to moderate therapeutic usefulness 
and their liability to abuse constitutes a substantial risk to 
public health. On a much smaller scale, pemoline, a 
substance included in Schedule IV of the 1971 Convention, 
has also been used in the treatment of ADHD. More 
recently, lisdexamfetamine, a prodrug of dexamphetamine 
(after consumption it metabolizes in the body to 
dexamphetamine) that is not under international control, 
has been developed. That substance is considered to be less 
liable to abuse than amphetamines and methylphenidate, 
and its use in the treatment of ADHD is spreading in some 
countries. A number of other substances that are not  
under international control are also used in the treatment 
of ADHD. 
293. The diagnosis of ADHD, in particular in children, is 
time-consuming and should follow complex assessments of 
medical, developmental and educational parameters to 
exclude the possibility that the behavioural and learning 
problems are caused by other disorders or by family and 
environmental circumstances. Diagnosis of ADHD and its 
treatment with the help of central nervous system 
stimulants, primarily in children, started to grow 
substantially in North America about two decades ago, and 
that growth has subsequently spread to many countries and 
regions. Since consumption of the substances used to treat 
ADHD improves academic performance and alleviates 
behavioural problems, there have been reports of pressure 
from schools or parents to prescribe such substances to 
pupils and students without a proper diagnosis of ADHD. 
ADHD was previously considered to be mainly a problem 
of schoolchildren; however, ADHD in pre-school children 
and in adults has also been increasingly diagnosed and 
treated with stimulants such as methylphenidate.  
294. Partly as a consequence of the developments 
described above, global use of the substances used in the 
treatment of ADHD has increased during the past two 
decades, although there have been changes in the use levels 
of the various substances mentioned above. Whereas global 
manufacture and use levels of amphetamines increased in 
the 1990s, when they were consistently much higher than 
the manufacture and use of methylphenidate, they have 
followed a downward trend since about 2000. The 
manufacture and use of pemoline were also much higher in 
the 1990s and have declined since. In contrast, the global 
manufacture of methylphenidate, which increased more 
than tenfold, from 4.2 tons in 1992 to 45.2 tons in 2011, and 
in 2009 surpassed the combined global manufacture of all 
amphetamines, continues to grow. The calculated global 
consumption increased during the same period from  
4.2 tons (139 million defined daily doses for statistical 
purposes (S-DDD)) to 51 tons (1.5 billion S-DDD). While 
the Board has no direct information on the levels of use of 
many stimulants such as lisdexamfetamine that are not 
internationally controlled, there are signs that the total 
manufacture and use of central nervous system stimulants 
for the treatment of ADHD are not levelling off.  
295. The high demand in the United States, where the use 
of methylphenidate and other substances for the treatment 
of ADHD is heavily advertised, including directly to 
potential consumers, and is promoted at schools, has been 
the major driving force for the manufacture and use of 
methylphenidate. The United States has traditionally been 
the major manufacturer and user of methylphenidate, in 
addition to being the major importer of amphetamines 
used in the manufacture of preparations to treat ADHD.  
In that country, the levels of calculated consumption25  
of methylphenidate increased steadily and sharply  
__________________ 
 25  The 1971 Convention does not require that 
Governments furnish to the Board statistics on the 
consumption of psychotropic substances. In 2011, the 
Commission on Narcotic Drugs, in its resolution 54/6, 
requested Governments to submit consumption 
statistics for psychotropic substances to the Board to 
enable it to evaluate the availability of psychotropic 
substances in countries and regions. Some Governments 
have started to submit such statistics; however, so far the 
data received are not sufficient for the comparison of 
statistics between countries and years. 
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from 1.5 S-DDD per 1,000 inhabitants per day in 1992  
to 10.8 S-DDD per 1,000 inhabitants per day26 in 2011.  
296. The use of methylphenidate for the treatment of 
ADHD has spread to a number of other countries. In 1992, 
the share of the United States in the total calculated use  
of methylphenidate was 86 per cent; in 2011, that  
figure dropped to 69 per cent. Whereas in 1992 a total  
of 63 countries and territories reported use of 
methylphenidate, in recent years over 100 Governments 
have reported such use. In 2011, Canada and Iceland, for 
the second consecutive year, showed higher calculated per 
capita consumption levels than the United States. Other 
countries in Europe and Oceania27 that show very high 
rates of per capita consumption of methylphenidate are also 
among the countries with very high per capita 
consumption levels of amphetamines. 
297. It should be noted that about half of the countries 
and territories in the world do not report any use of the 
psychotropic substances that are typically used in the 
treatment of ADHD. In particular, many countries where 
the population is much younger than in the countries 
reporting high consumption levels of stimulants used  
in ADHD, and that presumably would have a high rate  
of ADHD, hardly use such stimulants. 
298. The increase in the availability and use of the 
substances used to treat ADHD, in particular 
methylphenidate, has been accompanied by frequent 
reports of diversion and abuse of the pharmaceutical 
preparations containing those substances from licit 
distribution into illicit channels, in particular in countries 
where consumption levels have been high. The 
preparations are typically abused by two groups:  
(a) students and pupils who want to improve their 
academic performance and who seem to ignore the health 
risks involved in the use of such substances without 
medical supervision, and (b) abusers of amphetamine-type 
stimulants who crush and subsequently snort, dissolve or 
inject the substances in question, such as methylphenidate, 
or mix them with street drugs to create what is called a 
“speedball”. In the United States in the mid-1990s, the levels 
of abuse of substances that are used to treat ADHD were 
not less than the abuse levels of stimulants that were illicitly 
manufactured.28 Whereas most other amphetamine-type 
stimulants have been obtained from illicit manufacture, all 
__________________ 
 26  Since 2010, statistical data on consumption were 
reported by the United States. The reported data 
confirm excessively high consumption levels. 
 27  Namely, Australia, Belgium, Denmark, the Netherlands, 
New Zealand, Norway, Spain and Sweden. 
 28  Report of the International Narcotics Control Board for 
2006 (United Nations publication, Sales No. E.07.XI.11), 
para. 87. 
the methylphenidate found in illicit markets is believed to 
be diverted from domestic distribution channels. 
299. Many methods for the diversion of those 
preparations were identified. For example, methylphenidate 
is among the substances most often obtained through 
illegal Internet pharmacies. In several countries adolescents 
and young adults reported little difficulty in obtaining 
preparations containing methylphenidate or amphetamines 
from friends or schoolmates. Furthermore, schools have 
been broken into and medication supplies stolen. In some 
countries there were reports that methylphenidate could be 
obtained without a prescription, in contravention of the 
provisions of the 1971 Convention. At least one criminal 
network was identified that was involved in falsifying 
orders for preparations containing methylphenidate.29 
300. The Board recognizes the usefulness of stimulants in 
the treatment of ADHD when prescribed on the basis of 
careful and appropriate diagnosis and proper treatment 
evaluation. Nevertheless, the Board has repeatedly 
expressed its concern about the high level of consumption 
of methylphenidate and the other substances used in the 
treatment of ADHD, which has led to the widespread 
diversion and abuse of pharmaceutical preparations 
containing those substances. The Board has requested the 
countries concerned to ensure that the control measures 
foreseen in the 1971 Convention are applied to the 
stimulants listed in Schedule II of that Convention and to 
take additional measures, as necessary, to prevent both the 
diversion from licit distribution channels and the abuse of 
preparations containing that substance.30 The Board has 
also stressed on numerous occasions the importance of 
education and training for health professionals on the 
rational use of psychoactive drugs, to prevent the abuse of 
prescription drugs. In this connection, the Board noted 
that the significant increase in the use of stimulants for 
ADHD treatment in many countries could be attributed to 
possible overdiagnosis and overprescription.  
301. Diversions of methylphenidate and other substances 
used in the treatment of ADHD, direct advertising to the 
general public to promote their use and wide public 
dissemination of information about the misuse and abuse 
of such substances, as well as the sources where they can be 
obtained, have helped to create an illicit market for 
preparations containing such substances. The Board is 
therefore concerned about the unabated increase in 
consumption of methylphenidate in a number of countries. 
__________________ 
 29  Report of the International Narcotics Control Board for 
2009 (United Nations publication, Sales No. E.10.XI.1), 
para. 98. 
 30  For example, in recommendation 24 of the Report of the 
International Narcotics Control Board for 2009. 
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Inadequately controlled supplies of those substances at sites 
such as schools, private homes and illegal Internet 
pharmacies, as well as the continued lack of awareness on 
the part of potential abusers about the health risks 
associated with the abuse of those stimulants, may lead to 
increased diversion and abuse.  
302. The Board therefore reiterates that Governments 
should closely monitor the consumption levels of all 
stimulants that are used in the treatment of ADHD and 
ensure that they are prescribed in accordance with sound 
medical practice, as required under article 9, paragraph 2, 
of the 1971 Convention and in line with the rational use of 
psychoactive drugs, as recommended by WHO. The 
competent authorities of the countries concerned should 
further increase their vigilance with regard to the diversion 
of, trafficking in and abuse of stimulants in Schedule II 
used for the treatment of ADHD. Where necessary — for 
example, at schools — safety measures for storage and 
distribution should be enforced. Health professionals 
prescribing substances for the treatment of ADHD and 
health authorities should advise the general public, 
students and, in particular, parents of young patients of the 
risks and consequences of the abuse of such substances. 
The Board calls further on all Governments to inform it of 
any new development with regard to the diversion of, 
trafficking in and abuse of those substances. 
 
 4. Diversion of pharmaceutical preparations 
containing narcotic drugs or psychotropic 
substances  
 
303. Reported seizures of pharmaceutical preparations 
containing controlled substances and the reports of 
increasing abuse in many countries and regions (see  
paras. 281-302 above) prove that these preparations 
continue to be readily available on the illicit market. Unlike 
the case of heroin, cocaine and amphetamine-type 
stimulants, which are well known to be clandestinely 
manufactured, the illicit manufacture of pharmaceutical 
preparations containing controlled substances has rarely 
been reported, indicating that their supply has been 
originating primarily from diversion from licit domestic 
distribution channels. 
304. The most commonly diverted pharmaceutical 
preparations contain the following: 
 Strong analgesics such as fentanyl, hydrocodone, 
morphine and oxycodone 
 The substances buprenorphine and methadone 
which are mainly diverted from substitution 
treatment 
 Stimulants such as methylphenidate and 
phentermine 
 Many sedatives and tranquillizers (certain 
benzodiazepines and barbiturates, and GHB). 
Diverted pharmaceutical preparations containing narcotic 
drugs and psychotropic substances are frequently abused in 
the countries of diversion. However, they are also often 
smuggled from the countries where they were diverted to 
other countries and regions where they are abused, as 
reported by a number of countries. For instance, diverted 
preparations containing buprenorphine were smuggled 
from France into Mauritius, where the abuse of 
buprenorphine is a significant concern.  
305. Governments are increasingly aware that 
pharmaceutical preparations continue to be diverted to 
feed the illicit market, yet knowledge about how those 
drugs are being diverted remains limited. Of the  
65 Governments that have returned the 2011 annual report 
questionnaire, 25 Governments indicated that they had 
seized pharmaceutical preparations containing narcotic 
drugs and psychotropic substances; however, only  
7 Governments could identify the source of supply or 
methods of diversion. Lack of knowledge about the 
diversion methods makes it difficult to devise targeted 
countermeasures. 
306. On the basis of information available to the Board, 
the diversion of pharmaceutical preparations containing 
controlled substances continues to occur mainly in the 
domestic supply chain. While such diversion appears to be 
a problem in many countries, it is most prominent in 
countries where either the national legislation or its 
implementation is weak.  
307. Diversion is often facilitated knowingly or 
unknowingly in the health-care sector, for instance, 
through unethical practices of health-care professionals, 
such as prescribing controlled substances in a manner that 
is not medically appropriate. The role of some 
pharmaceutical companies is also important in this regard 
when they boost sales by offering incentives to medical 
practitioners for promoting their products. Pharmacies are 
another important source of diversion for pharmaceutical 
preparations containing controlled substances. 
Preparations that require a prescription are obtained in 
many countries illicitly from pharmacies with or without 
prescriptions, sometimes owing to a lack of qualified 
pharmacists in those pharmacies. For example, according 
to a report of UNODC, in South Asia significant quantities 
of pharmaceutical preparations are diverted from licensed 
and unlicensed pharmacies both with and without 
prescription. 
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308. Furthermore, pharmaceutical preparations 
containing controlled substances are often diverted by 
patients. The sale of legitimate prescriptions to 
unauthorized persons, forgery of prescriptions, “doctor 
shopping” using false identification and obtaining drugs 
from friends are indicated by Governments as being the 
major methods of diversion. In some cases, drug abusers 
misuse prescriptions from doctors by making repeated 
purchases from multiple pharmacies using a single 
prescription (“pharmacy shopping”). 
309. In recent years, illegal Internet pharmacies and mail 
and courier services have flourished as important channels 
for diversion, because shipments are difficult to track and 
the sheer volume of international mail makes it impossible 
to screen every package. Benzodiazepines appear to be the 
substances under international control that are most 
commonly ordered from illegal Internet pharmacies. There 
is another related concern: the majority of the drugs 
supplied by illegal Internet pharmacies may be counterfeit. 
310. Since 2009, the Board has been collecting 
information on the smuggling of internationally controlled 
substances by mail in response to the request by the 
Commission on Narcotic Drugs (resolution 50/11). To 
enable the Board to fully assess trends relevant to this issue, 
Governments are requested annually to provide the Board 
with information on all seizures of pharmaceutical 
products containing internationally controlled substances 
sent through the mail, whether ordered via the Internet or 
not, and add information regarding the use of the Internet 
in the relevant transactions, if possible. The Board notes 
that, while the number of responses received has increased 
since 2009, several countries with major experience in the 
control of narcotic drugs and psychotropic substances 
smuggled by mail did not submit data to the Board, which 
makes a full analysis of trends difficult. The Board 
therefore reminds all Governments, pursuant to 
Commission on Narcotic Drugs resolution 50/11, to submit 
to the Board the form entitled “Notification on seizures of 
internationally controlled licit substances smuggled 
through the mail, including those ordered via the 
Internet”,31 which is sent every year to all Governments. 
311. Theft from hospitals and warehouses has also been a 
method of diversion in many countries. For instance, in 
Canada between 2009 and 2011, over 3 million tablets were 
diverted, with over 70 per cent having been stolen. Most of 
the stolen tablets contained opioids such as oxycodone, 
hydromorphone and morphine, substances with a high 
potential for abuse. In the Russian Federation, theft from 
__________________ 
 31  Available from www.incb.org/incb/en/narcotic-
drugs/Yellowlist_Forms/forms.html. 
hospitals and doctors’ offices was the primary method of 
diversion for preparations containing fentanyl, 
benzodiazepines and barbiturates such as phenobarbital.  
312. Pharmaceutical preparations that are exempt from 
the prescription requirement under the international drug 
control treaties, such as cough syrup containing codeine, 
have often been targeted by traffickers, since they are easily 
available in large quantities for abuse or use in the illicit 
manufacture of other drugs. For instance, in the Russian 
Federation, codeine preparations that were exempt from 
the prescription requirement were found to be used in the 
illicit manufacture of desomorphine, a substance that has 
been much abused in that country.  
313. The Board is aware that some Governments have 
implemented targeted measures to address the specific 
challenges posed by the diversion of pharmaceutical 
preparations containing controlled substances in their 
country, or are planning to do so. For example, in the 
United States, prescription drug monitoring programmes 
have been established in 35 states to track controlled 
substances prescribed by authorized practitioners and 
dispensed by pharmacies. In India, where pharmacies were 
found to be frequent points of diversion of pharmaceutical 
preparations destined to feed the illicit market in the 
subregion of South Asia, a programme to monitor the 
distribution of pharmaceutical preparations to vulnerable 
areas close to international borders, as well as an online 
prescription monitoring system is planned. In Australia and 
China, law enforcement actions against illegal Internet 
pharmacies have been intensified, leading to the 
dismantling of a number of illegal online pharmacies and 
significant seizures of diverted preparations containing 
controlled substances. In June 2012, the Russian Federation 
introduced a prescription requirement for the purchase of 
any codeine preparation in order to reduce the diversion of 
such preparations. 
314. The Board believes that preventing the diversion of 
pharmaceutical preparations containing controlled 
substances requires a combination of actions to respond to 
specific methods of diversion, as shown in the examples 
above. Strengthening regulatory control measures and 
building up the capacity of law enforcement authorities so 
that they are fully aware of the problems associated with 
the diversion of prescription drugs, are essential. Where 
appropriate, Governments should introduce or expand 
programmes to monitor the movement of prescription 
drugs. New legislation might have to be adopted. For 
example, the sale of internationally controlled substances 
by Internet pharmacies should be prohibited. It is equally 
important for Governments that experience problems of 
diversion of pharmaceutical preparations to carry out 
studies of the domestic supply chain, from manufacture or 
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import of the preparations containing controlled 
substances to the point of their retail distribution, in order 
to ascertain the points that are most vulnerable to 
exploitation by traffickers. In addition, the origin of seized 
preparations should be investigated by law enforcement 
authorities to identify their sources and points of diversion. 
In this connection, the sharing of information and 
cooperation between the law enforcement authorities of the 
countries concerned is needed to investigate the smuggling 
of diverted pharmaceutical preparations.  
315. Furthermore, measures are needed to reduce the 
abuse of diverted pharmaceutical preparations (see  
paras. 281-291 above), since without such abuse there 
would be no diversion of those preparations. In this 
connection, awareness-raising programmes should be 
conducted for the health-care professions, targeting the 
legal and ethical aspects of prescribing and dispensing 
preparations containing controlled substances. Last but not 
least, Governments should make every effort to ensure that 
measures to strengthen control of the supply and 
distribution of controlled substances should never 
jeopardize the availability of those substances for medical 
treatment. 
 
 5. Substances not under international control 
 
316. In recent years, the Board has repeatedly drawn the 
attention of Governments to the reports of abuse of and 
international trafficking in ketamine, a substance currently 
not under international control. The Board has noted with 
concern that diversion or trafficking of ketamine has been 
noted in all regions of the world and that the abuse of 
ketamine has become a health risk in a number of 
countries. Widespread abuse of ketamine, particularly 
among youth, continues to be reported by countries in East 
and South-East Asia, as well as in the Americas.  
317. The international community shares those concerns 
of the Board. The Commission on Narcotic Drugs, at its 
forty-ninth session, in March 2006, adopted  
resolution 49/6, entitled “Listing of ketamine as a 
controlled substance”, in which the Commission called 
upon Member States to consider controlling the use of 
ketamine by placing it on the list of substances controlled 
under their national legislation, where the domestic 
situation so required. In March 2007, the Commission took 
further action in its resolution 50/3, encouraging Member 
States to consider adopting a system of precautionary 
measures for use by their government agencies to facilitate 
the timely detection of the diversion of ketamine.  
318. The Board notes the adoption of the above 
resolutions of the Commission on Narcotic Drugs and calls 
upon all Governments to implement those resolutions 
without delay. In 2008, the Board sent a questionnaire to all 
Governments requesting information on the specific legal 
or administrative measures adopted pursuant to 
Commission resolution 49/6, including, in particular, 
information on measures to control imports and exports  
of ketamine. The Board received information from  
104 countries and territories. Of those, over 50 per cent 
reported that ketamine had already been placed on  
the list of substances controlled under national  
legislation, pursuant to Commission on Narcotic Drugs  
resolution 49/6. With regard to the control of licit 
international trade in ketamine, 59 countries and territories 
informed the Board that they required import and export 
authorizations for ketamine. 
319. The Board has published, on a secure page of its 
website, information on the requirements for import and 
export authorizations for ketamine in individual countries, 
with a view to assisting trading countries in rapidly 
verifying the legitimacy of individual trade transactions 
involving that substance without unduly delaying licit 
trade. The Board calls upon the competent authorities of 
exporting and importing countries to consult that 
information before authorizing imports or exports of 
ketamine. Moreover, the Board reiterates its requests to all 
Governments that have not yet done so to furnish it with 
updated information on their national regulatory control 
measures for ketamine that are applied in their countries 
pursuant to Commission on Narcotic Drugs  
resolutions 49/6 and 50/3. 
320. In recent sessions of the Commission on Narcotic 
Drugs, a number of Governments have commented on the 
health risks and other problems associated with abuse and 
diversion of ketamine as experienced in their countries. 
Those countries expressed their disappointment with the 
fact that the substance was not under international control 
and called for urgent international action to counter the 
abuse of and trafficking in ketamine. Welcoming the 
national controls applied in many countries in accordance 
with the above Commission resolutions, those 
Governments stressed the need for concerted action by all 
Governments, which would best be achieved when 
ketamine was controlled under the international drug 
control treaties. 
321. The Board notes that ketamine has been illicitly 
manufactured in some countries, in addition to being 
diverted from licit channels, and has been subsequently 
trafficked between countries and regions, to satisfy the 
growing illicit demand for the substance. The Board shares 
the opinion of the Governments concerned that national 
control measures alone may not be sufficient to enable law 
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enforcement cooperation between the countries involved, 
the concerted investigation of such crimes or the 
prosecution of the criminals behind them, to name a few of 
the actions that need to be taken in this regard.  
322. The Board therefore recommends that Governments 
that do not apply control measures to ketamine remain 
vigilant, in view of the risk that ketamine might be diverted 
or abused in the country. The Board further encourages 
Governments to inform the Board and UNODC of cases of 
diversion or attempted diversion of ketamine that they may 
uncover and to collect epidemiological data on the abuse of 
the substance, and reminds Governments that experience 
difficulties with the diversion and abuse of ketamine  
to provide the relevant information to INCB, UNODC  
and WHO. 
323. Another development of concern is the increasing 
abuse of tramadol, a synthetic opioid not under 
international control, which has become a serious problem 
in a number of countries in Africa, notably Egypt. Abuse of 
tramadol has also been reported by Jordan, Lebanon, Libya, 
Mauritius, Saudi Arabia and Togo.  
324. In response to that emerging threat and concerned by 
the increasing abuse of tramadol preparations in the 
country, the Government of Egypt placed that substance, as 
well as its salts and derivatives and preparations containing 
tramadol, under national control in 2012. Tramadol is also 
under national control in other countries, such as Jordan 
and Saudi Arabia. 
325. According to information available to the Board, 
tramadol seems to be diverted mainly from international 
trade. For instance, Egyptian authorities seized in the 
country’s main seaports about 120 million tablets 
containing tramadol in 2011 and about 320 million tablets 
in the first quarter of 2012. The preparations were 
reportedly smuggled into Egypt mainly from China and 
India. Increasing amounts of seizures of preparations 
containing tramadol are also reported by Saudi Arabia. 
326. In West Africa, a series of large seizures of tramadol 
preparations, totalling more than 132 tons of such 
preparations, were effected between February and  
October 2012. The preparations had been concealed in sea 
containers coming from India and were intercepted by the 
law enforcement authorities of Benin, Ghana, Senegal  
and Togo. 
327. The Board is concerned about the growing abuse of 
tramadol in some African and West Asian countries and the 
increasing amount of trafficking in tramadol preparations 
to Africa, as evidenced by recent large seizures of such 
preparations in North and West Africa. The Board calls on 
countries in Africa and West Asia to take the measures 
necessary to address that problem and to furnish pertinent 
information on the extent and nature of the abuse of and 
trafficking in tramadol to the Board and WHO.  
 
 6. Plant materials not under international 
control containing psychoactive substances 
 
328. The utilization of plant-based preparations that are 
not under international control and which contain natural 
psychoactive ingredients is often part of traditional 
indigenous rituals, traditional medicine and religious 
ceremonies. Examples of the plants or parts of plants from 
which such preparations are concocted include khat (Catha 
edulis) from East Africa and the Arabian peninsula; 
ayahuasca, a preparation made from plants indigenous  
to the Amazon basin of South America, most importantly  
a jungle vine (Banisteriopsis capii) and another  
tryptamine-rich plant (Psychotria viridis), containing a 
number of psychoactive alkaloids, including DMT; the 
peyote cactus (Lophophora williamsii), containing 
mescaline; magic mushrooms (Psilocybe), which contain 
psilocybine and psilocine; Ephedra, containing ephedrine; 
“kratom” (Mitragyna speciosa), a plant indigenous to 
South-East Asia containing mitragynine; Salvia divinorum, 
a plant originating in Mexico that contains the 
hallucinogen salvinorin A; and iboga (Tabernanthe iboga), 
native to western Central Africa, containing the 
hallucinogen ibogaine. 
329. The Board pointed out some of the problems related 
to the use of those plant materials outside their original 
socioeconomic context in its annual report for 2010  
(paras. 284-287). Since then, increasing interest in the use 
of such plant materials for recreational purposes has been 
noted, possibly encouraged by a lack of clarity with regard 
to the control status of the plants at the national or the 
international level. At present, no plants, including the ones 
containing psychoactive ingredients, are controlled under 
the 1971 Convention, although the active ingredients they 
contain are sometimes subject to international control. For 
example, cathine and DMT are psychotropic substances 
included in Schedule I of the 1971 Convention, while the 
plants and plant-based preparations that contain them, 
namely khat and ayahuasca, respectively, are not subject to 
any restrictions or control measures. This situation is 
seemingly exploited by drug trafficking networks and 
online retailers, resulting in increased trade, use and abuse 
of these plant materials in many countries.  
330. The easy availability of those plant materials through 
the Internet is evidenced in the 2011 EMCDDA survey on 
the online availability of new psychoactive substances in 
the European Union. According to that survey, the most 
commonly sold new psychoactive substances based on 
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natural products in Europe include “kratom”, Salvia 
divinorum, ayahuasca and hallucinogenic mushrooms.  
331. Furthermore, the Board notes the increasing 
popularity of practices that purportedly have spiritual 
connotations, such as “spiritual tourism”, under the cover of 
which the plant-based psychoactive materials are 
consumed. Several centres around the world offer 
“initiatory journeys” with the presence and assistance of a 
shaman. Some online travel agencies offer “initiatory 
journeys” “supervised” by shamans, although such events 
are usually totally outside the sociocultural context that 
they claim to represent. Shamanic practices during such 
initiatory journeys, such as trance, ecstasies, hallucination 
and divination, are reached mainly through the ingestion of 
preparations made out of plant materials containing the 
psychoactive substances mentioned above.  
332. The Board notes with concern that the use of those 
substances has been associated with various serious health 
risks (both physical and psychological) and even with 
death. The Board therefore wishes to draw the attention of 
Governments to the fact that the use of such plant materials 
for whatever purpose could be unsafe practice. 
333. In view of the health risks associated with those 
materials, a growing number of Governments have placed 
such material or preparations under national control, or are 
considering doing so, and are taking other measures to 
prevent negative health consequences of such use. For 
example, in 2009 Salvia divinorum emerged in Canada as a 
substance of concern; in 2010, an estimated 1.6 per cent of 
Canadians aged 15 years and over had used the substance in 
their lifetime and 0.3 per cent reported having used it in the 
past year. Although Salvia divinorum is not currently 
scheduled under the Controlled Drugs and Substances Act, 
Health Canada has proposed to include it as a controlled 
substance under that Act. In the United States, the substance 
has been placed on the Drug Enforcement Administration’s 
“Drugs and Chemicals of Concern” list. In addition, several 
states in the United States have banned the substance.  
334. The Board reiterates its recommendation to the 
Governments of countries where the misuse and trafficking 
of such plant materials may occur to remain vigilant and 
recommends that appropriate action be taken at the 
national level where the situation so requires. 
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 III. Analysis of the world situation 
 
 
 A. Africa 
 
 
 1. Major developments 
 
335. The social and political changes in North Africa that 
began in Egypt, Libya and Tunisia in 2011 and were still 
ongoing in 2012 have reportedly caused deficiencies in 
the drug law enforcement capabilities of these countries.  
336. Major political changes also took place in  
Guinea-Bissau and Mali in early 2012, which may affect 
the fight against drug trafficking in West Africa and 
elsewhere. While transitional Governments have now 
been installed in the two countries, the situation remains 
unstable, in particular, in the case of Mali. That is of 
concern as both Guinea-Bissau, a hub for cocaine 
trafficking in the subregion, and Mali, a transit country 
for cocaine and cannabis resin, have been targeted by 
international drug traffickers.  
337. In recent years, West Africa has emerged as a transit 
area for the trafficking of narcotics, especially cocaine, 
from South America to the lucrative European market. 
Approximately 30 tons of cocaine were trafficked to West 
Africa in 2011. Cocaine trafficking in the subregion is 
estimated to generate $900 million in profit annually for 
criminal networks. There are an estimated 1.5 million 
cocaine abusers in West and Central Africa. Furthermore, 
trafficking in heroin and methamphetamine has 
increased in West Africa. Afghan heroin is trafficked 
through Pakistan and the Middle East into East and West 
Africa, and methamphetamine is manufactured in 
growing quantities across West Africa, mainly in Ghana 
and Nigeria.  
338. The Security Council has repeatedly expressed its 
concern at the illicit drug and crime situation in  
West Africa and the Sahel. In a presidential  
statement (S/PRST/2009/32), the Council invited the 
Secretary-General to consider drug trafficking, as well as 
other threats, as a factor in conflict prevention strategies 
and peacebuilding efforts. During its meeting on peace 
and security in Africa held on 21 February 2012, the 
Council acknowledged the importance of system-wide 
action by the United Nations to combat the spread of 
drug trafficking and illicit weapons in countries 
struggling to overcome the consequences of armed 
conflict and instability. 
339. East Africa continues to be used as a transit area for 
the trafficking of heroin. The increase in heroin seizures 
recently reported in East Africa suggests that illicit heroin 
trafficking is increasing in that area and, as a spillover 
effect of such trafficking, heroin abuse is increasing as 
well, notably in Kenya, Mauritius, Seychelles and the 
United Republic of Tanzania. Of particular concern is the 
increasing abuse of heroin by injection in a subregion that 
is seriously affected by HIV and AIDS.  
340. While cannabis remains the most widely cultivated, 
trafficked and abused drug in Africa, new threats have 
emerged, in particular, the illicit manufacture, trafficking 
and abuse of amphetamine-type stimulants. Until a few 
years ago, illicit manufacture and abuse of 
methamphetamine and methcathinone appeared to be 
largely confined to Southern Africa. Methamphetamine 
manufacture has now spread to West Africa, as 
corroborated by the detection of two methamphetamine 
laboratories in Nigeria, in the period 2011-2012. There is 
growing evidence to suggest that drug trafficking 
networks are increasingly exploiting East and West Africa 
for trafficking amphetamine-type stimulants, particularly 
methamphetamine, to other parts of the world, primarily 
East and South-East Asia. 
341. There continue to be attempts to divert precursor 
chemicals in Africa, predominantly precursors used in the 
illicit manufacture of amphetamine-type stimulants. 
Recent reports of significant thefts or losses of ephedrine 
and pseudoephedrine in countries in East Africa might be 
an indication that precursors of amphetamine-type 
stimulants are being diverted from licit domestic 
distribution channels into the illicit manufacture of 
amphetamine-type stimulants in other parts of Africa.  
342. Abuse of tramadol, a synthetic opioid not under 
international control, has become a serious problem in a 
number of African countries, notably in North Africa. 
Trafficking of tramadol to Africa seems to be increasing 
as well, as corroborated by a series of large seizures of 
tramadol effected in West Africa in 2012, totalling more 
than 132 tons, of preparations containing tramadol 
coming from India that were intercepted in Benin, 
Ghana, Senegal and Togo during that year. 
 
 2. Regional cooperation 
 
343. At the fifth session of the African Union Conference 
of Ministers for Drug Control and Crime Prevention, 
held in Addis Ababa in October 2012, participants 
endorsed the African Union Plan of Action on Drug 
Control and Crime Prevention (2013-2017). The plan 
provides a comprehensive approach to the problems of 
illicit drugs, crime, corruption and terrorism as 
impediments to development. It is expected that the plan 
will be presented for adoption at the Assembly of Heads 
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of State and Government of the African Union to be held 
in January 2013.  
344. The Conference also adopted the African Union 
Common Position on Controlled Substances and Pain 
Management. The Common Position, which will be 
submitted for endorsement at the African Union 
Conference of Ministers of Health to be held in  
April 2013, defines a harmonized African policy to 
improve the availability of and access to narcotic drugs 
and psychotropic substances for medical needs.  
The Board welcomes that initiative, which will facilitate 
wider access to effective medication for pain management 
in Africa. 
345. The Board notes that the Regional Action Plan to 
Address the Growing Problem of Illicit Trafficking, 
Organized Crime and Drug Abuse in West Africa of the 
Economic Community of West African States (ECOWAS) 
expired in 2011. The plan, adopted in 2008, coordinated 
the efforts of ECOWAS member States to address the 
growing problem of drug trafficking, organized crime 
and drug abuse in West Africa. The Board calls upon the 
ECOWAS Commission and its member States to renew 
and extend the regional action plan as soon as possible to 
ensure a sustained political framework for addressing the 
world drug problem in the subregion. 
346. At a meeting held in Algiers in July 2012, the 
Ministers for Foreign Affairs of States members of the 
Arab Maghreb Union (Algeria, Libya, Mauritania, 
Morocco and Tunisia) agreed on a common strategy to 
deal with recent developments and security threats in 
North Africa, notably trafficking in drugs and arms, 
organized crime, money-laundering and terrorism. 
347. The Twenty-second Meeting of Heads of National 
Drug Law Enforcement Agencies, Africa, was held in 
Accra in July 2012. The Meeting approved the Accra 
declaration, for consideration by the Commission on 
Narcotic Drugs at its fifty-sixth session, in March 2013. 
The declaration, which sets forth recommendations for 
improved cooperation among African States in the fight 
against drug trafficking, contains, inter alia, specific 
recommendations for improved regulatory controls over 
narcotic drugs, psychotropic substances and precursors. 
The Meeting also agreed on actions against illicit 
cultivation of, and trafficking in, cannabis, the promotion 
of good practices and strategies in the treatment and 
rehabilitation of drug abuse and the enhancement of the 
continent’s drug law enforcement capacity.  
348. In June 2012, Guinea joined the West Africa Coast 
Initiative. The initiative addresses the growing problem of 
illicit drug trafficking and transnational organized crime 
in West Africa. 
349. The INTERPOL-coordinated Operation Atakora, 
conducted in several countries of West Africa, resulted in 
the seizure of nearly 8 tons of illicit drugs and the arrest 
of 74 persons in July 2012. Funded by ECOWAS, the 
operation was carried out at airports, seaports and land 
borders across Benin, Ghana and Togo and led to seizures 
of cannabis, methamphetamine and large amounts of 
pain medication. The three-day operation was preceded 
by a joint INTERPOL/Colombian National Police 
training session held in Lomé. 
350. UNODC assists authorities in West African 
countries to address problems related to drug trafficking 
and abuse and organized crime through national 
integrated programmes. In 2012, national integrated 
programmes against illicit drugs and crime were launched 
in Burkina Faso and Ghana. Cape Verde updated its 
national drug control programme in 2012, and Cameroon 
officially requested assistance for the development of a 
national drug and crime strategy. In line with Security 
Council resolution 2039 (2012), the Government of Benin 
considered measures such as developing a national 
integrated programme to fight drug trafficking and 
organized crime, including piracy and armed robbery at 
sea. However, the implementation of such programmes in 
Guinea-Bissau and Mali had to be suspended following 
the coups d’état in those countries in early 2012.  
351. The UNODC Airport Communication Project, 
conducted in cooperation with INTERPOL and the World 
Customs Organization, is aimed at building drug 
interdiction capacity at international airports and 
establishing direct, secure communication lines 
connecting authorities at airports in West Africa and 
Central Africa with those at airports in Latin America and 
the Caribbean along the transatlantic routes used to 
traffic cocaine. The two-week operation “Operation 
Cocair 3”, led by the World Customs Organization and 
supported by INTERPOL, the European Commission and 
UNODC and involving 25 airports across West  
and Central Africa and in Brazil, conducted in  
December 2011, resulted in the seizure of more than  
500 kilograms (kg) of drugs, including cocaine, heroin, 
cannabis, methylenedioxymethamphetamine (MDMA, 
commonly known as “ecstasy”), methamphetamine  
and amphetamine, as well as cash of a value of  
2.5 million euros.  
352. The African subregional groups against  
money-laundering have continued to support the activities 
of African countries to combat money-laundering. The 
Middle East and North Africa Financial Action Task Force 
(MENAFATF), in collaboration with the World Bank, 
organized a subregional workshop to train bank 
supervisors on supervision of compliance with  
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anti-money-laundering regulations, held in Casablanca, 
Morocco, in May 2012. The Eastern and Southern Africa 
Anti-Money Laundering Group (ESAAMLG) convened its 
twelfth Council of Ministers Meeting and its twenty-fourth 
Task Force of Senior Officials Meeting, held in Maputo in 
August 2012. The Intergovernmental Action Group against 
Money Laundering in West Africa (GIABA) organized a 
number of expert meetings and seminars for its members 
in Dakar and Lagos, Nigeria, in August 2012.  
 
 3. National legislation, policy and action 
 
353. The Government of Burkina Faso finalized in  
April 2012 its national drug and crime strategy for the 
period 2013-2017. The strategy has a particular focus on 
drug trafficking, as well as the prevention of terrorism 
and trafficking in counterfeit medicine.  
354. The Government of Egypt, concerned by the 
increasing abuse of tramadol, placed the substance, as well 
as its salts and derivatives and preparations containing 
tramadol, under national control in 2012. Furthermore, the 
Government’s Fund for Drug Control and Addiction 
Treatment has developed a national action plan against 
drug abuse for 2012-2016, for adoption by Parliament.  
355. In Ghana, the narcotics law is currently under 
review. The amendment proposed by the Narcotics 
Control Board of Ghana foresees placing additional 
precursor chemicals under national control and 
introducing higher sanctions for the diversion of 
precursors into illicit drug manufacture. The Government 
has also allocated additional resources to the Narcotics 
Control Board, which will allow it to substantially 
increase its drug law enforcement workforce. 
356. The Government of Kenya established a national 
technical committee on drug trafficking and abuse in 
October 2011 to guide the national strategy to reduce illicit 
drug demand and suppress supply. All relevant ministries 
and institutions with responsibility for drug control 
matters in Kenya are represented on the committee. 
357. In Libya, the newly established anti-narcotics 
agency has, in collaboration with UNODC, prepared a 
new project to develop the agency’s intelligence 
capabilities and to strengthen its regional cooperation 
capacity. 
358. The Government of Nigeria has embarked upon a 
comprehensive programme covering the areas of 
countering drug trafficking, demand reduction, criminal 
justice reform and the fight against organized crime.  
359. In South Africa, the Central Drug Authority  
has drafted a new national master plan for the  
period 2012-2017 that takes an inter-agency approach to 
coordinating drug abuse prevention, treatment and 
intervention at the provincial and national levels and 
includes a nationwide database to track drug crimes. The 
Authority cooperates with the South African Police 
Service on a comprehensive anti-drug strategy.  
360. The Ministry of Health of Tunisia, in cooperation 
with the Pompidou Group of the Council of Europe and 
with the support of WHO, organized a seminar for 
officials from different ministries, doctors and managers 
in Tunis in May 2012 to discuss issues related to drug 
abuse and addiction and strategies and policies for the 
prevention and treatment of drug abuse and 
rehabilitation. 
361. In Uganda, draft legislation on comprehensive 
national drug control is before the Parliament. If 
approved, the legislation would increase criminal 
penalties for drug trafficking, strengthen the 
Government’s authority to confiscate assets, establish 
special drug courts and a national coordination body to 
oversee the drug abuse treatment and rehabilitation 
services and strengthen regional and international 
counter-narcotics cooperation efforts. 
362. The Government of Zimbabwe has established a 
national drug panel, composed of the Ministry of Health 
and Child Welfare, Zimbabwe Revenue Authority, the 
Office of the Attorney General, the Medicines Control 
Authority and the Police, to spearhead the launching and 
implementation of the country’s master plan to combat 
drug trafficking. The panel is also responsible for 
overseeing the proper disposal of seized drugs.  
363. A number of African Governments have taken  
steps to strengthen their legal framework against  
money-laundering. The Government of Algeria adopted 
an implementing regulation in February 2012 to 
strengthen the country’s law on the prevention and fight 
against money-laundering and the financing of terrorism 
of 2005, and the Government of Djibouti amended its 
anti-money-laundering act of 2002 to allow for asset 
confiscation. In the Gambia, a draft law on countering 
money-laundering and the financing of terrorism was 
submitted to Parliament in June 2012 to bring current 
national legislation into conformity with international 
standards, and in Togo, legislation has been drafted to 
deal with the forfeiture of assets.  
 
 4. Cultivation, production, manufacture and 
trafficking 
 
 (a) Narcotic drugs 
 
364. Illicit production of cannabis resin is concentrated 
in some countries in North Africa. Morocco has 
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traditionally been the predominant supplier of the 
cannabis resin abused in Europe, which is the world’s 
largest illicit market for cannabis resin. According to the 
World Customs Organization, about 72 per cent of the 
total amount of cannabis resin seized by customs 
authorities worldwide in 2011 originated in Morocco. 
However, recent UNODC data indicate that the supply of 
cannabis resin from other countries, notably Afghanistan, 
could be increasing. 
365. The Government of Morocco reported that the area 
under illicit cannabis cultivation amounted to 47,400 ha 
in 2010. No additional land was targeted for crop 
substitution in 2011. Large shipments of illicit cannabis 
cultivated in Morocco that are destined for Europe  
are transported via speedboats and other small  
non-commercial vessels. Smugglers continue to ship 
cannabis through the Spanish enclaves of Ceuta and 
Melilla and the Moroccan port of Tangier. Multi-ton 
seizures of cannabis continue to be made on a regular 
basis. In 2011, 138 tons of cannabis resin were seized. 
366. Other North African countries have reported large 
amounts of seized cannabis resin. Algerian authorities 
seized over 53 tons of cannabis resin transiting national 
territory in 2011 and 26 tons in the first half of 2012. The 
Government of Egypt reported that in 2011 it had seized 
more than 18 tons of cannabis resin, most of which had 
originated further west within Africa, with smaller 
amounts coming from Pakistan and Afghanistan. 
According to Egyptian authorities, no cannabis resin is 
produced in the country, although illicit cannabis plant 
cultivation is widespread, notably in the Sinai peninsula. 
367. Cannabis herb production and trafficking are 
reported in practically all African countries. Cannabis 
herb is abused locally or smuggled within the region. 
Africa is also one of the main sources of the cannabis 
herb seized in Europe. The largest producers of cannabis 
herb in Africa are countries in West and Central Africa 
(the Democratic Republic of the Congo, Ghana, Nigeria, 
Senegal and Togo), North Africa (Egypt and Morocco), 
East Africa (Ethiopia, Kenya and the United Republic of 
Tanzania) and Southern Africa (Malawi, South Africa, 
Swaziland and Zambia). 
368. In 2011, the National Drug Law Enforcement 
Agency (NDLEA) of Nigeria seized a total of 192 tons of 
cannabis herb, which represents a 10-per-cent increase 
over the total in 2010. Also in 2011, Nigerian authorities 
eradicated a total of 918 ha of cannabis plant cultivation, 
compared with 593 ha in 2010. According to the Agency, 
that amount of cultivation is equivalent to a yield of  
1,836 tons of cannabis herb. Other countries  
reporting seizures of cannabis herb in 2011 were  
Morocco (129 tons), Egypt (73 tons), Burkina Faso  
(33 tons), Sierra Leone (3 tons) and Cape Verde  
(2.6 tons). Compressed cannabis is smuggled from  
South Africa to Europe by parcel post and in air and  
sea containers.  
369. In the past decade, West Africa emerged as a new 
hub for the smuggling of cocaine from South America to 
Europe. However, cocaine trafficking routes leading to 
West Africa seem to have lost some of their attraction in 
the past several years. Since 2007, drug traffickers seem to 
have turned to using containerized shipping to smuggle 
cocaine into West Africa. Nine of the 14 large seizures 
effected in 2011 were made in Benin, Cameroon, Ghana, 
Nigeria, Sierra Leone and Togo. Almost half of all 
maritime seizures of cocaine concealed in containers had 
departed from Brazil. The Plurinational State of Bolivia 
was the second most important country of departure for 
cocaine destined for West Africa. The main destinations 
of cocaine consignments coming through Ecuador were 
Benin and Côte d’Ivoire. In November 2011, 530 kg of 
cocaine were seized from a sea freight container in Brazil 
destined for Europe via Benin. In October 2011, a record 
seizure of 1.5 tons of cocaine was made in Cape Verde. 
Furthermore, 480 kg of cocaine destined for Nigeria were 
seized in Brazil in October 2011, and 145 kg were 
intercepted in Cameroon on a ship coming from Brazil. 
In July 2012, Argentine customs officials at the Buenos 
Aires international airport seized more than half a ton of 
cocaine destined for Nigeria. 
370. In addition, traffickers use commercial aircraft and 
carriers to transport cocaine shipments to West Africa.  
In 2011, Lagos airport was the main hub of cocaine 
smuggled to Europe by air. That year, over half of the air 
couriers coming from West and Central Africa that were 
arrested in European airports had departed from Nigeria; 
26 per cent had departed from Cameroon, and 18 per 
cent had departed from Benin. Cocaine is also smuggled 
in air freight. In 2011, a consignment of 113 kg of cocaine 
was intercepted at the airport of Miami, United States; it 
had been sent from the Plurinational State of Bolivia and 
was destined for Benin. 
371. Significant amounts of cocaine are smuggled 
directly from South America to the illicit markets of 
South Africa. Some cocaine is trafficked from West Africa 
to South Africa, either directly or via Angola and 
Namibia. Cocaine is regularly intercepted in Ethiopia, 
Kenya, Uganda and the United Republic of Tanzania.  
In 2011, Tanzanian customs authorities intercepted 86 kg 
of cocaine coming mostly from Brazil, and authorities in 
Mozambique intercepted at Maputo international airport 
12 cocaine shipments, totalling 65 kg, on a route from 
India through Ethiopia to Mozambique.  
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372. Reports indicate that cocaine traffickers are 
increasingly attempting to smuggle cocaine to Europe 
through Morocco, with cocaine being shipped from 
South America to sub-Saharan Africa and the Sahel 
region and on to Morocco. 
373. Illicit opium poppy cultivation is confined to the 
Sinai peninsula in Egypt and is thought to be limited in 
scale. The opium produced there is abused locally, and 
there is no evidence of it being used for the manufacture 
of heroin. In Egypt, opium ranks fourth among the drugs 
of abuse. As a result of intensified drug control efforts 
over the past years, opium poppy cultivation has 
decreased. Opium is also smuggled to Egypt from  
South-East and South-West Asia. In 2011, about 11 kg of 
opium were seized in Egypt. 
374. Heroin is trafficked to Africa from South-East and 
South-West Asia. Africa has now emerged as a trafficking 
hub for heroin for abuse within Africa as well as for 
onward shipping to Europe and elsewhere. Most heroin 
enters Africa through the countries located along the East 
African coastline (Ethiopia, Kenya, Mozambique, Somalia 
and the United Republic of Tanzania), and consignments 
of Afghan heroin in amounts of up to several hundred 
kilograms enter East Africa after crossing the Indian 
Ocean from the Islamic Republic of Iran and Pakistan. 
Airports are used to move smaller quantities of heroin, 
making use of both air freight and air couriers. Some of 
the heroin smuggled to East Africa is then smuggled to 
West Africa and onward to Europe, while smaller 
quantities are smuggled into North America and some 
parts of Asia, and some of the heroin is smuggled from 
East Africa to Southern Africa. Major transit hubs  
for heroin trafficking in Africa include Nigeria and  
South Africa.  
375. Total heroin seizures in Africa rose from 311 kg in 
2008 to 695 kg (amounting to 7 per cent of global heroin 
seizures) in 2010, the latest year for which aggregate 
UNODC data are available. East Africa had the largest 
amount of heroin seizures in Africa in 2010 (245 kg), 
followed by North Africa (239 kg) and West and Central 
Africa (201 kg), suggesting that illicit heroin markets are 
expanding in all three subregions. That upward trend in 
African heroin seizures seems to have continued in 2011 
according to the World Customs Organization, which 
recorded an increase in the volume of heroin intercepted 
by African customs authorities, from 266 kg in 2010 to 
302 kg in 2011. 
376. East Africa’s unprotected coastline, major seaports 
and airports and porous land borders provide traffickers 
with a multitude of entry and exit points. Moreover, a lack 
of capacity to control borders and ports of entry, 
inadequate cross-border cooperation and weak criminal 
justice systems make East Africa attractive to 
international drug trafficking syndicates. Large seizures 
of heroin arriving in East Africa using maritime routes 
were first reported in 2011: 179 kg of heroin were 
intercepted in Dar es Salaam, United Republic of 
Tanzania, in February 2011, and 102 kg of heroin were 
intercepted in Mombasa, Kenya, in March 2011.  
In January 2012, the largest such seizure ever reported  
in East Africa, 211 kg of heroin, was effected in  
Dar es Salaam. Thus, in less than two years, almost  
750 kg of heroin were seized on the coast of East Africa. 
Furthermore, naval vessels effected two large seizures of 
heroin being transported on dhows in the Indian Ocean, 
south-east of Oman, in February and April 2012, in which 
240 kg and 180 kg of heroin, respectively, were seized.  
377. Afghan heroin smuggled into West and Central 
Africa is destined mainly for the illicit markets of Europe. 
Recently, however, there has been a significant increase in 
heroin trafficking in those subregions, which could result 
in the spillover effect of increased heroin abuse. While in 
the past heroin has been smuggled through West Africa in 
smaller quantities and not in bulk in sea freight 
containers, in recent years there have been a number of 
cases of heroin smuggled into West Africa in 
containerized vessels; since 2010, several large 
consignments of heroin have been intercepted in West 
Africa or en route to that subregion, including a 
consignment of 200 kg of heroin coming from Pakistan 
that was seized in Benin in April 2011. Altogether, almost 
400 kg of heroin were seized in West Africa in 2011.  
A seizure of 113 kg of heroin was effected at the seaport of 
Lagos in June 2012. Since January 2012, there have also 
been several heroin seizures at the international airport of 
Abidjan, Côte d’Ivoire. Most of the heroin seized in  
or bound for West Africa was destined for Benin,  
Côte d’Ivoire and Nigeria.  
378. In North Africa, heroin is smuggled into Egypt 
across the Gulf of Aqaba and through the eastern borders 
of the country, mainly from Afghanistan. 
 
 (b) Psychotropic substances 
 
379. Trafficking of amphetamine-type stimulants from 
West Africa to other regions and subregions has emerged 
as a new threat. Since 2008, there have been reports of 
methamphetamine being trafficked from countries of 
West Africa such as Benin, Cameroon, Côte d’Ivoire, 
Ghana, Guinea, Nigeria, Senegal and Togo to East Asia, 
predominantly Japan and the Republic of Korea. Seizures 
of methamphetamine from West Africa have been 
increasing since 2009. Currently, the most common 
destinations for methamphetamine trafficked through 
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Africa appear to be Japan, Malaysia, the Republic of 
Korea, Singapore and Thailand. The drugs are usually 
trafficked by air in quantities between 1 and 2 kg. 
380. Methamphetamine has been illicitly manufactured 
in Southern Africa and North Africa for some time. In 
West Africa, a clandestine methamphetamine laboratory 
was dismantled for the first time, in Lagos in July 2011. 
The laboratory had an estimated manufacturing capacity 
of 20-50 kg per production cycle. In February 2012,  
a similar laboratory was dismantled in Lagos, and about  
5 kg of finished methamphetamine were seized.  
381. So far, there have been no reports of illicit 
methamphetamine manufacture in East Africa. However, 
methamphetamine transits East Africa on a route from 
West Africa, notably on air routes to major consumer 
markets, passing through key transport hubs such as 
Addis Ababa and Nairobi. Methamphetamine was seized 
for the first time at the airport of Entebbe, Uganda,  
in 2011, when 3 kg of methamphetamine were seized 
from an air courier from West Africa en route to India. 
Total seizures of methamphetamine in Uganda amounted 
to 10 kg in 2011 and to 5 kg in the first three months  
of 2012. 
382. According to the World Customs Organization,  
14 African countries emerged as source countries or 
transit countries for shipments of methamphetamine 
bound for the Asia-Pacific region in 2011. Those 
countries were Benin, Burkina Faso, Burundi, Cameroon, 
Côte d’Ivoire, the Gambia, Ghana, Kenya, Mali, 
Mozambique, Nigeria, Senegal, South Africa and Togo, 
from which amounts up to 20 kg were trafficked. Nigeria 
is most frequently cited as the origin of trafficked 
amphetamine-type stimulants, largely methamphetamine. 
In 2010, Nigerian authorities reported total seizures of  
75 kg of amphetamines at the international airport in 
Lagos, compared with the 45 kg of amphetamines seized 
at that airport in 2011. Methamphetamine and 
amphetamine from West Africa are also smuggled  
to South Africa, the largest illicit market of  
amphetamine-type stimulants on the continent. In 2011, 
Libya emerged as the source country of two major 
amphetamine seizures, of over 2.1 million tablets (about 
720 kg) and of 2 million amphetamine tablets (about  
666 kg) effected by customs authorities in Saudi Arabia in 
July 2011 on the land border with Jordan. 
383. Illicit manufacture of methamphetamine, 
methcathinone and methaqualone continues to take place 
in South Africa. The substances are destined for domestic 
abuse as well as for trafficking to countries in Southern 
Africa. Methaqualone (Mandrax), a sedative banned in 
1977, is smuggled into South Africa from Asia but is also 
manufactured locally. In June 2012, authorities seized 
860,000 tablets (approximately 350 kg) of methaqualone 
being transported by road from Botswana and the United 
Republic of Tanzania and destined for Western Cape 
province, South Africa. In July 2012, South African police 
dismantled two methaqualone laboratories in 
Johannesburg and seized about 300,000 tablets 
(approximately 120 kg) of methaqualone. 
384. Another serious problem faced by many African 
countries is the availability of prescription drugs on 
unregulated markets. Often those drugs have been 
diverted or are counterfeit, and they contain controlled 
substances, possibly amphetamine-type stimulants, as 
well as sedatives and tranquillizers. In some African 
countries, there was an increase in the total amount of 
such substances seized: for instance, 2,985 kg of  
non-specified psychotropic substances were seized in 
Nigeria in 2011, as compared with 712 kg in 2009.  
385. In Mauritius, psychotropic substances such as 
diazepam (Valium) and clonazepam (Rivotril) are abused 
by drug-dependent persons who are supplied by dealers. 
Buprenorphine, a substance controlled under Schedule III 
of the 1971 Convention, is trafficked, mainly from 
France, in the form of Subutex tablets. After the 
implementation of stricter control measures, the 
availability of the drug on the local illicit market has 
decreased. In the first half of 2012, there have been only 
three significant seizures, totalling 9,353 Subutex tablets, 
in Mauritius. In contrast, diversion of sedatives and 
tranquillizers from local distribution channels has 
increased, mainly through purchases without medical 
prescription from rogue pharmacies. 
 
 (c) Precursors 
 
386. Kenyan authorities have been reporting significant 
thefts and/or losses of ephedrine and pseudoephedrine 
since 2009, and in 2010, Tanzanian authorities started  
to report thefts of pseudoephedrine. Between  
September 2009 and December 2011, the thefts of 
ephedrine and pseudoephedrine in Kenya and the United 
Republic of Tanzania combined totalled over 3.2 tons 
(2,062 kg of pseudoephedrine and 1,183 kg of ephedrine). 
Furthermore, stopped shipments of large amounts of 
ephedrine destined for Uganda (100 kg) and the Sudan 
(300 kg) were reported in 2011. The ultimate destination 
of those diversions and attempted diversions is unclear. 
387. Illicit manufacture of methamphetamine and 
methcathinone in Southern Africa takes place mainly in 
South Africa, where licitly imported ephedrine and 
pseudoephedrine are diverted from domestic distribution 
channels. Other countries in Southern Africa reporting 
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seizures or stopped shipments of ephedrine include 
Mozambique, Zambia and Zimbabwe. According to the 
authorities of Mozambique, ephedrine is smuggled by air 
from India to Maputo via Addis Ababa, for smuggling 
onward to clandestine laboratories in the subregion. In 
2011, 41 kg of ephedrine were seized in Mozambique, and 
in 2012, a shipment of 1,970 kg of 1-phenyl-2-propanone 
(P-2-P) from India to Mozambique was suspended after it 
was confirmed by authorities that the importing company 
had no import authorization. In 2011, a suspected 
shipment of 500 kg of P-2-P intended for Mozambique 
was suspended by authorities of the exporting country, 
India. 
388. The reported seizures described above show that 
many subregions of Africa are actively being targeted by 
traffickers for use as both transit areas and destinations 
for precursors. At the same time, monitoring and control 
mechanisms over precursor chemicals are still weak in 
many African countries, and exact data on legitimate 
trade in, and annual licit requirements for, precursor 
chemicals continue to be scarce. To assist the 
Governments of African countries in preventing the 
diversion of precursor chemicals into illicit drug 
manufacture, INCB has launched a three-month 
international operation in June 2012, Operation 
Ephedrine and Pseudoephedrine Intelligence Gaps in 
Africa (Operation EPIG), focusing on shipments of 
ephedrine and pseudoephedrine, including 
pharmaceutical preparations containing those substances, 
destined for or transiting through Africa. 
 
 (d) Substances not under international control 
 
389. Khat (Catha edulis), a substance that is widely 
consumed in countries in East Africa and parts of the 
Middle East for its stimulating effects, is cultivated mainly 
in Ethiopia and Kenya. Most khat is grown for export to 
Somalia and Yemen and for consumption by expatriate 
communities. Owing to the health risks associated with 
khat consumption, khat is prohibited in several countries 
in East Africa, as well as in the United States, Canada and 
a number of countries in Europe. In June 2012, the 
Government of the Netherlands banned khat. The United 
Kingdom thus remains the only major European country 
allowing the import of that substance. 
390. Abuse of tramadol is a serious problem in a number 
of African countries, including Egypt, Libya and 
Mauritius. In 2011 and 2012, Egypt witnessed an upsurge 
in trafficking in tramadol. While in 2011, total seizures of 
tramadol preparations amounted to 120 million tablets, 
about 320 million tramadol tablets were seized in the 
seaports of Alexandria, Damietta and Port Said in the first 
quarter of 2012. The preparations are smuggled to Egypt 
mainly from China and India. The Libyan anti-narcotics 
agency reported that Libya is facing large-scale trafficking 
and abuse of tramadol; however, exact statistics are not 
available due to the current restructuring of the country’s 
law enforcement institutions. Abuse of tramadol 
preparations is also reported by Mauritius and Togo.  
391. Under the UNODC/World Customs Organization 
Container Control Programme, a total of 24 containers 
with a total of more than 132 tons of tramadol 
preparations were seized between February and  
October 2012. All containers originated in India and were 
seized in West Africa. Of those, 16 containers were 
intercepted in Lomé, 7 containers in Cotonou, Benin, and 
1 container in Dakar. A further container is being held in 
Tema, Ghana. Nineteen of those intercepted containers 
were ultimately destined for the Niger. Because part of the 
seized preparations might be counterfeit, forensic 
examinations will be conducted to determine whether the 
seized preparations actually contain tramadol. 
 
 (e) Abuse and treatment 
 
392. Lack of capacity for the collection and analysis of 
drug-related data, in particular drug abuse 
epidemiological data by the national authorities, remains 
a serious challenge in many African countries. Such 
information is urgently required for policy formulation 
and to tailor demand reduction interventions to meet 
local needs. The Board reiterates the importance of States 
in the region taking concrete steps to improve 
frameworks for the collection and analysis of drug-related 
data, and encourages greater international cooperation to 
that end. 
393. Abuse of cannabis herb, the most widely abused 
illicit substance in Africa, is reported in all subregions of 
Africa, while abuse of cannabis resin occurs mainly in 
countries of North Africa. The annual prevalence rate of 
cannabis abuse among the African population aged 15-64 
is estimated to be 7.8 per cent (range: 3.8-10.4 per cent), 
which is higher than the global average of 3.8 per cent 
(range: 2.8-4.5 per cent). West and Central Africa are the 
subregions with the highest prevalence rates, estimated at 
12.4 per cent (range: 5.2-13.5 per cent). Within that 
subregion, the highest national annual prevalence rate for 
cannabis abuse is that of Nigeria: 14.3 per cent of the 
population aged 15-64. In South Africa, cannabis was the 
most common primary substance of abuse in 2011 for 
patients in treatment under the age of 20. 
394. According to UNODC estimates, there could  
now be some 1.5 million cocaine drug abusers  
(range: 0.5 million-2.3 million) in West and Central 
Africa, which corresponds to an annual prevalence rate 
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ranging between 0.3 per cent and 1.1 per cent of the 
population aged 15-64. Nigeria and South Africa are the 
countries with the highest annual prevalence rates, 
estimated at 0.8 and 0.7 per cent, respectively, of the 
population aged 15-64. In South Africa, cocaine is 
commonly a secondary substance of abuse. In contrast, 
cocaine abuse in North Africa and East Africa is 
considered to be low. 
395. In Africa, heroin abuse is perceived to be increasing 
and is mainly concentrated in East and West Africa, 
reflecting the fact that East Africa is Africa’s main area of 
entry for Afghan heroin and West Africa is an important 
area of exit. The prevalence of heroin abuse, including 
abuse by injection, is higher in East Africa than in any 
other subregion, particularly in Kenya, Mauritius, 
Seychelles and the United Republic of Tanzania.  
396. Mauritius, Kenya, Nigeria and South Africa, in that 
order, are reported to have the highest annual prevalence 
rates of heroin abuse in Africa (1.3 per cent, 0.7 per cent, 
0.7 per cent and 0.5 per cent, respectively). Abuse of 
heroin mixed with cocaine and various additives, known 
locally as “sugars” or “niaope”, is also reported. According 
to estimates of Kenya’s National Authority for the 
Campaign against Alcohol and Drug Abuse (NACADA), 
there are over 200,000 heroin addicts in Kenya. The 
number of injecting drug abusers in Coast Province alone 
is estimated at between 40,000 and 60,000, and the 
average age at which people begin to abuse drugs is 
decreasing. In North Africa, heroin abuse is also reported 
by Egypt. 
397. The annual prevalence of amphetamine-type 
stimulants in Africa is estimated at between 0.2 per cent 
and 1.4 per cent of the population aged 15-64. This wide 
range reflects the fact that there is either limited or no 
recent or reliable data available for most parts of Africa. 
Nigeria, South Africa and Egypt, in that order, seem to 
have the highest annual prevalence rates of abuse of such 
stimulants (1.4 per cent, 1 per cent and 0.5 per cent of the 
population aged 15-64, respectively). Burkina Faso,  
Cape Verde, Côte d’Ivoire, Egypt, Ghana, Kenya, Senegal 
and Sierra Leone and several other African countries  
have reported abuse of amphetamine-type stimulants in 
recent years. In South Africa, methcathinone, crystal 
methamphetamine and MDMA (“ecstasy”) remain the 
most abused amphetamine-type stimulants. 
Methamphetamine is abused mainly in Western Cape 
province, especially in Cape Town, while methcathinone 
abuse continues to be limited to Gauteng province. 
According to the South African Community 
Epidemiology Network on Drug Use (SACENDU), the 
proportion of patients that reported methamphetamine as 
their primary substance of abuse remained stable in 
Western Cape province, at 35 per cent, in 2011.  
398. South Africa is possibly the world’s largest  
illicit market for methaqualone (Mandrax),  
a sedative-hypnotic, which is often abused in 
combination with cannabis. Although in many 
communities Mandrax is now considered old-fashioned, 
methaqualone is still relatively common as a secondary 
substance of abuse in Western Cape province. Abuse of 
methaqualone also occurs in other countries in East and 
Southern Africa, notably Kenya and Mozambique.  
399. The abuse of over-the-counter and prescription 
medicines, such as slimming tablets containing controlled 
substances, analgesics and benzodiazepines (including 
diazepam and flunitrazepam), continues to be a problem 
in many African countries. In West African countries, 
including Burkina Faso, Mali, the Niger and Senegal, 
abuse of amphetamine is common among labourers 
doing heavy physical work. In those countries, 
psychotropic substances such as pemoline, secobarbital, 
diazepam (Valium), flunitrazepam (Rohypnol) and 
pentazocine are sold on the illicit market, as well as 
counterfeit substances often sold as those substances, and 
are subject to widespread abuse. The abuse of 
buprenorphine (Subutex) and sedatives is a serious 
problem in Mauritius. In Egypt, prescription drugs, 
notably trihexyphenidyl (Parkinol) and carisoprodol 
(Somadril), are now the second most abused group of 
substances, after cannabis. Most of those substances are 
manufactured locally for medical purposes and are 
diverted from domestic distribution channels. High levels 
of non-medical use of prescription drugs (mainly 
benzodiazepines, analgesics, codeine preparations and 
sedative-hypnotics) are reported in South Africa.  
400. The increasing levels of drug abuse reported by 
many African countries will translate into a greater 
demand for treatment and rehabilitation. Yet the national 
health-care systems of many countries in Africa are not 
able to adequately meet such demand. Treatment is 
usually offered — mostly in the form of detoxification — 
in State mental health hospitals and/or psychiatric 
institutions. The number of trained personnel is 
insufficient, and there is a lack of access to and 
availability of drug dependence treatment and 
rehabilitation facilities for people in need. The Board 
therefore calls upon the Governments of African 
countries to improve the treatment available to  
drug-dependent persons and to facilitate their access to 
quality and affordable treatment services by providing 
support for the development and strengthening of such 
services and capacity-building for the entities that 
provide such services. 
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401. Under the joint UNODC/WHO project entitled 
“Treating drug dependence and its health consequences” 
(Treatnet II), assistance is provided to participating States 
to increase their technical competence in providing 
effective treatment and rehabilitation of drug-dependent 
persons tailored to the needs of different geographical 
regions. In Africa, the project is being implemented in 
Côte d’Ivoire, Egypt, Kenya, Morocco, Mozambique, 
Nigeria, Sierra Leone, the United Republic of Tanzania 
and Zambia. In Kenya, over 700 health workers were 
trained in drug dependence treatment. A regional 
training-of-trainers seminar held in Nairobi in  
September 2012 trained 54 health professionals from  
11 countries in Africa.  
402. In Algeria, a multi-year project has been put in 
place aimed at setting up a network of over 50 drug 
addiction treatment centres. So far, seven addiction care 
centres are already operational, in addition to existing 
facilities. 
403. In Kenya, the National Authority for the Campaign 
against Alcohol and Drug Abuse has started to develop an 
opiate substitution therapy programme and a syringe 
exchange programme.  
404. The commitment of the Government of  
Morocco to prevention, treatment and rehabilitation of 
drug-dependent persons is reflected in its national 
programme launched in 1999, which provides for the 
establishment of treatment centres for young people with 
addictive behaviours and offers awareness-raising, 
diagnosis, prevention and social reintegration to patients. 
Since 2010, Morocco has also had a methadone 
substitution programme in place.  
405. In the United Republic of Tanzania, where a 
methadone maintenance programme was launched in 
2011 for persons who abuse drugs by injection, one 
further opioid treatment centre was opened in 2012. It is 
expected that the programme will be able to serve up to 
1,500 injecting drug abusers. 
 
 
 B. Americas 
 
 
  Central America and the Caribbean 
 
 
 1. Major developments 
 
406. The region of Central America and the Caribbean 
continues to be used as a major transit area for South 
American cocaine heading northwards to the North 
American market. In general, the region experienced a 
decline in seizures of cocaine in 2010, possibly as a result 
of declining demand in North America. That 
notwithstanding, the increasing power of drug gangs has 
helped to raise corruption and homicide rates in the 
region, especially in Belize, El Salvador, Guatemala and 
Honduras, the “Northern Quadrangle”, which are 
particularly affected by significant levels of drug-related 
violence. Areas exposed to intense drug trafficking in 
Central America show higher homicide rates. Drug 
trafficking has corrupted some State institutions, which in 
a number of cases have been overwhelmed by the 
resources deployed by trafficking organizations. 
407. UNODC estimates that about 280 tons of South 
American cocaine (purity-adjusted) are destined for 
North America. Much of it travels by way of Central 
America and the Caribbean, where cocaine use is also 
increasing. Recently, cocaine shipments destined for 
countries in Central America, with further deliveries for 
Mexico and the United States of America, have increased. 
Cocaine prevalence rates in Central America and in the 
Caribbean have been estimated by UNODC at 0.5 per 
cent and 0.7 per cent (2010), respectively.  
408. In 2011 and 2012, there was increased trafficking in 
precursor chemicals in countries in Central America, in 
particular non-scheduled chemicals used in the illicit 
manufacture of methamphetamine. El Salvador, 
Guatemala and Nicaragua reported incidents in 2011 and 
2012 involving significant seizures of esters of 
phenylacetic acid and methylamine. Illicit laboratories 
have also been reported in the region. Similarly, seizures 
of chemical precursors, raw material (coca paste) and 
laboratories in Guatemala and Honduras indicate the 
likely existence of both cocaine- and heroin-refining 
facilities. Large seizures of chemicals effected over a short 
period present a challenge to the local authorities in 
terms of safe handling and environmentally friendly 
disposal. Furthermore, the abuse of MDMA (“ecstasy”), 
generally imported from Europe, has been spreading  
in Central America and the Caribbean since the  
period 2010-2011.  
409. The destabilizing effects of drug trafficking and 
their impact on regional security have increased and the 
region has been affected by links between drug trafficking 
and increased levels of violence. The links between drug 
trafficking, trafficking in weapons and the related higher 
levels of violence that characterized drug-related crime in 
a number of countries of the region over the past year 
continue to exist, including an increased homicide rate. 
According to the latest data of UNODC, Honduras and  
El Salvador are the most violent countries in the world, 
with homicide rates of 92 and 69 per 100,000 population, 
respectively, and Central America is the most violent 
region, with a rate of 41 per 100,000 population — one 
third higher than Southern Africa and twice the rate of 
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Central Africa and South America. The situation 
regarding crime- and drug-related violence in the region 
is critical, as in some areas people’s security continues to 
be threatened by increasing rates of violence, in particular 
drug-related crime. The number of recent arrests and 
extraditions of key drug traffickers in Guatemala, some 
with links to Mexican cartels, underscores the presence of 
drug cartels in Guatemala, as do reports of increasing 
violence in the country, where the homicide rate is  
38.5 per 100,000 population. 
410. Jamaica continued to be the largest producer of 
cannabis in the Caribbean and has been exploited by 
cocaine traffickers as a trans-shipment point for other 
illicit drugs. The illegal drug trade continues to play a 
critical role in providing capital to gang members and 
other organized criminal groups operating in Jamaica. In 
2010, the re-emergence of Curaçao as a major point of 
exchange (cannabis/cocaine) via drug mules was noted; 
nevertheless, in 2011 there was a shift back to Barbados 
and Trinidad and Tobago. Furthermore, Colombian 
traffickers are increasingly using routes through Panama, 
as a hub, and other Central American countries to move 
drugs to the United States.  
411. The Board is deeply concerned about the recent 
developments in Central America, in particular the  
high-level call in some countries to pursue legalization of 
illicit drugs, on the assumption that decriminalization of 
trafficking would reduce drug-related violence, which 
appear to be proposals that would be inconsistent with 
the obligations of parties under the international drug 
control conventions. The Board notes with concern the 
increasing influence of powerful drug cartels on the 
maras (local gangs), which have become diversified and 
internationalized and are now conducting their illicit 
drug-related activities and trafficking with the support of 
small- and medium-sized cartels. This poses a new 
challenge to the Governments of the region in tackling 
illicit drug trafficking and drug-related violence. 
412. UNODC has been implementing its regional 
programme for Central America for the period 2009-2012, 
which is being revised and will have a second phase for 
the period 2013-2015, and is also finalizing a regional 
programme for the Caribbean in close cooperation with 
the secretariat of the Caribbean Community 
(CARICOM). This work is being led by the regional hub 
for Central America and the Caribbean in Panama 
recently developed by UNODC. On 15 October 2012, 
UNODC established the Liaison and Partnership Office 
in Mexico as the first of its kind. This initiative may serve 
as a model for other countries in various regions and 
reinforces cooperation between Mexico and UNODC, 
taking advantage of Mexico’s expertise and experience in 
combating illicit drugs and organized crime. As a sign of 
regional cooperation, centres of excellence are being 
created in the Dominican Republic and Mexico with a 
view to promoting evidence-based drug demand 
reduction programmes and criminal justice responses. 
Criminal justice in Central America has been reinforced 
by the Central American Network of Organized Crime 
Prosecutors (REFCO) using best practices to strengthen 
transnational investigations to counter organized crime. 
Furthermore, the global Container Control Programme, a 
joint initiative of UNODC and the World Customs 
Organization, continued to expand, operating in more 
countries in the region and controlling containers 
transported by sea.  
 
 2. Regional cooperation 
 
413. The Twenty-first Meeting of Heads of National 
Drug Law Enforcement Agencies, Latin America and the 
Caribbean, was held in Santiago in October 2011. The 
Meeting considered three main issues: building 
partnerships with the chemical industry to strengthen 
precursor control, implementing effective border 
controls, and addressing the proceeds of drug trafficking. 
Participants discussed measures taken to counter drug 
trafficking, practical problems that impede cooperation at 
the regional and subregional levels, as well as measures to 
overcome such problems. The Board acknowledges the 
recommendations made at the Meeting, in particular that, 
in order to better target attempts at illicit diversion of 
precursor chemicals, Governments of the region should 
review the information they share on cocaine analysis and 
seized chemical precursors so as to ensure that such 
information supports trend analysis. The Board 
encourages continued and enhanced regional 
cooperation, coordination and exchange of information 
among law enforcement authorities of the region. The 
Board notes the important role and contribution of drug 
liaison officers in sharing of information and conducting 
joint investigations.  
414. The secretariat of CICAD Group of Experts on 
Chemical Substances and Pharmaceutical Products held a 
meeting in Santo Domingo from 25 to 29 June 2012, with 
the participation of the Board. The Board provided an 
overview of shortcomings in the control of precursor 
chemicals in the region and of tools available to 
Governments to counter such weaknesses, referring to 
article 12, paragraph 10 (a), of the 1988 Convention and 
encouraging registration with the new Precursors 
Incident Communication System (PICS) and establishing 
annual legitimate requirements for the import of 
amphetamine-type stimulant precursors.  
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415. The Ministry of Health of Belize hosted the Fifth 
Meeting of the Directors of National Drug Councils in 
Belize City on 3 and 4 May 2012. Building human 
resources in drug demand reduction for sustainable 
development was the theme of the annual regional 
gathering, which brought together 20 directors of drug 
councils of CARICOM States. Participants discussed 
Caribbean strategies to reduce the demand and supply of 
illicit drugs in the countries of the subregion in order to 
improve treatment and expand access to care for 
substance abuse disorders, and to reduce the psychosocial 
costs of substance addiction.  
416. The Dominican Republic hosted a regional 
conference on organized crime on 16 and 17 May 2012, 
organized by REFCO, a network of prosecution units in 
Central America and the Caribbean. Twelve 
representatives of public prosecutors’ offices discussed 
issues such as drug gangs and strategies to  
strengthen public prosecutors’ offices and to combat 
money-laundering.  
417. The President of the Republic of Honduras hosted 
the Presidents of the Central American Integration 
System (SICA) in Tegucigalpa on 6 March 2012. 
Presidents of the following countries participated in the 
event: Costa Rica, El Salvador, Guatemala, Honduras, 
Nicaragua and Panama. The meeting issued a joint 
declaration on the importance to the region of the safety 
and welfare of its citizens, and the need to continue the 
dialogue on the Central American Security Strategy and 
its importance in relation to the economic and social 
development of the region. The Minister for Foreign 
Affairs of the Dominican Republic and the Vice-President 
of the United States of America also participated in the 
meeting. Issues discussed included drug trafficking, 
money-laundering, arms trafficking, trafficking in 
precursor chemicals and the human, social and economic 
costs that those illegal activities had for the countries of 
the region. Participants recalled the commitments made 
by the international community in the framework of the 
International Conference in Support of the Central 
American Security Strategy in Guatemala City on 22 and 
23 June 2011. Participants also recognized the importance 
of strengthening regional mechanisms for information 
exchange between Central America and other countries in 
the international community, as well as the need to 
address the problem of drug trafficking in a 
comprehensive manner, taking into account not only 
interdiction efforts but also the reduction of supply and 
consumption in particular.  
418. The transregional Airport Communication Project 
(AIRCOP) and the Container Control Programme are 
both being actively implemented in Central America and 
the Caribbean. AIRCOP was activated at the UNODC 
Regional Office for Central America and the Caribbean in 
Panama in July 2012. Joint airport interdiction task forces 
will be set up for the project in a number of countries  
in Latin America and the Caribbean and will be 
connected to international law enforcement databases. 
Communication networks of INTERPOL and the  
World Customs Organization will be secured to enable 
the real-time transmission to international airports of 
operational information aimed at identifying illicit 
networks and intercepting illicit shipments. This initiative 
provides targeted programmes of training in the methods, 
techniques and systems of risk analysis, drug detection 
and criminal network investigation. In the Central 
American and Caribbean region, implementation of the 
project was planned for the Dominican Republic and 
Jamaica, and is expected to expand to other key locations 
in the region. The Container Control Programme is in 
operation in Costa Rica, Guatemala and Panama, as well 
as other South American countries. This joint effort 
enables countries to improve the information exchange 
between law enforcement agencies, enhance capabilities 
with counterparts, provide information exchange and 
container alerts, plan target operations, deploy special 
investigative techniques and aid in post-seizure 
investigations. In 2011, law enforcement officers 
cooperating with the Container Control Programme  
in Latin America seized about 10 tons of drugs and 
166,000 litres of various chemicals. The Programme will 
keep expanding in the region, with units planned to go 
into operation in the period 2012-2013 in Chile, the 
Dominican Republic, Guyana, Jamaica and Suriname. 
Comprehensive port assessments are being conducted, 
and memorandums of understanding are being 
negotiated with each of those countries. 
 
 3. National legislation, policy and action 
 
419. Costa Rica reported that it had continued to 
implement its national drug control plan for the period 
2008-2012. The strategy included a drug demand 
component, as well as areas relating to education, 
security, justice and non-governmental organizations.  
420. In 2011, Cuba continued its Operation Hatchet, led 
by the Ministry of the Interior and with the participation 
of other ministries, with a view to reducing the supply of 
illicit drugs through increased observation of the 
coastline and borders for detection and interdiction 
efforts. The Government of Cuba continued to interdict 
suspicious vessels and aircraft and to share information 
on “go-fast” vessels with neighbouring countries, 
including the United States. In 2011, some 45 real-time 
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reports of go-fast drug trafficking incidents were made by 
Cuba to the United States Coast Guard. 
421. In 2011, in order to better counter illicit drugs, the 
Government of El Salvador created a series of innovative 
procedural mechanisms to enhance criminal investigation 
from a scientific perspective, such as the use of special 
techniques — controlled delivery, controlled purchase 
and covert operations — as well as regulations on the 
forfeiture of assets of crime. The Government of  
El Salvador is implementing, in cooperation with OAS, 
drug-related programmes such as the Training and 
Certification Programme for Prevention, Treatment and 
Rehabilitation of Drug Abuse and Violence (PROCCER). 
In March and June 2012, REFCO provided a national 
training programme and workshop on wiretapping, 
organized by the Office of the Public Prosecutor of  
El Salvador for national prosecutors. These activities 
encouraged the exchange of information based on the 
needs and opinions of those involved in implementing 
wiretapping legislation. The Special Law on 
Telecommunications Intervention was adopted in 2010 
and includes provisions for wiretapping. 
422. Guatemala continued to support the United 
Nations-led International Commission against Impunity 
in Guatemala in order to investigate high-profile 
corruption cases and organized criminal activity, with a 
view to reinforcing the national justice system. In 
November 2011, the President, in an unprecedented 
measure, signed the final extradition order to extradite 
the former President to the United States on  
money-laundering charges. With the support of the 
United States Government, the Government of Honduras 
engaged in bolder narcotics interdiction operations, while 
also working to develop institutions capable of preparing 
criminal cases, bringing suspects before a judge and 
sending convicted criminals to prison. 
423.  The Government of Jamaica continues to work 
with its regional counterparts, such as Cuba, to combat 
trafficking in illicit narcotics. The Government is in the 
process of developing bilateral agreements with Cuba and 
Haiti to address the illicit drug trade, the “guns-for-
drugs” trade and other organized criminal activities. 
Regarding trafficking by sea, Jamaica reported that it had 
in place bilateral agreements with Cuba and the United 
States, and also envisaged cooperation agreements with 
the Bahamas and the Dominican Republic. Concerning 
individuals arrested for being involved in the illicit drug 
trade and other drug-related offences, the total number of 
Jamaicans arrested in 2011 amounted to 20,216, which 
surpassed the number of overall arrests for 2010. 
However, there has been an increase in the number of 
foreign nationals being used as couriers to smuggle drugs 
into Canada, the United Kingdom and the United States. 
In Jamaica, the recently re-established Ian Fleming 
International Airport and Falmouth Pier presented 
opportunities for drug traffickers to smuggle drugs, but 
this threat has been mitigated by the vigilance of the 
country’s law enforcement institutions. The Ministry of 
National Security was in the process of finalizing the 
National/Master Drug Abuse Prevention and Control 
Plan for the period 2012-2016. During 2011-2012, an 
annual anti-drug strategy was established under the 
Narcotics Review Committee in order to disrupt and 
dismantle major criminal drug groups and to speed up 
the cannabis eradication programme. 
424. Trinidad and Tobago continues to be a  
trans-shipment point for narcotics and precursor 
chemicals and for other illicit transnational activities. The 
Government is actively pursuing supply and demand 
reduction initiatives through legislative review, 
institutional strengthening, enhanced inter-agency 
collaboration, capacity-building, border control 
initiatives, information- and intelligence-sharing, public 
awareness and standardization of the operations of 
treatment and rehabilitation centres. To further those 
initiatives, several law enforcement and security agencies 
in the country have engaged in a number of interdiction 
strategies to tackle drug trafficking. In 2010-2011, the 
country’s law enforcement authorities participated in 
joint investigations with counterparts in France, 
Germany, Spain, the United Kingdom and the United 
States, which led to a number of seizures and arrests.  
 
 4. Cultivation, production, manufacture and 
trafficking 
 
 (a) Narcotic drugs 
 
425. While Central American and Caribbean countries 
produce cannabis and some opium and their residents 
also consume drugs, the primary risk in the region arises 
from its use in the transit of South American cocaine. In 
some countries in the region, higher homicide rates are 
linked to organized crime and conflicts between criminal 
groups over the control of drug trafficking routes to illicit 
markets further north. Organized criminal groups based 
in Colombia and Mexico have had an increasing 
influence over the illicit drug trade and growing violence 
throughout the region. In April 2012, Guatemalan law 
enforcement authorities arrested the head of a major drug 
trafficking and money-laundering organization based in 
Guatemala. The suspect had smuggled thousands of 
kilograms of cocaine to Mexico and into the United 
States, and was believed to be responsible for bringing the 
Mexican criminal group Los Zetas into Guatemala in 
2008. The individual had close ties to Los Zetas and 
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represented a dangerous and critical figure in the trade in 
illicit drugs in Central America.  
426. After a decline in recent years, there are indications 
that trafficking in cocaine through the Caribbean is 
increasing. Colombian authorities reported that most of 
their recent seizures pointed to the increasing importance 
of the Caribbean route as opposed to previous years, 
when seizures occurred mostly in the Pacific.  
In May 2012, United States authorities seized 1,288 kg of 
cocaine packaged in 50 large bales on a go-fast vessel in 
Caribbean international waters. Colombian authorities 
reported that, of 155.8 tons of cocaine seized in 2011,  
55 per cent had been seized in territorial and 
international waters. Traffickers are now usually sending 
shipments by sea, using boats or semi-submersibles, 
through the Caribbean to the Central American/Mexican 
corridor and afterwards overland into the United States. 
Jamaica reported that there had been a significant 
increase in the amount of cocaine seized in 2011 
compared with the previous year — 553 kg in 2011 
compared with 178 kg in 2010. About 1.5 kg of “crack” 
cocaine was seized in Jamaica in 2011. According to the 
report of the Twenty-first Meeting of Heads of National 
Drug Law Enforcement Agencies, Latin America and the 
Caribbean, held in Santiago from 3 to 7 October 2011, a 
new issue in the region has been the emergence of 
trafficking by air of liquid cocaine ingested by 
individuals. This method of concealment is on the 
increase, and airports of the region should take further 
measures to facilitate the identification of such cases. At 
that meeting, attention was also drawn to the trafficking 
of ingested cannabis products, a development that was 
reportedly the consequence of the high price of cannabis 
products in illicit markets. 
427. The Dominican Republic remains an important 
transit country for illicit drugs; however, due to 
increasing interdiction efforts, drug smuggling through 
the territory of that country has declined. The country’s 
efforts resulted in an increase in the amount of narcotics 
seized in 2011 as compared with 2010, with most seizures 
being made at the country’s six international airports and 
seaports. In 2011, Dominican authorities seized 6.7 tons 
of cocaine, 42 kg of heroin, 845 kg of cannabis and  
5,551 MDMA (“ecstasy”) tablets. During 2010, 4.85 tons 
of cocaine, 30 kg of heroin, 642 kg of cannabis and  
138 “ecstasy” tablets were seized by law enforcement 
authorities.  
428. In Trinidad and Tobago, the local drug problem is 
two-pronged, consisting of cocaine, originating primarily 
in Colombia, and potent varieties of cannabis trafficked 
from Colombia, Jamaica and Saint Vincent and the 
Grenadines for domestic consumption. Most of the 
cocaine transiting Trinidad and Tobago arrives via 
Guyana, Suriname and Venezuela (Bolivarian Republic 
of), and is transported in cargo containers destined 
primarily for Europe and smaller boats operating between 
Trinidad and South America. In 2010, according to the 
Trinidad and Tobago Police Service, 85 kg of cocaine  
were seized in the country, compared with 98 kg seized  
in the first half of 2011. During the same period  
(2010-2011), cannabis seizures decreased from 
approximately 1,848 kg to 825 kg. 
429. In 2010, Jamaica eradicated an area of cannabis 
plant cultivation equivalent to 447 ha, and, as at 
September 2012, 373 ha of cannabis plant  
(1,053,000 plants) had been eradicated by the 
Government. However, because of the lack of reliable 
information, the exact area under cultivation, the 
harvestable area and the extent of production of cannabis 
in Jamaica are not known. Jamaica continues to be a 
significant exporter of cannabis herb in the region. The 
country is also a source for trafficking in cannabis resin 
(“hashish”). In 2011, Jamaica seized about 36,732 kg of 
cannabis herb, 9 kg of hashish, 170 kg of cannabis oil and 
130 kg of cannabis seeds. 
430. Illicit cultivation of opium poppy in Central 
America, notably in Guatemala, is of increasing concern. 
Eradication reports suggest that illicit cultivation is 
increasing in Guatemala, which could substitute for the 
declining opium production in Colombia, where abuse of 
heroin has apparently increased, leaving less heroin for 
trafficking to other consumer countries. The amount of 
opium poppy eradicated in Guatemala rose from 489 ha 
in 2005 to 1,490 ha in 2011. Heroin seizures also 
increased along Central American trafficking routes, 
supporting the likelihood of increased opium production 
and supply of heroin. However, at present, no remote 
sensing or ground reviews of opium poppy cultivation 
and eradication activities are being carried out in Central 
America: so few precise cultivation and yield data or 
estimates of production currently exist.  
431. El Salvador reported cases involving criminal 
organizations trafficking in pharmaceutical preparations, 
in particular oxycodone, methadone and hydrocodone — 
medications that are used licitly for pain relief and for the 
treatment of heroin addicts. Investigations resulted in 
arrests of individuals involved in those activities, 
including medical personnel. The Board draws attention 
to the risks of abuse of such substances and calls upon 
Governments to monitor the situation in the region and 
to exercise effective control over distribution 
mechanisms.  
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432. In Saint Vincent and the Grenadines, an important 
producer of cannabis, officials estimated that more than 
300 acres (121 ha) of cannabis plants were under 
cultivation. During 2011, the Government eradicated  
70 acres (28 ha) of cannabis plant cultivation, destroying 
1,696,021 plants and seizing 10.1 tons of cannabis,  
39 kg of cocaine and 180 cocaine rocks. According to the 
UNODC 2011 Global Study on Homicide: Trends, 
Contexts, Data, homicide rates in Saint Vincent and the 
Grenadines reached a high of 33 per 100,000 inhabitants 
in 2007. The latest figure for 2010 is estimated at  
22 per 100,000 inhabitants. In 2011, Saint Vincent  
and the Grenadines also reported 522 drug-related 
prosecutions, 322 convictions and 432 persons arrested 
for drug offences.  
 
 (b) Psychotropic substances 
 
433. The misuse of pharmaceutical preparations, 
including those containing tranquillizers, sedatives and 
stimulants, continues to be a serious concern in Central 
America, especially among women. Central America 
remains a region of concern regarding the abuse of 
pharmaceutical preparations that contain stimulants, as 
well as of prescription stimulants. General data on 
prevalence for the region of Central America and the 
Caribbean are either not available or are not reported by 
countries. 
434. Central America has a high prevalence of abuse of 
amphetamine-type stimulants. Illicit manufacture of 
amphetamine-type stimulants and increased seizures of 
their precursors have been reported in several countries, 
in particular Guatemala, where a methamphetamine 
laboratory was dismantled by the authorities in  
December 2011. The laboratory was located in  
San Marcos, some 275 km from Guatemala City. At least 
500 kg of methamphetamine, estimated in value at more 
than 32 million United States dollars, were believed to 
have been manufactured by the clandestine laboratory. 
Guatemalan law enforcement authorities also confiscated 
manufacturing equipment and chemicals that could have 
been used in the synthesis of methamphetamine. In 2011, 
clandestine laboratories producing amphetamine-type 
stimulants were also dismantled in Nicaragua.  
435. According to a recent report released by CICAD, 
with respect to seizures, countries in Central America 
have reported on seized pharmaceutical products in 
terms of quantities and types of controlled substances, 
which varied from one country to another. These 
included primarily tranquillizers, such as the 
benzodiazepines diazepam, alprazolam and clonazepam. 
Smaller seizures of stimulants, such as methylphenidate, 
and anorectics such as amfepramone, phentermine and 
mazindol were also recorded.  
 
 (c) Precursors 
 
436. During 2011, measures taken by the police in  
El Salvador helped to expose a number of international 
drug trafficking networks using, as a modus operandi, 
imports of substantial quantities of precursors 
(ephedrine, pseudoephedrine, ethyl phenylacetate and 
methylamine) from China through the port of Acajutla. 
Those substances were then transported in small amounts 
by land to Guatemala for the illicit manufacture of 
synthetic drugs. In 2011, approximately 213 kg of such 
precursors were seized in El Salvador. 
437. In Guatemala, approximately 100 kg of ephedrine, 
95 kg of pseudoephedrine and 550,310 pseudoephedrine 
tablets were seized by the National Civil Police in  
2011-2012. Some 212 litres of sulphuric acid and  
512 litres of acetic anhydride were also seized during  
that period.  
438. In January 2012, the Tax Administration Service, the 
secretariat of the Navy and the Attorney General’s Office 
of Mexico seized 12 containers of monomethylamine, a 
non-controlled chemical used to manufacture 
methamphetamine, with an approximate weight of  
195 tons. The containers had arrived at the Mexican port 
of Lázaro Cárdenas from China. Ten of the containers 
were bound for Puerto Quetzal in Guatemala and the 
remaining two were headed for the port of Corinto  
in Nicaragua.  
 
 5. Abuse and treatment 
 
439. The annual prevalence of cocaine abuse among the 
general population in Central America and the Caribbean 
(0.5 per cent and 0.7 per cent, respectively) remains 
higher than the global average as trafficked cocaine spills 
into the general population. 
440. Annual prevalence of abuse of amphetamine-type 
stimulants has been reported as considerably higher in 
Central America than the global average, in particular in 
El Salvador (3.3 per cent), Belize and Costa Rica (1.3 per 
cent) and Panama (1.2 per cent). UNODC has estimated 
that some 330,000 and 220,000 people abuse 
amphetamine-type stimulants (excluding “ecstasy”) in 
Central America and in the Caribbean, respectively. 
Those numbers correspond to an estimated annual 
prevalence of abuse of amphetamine-type stimulants of 
1.3 per cent in Central America and 0.8 per cent in the 
Caribbean. Some 30,000 and 80,000 people are estimated 
to be MDMA (“ecstasy”) abusers in Central America and 
in the Caribbean, respectively, which would represent 
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respective estimated annual prevalence rates of abuse of 
“ecstasy” of 0.1 per cent and 0.3 per cent.  
441. The annual prevalence of cannabis abuse has been 
estimated at 2.4 per cent in Central America and 2.8 per 
cent in the Caribbean, with some 590,000 persons 
abusing cannabis in Central America and 760,000 persons 
in the Caribbean. According to UNODC, the annual 
prevalence of abuse of opioids was 0.5 per cent in Central 
America and 0.4 per cent in the Caribbean. Some 120,000 
and 100,000 people are estimated to be opioid abusers in 
Central America and in the Caribbean, respectively. As 
regards opiates, UNODC has estimated the annual 
prevalence at 0.1 per cent and 0.3 per cent for Central 
America and the Caribbean, with a low estimate of opiate 
abuse by 20,000 and 80,000 people, respectively.  
442. In Central America and the Caribbean, according to 
the latest figures available, an estimated 0.1 million people 
abuse cocaine in each subregion, which represents 2 per 
cent of the total population of cocaine abusers in the 
Americas (8.4 million people). The tentative estimate of 
the amount of cocaine consumed in Central America was 
5 tons, with an estimated 6 tons consumed in the 
Caribbean (of the tentatively estimated total of 275 tons 
of cocaine consumed in the Americas). 
443. According to the Caribbean Regional Strategic 
Framework on HIV and AIDS 2008-2012, a study 
conducted by CARICOM and the Pan Caribbean 
Partnership against HIV and AIDS, the HIV epidemic in 
the Caribbean is due primarily to sexual, mainly 
heterosexual, transmission. Surveys conducted in the 
region have suggested that there is an adequate level of 
knowledge about HIV in the Caribbean, although that 
knowledge has yet to sufficiently change behaviours. 
Countries have attempted to implement specific targeted 
interventions among most-at-risk populations, including 
drug abusers. 
444. The global programme for the prevention of drug 
use, HIV/AIDS and crime among young people continues 
in El Salvador, Honduras, Nicaragua and Panama, with 
evidence-based family skills, training programmes 
intended to prevent drug abuse, HIV/AIDS and crime 
and delinquency among young people by strengthening 
and improving the capacity of families to take better care 
of children. In addition, 115 families from the 
Panamanian provinces of Panamá and Colón have 
participated in outreach groups; 28 parent groups have 
been established in Honduras; and training has been 
given in Nicaragua to professionals of the National 
Institute against Alcoholism and Drug Addiction, the 
community police, the Ministry of Education and certain 
non-governmental organizations. To ensure the 
sustainability of the programme, additional train-the-
trainer programmes have been organized in Honduras, 
Nicaragua and Panama, reaching approximately  
80 facilitators, who are expected to continue the 
programmes at the national level for prevention and for 
strengthening the family. 
445. In Cuba, the national policy against drug abuse 
focuses primarily on preventive measures. Prevention 
programmes are oriented towards the promotion of 
healthy lifestyles and are tailored according to the 
particularities of each province (urban, rural or coastal 
areas). These programmes aim at improving 
identification of and support for groups at risk, early 
detection and suitable treatment of drug-dependent 
persons and rehabilitation through community 
participation. Family doctors are trained in the  
early detection of drug abuse. In Cuba, the network  
of specialized services for the treatment of  
addictions consists of mental health teams in polyclinics, 
community mental health centres, hospitals and 
detoxification centres. 
 
 
  North America 
 
 
 1. Major developments 
 
446. Despite declining prevalence rates for some drugs, 
North America remains the biggest illicit drug market in 
the world, as well as the region reporting the highest 
drug-related mortality rate. According to figures 
contained in the World Drug Report 2012,32 
approximately 1 in every 20 deaths among persons  
aged 15-64 in North America is related to drug abuse. 
That figure takes into account overdose deaths and 
HIV/AIDS acquired through shared use of contaminated 
drug paraphernalia, as well as trauma-related deaths, 
including motor vehicle accidents caused by driving 
under the influence of drugs.  
447. Annual prevalence of cocaine use fell in North 
America from 2.4 per cent of the population aged 15-64 
in 2006 to 1.5 per cent in 2011, equivalent to a decrease of 
some 38 per cent over that five-year period. The decline 
was linked to important drops in the clandestine 
manufacture of cocaine in Colombia over that period, as 
well as intensified measures by the Mexican authorities to 
prevent drug cartels from smuggling cocaine from the 
Andean countries to Mexico and the United States. 
448. Prescription drug abuse in North America 
continues to represent a major threat to public health and 
__________________ 
 32  United Nations publication, Sales No. E.12.XI.1. 
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remains one of the biggest challenges to the drug control 
efforts being deployed by Governments in the region. In 
the United States, overdose deaths caused by the abuse of 
prescription opioids are reported to have quadrupled 
since 1999. According to figures released by the Centers 
for Disease Control and Prevention, the number of deaths 
from opioid drug overdoses in the country since 2003 
exceeded those attributable to cocaine and heroin 
combined. It is also estimated that, for every death related 
to opioid overdoses, there were an estimated  
nine admissions to treatment for addiction to that 
category of drug. 
449. Drug-related data in the United States released in 
2012 confirmed significant increases in per capita sales of 
oxycodone and hydrocodone between 2000 and 2010 in 
several states. The increases in oxycodone sales were on 
the order of 565 per cent in Florida, 519 per cent in  
New York, 515 per cent in Tennessee and 439 per cent in 
Delaware, while hydrocodone sales increased by 322 per 
cent in South Dakota and 291 per cent in South Carolina 
and Tennessee. While part of those increases may be 
explained by an ageing population and a greater 
willingness of physicians to prescribe such medications 
for the treatment of pain, their greater availability has also 
contributed to increased abuse and addiction. The Board 
notes this development with concern and reiterates the 
importance for Governments of establishing effective 
control measures for the prescribing of drugs by medical 
practitioners, their distribution by wholesalers and their 
sale by pharmacies and continuing to develop and 
implement prevention and treatment programmes. It 
notes the measures taken by Governments in the region 
to control these drugs more effectively through such steps 
as more effective record-keeping and oversight of 
individual physicians and encourages broader adoption of 
such procedures. 
450. According to research published in the Journal of 
the American Medical Association, the number of babies 
born in the United States showing symptoms of opiate 
withdrawal tripled from 2000 to 2009, affecting 1 of  
every 1,000 newborns. In 2009 alone, approximately 
13,500 babies were born with withdrawal symptoms, 
which include seizures, breathing problems and feeding 
difficulties.  
451. On 6 November 2012, voters in the states of 
Colorado, Washington and Oregon voted on ballot 
initiatives to legalize the use of cannabis for recreational 
purposes in their respective states. In Colorado and 
Washington, the initiatives passed while voters in Oregon 
rejected cannabis legalization for non-medical and  
non-scientific purposes. The Board reiterates that the 
legalization of cannabis for non-medical and  
non-scientific purposes would be in contravention to the 
provisions of the 1961 Convention as amended by the 
1972 Protocol.  
452. As in other regions, traffickers in North America 
have continued to develop so-called “designer drugs”, 
substances whose chemical composition is engineered to 
remove them from the scope of existing control already 
applicable to substances with analogous properties. The 
two categories of “designer drugs” that are the most 
commonly abused are synthetic cathinones and synthetic 
cannabinoids. According to data released by the American 
Association of Poison Control Centers, calls to poison 
control centres in 2011 for human exposure to synthetic 
cannabinoids or synthetic cathinones more than doubled 
over the number reported for 2010. The Board urges 
Governments in the region to take cognizance of the 
content of chapter II of the present report, on emerging 
substances of abuse, and to consider implementing the 
recommendations to Governments which are contained 
therein. It takes note of the steps taken by Governments 
in North America to better control these substances 
through new statutes, as well as effective use of existing 
legal measures. 
453. In early 2012, Canada reported shortages of certain 
injectable drugs, caused by problems related to 
manufacturing standards at one of the country’s leading 
suppliers of generic drugs. Shortages were also 
compounded by a fire which destroyed part of a 
manufacturing plant, as well as by a recall of 57,000 vials 
of injectable morphine from health facilities across the 
country owing to incorrect labelling. The Board wishes to 
remind Governments in the region of the importance of 
diversifying sources of controlled medications and of the 
necessity of developing contingency plans to be 
implemented should the supply of these drugs be 
disrupted.  
454. The issue of drug shortages was also addressed by 
United States lawmakers through their adoption of the 
Food and Drug Administration Safety and Innovation 
Act, which was signed into law in July 2012. The Act is a 
comprehensive piece of legislation concerning a wide 
range of issues surrounding the manufacturing of drugs 
and medical devices, with a focus on safety, affordability 
and biomedical innovation. In order to prevent shortages 
of important drugs in the United States, the Act requires 
manufacturers of certain drugs to notify the Food and 
Drug Administration of any circumstances they 
encounter that may lead to shortages of the drugs  
they produce. 
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455. In Mexico, drug-related violence continued to 
constitute a major threat to public security nationwide. 
According to figures released by the Government of 
Mexico, over 60,000 people have been killed as a result of 
drug-related violence since 2006. The Attorney General 
reported that 12,903 people were killed between January 
and September 2011 alone, representing an 11-per-cent 
increase over the same period the previous year. 
Journalists reporting on organized crime continued to be 
targeted by traffickers and subjected to threats, 
intimidation, violence and murder. The President of 
Mexico has stated that the extent of drug-related violence 
in his country is attributable to sustained demand for 
illegal drugs in the United States. The Board notes that 
solutions to drug abuse and drug-related violence can be 
effective only if they are built upon supply and demand 
reduction initiatives, based on the principle of shared 
responsibility, and takes note of the joint efforts by the 
United States and Mexico, including measures to curb 
both supply and demand, to address this extraordinary 
challenge. 
 
 2. Regional cooperation 
 
456. In March 2012, Mexico hosted a high-level 
hemispheric meeting on transnational organized crime. 
The meeting, which was attended by representatives of  
33 members of OAS, was aimed at identifying new threats 
posed by international criminal syndicates and at 
identifying effective strategies to deal with organized 
crime in its many forms. The participants agreed on the 
need for closer regional cooperation based on the 
principle of shared responsibility. During the meeting, the 
Secretary General of OAS announced the creation of the 
Centre for Cooperation in Combating Transnational 
Organized Crime. 
457. Also in March 2012, the first-ever trilateral meeting 
of North American Defence Ministers was held in Ottawa. 
The meeting was intended to lead to the development of a 
common threat assessment mechanism for the region, as 
well as to foster increased cooperation to jointly address 
common security threats, including drug trafficking. 
458. On 2 April 2012, the sixth North American Leaders’ 
Summit was convened in Washington, D.C., bringing 
together the Presidents of the United States and Mexico 
and the Prime Minister of Canada. The three leaders 
discussed the regional economy, trade and energy, as well 
as transnational drug trafficking, and issued a joint 
statement reaffirming their commitment to continue to 
work together to address security threats, based on the 
principles of shared responsibility, mutual trust and 
respect. They also announced their intention to enhance 
interregional cooperation with Central America, in 
particular by launching a Central American Integration 
System — North America dialogue on security challenges. 
The Board acknowledges the commitment demonstrated 
by North American leaders in improving regional 
cooperation and welcomes initiatives aimed at fostering 
greater interregional cooperation.  
459. The leaders of Canada, Mexico and the United 
States participated in the Sixth Summit of the Americas, 
held in Colombia in April 2012. The Summit focused  
on regional cooperation and economic integration,  
as well as security challenges, including those related  
to drug abuse and drug-trafficking-related violence (see 
para. 514 below). 
460. The President of Mexico participated in the Second 
Mexico-Caribbean Community Summit, which was held 
in Bridgetown on 20 and 21 May 2012. The issues 
discussed during the summit included economic 
development and integration, environmental protection 
and transnational organized crime. The participating 
States agreed to continue to work together to develop 
regional solutions to the challenges with which they were 
confronted. 
461. On 30 and 31 August 2012, the Meeting on Social 
Integration and Drugs in Latin America, organized by 
CICAD, was held at OAS headquarters in Washington, 
D.C. The meeting, which was financed jointly by OAS 
and the Government of Spain, was aimed at providing a 
forum for discussion of issues related to social integration 
and vulnerability to drug abuse in order to contribute to 
the development of comprehensive policies to address 
that problem. 
462. Throughout 2012, the Governments of Canada and 
the United States continued to implement measures 
under their joint “Beyond the Border Action Plan for 
Perimeter Security and Economic Competitiveness”. The 
action plan provides for greater cooperation between 
customs and law enforcement authorities in both 
countries, including through the sharing of intelligence 
and an increase in the joint screening of land and air 
cargo and passenger baggage. In June 2012, both 
Governments announced the creation of binational port 
operations committees, mandated with streamlining 
implementation of the action plan, at eight Canadian 
airports. 
463. In August 2012, the United States Drug 
Enforcement Administration and the Government of 
Mexico announced the conclusion of a memorandum of 
understanding aimed at coordinating their efforts to 
address the significant increase in illegal 
methamphetamine laboratories on both sides of their 
shared border. The agreement is aimed at bolstering the 
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exchange of information and intelligence, joint chemical 
control efforts and training and resources for dismantling 
illegal laboratories.  
464. The United States State Department has also set 
aside Merida Initiative funding to increase the capacity of 
Mexican law enforcement to detect and dismantle illegal 
drug laboratories operated by Mexican traffickers, to 
gather evidence and to destroy chemical precursors used 
in the manufacturing of illicit drugs. 
465. Drug trafficking networks have continued to use 
submersible and semi-submersible vessels to smuggle 
large quantities of drugs from South America along the 
Central American coast to northern markets. In response 
to that threat, the United States and Canada have 
continued to participate in Operation Martillo, a 
collaborative law enforcement programme that brings 
together 14 countries from the Americas and Europe and 
is aimed at disrupting maritime smuggling along both 
sides of the Central American isthmus. According to 
United States authorities, in 2011 the operation resulted 
in the interception of 119 tons of cocaine, with a 
wholesale value of $2.35 billion, before it could reach 
destinations in the United States. The Board 
acknowledges the positive results achieved by the States 
participating in Operation Martillo and encourages them 
to continue to implement this project, as well as to 
explore further avenues of cooperation. 
 
 3. National legislation, policy and action 
 
466. In April 2012, the United States Administration 
released its 2012 National Drug Control Strategy, which is 
aimed at building upon the framework established by the 
2010 and 2011 strategies, as well as the Prescription Drug 
Abuse Prevention Plan. The strategy lays out the 
Administration’s proposed measures to: prevent drug 
abuse in the community; expand treatment and 
rehabilitation support and integrate them into the  
health-care system; address problems related to drug 
abuse, delinquency and incarceration; disrupt domestic 
drug trafficking and production and strengthen 
international cooperation; and improve information 
systems for analysis and assessment. The 2012 strategy 
also continues the Administration’s focus on the 
prevention of prescription drug abuse and driving under 
the influence of drugs and retains the emphasis on 
“special populations”, a term encompassing college and 
university students, women and families, former and 
serving members of the military and their families, and 
groups considered to have particular treatment needs. 
Projected expenditures for prevention and treatment 
initiatives undertaken under the strategy for the 2012 
fiscal year are $10.1 billion. 
467. Throughout 2012, the Government of Mexico 
continued to implement the strategic objectives for that 
year set out in its action plan for the prevention and 
treatment of addictions, including opening additional 
Nueva Vida (“New Life”) referral centres, increasing 
training of health-care workers working with addiction, 
fostering a national and international approach to 
prevention activities and further developing and 
integrating the addiction treatment network.  
468. In April 2012, the fourth National Prescription 
Drug Take-Back Day was held in the United States, 
allowing the Drug Enforcement Administration and its 
partners across the country to collect 276 tons of 
unneeded prescription medications at 5,659 collection 
points. The total amount of prescription drugs collected 
in 2012 brought the four-year total to more than 680 tons. 
According to new figures released by the Office of 
National Drug Control Policy, 68 per cent of new  
past-year abusers of prescription pain relievers obtained 
the pills from a friend or family member for free or took 
the pills from them without asking. INCB welcomes this 
initiative by the United States authorities and wishes to 
remind Governments that the development of effective 
disposal mechanisms for unneeded pharmaceuticals is an 
essential component in any effective strategy against 
prescription drug abuse. 
469. In response to the problem of prescription drug 
abuse, several states in the United States have introduced 
legislation aimed at curbing abuse, including through the 
creation of prescription monitoring systems designed to 
ensure that doctors are not overprescribing prescription 
drugs and that the same individuals are not obtaining 
them from multiple doctors and pharmacies. At the 
federal level, the Food and Drug Administration in  
July 2012 approved a risk evaluation and mitigation 
strategy for extended-release and long-acting opioid 
drugs. The strategy is aimed at increasing the number of 
health-care professionals trained on how to prescribe 
certain painkillers and help patients use the drugs safely. 
470. The Government of Canada announced plans to 
comprehensively review existing regulations governing its 
Marihuana Medical Access programme, based on 
extensive public consultations held in 2011. The 
consultation process, which solicited input from 
individuals licensed under the current programme, 
provincial and territorial health and public safety 
officials, physicians and medical associations, 
pharmacists and municipalities, was undertaken with the 
stated purpose of reducing the risk of abuse and 
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exploitation by criminal elements, increasing community 
safety and improving the way programme participants 
access medical cannabis. According to information 
provided by Health Canada, changes to the programme 
are expected to include the phasing out of personal 
cultivation by licensed individuals in order to reduce the 
risk of diversion to illicit channels, as well as the 
tightening of controls on cannabis producers licensed 
under the programme. These changes are expected to 
enter into force in 2013. The Minister of Health of 
Canada has publicly acknowledged that strengthening the 
current compliance and enforcement regime is necessary 
to ensure adequate regulation of licensed producers. The 
Board notes the steps taken by the Government of 
Canada to adopt measures to reduce the risk of diversion 
of cannabis administered under this programme and will 
continue to monitor the outcomes of the consultation 
process. 
471. In the United States, the issue of the sale and use of 
cannabis for medical purposes has remained a 
contentious one. In May 2012, Connecticut became the 
seventeenth state to enact legislation allowing such sale 
and use, which is also permitted in the District of 
Columbia despite the existence of the Controlled 
Substances Act, a federal statute explicitly prohibiting the 
possession, manufacture and distribution of cannabis 
except for limited legitimate uses. In November 2012, the 
electorate of the states of Arkansas, Massachusetts and 
Montana were asked to vote on ballot initiatives related to 
the use of “medical cannabis” in their respective states. 
Voters in Massachusetts approved the initiative in their 
state, while those in Arkansas and Montana rejected the 
establishment of state-sanctioned medical cannabis 
schemes.  
472.  The Los Angeles City Council voted in August to 
instruct the city’s police department to work with the 
Drug Enforcement Administration and the city’s district 
attorney to enforce its municipal ban on “medical” 
cannabis dispensaries. The ban is currently being 
challenged before the California Supreme Court. 
Throughout California, concerted action by state officials 
and law enforcement agencies has led to the closure of 
nearly half of the 1,400 cannabis dispensaries operating in 
the state. The Board notes that the control requirements 
that have been adopted in the 17 states in question and in 
the District of Columbia under the “medical” cannabis 
schemes fall short of the requirements set forth in  
articles 23 and 28 of the 1961 Convention as amended by 
the 1972 Protocol.  
473. In June 2012, the Chicago City Council voted to 
decriminalize possession of 15 grams of cannabis or less. 
The Council ordinance confers discretion upon Chicago 
police to issue citations of between $250 and $500 for 
possession of up to 15 grams. Police will continue to 
arrest individuals smoking cannabis in public, individuals 
under the age of 17 caught with the drug and any 
individual they believe to be selling the drug. In addition 
to the fine imposed for violations of the ordinance, the 
director of administrative hearings is also authorized by 
the ordinance to require violators to attend a drug 
awareness programme and/or perform community 
service. Also in June 2012, the Governor of New Jersey 
vetoed a bill adopted by the New Jersey General Assembly 
that would have decriminalized the possession of up to  
15 grams of cannabis and making it subject to fines of 
between $150 and $500, with mandatory drug education 
classes for repeat offenders. The Governor based his 
opposition to the bill on its incompatibility with federal 
law, which classifies cannabis as an illegal drug.  
In New York state, a cannabis decriminalization bill put 
forward by the Governor was defeated by lawmakers on 
the same grounds. The Board requests that the 
Government of the United States take effective measures 
to ensure the implementation of all control measures  
for cannabis plants and cannabis, as required under the 
1961 Convention, in all states and territories falling 
within its legislative authority.  
474. In January 2012 and as part of the process aimed at 
strengthening the capacity of the federal institutions of 
Mexico to combat criminal and drug trafficking 
organizations, the Ministry of Public Security requested 
UNODC to evaluate the New Police Model, developed by 
the Government of Mexico as a cornerstone of its new 
security policy, which has been gradually implemented 
since 2007. The evaluation was undertaken by a team of 
international experts recruited, coordinated and advised 
by UNODC. The process was completed in May with the 
submission to the Ministry of Public Security of a 
detailed report on the structure, capacity and processes of 
the newly established Federal Police, as well as a set of 
recommendations for the further strengthening of the 
model. 
475. In February 2012, the Canadian Centre on 
Substance Abuse hosted a national dialogue on the abuse 
of prescription drugs in Canada. The consultation process 
with expert advisory committees on treatment, education, 
prevention and monitoring and enforcement was 
expected to culminate in the elaboration of a national 
strategy, to be released in 2013. 
476. At a meeting held in July 2012, the Canadian 
Association of Chiefs of Police approved a draft 
resolution on the illicit use of pharmaceuticals, to be 
presented at the Association’s next annual meeting. The 
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resolution calls for increased cooperation between police 
and other stakeholders, including health-care 
professionals, in collecting data on the issue and calls for 
the creation of a national prescription drug drop-off day. 
A drop-off day for unused prescription drugs was held in 
the Niagara region of the province of Ontario in  
May 2012, allowing the collection by local authorities of 
large quantities of oxycodone, codeine, fentanyl and 
hydromorphone. 
477. In February 2012, the Drug Enforcement 
Administration of the United States issued a six-month 
extension of the placement of five synthetic cannabinoids 
in schedule I of the Controlled Substances Act, subjecting 
them to strict control measures. The comprehensive Food 
and Drug Administration Safety and Innovation Act, 
mentioned above, also contained the Synthetic Drug 
Abuse Prevention Act, which places 15 specific 
cannabimimetic agents, 2 synthetic cathinones and  
9 synthetic phenethylamines under national control. The 
Act also extends the validity period of orders issued by 
the Attorney General under the Controlled Substances 
Act, temporarily placing a substance in schedule I “to 
avoid an imminent hazard to the public safety” for a 
period of between one and two years and extends 
temporary scheduling from six months to one year when 
rule-making proceedings to permanently schedule the 
drug are in progress.  
478. Also, in July 2012, the Drug Enforcement 
Administration conducted Operation Log Jam, a 
coordinated enforcement action targeting synthetic 
cannabinoids and synthetic cathinones in which  
250 search warrants were served at locations across the 
United States. The operation resulted in 90 arrests and 
seizures of 4.9 million packets of synthetic cannabinoids 
and material to process an additional 13.6 million 
packets, 167,000 packets of synthetic cathinones and  
$36 million in United States currency. While 
acknowledging that several of the substances seized in 
Operation Log Jam were not prohibited as such by the 
Controlled Substances Act, the Drug Enforcement 
Administration has stated that federal prosecutions 
related to these substances will take place pursuant to the 
Controlled Substance Analogue Enforcement Act, which 
allows drugs to be treated as controlled substances if they 
are proven to be chemically or pharmacologically similar 
to substances already controlled under the Controlled 
Substances Act.  
479. On 20 September, the Government of Canada 
added methylenedioxypyrovalerone (MDPV), a synthetic 
cathinone marketed as “plant food” and “bath salts”, to 
schedule I of the Controlled Drugs and Substances Act 
banning possession, trafficking, import, export and 
production of the substance without Government 
authorization. 
480. In response to persistent attacks by drug syndicates 
against members of the media in his country, the 
President of Mexico in June 2012 signed the Law for the 
Protection of Human Rights Defenders and Journalists. 
The law contains concrete measures aimed at addressing 
acts of violence and intimidation against journalists; the 
measures include increased cooperation between the 
federal and state governments and the strengthening of 
protective and preventive measures. The law also calls for 
the creation of a special fund for the implementation of 
the law, as well as the creation of a governing body, an 
advisory board and a national executive coordinating 
office. The Ministry of the Interior of Mexico also 
supported UNODC in the completion of a pilot project 
supported by Germany on violence committed by drug 
trafficking and criminal organizations against members 
of the media in Mexico. The project analysed patterns and 
causes of violence against members of the media, with the 
involvement of local academia, media representatives and 
state and local institutions. One of the outcomes of the 
analysis was the identification of existing best practices 
aimed at reducing the exposure to risk of members of the 
media and the formulation of a set of recommendations 
aimed at improving institutional capacity in responding 
to requests for protection of members of the media and 
reducing their exposure to risk.  
 
 4. Cultivation, production, manufacture and 
trafficking 
 
481. Drug-smuggling syndicates have continued to 
innovate in their efforts to smuggle drugs into and within 
the region, including through the use of submersible and 
semi-submersible vessels to smuggle drugs from South 
America along the Central American coast to northern 
markets. In addition, the building of sophisticated  
cross-border tunnels has continued. According to 
Immigration and Customs Enforcement of the United 
States, more than 150 tunnels equipped with lighting, 
ventilation and, in some cases, railcar systems, have been 
discovered since 1990. The discovery of the tunnels has 
resulted in the seizure of several tons of illegal drugs, 
mostly cannabis.  
 
 (a) Narcotic drugs 
 
482. Cannabis continues to be widely produced and 
trafficked in all three countries in the region, with 
substantial seizures being reported by each of them. 
Cross-border cannabis trafficking within North America 
also remains an issue of great concern. Information 
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provided to the Board by the Government of Mexico 
shows a significant decline in cannabis seizures, from 
over 2,248 tons in 2010 to 1,795 tons in 2011. Meanwhile, 
United States seizure data for 2011 reveal a decrease in 
cannabis seizures, from over 1,895 tons in 2010 to  
1,834 tons in 2011. In contrast, the quantity of cannabis 
seized in Canada in 2011 increased slightly, from 105 tons 
in 2010 to a five-year high of 111 tons. In addition to the 
large quantities of cannabis produced in the United States 
for internal consumption, Canada and Mexico remain 
major source countries. 
483. Extensive outdoor production of cannabis has 
continued to be identified by national law enforcement 
agencies in North America. United States authorities have 
identified increased attempts by traffickers to cultivate 
cannabis on public lands, such as in forests. Widespread 
indoor production of cannabis has also continued in the 
region, mainly in the United States and Canada. 
According to United States law enforcement data, indoor 
growing operations discovered in 2010 were heavily 
concentrated in Florida and California. 
484. According to Statistics Canada, although the 
general crime rate in Canada continued to decline in 
2011, drug-related crime increased slightly, reflecting  
a trend which began in the 1990s. Of a total of  
113,100 drug-related crimes reported by police in 2011, 
more than half (54 per cent) were related to cannabis 
possession, a 7-per-cent increase over the previous year. 
485. The cultivation of opium poppy in Mexico has 
increased, with Mexican authorities reporting opium 
seizures in 2011 totalling 1.45 tons, representing a 
significant increase over the 1 ton reported in 2010. After 
a spike in 2010, when over 2.9 tons of opium were 
reported seized in the United States, seizure numbers for 
2011 showed a considerable drop, to slightly over 48.5 kg. 
486. Large-scale law enforcement operations targeting 
the cultivation of opium poppy and the manufacturing of 
heroin in Mexico have yielded unprecedented results. 
While the country reported heroin seizures for 2011 
totalling more than 685 kg, National Defence Ministry 
officials confirmed having seized 3,640 litres of a liquid 
which laboratory tests revealed to be heroin. The seizure 
represented the largest of its kind ever carried out in 
Mexico.  
487. According to the United States Office of National 
Drug Control Policy, Mexico and Colombia have 
remained the main source countries for heroin abused in 
the United States, with Mexican heroin more prevalent in 
states west of the Mississippi river and Colombian heroin 
more prevalent to the east of it. After nearly doubling 
between 2005 and 2010, reported heroin seizures in the 
United States continued their increase, to 2.95 tons in 
2011 compared with 2.42 tons in 2010. Afghanistan 
remained the primary source of heroin in Canada. In 
2010, Canada seized 98 kg of heroin, while reported 
seizures for 2011 totalled 39 kg, continuing a decline that 
was first observed in 2008. 
488. Although North America still represents the largest 
global market for cocaine, abuse of the drug in the region 
has continued to decline. That can be attributed in part to 
reduced supply caused by a 47-per-cent drop in cocaine 
manufacturing in Colombia, the primary source country 
for cocaine smuggled into the region, as well as the 
disruption of supply routes through Mexico owing to both 
the efforts of law enforcement authorities and the conflict 
between criminal syndicates in that country. The decline is 
also the result of traffickers increasingly targeting emerging 
markets in Europe, South America and Oceania. The 
decrease in the availability of cocaine in the region has led 
to increased prices and decreased purity.  
489. Cocaine seizures in Mexico remained relatively 
stable in 2011 at 9.4 tons, following a substantial decline 
from 21.6 tons in 2009 to 9.4 tons in 2010. Cocaine 
seizures in the United States in 2011 declined slightly, 
from 66.7 tons in 2010 to 58.2 tons. In Canada, cocaine 
seizures plummeted to 4.64 kg in 2011 from more than 
1.1 tons reported in 2010. 
490. Prescription drug abuse, mostly of opioid 
analgesics, has remained an issue of considerable concern 
for Governments in the region. Efforts to control abuse of 
these drugs have been hampered by their widespread 
availability and by the ease with which they can be 
obtained from friends and family members, who remain 
by far the primary source of abused pharmaceuticals. 
Abusers of prescription medications have also continued 
to exploit weak control measures for monitoring 
prescriptions in many jurisdictions. With the 
strengthening of control measures and a growing 
awareness among pharmacists and health-care 
professionals of the dangers of prescription drug abuse, 
illegal Internet drug sites and dealers have become a 
growing source of prescription drugs. 
491. Large-scale abuse of prescription drugs in North 
America has led to widespread diversion and 
counterfeiting of these substances. According to 
information provided by Health Canada, over  
3 million tablets were diverted in Canada between 2009 
and 2011, with over 70 per cent having been stolen in 
armed robberies or as a result of breaking and entering 
and 3 per cent having been lost in transit; the 
disappearance of a further 19 per cent remained 
unexplained. The vast majority of the tablets stolen were 
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opioids, with oxycodone, hydromorphone and morphine 
constituting the main drugs sought by traffickers. In the 
United States, the Drug Enforcement Administration has 
continued to focus on drug wholesalers and pharmacies 
in an effort to counter prescription drug diversion. In 
2012, it moved to revoke the controlled substances 
authorizations of several pharmacies suspected of having 
diverted controlled substances, primarily opioid 
analgesics.  
 
 (b) Psychotropic substances 
 
492. Illicit large-scale manufacturing of 
methamphetamine in Mexico has continued to expand, 
and falling prices and increased purity levels have spurred 
increased availability of the drug in the United States. 
Another factor that has increased the availability of 
methamphetamine has been the further development of 
new manufacturing processes, which have led to faster 
and easier manufacturing of the drug. 
493. According to UNODC, 22 tons of 
methamphetamine were seized in North America in 2010, 
accounting for approximately half of all such seizures 
globally. Figures released jointly by the Government of 
Mexico and the Drug Enforcement Administration  
of the United States reveal that Mexico experienced a 
1,000-per-cent increase in seizures of clandestine 
methamphetamine laboratories between 2010 and 2011. 
The figures also show that seizures of methamphetamine 
by United States law enforcement officers at the country’s 
border with Mexico in 2011 totalled 7.4 tons, more than 
double the amount seized in 2009. 
494. The resurgence of MDMA (“ecstasy”) abuse in the 
United States, noted by the Board in its previous annual 
report, has continued, with availability of the drug 
steadily increasing. Canada remains a significant source 
country for “ecstasy” abused in the United States, with 
Canadian drug syndicates also increasingly targeting 
emerging markets. Law enforcement authorities in 
Canada have also identified possible incidences of 
polydrug manufacture in which “ecstasy” was being 
manufactured in methamphetamine laboratories. 
 
 (c) Precursors 
 
495. Over the past decade, Governments in North 
America have introduced increasingly stringent control 
measures for precursors and have bolstered efforts to 
prevent diversion, in particular through the use of the 
Pre-Export Notification (PEN) Online system, as well as 
through participation in successful multilateral precursor 
control initiatives such as Project Prism and Project 
Cohesion.  
496. Despite decisive action taken by Governments in 
the region, traffickers have persisted in their attempts to 
smuggle precursors into the region and to divert them 
from licit trade. Traffickers have also increasingly sought 
to circumvent existing control measures by substituting 
controlled substances, such as ephedrine and 
pseudoephedrine, in their manufacturing processes with 
alternative chemicals such as esters of phenylacetic acid, 
which are not under international control. Thus, while 
declines in the use of ephedrine and pseudoephedrine 
have been noted, they have not necessarily translated into 
a long-term reduction in illicit methamphetamine 
manufacturing. 
 
 (d) Substances not under international control 
 
497. Illicit drug manufacturers in North America have 
continued to innovate in developing new substances of 
abuse and in identifying ways to circumvent existing 
controls on the ingredients they require for their 
manufacturing activities. As was discussed in chapter II, 
new psychoactive substances, which are being marketed 
as “spice”, “plant food”, “bath salts” and so-called “legal 
highs” and which have analogous effects to cannabis, 
“ecstasy” and amphetamines, are becoming increasingly 
available through commercial outlets and on the Internet. 
498. The smuggling of khat into Canada has continued, 
with the Canada Border Services Agency reporting 
having made seizures of khat 9,482 times between 
January 2005 and July 2011, making it the third most 
commonly seized drug at the Canadian border, after 
cannabis plant and steroids.  
499. According to the World Drug Report 2012, Salvia 
divinorum, a perennial herb native to Mexico, where it is 
used by indigenous groups in religious ceremonies, is 
increasingly being abused in Canada for its 
hallucinogenic effects. Although Salvia divinorum is not 
currently scheduled under the Controlled Drugs and 
Substances Act, Health Canada has proposed including it 
as a controlled substance. In the United States, it is not 
under national control under the Controlled Substances 
Act but has been placed on the Drugs and Chemicals of 
Concern list of the Drug Enforcement Administration. In 
addition, several United States states have banned the 
substance. 
 
 5. Abuse and treatment 
 
500. According to the figures for 2010 contained in the 
World Drug Report 2012, the annual prevalence rate for 
cannabis abuse in North America remained stable at  
10.8 per cent of the population aged 15-64 and continued 
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to be significantly higher than the estimated world annual 
prevalence rate of 2.6-5.0 per cent. Data for the United 
States, however, reveal an upward trend. The annual 
prevalence of cannabis use in the United States rose from 
10.1 per cent of the population aged 12 and older in 2007, 
to 11.5 per cent in 2011.  
501. North America had a considerably higher estimated 
opioid prevalence rate, at 3.8-4.2 per cent, than the global 
average of roughly 0.6-0.8 per cent. The report pointed 
out, however, that the level of abuse of prescription 
opioids in the region was greater than that of heroin. At 
0.9 per cent, past-year “ecstasy” use in North America was 
also higher than the global average of 0.2-0.6 per cent. 
502. UNODC data for 2010 (the most recent year 
available) reveal that cocaine abuse continues to represent 
a major problem in North America. There were an 
estimated 5 million past-year cocaine users in the region, 
representing nearly one third of the global total. The data 
did indicate a decrease in the annual prevalence of 
cocaine use, from 2.4 per cent among the population  
aged 15-64 in 2006 to 1.9 per cent in 2009, 1.6 per cent  
in 2010 and 1.5 per cent in 2011. 
503. The United States National Survey on Drug Use and 
Health for 2011 released in August 2012 shows decreases 
in the estimates of non-medical use of psychotherapeutic 
drugs (a term used to describe both over-the-counter 
pharmaceuticals and prescription drugs) in the United 
States, compared with the estimates for 2010. The survey 
for 2011 estimates that 2.4 per cent of the population  
aged 12 or older used psychotherapeutic drugs for  
non-medical purposes in that year (down from 2.7 per 
cent in 2010 and 2.8 per cent in 2009). This included 
declines in the percentage of those aged 12 or older using 
pain-relieving drugs “non-medically” from 2.1 per cent in 
2009 to 2 per cent in 2010 and 1.7 per cent in 2011, and a 
decline in the percentage of those using tranquillizers  
for non-medical purposes from 0.9 per cent in 2010 to  
0.7 per cent in 2011. The proportion of those individuals 
aged 12 or older using stimulant and sedative 
psychotherapeutic drugs remained constant, at 0.4 per 
cent and 0.1 per cent respectively.  
504. The same survey also presented data on the 
methods used to obtain psychotherapeutic drugs for non-
medical use. As in the previous National Survey on Drug 
Use and Health (for 2010), the most recent data show that 
over one half of non-medical users of pain relievers, 
tranquilizers, stimulants and sedatives aged 12 or older 
obtained the prescription drugs they most recently used 
“from a friend or relative for free”. 
505. According to figures for 2011 contained in the 
Canadian Alcohol and Drug Use Monitoring Survey, the 
rates for both lifetime and past-year abuse of several 
drugs in Canada declined. According to the survey, 
lifetime cannabis use reported among Canadians 15 years 
of age or older in 2011 was 39.4 per cent, compared with 
the 44.5 per cent reported for 2004. The number of 
respondents reporting having used cannabis in the past 
year also significantly declined to 9.1 per cent in 2011, 
from 14.1 per cent for 2004. Rates of past-year abuse of 
cocaine for 2011 (0.9 per cent), MDMA (“ecstasy”)  
(0.7 per cent) and methamphetamine (0.7 per cent) 
remained relatively unchanged. The survey also  
reveals that, in 2011, 22.9 per cent of Canadians aged  
15 years or older used psychoactive pharmaceuticals 
(tranquillizers/sedatives, stimulants, opioid pain 
relievers). 
506. According to figures for 2010/11 reported in the 
Youth Smoking Survey, past-year use of cannabis among 
Canadian students in grades 7 to 12 significantly 
decreased, from 27 per cent in 2008/09 to 21 per cent in 
2010/11. At 23 per cent, past-year use among males 
continued to be higher than among females (19 per cent). 
The average age of first use of cannabis remained 
unchanged from 2008/09 at 13.7 years of age. The survey 
findings also reveal that the decline in abuse of other 
drugs in the general population, as reported in the 
Canadian Alcohol and Drug Use Monitoring Survey, was 
also observed among this age group. According to the 
Youth Smoking Survey, prevalence of past-year use of 
MDMA (“ecstasy”) declined from 6 per cent in 2008/09 to 
5 per cent in 2010/11, while abuse of hallucinogens 
during the same period declined from 7 per cent to 4 per 
cent. A decrease in abuse of psychoactive substances 
among the students surveyed was also noted, with 5 per 
cent of respondents reporting having abused psychoactive 
substances, a 2-per-cent decrease over the same figures 
for 2008/09. 
507. In the United States, the Monitoring the Future 
study revealed that the prevalence rates for past-month, 
past-year and lifetime abuse of cannabis among high 
school students had increased for the third consecutive 
year. The study also reported a significant increase in 
daily cannabis abuse among respondents in 2011, 
continuing a trend noted in 2010 data. According to the 
2011 figures, 1.3 per cent of eighth graders, 3.6 per cent of 
tenth graders and 6.6 per cent of twelfth graders 
(representing 1 in 15 twelfth graders) reported abusing 
cannabis on a daily or near-daily basis. Those increases 
were accompanied by decreases in the perception of risks 
associated with the use of cannabis. The Board notes that 
this development occurred in the context of campaigns 
promoting the legalization of cannabis for medical 
purposes as well as the decriminalization of cannabis for 
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non-medical purposes. With respect to the abuse of 
synthetic cannabinoids by high school students, the study 
cited data from its 2011 survey (predating the scheduling 
of those substances) indicating that 11.4 per cent of 
twelfth graders had reported abusing those substances in 
the previous 12-month period, making the substance 
second only to cannabis among illicit drugs abused by 
twelfth graders. 
508. According to figures released in June 2012 by the 
United States Department of Health and Human Services 
in its Treatment Episode Data Set, the percentage of 
admissions to state-funded substance abuse treatment 
facilities for non-heroin opiates as the primary substance 
of abuse continued to increase. The data reveal that, from 
1997 to 2010, admissions for opiates other than heroin, 
including oxycodone, hydrocodone and codeine, as the 
primary substance of abuse increased from 1 per cent to 
8.6 per cent, making those substances more likely than 
cocaine or methamphetamine to lead to admission for 
treatment. Admissions for primary abuse of cannabis 
increased from 16 per cent in 2007 to 18.4 per cent in 
2010, while admissions for heroin remained stable. 
509. In Canada, widespread abuse of OxyContin, 
particularly among the country’s First Nations 
communities, led to its removal from the market in 
March 2012 and its replacement by OxyNeo, a new 
medication the manufacturer claimed was more difficult 
to abuse and less likely to cause addiction. In recent years, 
abuse of OxyContin continued to plague many First 
Nations communities, particularly in the country’s vast 
north. Traffickers took advantage of the drug’s highly 
addictive properties and of the scarcity of supply in 
remote northern regions to inflate prices and increase 
profits. In some communities, the rate of abuse of 
oxycodone was over 80 per cent of the working age 
population, leading one First Nations chief to declare a 
state of emergency in his community. Drug abuse among 
Canada’s First Nations communities has remained a 
major threat to public health in these communities. 
Despite the challenges caused by widespread drug 
addiction among First Nations communities, the 
Government of Canada has reduced or eliminated 
funding for many First Nations health initiatives pursuant 
to austerity measures contained within the federal budget 
it presented in March 2012. The Board wishes to remind 
the Government of Canada of the importance of ensuring 
adequate support for community-based drug prevention, 
treatment and rehabilitation initiatives, including those 
within First Nations communities. 
 
  South America 
 
 
 1. Major developments 
 
510. The region of South America suffers from the illicit 
cultivation of coca bush, opium poppy and cannabis 
plant, as well as the manufacture and production of and 
trafficking in the illicit drugs stemming from that 
cultivation. There is significant and growing abuse of 
these plant-based drugs among the region’s population, as 
well as growing use of synthetic drugs of abuse, both 
those manufactured illicitly and those diverted from licit 
channels. In 2011, the total area of illicit coca bush 
cultivation significantly decreased in Bolivia 
(Plurinational State of) (27,200 ha) and slightly increased 
in Colombia (64,000 ha) and Peru (62,500 ha). The total 
area under illicit coca bush cultivation in South America 
in 2011 was estimated at 153,700 ha, indicating a minor 
decrease from the 154,200 ha reported in 2010.  
511. As research is ongoing to determine the ratios for 
the conversion of coca leaf to cocaine in South America, 
UNODC did not provide any estimate of the global 
potential manufacture of cocaine in 2011. In 2010, 
UNODC estimated that the total global potential 
manufacture of cocaine ranged from 788 to 1,060 tons, 
indicating a decline in cocaine manufacture since the 
period 2005-2007.  
512. Following the rejection of a proposal to amend 
article 49 of the Single Convention on Narcotic Drugs of 
1961 as amended by the 1972 Protocol, concerning the 
abolishment of coca-leaf chewing by the parties to the 
Convention, the Government of the Plurinational State of 
Bolivia formally deposited with the Secretary-General an 
instrument of denunciation of the 1961 Convention as 
amended by the 1972 Protocol. The denunciation of the 
Convention took effect on 1 January 2012. In 2012,  
the Government launched an international campaign  
to solicit the support of States parties to the  
1961 Convention for its strategy to re-accede to that 
Convention with a reservation. The Board expressed its 
concern in its annual report for 2011 that if the 
international community were to adopt an approach 
whereby States parties would use the mechanism of 
denunciation and re-accession with reservations to 
overcome problems in the implementation of certain 
treaty provisions, the integrity of the international drug 
control system would be undermined.  
513. The Board noted with concern that in August 2012, 
the Government of Uruguay presented to its national 
congress a proposed law to legalize the production and 
sale of cannabis in the country. According to the proposed 
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law, the Government would assume control and 
regulation over the activities of importing, producing, 
acquiring title to, storing, selling and distributing 
cannabis herb and its derivatives. If adopted, the law 
could be in contravention of the international drug 
control conventions to which Uruguay is a party. The 
Board, in line with its mandate, has sought a dialogue 
with the Government of Uruguay to promote the 
country’s compliance with the provisions of the 
international drug control treaties, in particular the  
1961 Convention.  
514.  The Heads of State and Government of the 
Americas attending the Sixth Summit of the Americas 
held in Cartagena de Indias, Colombia, in April 2012 
released a final communiqué in which they expressed 
concern that criminal organizations involved in drug 
trafficking continue their attempts to infiltrate societies 
and undermine democratic institutions. The Heads of 
State and Government also mandated OAS to prepare a 
report on the drug problem in the Americas.  
515. The abuse of cocaine in the Americas is no longer 
confined to North America and a few countries in the 
Southern Cone, but has spread across Latin America  
and the Caribbean. According to a CICAD report  
entitled Report on Drug Use in the Americas: 2011, in the 
period 2002-2009 about 27 per cent of cocaine abusers  
in the hemisphere were found in South America. The 
report, released in March 2012, also warns about the 
adverse health effects of the abuse of a variety of 
smokeable substances that are produced during the 
processing of cocaine hydrochloride.  
 
 2. Regional cooperation  
 
516. The aim of the CICAD Multilateral Evaluation 
Mechanism is to make periodic recommendations to 
CICAD member States on improving their capacity to 
address drug trafficking and abuse and enhance 
multilateral cooperation. At its fiftieth regular session, 
held in Buenos Aires from 2 to 4 November 2011, CICAD 
approved a draft resolution entrusting an 
intergovernmental working group with the development 
of a draft proposal for a new assessment instrument to 
replace the current Multilateral Evaluation Mechanism 
questionnaire, considering the objectives of the current 
Hemispheric Drug Strategy.  
517. In an effort to strengthen the fight against drug 
trafficking and organized crime in the region, the 
International Criminal Police Organization (INTERPOL) 
Regional Bureau for South America held the American 
Meeting of National Agencies Related to the Fight against 
Drugs Traffic in South America, in Buenos Aires  
from 9 to 11 November 2011. The meeting, among  
other things, approved the establishment of a permanent 
group of national experts in the fight against drugs to 
foster efforts to build and implement future joint 
transnational operative activities in the region. 
518. The Cooperation Programme between Latin 
America and the European Union on Drug Policies 
organized the International Conference on the theme 
“Synthetic drugs, an emerging phenomenon in Latin 
America”, held in Cartagena de Indias, Colombia,  
from 1 to 4 November 2011. Experts from counter-
narcotics police units and national prosecution agencies 
from Argentina, Bolivia (Plurinational State of), Chile, 
Colombia, Ecuador and Uruguay, together with delegates 
from Europe, Central America and North America and 
international organizations including the Police 
Community of the Americas (AMERIPOL), EMCDDA 
and Europol shared their experiences regarding the use of 
the early warning system, the importance of reference 
laboratories for forensic analysis and police research and 
investigations on legal psychoactive substances (“legal 
highs”), precursors and chemical substances used to 
manufacture synthetic drugs.  
519. The issue of combating microtrafficking of illicit 
drugs received increased attention from experts from 
Argentina, Bolivia (Plurinational State of), Brazil, Chile, 
Colombia, Ecuador, Paraguay, Peru, Uruguay and 
Venezuela (Bolivarian Republic of) who attended the 
meeting of the Union of South American Nations South 
American Council on the World Drug Problem, held in 
Asunción, on 22 and 23 March 2012. The participants in 
the meeting called for a major commitment at the 
international level to address the problem.  
520.  “Drugs in severely excluded populations” was the 
theme of the XIV Ibero-American Seminar on Drugs and 
Cooperation, which took place in Santiago from 16 to  
20 April 2012. The event was jointly organized by the 
Ibero-American Network of Non-Governmental 
Organizations Working in Drug Addiction, the National 
Service for the Prevention and Rehabilitation of Drug and 
Alcohol Use of Chile (SENDA) and the Central University 
of Chile, and was sponsored by CICAD and the National 
Plan on Drugs of Spain.  
521. In Lima in June 2012, the Andean Community, the 
European Union and the Pan American Health 
Organization launched an Andean region drug-abuse 
prevention programme entitled “Strong families: love and 
limits”. The initiative will be implemented jointly through 
workshops in households with teenagers between 10 and 
14 years of age from Bolivia (Plurinational State of), 
Colombia, Ecuador and Peru. The project is based on 
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validated experiences and work carried out in several 
countries in Central and South America. 
522. The Government of Peru hosted the International 
Conference of Ministers of Foreign Affairs and Heads of 
Specialized National Agencies against the World Drug 
Problem, in Lima on 25 and 26 June 2012. The heads of 
delegation adopted the Lima Declaration recognizing the 
need to intensify efforts to achieve the goals established in 
the Political Declaration and Plan of Action on 
International Cooperation towards an Integrated and 
Balanced Strategy to Counter the World Drug Problem. It 
was also re-emphasized at the meeting that this issue 
must be addressed in a multilateral, regional and bilateral 
framework, under the principle of common and shared 
responsibility.  
 
 3. National legislation, policy and action  
 
523. Reduction of drug abuse and the strengthening of 
policies and prevention programmes, focused in 
particular on vulnerable population groups, as well as the 
regular conduct of drug-abuse surveys, were among the 
objectives of a drug strategy for 2011-2015 adopted by the 
Government of the Plurinational State of Bolivia. In the 
area of drug supply reduction, the objectives of the 
strategy also include eradication of any coca bush 
cultivation in excess of the 20,000 ha authorized by  
the Government of the Plurinational State of Bolivia 
(12,000 ha of coca in the Yungas of La Paz, 7,000 ha in  
the Tropics of Cochabamba and 1,000 ha in Caranavi), 
and strengthening of activities addressing drug 
trafficking and the diversion of precursors.  
524. In 2011, the Brazilian authorities increased control 
of the psychoactive substances lisdexamfetamine and 
atomoxetine (which are not currently under international 
control) by placing those substances under national 
control and including them on the national list of 
substances under special control. The Government also 
included the psychoactive substance mephedrone on the 
list of substances of prohibited use in Brazil.  
525. In 2011, the Chilean Congress approved the law that 
created the Ministry of Interior and Public Safety and the 
National Service for the Prevention and Rehabilitation of 
Drug and Alcohol Use. The National Service will assume 
responsibility for the implementation of drug abuse 
prevention, treatment, rehabilitation and social 
reintegration policies, as well as the development of a 
national strategy for drugs and alcohol, and will 
cooperate with the Ministry of Interior and Public Safety 
in that regard.  
526. In March 2012, representatives of the Chilean 
Government, including judicial authorities, and of the 
private sector signed an agreement that institutionalizes 
drug treatment courts as public policy. The agreement 
allows drug abusers who commit minor crimes, if it is 
their first offence, to receive a therapeutic intervention, 
on a voluntary basis, in order to reduce the recurrence of 
drug abuse and commission of crime.  
527. The drug control legislation adopted by the 
Government of Colombia on 31 July 2012 recognizes that 
the consumption and abuse of and addiction to 
psychoactive substances is a matter of public health and 
the welfare of the family, the community and individuals. 
According to that law, drug addicts have the right to 
comprehensive care by the State and drug abuse and drug 
addiction should be treated as illnesses. 
528. In January 2012, the Board of the National Narcotic 
and Psychotropic Substances Control Board of Ecuador 
approved the National Plan for Integrated Drug Abuse 
Prevention 2012-2013. The National Plan awaits approval 
by the President.  
529. UNODC estimates that Paraguay is the largest illicit 
producer of cannabis in South America. In addition, large 
amounts of cocaine are trafficked through its territory 
from Bolivia (Plurinational State of), Colombia and Peru. 
The Board notes that in October 2011, the Government of 
Paraguay, in cooperation with UNODC, launched a  
four-year national integrated programme, to increase the 
responsiveness, effectiveness and efficiency of the 
Paraguayan State in facing the challenges posed by 
organized crime and drug trafficking in the country.  
530. In March 2012, the Government of Peru approved 
the National Drug Control Strategy 2012-2016. The 
Strategy promotes the development of projects and 
activities supporting integrated and sustainable 
development in areas where coca bush is grown, control 
of the drug supply and the prevention and rehabilitation 
of drug abuse. Its main goals include reduction of the 
potential production of coca leaf by 30 per cent by 2016.  
531. To improve port security and prevent the illegal use 
of sea containers in transnational organized criminal 
activities, including drug and precursor trafficking, the 
Governments of Guyana and Suriname joined the 
UNODC Container Control Programme in August 2012. 
In addition, in 2011 the Suriname Government approved 
the National Drug Master Plan 2011-2015 and the 
National Drug Prevention Plan 2011-2014.  
532. The Government of Uruguay, to address the risk of 
diversion of pharmaceutical preparations containing 
ephedrine and pseudoephedrine, adopted a decree in 
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January 2012 requiring the issuance of a prescription for 
their dispensation.  
 
 4. Cultivation, production, manufacture and 
trafficking 
 
 (a) Narcotic drugs 
 
533. In recent years, most countries in South America 
have registered increases in cannabis herb seizures. In the 
Plurinational State of Bolivia, aggregate seizures of 
cannabis plant and cannabis herb rose gradually from  
125 tons in 2006 to 1,900 tons in 2009. Although such 
seizures declined to about 1,100 tons in 2010 and about 
380 tons in 2011, the amount of cannabis plant and 
cannabis herb seized in the Plurinational State of Bolivia 
from 2008 to 2011, amounting to 3,500 tons, continued to 
be a matter of concern.  
534. In Brazil, seizures of cannabis herb increased by  
12 per cent, from 155 tons in 2010 to 174 tons seized in 
2011. Most of the seized cannabis originated in Paraguay.  
535. In the period 2004-2006, Colombian authorities 
seized an average of 130 tons of cannabis herb per year; in 
the period 2007-2009, that figure rose to about 215 tons 
per year. In 2011, the seizures of cannabis herb further 
increased to 321 tons. According to the past reports of the 
national authorities, cannabis seized in some parts of the 
territory contained high levels of tetrahydrocannabinol 
(THC), ranging from 8 to 20 per cent. Cannabis 
cultivated in Colombia is abused locally but also has been 
smuggled to countries in Central America.  
536. Seizures of cannabis herb in Chile increased from 
8.4 tons in 2010 to 14.6 tons in 2011; in Ecuador such 
seizures almost doubled, from 2.5 tons in 2010 to 4.6 tons 
in 2011. The 310 tons of cannabis herb seized in Paraguay 
in 2011 was more than three times as much as that seized 
in 2009; the 2 tons of cannabis herb seized in Uruguay in 
2011 was the largest amount seized in the country in the 
past decade; and in Peru, the 157 tons of eradicated 
cannabis plants was the largest amount eradicated in the 
country in the past decade.  
537. In the Bolivarian Republic of Venezuela, the 
Government increased sanctions for trafficking in 
genetically modified cannabis in order to discourage 
trafficking of cannabis with a high THC content. 
According to the Government, cannabis trafficking 
towards the Bolivarian Republic of Venezuela 
significantly decreased, as corroborated by the amounts 
of seizures of cannabis herb, which dropped from 39 tons 
in 2010 to 15.8 tons in 2011. Seizures of cannabis with 
high levels of THC, however, still occurred. 
538. The large seizures of cannabis in South America are 
a source of concern, as they might be a sign of a 
significant increase in the magnitude of cannabis 
production in the region. The Board calls upon the 
Governments of the countries in South America to 
determine, to the extent possible and in cooperation with 
UNODC, the magnitude of and current trends in the 
illicit cultivation and use of cannabis plants in their 
territories and to further strengthen their efforts to 
combat such cultivation.  
539. The Bolivian drug strategy for 2011-2015 envisages 
measures to limit the cultivation of coca bush to  
20,000 ha that have been authorized by the Government 
for that use. The measures include the publication of 
maps delimiting areas of authorized cultivation, voluntary 
eradication of at least 5,000 ha per year, forced 
eradication and activities to prevent the cultivation of 
new coca plants.  
540. From 2006 to 2010, the area of eradicated, illicitly 
cultivated coca bush in the Plurinational State of Bolivia 
ranged from 5,070 to 8,200 ha. In 2011, eradication efforts 
increased in the country. The Bolivian authorities 
eradicated a total of 10,500 ha under illicit coca bush 
cultivation, 2,300 ha more than in 2010. The Board notes 
with appreciation that the area under illicit cultivation in 
the Plurinational State of Bolivia decreased by 12 per 
cent, from 31,000 ha in 2010 to 27,200 ha in 2011, and 
wishes to encourage the Government to further step up 
its efforts to prevent the illicit cultivation of coca bush in 
the country.  
541. The area under coca bush cultivation in Colombia 
rose to 64,000 ha in 2011, up by 2,000 ha (or 3 per cent) 
compared with 2010. More than half of the area under 
coca bush cultivation (63 per cent) was concentrated in 
four departments: Nariño, Putumayo, Guaviare and 
Cauca. In 2011, the Government manually eradicated 
34,170 ha of coca bush and sprayed a total of 103,302 ha. 
While aerial spraying remained at 2010 levels, manual 
eradication decreased by 22 per cent.  
542. Recent studies carried out by the Government of 
Colombia and UNODC indicate that the coca leaf yield 
per hectare has decreased. According to these studies, a 
number of factors, including reduced use of fertilizers 
and the pressure exerted by eradication leading to smaller 
coca bush plots further away from settlements could have 
contributed to the decreased coca leaf yield. The potential 
cocaine manufacture in Colombia in 2011, 345 tons 
(down 1 per cent, from 350 tons in 2010), was the 
smallest since 1998.  
543. The goals of the Peruvian National Drug Control 
Strategy 2012-2016 include reducing the potential 
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production of coca leaf by 30 per cent by 2016. To achieve 
that goal, the strategy envisages gradually increasing 
eradication efforts, starting with 14,000 ha to be 
eradicated in 2012 and up to 30,000 ha in 2016. In 2011, 
the Peruvian authorities eradicated 10,290 ha under illicit 
coca bush cultivation, about 1,700 ha less than in 2010.  
544. In 2011, Peru changed its methodology for 
calculating the area under illicit coca bush cultivation. 
The area under such cultivation increased, and at the end 
of 2011 amounted to 62,500 ha.  
545. The illicit cultivation of coca bush, albeit on a small 
scale, slightly increased in Ecuador in 2011. During that 
year the national competent authorities eradicated 14 ha 
of coca bush.  
546. Although global seizures of cocaine remained 
rather stable in the period 2006-2010, the purity of 
cocaine seized over that period decreased. As a result, the 
total amount of pure cocaine seized worldwide actually 
decreased.  
547. In 2011, cocaine seizures decreased in several 
countries, including Brazil, Colombia, Peru and Uruguay. 
In Colombia, seizures of cocaine (salts) decreased from 
164.8 tons in 2010 to 146.1 tons in 2011, and in Peru 
seizures of cocaine (base and salts) decreased from  
31.1 tons in 2010 to 24.7 tons in 2011.  
548. In Brazil, seizures of cocaine (base and salts) 
decreased from 27.1 tons in 2010 to 24.5 tons in 2011. 
More than 50 per cent of cocaine seized in Brazil 
originated in Bolivia (Plurinational State of), about 40 per 
cent in Peru and less than 10 per cent in Colombia.  
549. In the Plurinational State of Bolivia, seizures of 
cocaine (base and salts) increased from 29.1 tons in 2010 
to 34 tons in 2011. Seizures of cocaine (base and salts) 
also increased in Ecuador, from 15.5 tons in 2010 to  
21.3 tons in 2011, and in Venezuela (Bolivarian Republic 
of), from 24.9 tons in 2010 to 26.3 tons in 2011. In 
Ecuador, microtrafficking in drugs has increased. In 
Chile and Paraguay seizures of cocaine remained 
relatively stable. 
550. Semi-submersible and submersible vessels have 
been used by drug trafficking organizations operating in 
South America to minimize the risk of detection of the 
smuggling of cocaine from the region at least since 1993, 
when the first semi-submersible vessel was seized.  
From that time until mid-2012, law enforcement agencies 
seized over 70 submersible and semi-submersible vessels 
worldwide. In 2011, 33 per cent of cocaine seized by the 
Colombian army was transported by “go-fast” vessels and 
17 per cent by submersible and semi-submersible vessels. 
In June 2012, the Colombian army seized a 20-metre-long 
semi-submersible vessel made of fibreglass. It is estimated 
that the construction of the vessel cost about $1 million.  
551. In 2011, laboratories illicitly manufacturing cocaine 
hydrochloride were dismantled in all main coca  
leaf-producing countries. In Bolivia (Plurinational State 
of) 25 laboratories were dismantled, in Colombia  
200 laboratories and in Peru 19 laboratories. In 
Colombia, farmers process about 1 per cent of coca leaf 
into coca paste and 66 per cent into coca base; only 33 per 
cent of coca leaf is sold unprocessed. Currently, the 
traffickers use the process of reoxidation of coca base 
before its conversion into cocaine hydrochloride.  
552. Cocaine processing laboratories were also destroyed 
in Ecuador and Venezuela (Bolivarian Republic of) in 
2011. In Ecuador, police authorities dismantled five 
laboratories processing cocaine base originating in 
Colombia and Peru. In the Bolivarian Republic of 
Venezuela, in the states of Táchira and Zulia, bordering 
Colombia, the national authorities destroyed a total of  
17 illicit drug laboratories.  
553. Although the illicit cultivation of opium poppy still 
exists in some countries in South America, the magnitude 
of that cultivation is much less than that of cannabis plant 
and coca bush cultivation. In Colombia, the potential 
manufacture of heroin was estimated to be one ton  
in 2011. 
554. In recent years, small areas of opium poppy were 
reportedly eradicated in Colombia, Ecuador and Peru. In 
2011, the illicit cultivation of opium poppy in Colombia 
(338 ha) represented about 0.2 per cent of worldwide 
cultivation. Heroin manufactured in Colombia is destined 
for markets in Europe, Mexico and the United States. 
There are also indications of increased demand for the 
substance within the country. In 2011, the Colombian 
authorities destroyed one illicit laboratory manufacturing 
heroin and seized 522 kg of heroin and 205 kg of opium.  
555. From 2001 to 2010, the Peruvian authorities 
eradicated a total of 585 ha of opium poppy in the 
country. No eradication of opium poppy was reported in 
2011. In addition to five ha of illicit opium poppy 
eradicated in Ecuador in 2011, the national competent 
authorities reported over 100 incidents of heroin seizures, 
totalling 155 kg. Seizures of small amounts of opium or 
heroin were also reported by other countries in South 
America.  
 
 (b) Psychotropic substances 
 
556. Although the issue of the non-medical use of 
pharmaceutical drugs and the use of prescription  
drugs without a medical prescription, whether as  
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self-medication or for recreational use, has gained greater 
attention in the Americas, specific information on such 
non-medical use in the region is still limited. For 
example, standardized surveys on drug abuse among high 
school students in the Americas enquire about the use of 
pharmaceuticals in the broad categories of tranquillizers 
and stimulants. 
557. According to the recent CICAD Report on Drug Use 
in the Americas: 2011, the past-year prevalence of the use 
of tranquillizers without a medical prescription among 
secondary school students in Bolivia (Plurinational State 
of), Colombia and Paraguay was higher than 6 per cent. 
The report also indicates that although the prevalence of 
non-medical use of pharmaceutical substances varies a 
great deal from country to country, many countries in the 
Americas that have relatively low rates of abuse of illicit 
drugs showed higher rates of misuse of pharmaceutical 
and prescription drugs.  
558. Justifiable concerns over the spreading abuse of 
synthetic drugs in South America can be corroborated by 
seizures of sizeable amounts of amphetamine-type 
stimulants in the region, including in Argentina, Brazil, 
Chile, Colombia, Ecuador and Uruguay in 2011. For 
example, in Brazil alone, 170,000 units of amphetamine, 
48,000 units of methamphetamine and 259,000 units of 
MDMA (“ecstasy”) were seized in 2011.  
 
 (c) Precursors 
 
559. Most of the world’s reported seizures of Table II 
acids and solvents occur primarily in the three  
coca-producing countries of the Andean region. Between 
2005 and 2011, Bolivia (Plurinational State of), Colombia 
and Peru accounted for roughly 40 per cent of global 
seizures of sulphuric acid and hydrochloric acid. 
560. In Colombia, traffickers recycle liquid precursors in 
order to minimize the risk of disclosure of illicit 
manufacture of cocaine, as well as to minimize the costs 
of cocaine manufacture. Perhaps as a result, seizures of 
acids and solvents decreased in Colombia in the past two 
years. The Colombian authorities also reported cases of 
clandestine manufacture of sulphuric acid from sulphur 
that can be found in mines in volcanic areas in the 
country.  
561. Although the extent of illicit use of potassium 
permanganate and the methods of its diversion have 
changed in South America in the past few years, the 
substance remains the key oxidizing agent used in the 
manufacture of cocaine hydrochloride in the region. In 
2011, countries in South America accounted for 97 per 
cent of global seizures of potassium permanganate  
(36.9 tons). In that year Colombia seized 24.0 tons, 
Bolivia (Plurinational State of) 9.9 tons and Peru 2.0 tons 
of the substance. In addition, the Colombian authorities 
dismantled seven illicit laboratories manufacturing 
potassium permanganate. 
 
 5. Abuse and treatment  
 
562. According to UNODC and the latest Government 
sources, the annual prevalence rates of cannabis abuse in 
the general population in Bolivia (Plurinational State of) 
(4.5 per cent), Chile (4.9 per cent), Suriname (4.3 per 
cent) and Uruguay (8.3 per cent) were the highest in 
South America. Among youth, the prevalence of cannabis 
abuse is even higher. For example, in Chile, 16.2 per cent 
of young people 15 to 16 years old and in Uruguay  
12.5 per cent of youth 13 to 17 years old used cannabis in 
the past year.  
563. According to the preliminary results of a drug abuse 
survey released in 2012 by the National Institute of Public 
Policy for Alcohol and Other Drugs and the Federal 
University of São Paulo in Brazil, 7 per cent of the adult 
population in the country aged 19 to 59 have consumed 
cannabis at least once in their lives; over 60 per cent of 
those had done so before the age of 18. Even though 
cannabis consumption rates in Brazil are relatively low, 
the dependence rates are high; 37 per cent of cannabis 
users are dependent on the substance. The survey also 
found that three quarters of the Brazilian population was 
against the legalization of cannabis.  
564. The results of the national survey on the 
consumption of psychoactive substances in the school 
population, conducted in Colombia in 2011, indicated 
that 7.0 per cent of the school population in the country, 
11 to 18 years old, had abused cannabis herb at least once 
in their lives.  
565. UNODC estimated that the overall average of the 
annual prevalence of cocaine abuse in South America in 
2010 remained essentially stable, estimated at 0.7 per 
cent. The recent Brazilian drug abuse survey indicates 
that the last-year prevalence of cocaine abuse (any form 
of cocaine) among the adult population was 2 per cent. 
Despite a reported decline in cocaine abuse in some 
countries in the region, including Argentina and Chile, 
the demand for treatment for cocaine abuse exceeds 
demand for treatment for abuse of any other illicit drug.  
566. Coca-based products obtained at various processing 
stages, mostly referred to as cocaine base paste, are likely 
to be some of the most addictive and noxious substances 
abused in several countries in South America. According 
to the recent CICAD survey on drug abuse in the 
Americas, the lifetime prevalence rates for cocaine base 
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paste in Argentina, Bolivia (Plurinational State of), Chile, 
Colombia, Ecuador, Peru and Uruguay were found to be  
1 per cent or higher. There appears to be a variety of local 
forms of cocaine base paste, known as paco, basuco, pasta 
base or coca paste. More research, however, needs to be 
done in the different countries to determine whether 
these substances are indeed different substances or 
whether they should be classified as variants of the same 
substance.  
567. The latest estimates of annual prevalence of the 
abuse of opioids for most of the countries in South 
America are at least five years old; therefore, a reliable 
comparison of opioid abuse within the region is not 
possible. According to the available data, the lowest rate of 
abuse of opioids in South America, 0.02 per cent, was 
reported in Colombia in 2008 and Venezuela (Bolivarian 
Republic of) in 2011, respectively. The highest rates of 
abuse of opioids were reported in Bolivia (Plurinational 
State of) in 2007 (0.6 per cent) and Brazil, in 2005 (0.5 per 
cent). In Brazil, non-medical use of prescription opioids 
accounted for most of the opioids abused.  
568. Concern over rising levels of the abuse of  
synthetic drugs among South American youth also 
continued to grow. High annual prevalence of abuse of 
amphetamine-type stimulants among young people was 
reported, for example, in Argentina, Chile and Colombia. 
According to the latest information provided by 
Governments, 1.4 per cent and 1.6 per cent of youth aged 
15 to 16 years old in Argentina and Chile, respectively, 
used MDMA (“ecstasy”) in the past 12 months.  
569. According to the CICAD Report on Drug Use in the 
Americas: 2011, inhalant abuse may be a growing problem 
in the Americas, as youth seek out licit and easily available 
substances. Once considered to be a drug used almost 
exclusively by street children, the report indicates that 
inhalant abuse is firmly established among high school 
students in Latin America and the Caribbean. In most 
countries in both Latin America and the Caribbean, 
inhalants are the most common substance of abuse  
after cannabis and, in some countries, the past-year  
prevalence of abuse of inhalants exceeds the prevalence  
of cannabis abuse. 
 
 
 C. Asia 
 
 
  East and South-East Asia 
 
 
 1. Major developments 
 
570. In 2011, East and South-East Asia continued to be 
the region with the second largest total area under illicit 
opium poppy cultivation, accounting for over 20 per cent 
of illicit opium poppy cultivation worldwide. Increased 
illicit opium poppy cultivation was reported by the  
Lao People’s Democratic Republic and Myanmar for  
six consecutive years, beginning in 2007. From 2011 to 
2012, the total estimated area under cultivation in the  
two countries increased by approximately 66 per cent and 
17 per cent, respectively, indicating potential growth in 
opium production. In view of the continued increase in 
illicit opium poppy cultivation in the region, the Board 
again urges the Governments of the Lao People’s 
Democratic Republic and Myanmar to take the necessary 
actions to curtail illicit opium poppy cultivation. The 
Board calls upon the international community, in 
particular UNODC, and other countries of the region, to 
strengthen assistance to the Lao People’s Democratic 
Republic and Myanmar, including for alternative 
development programmes and illicit crop eradication. 
571. East and South-East Asia continued to be a 
manufacturing hub and a growing illicit market for 
amphetamine-type stimulants, in particular 
methamphetamine. Seizures of methamphetamine in East 
and South-East Asia accounted for almost half of the 
global total in 2010. In 2011, most countries of the region 
continued to report increased seizures of 
methamphetamine. Furthermore, evidence has shown 
that the illicit manufacture of amphetamine-type 
stimulants has expanded from traditional manufacturing 
countries such as China and Myanmar to other countries, 
including Cambodia, Indonesia, Malaysia, the Philippines 
and Thailand. Ephedrine and pseudoephedrine, 
substances used in the illicit manufacture of 
amphetamine-type stimulants, continued to be trafficked 
in large quantities in the region.  
572. Trafficking in and abuse of prescription drugs and 
over-the-counter pharmaceutical preparations containing 
internationally controlled substances are serious 
problems in East and South-East Asia. In Malaysia, a 
clandestine laboratory manufacturing tablets containing 
nimetazepam (a sedative-hypnotic benzodiazepine, also 
known as Erimin 5) was dismantled in 2010. Few 
benzodiazepines had ever been illicitly manufactured in 
other countries. That operation, together with the recent 
seizures of nimetazepam tablets, raised concern about 
Malaysia emerging as a country used for the illicit 
manufacture of, and as a transit area for, benzodiazepines 
destined for illicit markets in other countries. Many 
countries of the region have also reported abuse and 
seizures of drugs containing morphine, codeine and 
benzodiazepines, some of which had been smuggled out 
of South Asia, stolen or obtained from pharmacies with 
forged prescriptions. The Board therefore urges 
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Governments of the region to strengthen control 
measures over international trade in and domestic 
distribution of prescription drugs and over-the-counter 
pharmaceutical preparations containing internationally 
controlled substances and to closely monitor patterns of 
and trends in trafficking in and abuse of those drugs in 
order to devise effective countermeasures. 
573. In response to the recent challenges posed by the 
abuse of emerging psychoactive substances, in 2011 the 
Government of the Republic of Korea introduced a 
temporary scheduling scheme and a drug analogue 
management system in order to bring new substances 
under national control in a timely manner. The 
substances that have been scheduled under these control 
schemes include synthetic cannabinoid receptor agonists 
and MDPV. 
 
 2. Regional cooperation 
 
574. The Fifth Association of Southeast Asian Nations 
(ASEAN) Plus Three Ministerial Meeting on 
Transnational Crime, for ASEAN members plus China, 
Japan and the Republic of Korea, was convened in Bali, 
Indonesia, in October 2011. Delegates at the meeting 
reaffirmed the commitment of their countries to 
consolidating cooperation between ASEAN member 
States and China, Japan and the Republic of Korea in 
combating transnational crime. In addition, a plan of 
action to implement the memorandum of understanding 
between ASEAN and China on cooperation on non-
traditional security issues, including the issue of drug 
trafficking, was adopted to further enhance cooperation 
between the two parties in the areas of information 
exchange, personnel training, law enforcement, and 
research and analysis.  
575. In November 2011, the International Seminar 
Workshop on Sustainable Alternative Development was 
held in Chiang Rai and Chiang Mai, Thailand. The 
seminar was jointly organized by the Governments of 
Peru and Thailand and attended by over 100 participants 
from 27 countries. The purpose of the seminar was to 
gather and assess information for developing a set of 
international guidelines for more effective alternative 
development programmes in areas where illicit crops are 
grown. The outcome of the meeting was reported to the 
Commission on Narcotic Drugs at its fifty-fifth session, 
in March 2012.  
576. The seventeenth Asia-Pacific Operational Drug 
Enforcement Conference was held in Tokyo in  
February 2012. Participants from 38 countries shared 
information on the current drug situation in the  
Asia-Pacific region, with the aim of strengthening 
international cooperation in drug law enforcement, in 
particular to counter the threat posed by trafficking in 
amphetamine-type stimulants. 
577. The twentieth ASEAN Summit was held in Phnom 
Penh in April 2012. At that summit, Heads of State and 
Government of ASEAN member States adopted a 
declaration in which they affirmed the goal of a drug-free 
ASEAN community by 2015 and decided that relevant 
ministers should accelerate the implementation of the 
ASEAN Work Plan on Combating Illicit Drug 
Production, Trafficking and Use (2009-2015). The leaders 
also decided that annual reports on the progress of 
implementation in the area of drug control should be 
submitted to ASEAN. Furthermore, they stressed the 
importance of sharing information and best practices of 
law enforcement and the necessity of enhancing 
cooperation with ASEAN external partners. 
578. In February 2012, the Asian Centre for Certification 
and Education of Addiction Professionals (ACCE), 
established by the Colombo Plan for Cooperative 
Economic and Social Development in Asia and the 
Pacific, organized the Second Regional Training of 
Trainers for Addiction Treatment Practitioners in 
Bangkok. Medical professionals working in the area of 
treatment of substance abuse in Malaysia, Maldives, 
Pakistan, the Philippines, Singapore, Sri Lanka and 
Thailand attended the training. A similar training session 
organized by ACCE took place in Kuala Lumpur in April 
2012. Those training initiatives were aimed at training, 
expanding and professionalizing the drug abuse 
treatment workforce in the region. 
579. In February 2012, the Government of Thailand 
entered into an agreement with UNODC to support 
alternative development efforts in the Lao People’s 
Democratic Republic. Furthermore, in March 2012, Thai 
authorities launched a regional partnership on drug 
control aimed at strengthening drug control cooperation 
with neighbouring countries, in particular Cambodia, 
China, the Lao People’s Democratic Republic, Myanmar 
and Viet Nam. Under the strategy, capacity-building 
projects and intelligence exchange between Thailand and 
those countries have been implemented. Additionally, the 
Thai authorities have taken part in joint patrols along the 
Mekong river with the authorities of China, the Lao 
People’s Democratic Republic and Myanmar to intercept 
vessels used by drug traffickers. 
580. The twenty-ninth International Drug Enforcement 
Conference took place in Bali, Indonesia, in June 2012. 
Law enforcement officials from over 70 countries 
participated in the annual meeting under the theme of 
enhancing international partnerships to combat drug 
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crimes. Meeting participants stressed the importance of 
strengthening international and regional cooperation and 
sharing intelligence in fighting drug trafficking, including 
transnational drug trafficking with links to terrorism. The 
new modi operandi of drug traffickers for financing 
terrorist acts were also discussed. 
581. In July 2012, a regional workshop was organized by 
the UNODC global SMART programme in Phnom Penh. 
At that workshop, participants were given an update on 
the trafficking and abuse of amphetamine-type stimulants 
in the region, as well as national countermeasures. The 
threats and challenges posed by emerging new 
psychoactive substances on the market were also 
discussed. Over 40 drug control officials from  
11 countries (Brunei Darussalam, Cambodia, China, 
Indonesia, the Lao People’s Democratic Republic, 
Malaysia, Myanmar, the Philippines, Singapore, Thailand 
and Viet Nam) attended the workshop.  
582. Cooperation between ASEAN and the Government 
of the Republic of Korea in the area of drug control 
continued to be further strengthened. There are plans for 
the establishment in Seoul of the Asia-Pacific information 
and coordination centre, a joint project of the 
Government of the Republic of Korea and ASEAN. The 
member agencies of the centre will include law 
enforcement authorities from Brunei Darussalam, 
Cambodia, Indonesia, the Lao People’s Democratic 
Republic, the Philippines, the Republic of Korea, 
Singapore, Thailand and Viet Nam. The mandate of the 
centre will be to improve information-sharing and 
cooperation with respect to countering drug trafficking in 
the region. The centre will also facilitate the formulation 
of regional drug control strategies and provide technical 
assistance in drug law enforcement.  
 
 3. National legislation, policy and action 
 
583. In 2012, the Government of China adopted a series 
of control measures to prevent the diversion of 
pharmaceutical preparations containing ephedrine and 
pseudoephedrine from domestic distribution channels to 
the illicit market. Such measures include requiring 
prescriptions for purchasing those pharmaceutical 
preparations at pharmacies and the registration of 
personal information (such as name and identification 
number) when making such a purchase. Manufacturers 
and distributors found to have engaged in diverting such 
preparations will be subject to severe legal liabilities, such 
as the revocation of their licences. Those control 
measures were introduced in response to the increase in 
illegal sales of pharmaceutical preparations containing 
ephedrine and pseudoephedrine by pharmaceutical 
companies and pharmacies to drug traffickers in the 
country.  
584. Two new pieces of legislation were recently enacted 
by the Government of Indonesia. A regulation on 
compulsory reporting by drug addicts provides that drug 
abusers, or their family members, have to report to the 
authorities in order to receive treatment and 
rehabilitation services. A regulation on precursors 
provides Government control over all activities involving 
precursors, from manufacture, import and export to 
packaging and distribution. The regulation requires that 
relevant Government agencies prepare annual legitimate 
requirements for precursors used in the country and 
report such statistics to the Board.  
585. The Government of the Republic of Korea has 
strengthened controls over precursor chemicals in the 
form of raw materials. As at June 2012, any activities 
relating to the manufacture, import or export of 
precursor chemicals must be approved by the competent 
national authorities.  
586. The Government of Singapore has amended the 
Misuse of Drugs Act to expand the reporting obligations 
of medical practitioners. The amended Act requires 
medical practitioners to report the duration of treatment 
periods and the dosage and quantities of selected 
prescription drugs that are prescribed to suspected drug 
addicts, such as those containing benzodiazepines, 
zolpidem, codeine and substances not under international 
control such as dextromethorphan and tramadol. This 
additional information would assist relevant authorities 
in identifying possible trends in the abuse of prescription 
drugs. Furthermore, to facilitate the submission of such 
reports, a web-based electronic notification system has 
been introduced. 
587. The Government of Viet Nam launched its new 
national drug control and crime prevention strategies in 
July 2012. The strategies highlight the need for a 
comprehensive national response that combines effective 
law enforcement, drug abuse treatment and rehabilitation 
measures that allow for better integration of former drug 
dependent persons into society and the active 
participation of communities in crime prevention. 
 
 4. Cultivation, production, manufacture and 
trafficking 
 
 (a) Narcotic drugs 
 
588. Illicit opium poppy cultivation in the Lao People’s 
Democratic Republic and Myanmar continued to increase 
in 2012. Approximately 51,000 ha of opium poppy were 
estimated to have been illicitly cultivated in Myanmar in 
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2012, representing an increase of about 17 per cent over 
2011. UNODC estimates that about 300,000 households 
were involved in illicit opium poppy cultivation in 
Myanmar, the majority in Shan state. In the Lao People’s 
Democratic Republic, illicit opium poppy cultivation 
continued its steady increase, from 1,500 ha in 2007 to 
6,800 ha in 2012. 
589. Some eradication of illicit opium poppy took place 
in the Lao People’s Democratic Republic, Myanmar and 
Thailand. According to the UNODC South-East Asia 
Opium Survey 2012, the authorities of the Lao People’s 
Democratic Republic and Myanmar eradicated about  
700 ha and 23,700 ha of opium poppy, respectively,  
in 2012, which was equivalent to approximately 42 per 
cent of that year’s total estimated cultivation in the  
two countries. The Government of Thailand eradicated 
205 ha, which accounted for nearly 98 per cent of the total 
estimated cultivation during 2011-2012. 
590. Illicit cannabis cultivation and cannabis seizures 
continued to be reported by Indonesia and the 
Philippines, the countries with the largest illicit 
cultivation of cannabis plants in East and South-East Asia. 
In Indonesia, approximately 24 tons of cannabis herb 
were seized in 2011, a slight increase over the total 
amount seized in 2010. About 1.8 million cannabis plants 
were eradicated in 2011, most of which was concentrated 
in Aceh province. In addition to the supply of cannabis 
through large-scale domestic cultivation, small quantities 
of cannabis resin from Denmark and France had been 
smuggled into Indonesia. The authorities of the 
Philippines eradicated about 4 million illicitly cultivated 
cannabis plants in 2011. Other countries, including 
Cambodia, China, Japan, the Lao People’s Democratic 
Republic, Myanmar, the Republic of Korea and Thailand 
continued to report cannabis seizures in 2011. 
591. The region of East and South-East Asia continues to 
be an important market for heroin. Significant increases 
in heroin seizures were reported in China, where over  
7 tons were seized in 2011, compared with 5.4 tons in 
2010. In 2012, authorities of the Lao People’s Democratic 
Republic destroyed over 12 kg of heroin that had been 
seized in the country. Most of the heroin seized in the 
region continued to be manufactured in and smuggled 
out of the area known as the Golden Triangle. In addition, 
the smuggling of heroin from Afghanistan and mainly 
through Pakistan into East and South-East Asia increased 
in 2011. 
592. Total cocaine seizures in the region declined and 
remained at low levels in 2011. In July 2012, however, a 
record seizure of 650 kg of cocaine found in a shipping 
container arriving from Ecuador was made in Hong 
Kong, China. This seizure, together with the 560 kg of 
cocaine seized in Hong Kong, China, in 2011, raised the 
concern of the city becoming a transit point for cocaine 
consignments originating in South America and Central 
America and destined for mainland China.  
 
 (b) Psychotropic substances 
 
593. Seizures of methamphetamine in East and  
South-East Asia continued to increase significantly  
in 2011. In China, seizures of methamphetamine 
amounted to over 14 tons in 2011, increasing by 45 per 
cent from 10 tons in 2010. In Thailand, 54.8 million 
methamphetamine tablets and 1.2 tons of crystalline 
methamphetamine were seized in 2011; both of those 
figures represent an increase over 2010 levels. During the 
first eight months of 2012, the Thai authorities had 
already seized 50.8 million methamphetamine tablets and 
870 kg of crystalline methamphetamine, indicating a 
possible increase in total seizures in 2012. Other 
countries, such as Cambodia, Indonesia and Myanmar, 
also reported increased quantities of amphetamine-type 
stimulants seized in 2011. 
594. Most of the seized amphetamine-type stimulants in 
East and South-East Asia continued to be illicitly 
manufactured within the region. In 2011, China reported 
having dismantled 357 clandestine laboratories, most  
of which were found to have manufactured 
methamphetamine and ketamine. The authorities  
of Indonesia and the Philippines dismantled 14  
and 6 clandestine methamphetamine laboratories, 
respectively, in 2011. In addition, illicit manufacture of 
amphetamine-type stimulants has been reported by 
Cambodia, Malaysia and Thailand, though on a  
small scale. 
595. Myanmar remained an important source of illicit 
supply of amphetamine-type stimulants. A total of  
6 million methamphetamine tablets and 33 kg of 
crystalline methamphetamine were seized in the country 
in 2011. Although no dismantling of clandestine 
laboratories was reported, the authorities of Myanmar 
indicated that all amphetamine-type stimulants seized 
had been domestically manufactured. There are 
indications that methamphetamine originating in 
Myanmar had been smuggled to China, the Lao People’s 
Democratic Republic and Thailand, and from those 
countries to Cambodia and Viet Nam. Furthermore, 
recent armed clashes between drug syndicates and law 
enforcement authorities along the Mekong river indicated 
that the Mekong river was increasingly being used as a 
trafficking route for smuggling methamphetamine from 
Myanmar into its neighbouring countries.  
 CHAPTER III. ANALYSIS OF THE WORLD SITUATION
 
81 
596. Seizures of MDMA (“ecstasy”) were reported mainly 
by Indonesia and Malaysia; in recent years, the total 
amount of “ecstasy” seized in those two countries has 
continued to grow. In 2011, over 1 million “ecstasy” 
tablets were seized in Indonesia, the highest level since 
2008 and almost triple the number seized in 2010. In 
addition, five clandestine “ecstasy” laboratories were 
dismantled in the country. Apart from illicit domestic 
supply, MDMA (“ecstasy”) tablets from Malaysia and the 
Netherlands continued to be smuggled into Indonesia. In 
Malaysia, according to UNODC, an MDMA (“ecstasy”) 
clandestine laboratory was dismantled in 2010, indicating 
that in addition to Indonesia, Malaysia has been targeted 
by traffickers of “ecstasy”. 
597. Seizures of nimetazepam tablets in Malaysia 
increased significantly from 2010 to 2011. In 2010,  
2 million nimetazepam tablets originating in India were 
seized in Malaysia. In July 2012, 3 million nimetazepam 
tablets were seized in a shipping container arriving in 
Malaysia from India via Hong Kong, China. The drugs 
were stuffed in black plastic bags hidden among sacks of 
tobacco. This seizure was one of the largest drug seizures 
in Malaysia in the past 10 years. Other countries, such as 
Indonesia and Singapore, reported large seizures of 
nimetazepam tablets arriving from Malaysia in 2010  
and 2011.  
 
 (c) Precursors 
 
598. One of the biggest challenges related to precursor 
control in East and South-East Asia remains the 
trafficking in precursors used for the illicit manufacture 
of amphetamine-type stimulants, particularly 
pharmaceutical preparations containing ephedrine and 
pseudoephedrine. In 2011, the Chinese authorities 
continued to seize large quantities of pharmaceutical 
preparations containing pseudoephedrine, which had 
been diverted from domestic distribution channels to 
supply domestic as well as foreign clandestine 
laboratories. 
599. With the strengthening of control over 
pharmaceutical preparations containing ephedrine and 
pseudoephedrine in many countries of the region, 
traffickers have turned to countries with less or no 
control over such preparations, such as the Republic of 
Korea. In December 2011, 2 million tablets containing 
pseudoephedrine originating in the Republic of Korea 
were seized in Thailand. The seized drugs were intended 
for use in the illicit manufacture of methamphetamine in 
the Golden Triangle area bordering northern Thailand. 
600. In July 2011, approximately 16 tons of acetic 
anhydride were seized as a result of a joint operation of 
the Chinese and Pakistan authorities. The substance had 
originated in China and was destined for use in illicit 
heroin manufacture in Afghanistan. 
601. In April 2012, a joint operation of the authorities of 
Australia and China led to the dismantling of a 
transnational drug trafficking group that intended to 
smuggle a total of 3.4 tons of safrole-rich oil from China 
to Australia. Most of the safrole-rich oil, disguised as 
liquid hair products, had been smuggled between April 
and August 2011 and seized by the Australian authorities 
after the arrival of the shipments in Sydney. The seized 
substance was probably intended to be used in the illicit 
manufacture of MDMA (“ecstasy”) in Australia. 
 
 (d) Substances not under international control 
 
602. Ketamine seizures continued to be reported in  
East and South-East Asia. In 2011, China (including  
Hong Kong, China) reported seizures of 5.7 tons of 
ketamine, accounting for the majority of the total seizures 
of ketamine in the region. Illicit manufacture of ketamine 
continued to be detected in China. Furthermore, about  
95 kg of ketamine were seized in 2011, indicating that 
Indonesia might have become an emerging market for 
ketamine. In addition, it is worth noting that many tablets 
seized in Indonesia that were to be marketed as “ecstasy” 
contained ketamine rather than MDMA. 
603. New psychoactive substances are gaining popularity 
on the illicit markets in East and South-East Asia. The 
Republic of Korea has reported seizures of products 
containing synthetic cannabinoids and sold under the 
brand name “spice”, as well as products containing MDPV 
and sold as “bath salts”. Those substances are being 
increasingly smuggled into the country by mail and used 
as substitutes for cocaine or “ecstasy”. Viet Nam  
and Indonesia have also reported seizures of  
1-(3-trifluoromethylphenyl)piperazine (TFMPP) and  
N-benzylpiperazine (BZP).  
 
 5. Abuse and treatment 
 
604. Heroin continues to be the primary drug of abuse in 
China, Malaysia, Myanmar, Singapore and Viet Nam.  
In China, there were about 1.2 million registered  
heroin-dependent persons in 2011, accounting for over  
64 per cent of the total registered drug-dependent 
population group that year. In Myanmar, 87 per cent of 
the persons who received drug abuse treatment in 2011 
did so for heroin abuse. While most countries of East and  
South-East Asia have reported heroin abuse to be stable 
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or decreasing, Malaysia and Singapore have reported 
increased heroin abuse in recent years.  
605. Cannabis remains the most popular drug of abuse 
in Indonesia, owing mainly to its abundant domestic 
supply. A survey of secondary schools in Indonesia in 
2011 showed that annual prevalence of cannabis abuse 
among students was 1.3 per cent, significantly higher 
than among the general population (0.5 per cent). 
Cannabis is the second most commonly abused drug in 
Japan, the Philippines, the Republic of Korea and 
Thailand, and the third most commonly abused drug in 
Malaysia and Myanmar.  
606. A common trend that has been observed in most 
countries of the region is the increased abuse of 
amphetamine-type stimulants, most notably 
methamphetamine. Methamphetamine remains the most 
common drug of abuse in Brunei Darussalam, Cambodia, 
Japan, the Philippines, the Republic of Korea and 
Thailand. A considerable increase in the abuse of 
synthetic drugs, particularly amphetamine-type 
stimulants, has been reported in China, where registered 
cases of abuse increased by 36 per cent from 2010 to 2011. 
Malaysia and Singapore have also reported increased 
abuse of amphetamine-type stimulants. 
607. Another concern relates to drug abuse among 
young people in the region. In China, people under the 
age of 35 constituted nearly 70 per cent of all synthetic 
drug abuse reported cases. In Thailand, young people 
between the ages of 15 and 19 represented the biggest 
drug abuse population group. In Indonesia and Myanmar, 
the average age of people under treatment for drug abuse 
was less than 30 years old. 
608. An emerging challenge for the countries of East and 
South-East Asia is the abuse of prescription drugs  
and over-the-counter pharmaceutical preparations 
containing internationally controlled substances, mainly 
morphine, codeine, benzodiazepines and barbiturates.  
In Brunei Darussalam, a large increase in the abuse of 
Erimin 5 tablets, containing nimetazepam, has been 
reported. Benzodiazepines and barbiturates were the 
third most commonly abused drug group in Indonesia 
and the fourth most commonly abused drug group in 
China. Myanmar also reported increased abuse of 
benzodiazepines. In Malaysia, morphine was the second 
most commonly abused substance among individuals 
receiving drug abuse treatment. In Thailand, over  
260 drug-related deaths in 2010 were related to the abuse 
of benzodiazepines.  
609. Drug abuse by injection was reported by almost all 
countries of the region. Drugs that are commonly 
injected included heroin, amphetamine-type stimulants 
and benzodiazepines. The high prevalence of HIV/AIDS 
among people who abuse drugs by injection remains  
a serious public health risk in some countries.  
The Government of Indonesia estimated in 2009 that 
HIV prevalence among people who abused drugs  
by injection was nearly 50 per cent. In Myanmar,  
HIV prevalence among that group was about 22 per cent; 
in the Republic of Korea, HIV prevalence among the 
adult population remained very low.  
610. Heroin abuse was the primary reason for people 
receiving treatment for drug abuse in China, Indonesia, 
Malaysia, Myanmar and Singapore, whereas in the 
Philippines, the Republic of Korea and Thailand, abuse of 
amphetamine-type stimulants, in particular 
methamphetamine, accounted for the majority of the 
drug addicts who received treatment. Cannabis was the 
most common drug of abuse of those receiving treatment 
in Japan. In many countries, demand for treatment 
increased in the past two years, in particular among 
persons dependent on amphetamine-type stimulants. 
Furthermore, a number of countries, such as China, 
Indonesia, Malaysia and Singapore, reported treatment of 
people who had abused prescription drugs, in particular 
those containing morphine, buprenorphine and 
benzodiazepines. 
611. In China at the end of 2011, there were over  
220,000 people receiving drug abuse treatment in 
compulsory treatment centres; in addition, 97,000 people 
were receiving drug abuse treatment in community 
treatment and rehabilitation centres. Methadone 
substitution treatment programmes continued to be 
expanded. By the end of 2011, there were 719 treatment 
units nationwide, which had provided drug substitution 
treatment to a total of 337,000 people.  
612. In Cambodia, the UNODC-supported community-
based drug treatment programme has been expanded as 
an alternative to compulsory treatment service since  
its launch in 2010. The programme provides  
drug-dependent persons with voluntary drug abuse 
treatment and care services in a variety of health  
centres, referral hospitals and non-governmental 
organizations. The services include tailored  
treatment plans for counselling, assessment and 
evaluation, vocational training and the provision of  
sterile injecting equipment.  
613. One obstacle to effective and targeted treatment 
services for many countries of East and South-East Asia is 
the lack of surveys of drug abuse among the general 
population. Only a few countries, such as Indonesia, the 
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Philippines and Thailand, indicated that general 
population surveys and school surveys had been carried 
out on a regular basis. Other countries had usually based 
their analysis of the drug abuse situation on statistics on 
arrests or treatment. Such data are not comprehensive 
and may reflect only a fraction of the drug abuse 
problems in a country. The Board therefore encourages 
the Governments of countries of the region to establish, 
in collaboration with regional and international 
organizations, including UNODC, mechanisms for 
routinely monitoring the trends and patterns related to 
drug abuse among the general population, including 
abuse of prescription drugs, in order to devise targeted 
prevention and treatment policies and strategies. 
 
 
  South Asia 
 
 
 1. Major developments 
 
614. South Asia continues to face diversion of  
and trafficking in pharmaceutical preparations 
containing internationally controlled substances and  
a serious problem of abuse of prescription drugs  
and over-the-counter pharmaceutical preparations. 
Pharmacies represent one of the key points at which 
diversion occurs. Drug abusers are often able, in all 
countries of the region, to obtain prescription 
pharmaceutical preparations containing internationally 
controlled substances without a prescription. In some 
cases, diversion also occurs from manufacturers. As well 
as being sold within the region, the diverted 
pharmaceuticals are also trafficked on to other countries, 
in significant part through illegal Internet pharmacies.  
615. The main problem behind the diversion of and 
trafficking in prescription pharmaceutical preparations 
appears to be that enforcement of national laws and 
regulations designed to control those preparations is 
weak, though the laws and regulations themselves are 
largely adequate. At the pharmacy level, for example, it is 
common for pharmacies to lack a qualified pharmacist in 
some countries in South Asia. In all countries in South 
Asia, the main reason for weak enforcement of 
regulations is weakness in the organizations responsible 
for regulating pharmacies and pharmaceutical 
manufacturers, in particular a lack of 
monitoring/inspection personnel. There is also 
insufficient awareness of enforcement powers and the 
extent of the problem. The Board urges Governments in 
South Asia to strengthen the enforcement capacity of 
their national agencies responsible for regulating 
pharmacies that dispense pharmaceuticals containing 
narcotic drugs and psychotropic substances. Further, 
there are certain gaps in the regulations on the 
pharmaceutical industry themselves: control measures for 
the manufacture of some pharmaceuticals containing 
controlled substances (for example, some of those 
containing pseudoephedrine) are insufficient, which can 
lead to those substances being diverted. Countries in 
South Asia also have few regulations with respect to 
online pharmacies.  
616. In response to the threat posed to the region by the 
abuse of and trafficking in pharmaceutical preparations 
and other drugs, Governments in South Asia are 
renewing their efforts and are undertaking major new 
initiatives to tackle the problem. Governments across the 
region have revised policies and legal and criminal justice 
frameworks on drug control. India has approved a new 
national policy on narcotic drugs and psychotropic 
substances, while Maldives has approved a new drugs act 
regulating how the criminal justice system will deal with 
drug abuse and trafficking. The Government of 
Bangladesh has been working on a new national drug 
policy, while the Government of Bhutan has adopted the 
revised Bhutan Medicines Rules and Regulation 2012. In 
addition, India has undertaken significant initiatives to 
strengthen its law enforcement agencies and to upgrade 
border security. The Board welcomes the strong 
commitment of Governments in South Asia to tackling 
the illicit drug problem in the region and urges them to 
build on those measures and to continue to further 
strengthen efforts to combat drug abuse and trafficking. 
The Board believes, in particular, that efforts could be 
further enhanced (a) through better working-level 
contacts and information-sharing between government 
agencies in the region engaged in tackling drug abuse and 
trafficking; and (b) by improved primary prevention, for 
example, working through schools, encouraging the 
industry to self-regulate (for example, through voluntary 
codes of conduct) and adopting the measures mentioned 
above against abuse of and trafficking in pharmaceutical 
preparations. 
 
 2. Regional cooperation 
 
617. At a meeting between the Prime Minister of India 
and the President of Maldives in November 2011, India 
and Maldives signed a memorandum of understanding 
on combating international terrorism, transnational 
crime, illicit drug trafficking and enhancing bilateral 
cooperation in capacity-building, disaster management 
and coastal security.  
618. The Central Bureau of Narcotics of India hosted the 
second meeting of the Expert Working Group on 
REPORT OF THE INTERNATIONAL NARCOTICS CONTROL BOARD  
 
84 
Precursors of the Paris Pact initiative in November 2011. 
More than 50 participants from 30 countries and 
organizations took part in the meeting, which dealt with 
the use of precursor chemicals in heroin production in 
Afghanistan and ways to improve control over trade in 
precursors to prevent diversion. 
619. A meeting between the Home Secretary of India 
and the Deputy Union Minister for Home Affairs of 
Myanmar was held in January 2012. Both sides agreed to 
interaction between their drug control agencies at the 
director-general level once a year and at the deputy 
director-general level twice a year.  
620. In December 2011, UNODC published a report 
entitled Misuse of Prescription Drugs: A South Asia 
Perspective on the abuse of prescription pharmaceutical 
preparations in South Asia. The report was based on 
information gained from seminars with policymakers and 
experts in the fields of drug law enforcement and drug 
treatment in South Asia and representatives of the 
pharmaceutical industry in the region. The Board 
welcomes the report, which contributes to improving 
understanding of prescription drug abuse in South Asia. 
621. In 2009, the Colombo Plan for Cooperative 
Economic and Social Development in Asia and the Pacific 
established the Asian Centre for Certification and 
Education of Addiction Professionals. In March and  
April 2012, the Centre held a training of trainers in Kuala 
Lumpur, with support from the Government of the 
United States of America. Further, in February 2012, the 
National Dangerous Drugs Control Board of Sri Lanka 
and the Colombo Plan, also with support from the 
Government of the United States, launched an initiative 
for the certification of addiction treatment professionals 
in Sri Lanka, whose aim is to train, professionalize and 
expand the addiction treatment workforce in the country.  
622. In June 2012, an expert group meeting was hosted 
by UNODC in New Delhi to discuss various subjects, 
including drug trafficking and crime prevention. 
Government experts from Bangladesh, Bhutan, India, 
Maldives, Nepal and Sri Lanka participated in the 
meeting. The following key decisions were reached on 
how to improve regional cooperation to combat drug 
abuse and transnational organized crime, including drug 
trafficking, in the region: to strengthen border 
management in relation to drugs and crime and to 
promote the gathering and sharing of intelligence and 
information to strengthen the implementation of 
normative and legal frameworks; to undertake  
capacity-building, including through the expansion of 
computer-based training; to connect drug abuse and 
crime prevention strategies; to promote cooperation  
and coordination among health practitioners, law 
enforcement and regulators; to train criminal justice 
officials on drugs and crime and to use a regional forum 
to make regular reviews of the drug and crime situation 
and national and regional policy responses. 
623. UNODC, in partnership with India’s National 
Academy of Customs, Excise and Narcotics, in 2012 
continued to provide technical assistance to enhance drug 
law enforcement capacities in the region through 
computer-based training. Computer-based training centres 
have been established in Bhutan, India, Maldives and 
Nepal and by the end of 2012 computer-based training for 
drug law enforcement will be set up in Bangladesh and in 
Sri Lanka. More than 500 drug law enforcement officers 
have been trained at regional- and national-level training 
programmes. Three training tools — a training manual, 
training guidelines and a training curriculum — were also 
developed for use by officers in the implementation of their 
domestic drug laws in accordance with the international 
drug control conventions. 
624. The Governments of all countries in South Asia 
worked with UNODC to finalize the UNODC regional 
programme for the period 2013-2015. The programme 
will include measures to counter transnational organized 
crime, including drug trafficking, and drug abuse 
prevention and treatment. The focus is on the  
cross-border dimension of those challenges and the 
establishment of the instruments necessary for regional 
cooperation. Efforts will be made to strengthen data 
collection, research and analysis as the basis for  
evidence-based interventions, to enhance data- and 
information-gathering, analysis and sharing, to improve 
border control and to provide training to law 
enforcement and customs personnel at airports  
and seaports.  
 
 3. National legislation, policy and action 
 
625. The authorities of Bangladesh have continued their 
efforts to raise awareness of and provide education on the 
dangers of drug abuse. To that end, in 2011, they 
distributed some 60,000 posters, 10,500 leaflets and 
10,000 stickers and organized some 4,000 discussion 
meetings and 200 speeches at schools and colleges. They 
also formed around 800 anti-drug committees in 
educational institutes. The number of cases tried in  
drug courts in Bangladesh rose from 1,500 in 2010  
to 3,700 in 2011. Prevention activities in Bangladesh also 
target the abuse of prescription-only pharmaceutical 
preparations. 
626. In March 2012, the Government of Bhutan and 
UNODC organized training for forensic chemists and  
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law enforcement officers on drugs and precursors. 
Participants from a range of Bhutanese agencies attended.  
627. As mentioned above, in January 2012, India’s 
Cabinet approved a new National Policy on Narcotic 
Drugs and Psychotropic Substances, including a  
detailed action plan focused on implementing the 
recommendations that the Board made during its last 
mission to India, in December 2010. The Board welcomes 
the Government of India’s responsiveness to the Board’s 
recommendations. As regards measures against 
trafficking in drugs and precursors, under the policy 
India will use satellite imagery to detect and eradicate 
illicit cultivation of opium poppy and cannabis plant. 
India will also strengthen its international cooperation on 
precursor control, including by helping other countries to 
strengthen their precursor control measures. As regards 
targeting drug abuse, drug treatment services will 
prioritize de-addiction. Where those who abuse by 
injection refuse such treatment, they may be offered 
needle exchange or oral substitution therapy, services that 
have already been offered in India for some time. Such 
services will be restricted to centres established, 
supported or recognized by the Government.  
628. The Department of Border Management of India is 
undertaking a major programme of upgrading the 
country’s border security, which should help to combat 
cross-border drug trafficking. The Department will fence 
around 3,400 km of India’s border with Bangladesh and 
construct some 4,400 km of border patrol roads; at least 
80 per cent of the fences and at least 80 per cent of the 
roads have already been constructed. Around 60 per cent 
of India’s border with Pakistan are to be fenced and 60 per 
cent floodlit; at least 95 per cent of the fences and at least 
95 per cent of the floodlighting is already complete. India 
also plans to build some 800 km of strategic roads along 
its border with China, and has deployed a 25-battalion 
border guard force and established 450 border outposts 
along its border with Nepal. The Board notes these 
measures and their potential to reduce drug trafficking 
across India’s borders.  
629. As mentioned above, in December 2011 the 
Parliament of Maldives ratified the Drugs Act, which 
established a national drug control council, a national 
drug agency and drug courts. The Drugs Act regulates the 
prohibition of illegal drug use in Maldives and prevention 
of peddling and trafficking in drugs. The law also makes a 
legal distinction between drug abusers, drug peddlers and 
drug traffickers. Individuals convicted of abusing drugs 
are given a suspended sentence to undergo rehabilitation, 
which is revoked if they opt for and complete the course 
of treatment. Under the regulation, a clear distinction is 
made between drug users, who are provided with a 
chance to reintegrate into society as responsible citizens, 
and drug dealers, who will be convicted for their offence 
and face harsher penalties. The Act also paves the way for 
increased access to rehabilitation programmes for those 
addicted to illicit drugs in order to provide them a chance 
to better reintegrate into society and remain drug-free. 
Establishment of drug treatment rehabilitation and 
aftercare services is mandated under the purview of the 
National Drug Agency. Separate provisions for treatment 
centres for persons under 18 years and for women will be 
implemented so as to address the specific needs of those 
population groups.  
630. In Sri Lanka, the research division of the National 
Dangerous Drugs Control Board began a national 
household survey on drug abuse in late 2011. In  
January 2012, the Minister of Health of Sri Lanka 
announced plans to create a national drug control 
authority.  
 
 4. Cultivation, production, manufacturing and 
trafficking 
 
 (a) Narcotic drugs 
 
631. Pharmaceutical preparations containing narcotic 
drugs continue to be diverted from India and India 
continues to be the main source for those substances and 
for preparations smuggled into other countries in South 
Asia, as well as an important source for smuggling to 
other regions in the world. The preparations containing 
narcotic drugs that are most commonly diverted in India 
are codeine-based cough syrups, dextropropoxyphene 
and pethidine. Large quantities of preparations 
containing narcotic drugs are known to be smuggled 
from India into Bangladesh, Bhutan and Nepal. 
632. From India to Bangladesh there is smuggling of 
codeine/diazepam combination tablets and ampoules of 
pethidine (which can be easily injected), among other 
drugs. In Bangladesh, seizures of ampoules of injectable 
drugs rose to some 120,000 ampoules in 2011, compared 
with a previous high of 90,000 in 2009. Codeine-based 
preparations are also smuggled into Bangladesh, largely 
overland. Seizures of codeine-based cough syrups in 
Bangladesh have increased considerably, with the number 
of litres of codeine-based cough syrups doubling between 
2006 and 2010. Codeine-based cough syrups are also 
smuggled from India to Bhutan, Nepal and Sri Lanka.  
In 2011, India seized over 1.16 million bottles of 
pharmaceutical preparations containing codeine. 
633. Other routes for smuggling of pharmaceutical 
preparations in South Asia are from Pakistan to Sri Lanka 
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and from Sri Lanka to Maldives; Sri Lanka is, alongside 
India, one of the leading sources for pharmaceutical 
preparations smuggled into Maldives. 
634. The Board recommends that the Government of 
India, as part of its efforts to tackle the diversion of and 
trafficking in pharmaceutical preparations, consider 
further strengthening its framework against the 
smuggling of codeine-based cough syrups.  
635. The Government of India is pursuing a sustained 
effort to reduce the level of illicit cultivation of cannabis 
plant in the country. In 2010, the estimated area under 
illicit cultivation was 552 ha, following the eradication of 
681 ha of illicitly cultivated cannabis plant during the 
course of that year. A further 1,114 ha were eradicated  
in 2011. In Bhutan, illicit cultivation of cannabis plant has 
historically been minimal: seizures of cannabis in Bhutan 
in 2010 totalled around 4 kg, but increased to around  
75 kg in 2011. Significant quantities of high-potency 
cannabis resin are produced in Nepal. Sri Lanka seized 
around 204 tons of cannabis plant in 2011. 
636. In India, the authorities were successful in 
destroying almost 6,000 ha of illicitly cultivated opium 
poppy in 2011. Around 528 kg of heroin (a decrease from 
766 kg in 2010) and around 2.3 tons of opium were seized 
in India in 2011.  
637. In Nepal, following an apparent brief upsurge in 
illicit cultivation of opium poppy from 2007 to 2010,  
the Government stated in 2011 that it had become  
poppy-free. There have been isolated cases of illicit 
cultivation of opium poppy in Bangladesh: in 2011,  
22 ha were eradicated along the border with Myanmar. 
The Board welcomes the strong commitment shown by 
the Governments of Bangladesh, India and Nepal to 
eradicating illicit cultivation of cannabis plants and 
opium poppy within their territory and welcomes the 
success of their eradication campaigns.  
638. It appears that heroin is increasingly being 
trafficked through Bangladesh, which is being used as an 
alternative to heroin trafficking routes through India and 
Myanmar. Heroin from Afghanistan has also recently 
begun to be sold in Bangladesh. Heroin enters 
Bangladesh via forest areas, hill tracks and the sea, 
including from Myanmar. The airport in Dhaka and the 
port of Chittagong are used as exit points. Seizures of 
heroin in Bangladesh fell, however, from some 190 kg  
in 2010 to 100 kg in 2011. There remains room for 
improvement in cooperation between Bangladesh and 
neighbouring countries in South Asia with regard to 
combating illicit trafficking and organized criminal 
groups. In Sri Lanka, the authorities estimate that in 2011 
around 75 per cent of heroin trafficked into the country 
entered from Pakistan, with 23 per cent coming from 
India and 2 per cent from Maldives. The authorities in  
Sri Lanka estimate that in 2011 over 50 per cent of 
smuggled heroin came into the country by air, with the 
remainder being brought in by sea. 
639. Drug trafficking has shown significant increases in 
Maldives in recent years. Cannabis is the substance most 
commonly trafficked into the country. According to data 
on seizures made by the Maldives Customs Service, the 
most commonly used route for trafficking narcotic drugs 
into Maldives is from Trivandrum in the south of India to 
Male. In Sri Lanka, illicit manufacture of drugs and 
precursor chemicals is negligible.  
 
 (b) Psychotropic substances 
 
640. Pharmaceutical preparations containing 
psychotropic substances continue to be diverted from 
India’s pharmaceutical industry and smuggled into 
neighbouring countries (in particular Bangladesh, 
Bhutan and Nepal) and elsewhere. The preparations 
containing psychotropic substances most commonly 
diverted from India’s pharmaceutical industry are 
benzodiazepines and buprenorphine. In Bangladesh, 
ampoules of buprenorphine are smuggled in from India. 
The number of ampoules of buprenorphine seized in 
Bangladesh has risen dramatically in recent years: the 
number seized in 2010 (some 70,000 ampoules), was 
around 40 times the number seized in 2006. In Nepal, 
seizure data suggest that smuggling of benzodiazepines 
into that country is increasing.  
641. Regarding amphetamine-type stimulants, 
trafficking in methamphetamine pills from Myanmar into 
South Asia continues to rise. In Bangladesh, seizures of 
“yaba” amphetamine-type stimulant tablets (pills 
containing methamphetamine and caffeine) in 2011 rose 
to their highest levels in the past few years: 1.4 million 
tablets of “yaba” were seized, compared with a previous 
high of 800,000 in 2010. This is a dramatic rise compared 
with 2006, when just 2,000 were seized. In the region of 
Myanmar that borders Bangladesh, 14 illicit 
methamphetamine factories were identified; Myanmar is 
a known route for trafficking in amphetamine-type 
stimulants into Bangladesh. In Nepal, no illicit 
manufacture of amphetamine-type stimulants was 
reported. Seizures of amphetamine-type stimulants, 
excluding MDMA (“ecstasy”), increased in Sri Lanka 
from 8 kg in 2009 to 25 kg in 2010. According to data 
from the World Customs Organization, India was the 
source of 81 kg of the methamphetamine seized 
worldwide reported to the Organization in 2011. 
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642. In India, 72 kg of methaqualone were seized 
in 2011. No clandestine laboratories manufacturing 
methaqualone have been dismantled in that country  
since 2009. Regarding amphetamine, 473 kg of the 
substance were seized in India in 2011.  
 
 (c) Precursors 
 
643. South Asia continues to be targeted by organized 
criminal groups as a source of precursors of 
amphetamine-type stimulants, in particular ephedrine 
and pseudoephedrine. In India, the authorities seized  
7.2 tons of ephedrine and pseudoephedrine in 2011  
and 2.3 tons in the first six months of 2012. This 
represents a substantial increase compared with the 
period 2008-2010, when the most seized in any one year 
was 2.2 tons (2010). From November 2011 to the end  
of June 2012, Indian authorities reported seizing  
over 30 million tablets containing pseudoephedrine,  
over 13 million of which were destined for Myanmar. 
Seizures of acetic anhydride in India have decreased 
significantly since 2008, when around 2.8 tons were 
seized; no seizures were recorded in 2011. Attempted 
diversions and seizures of pharmaceutical preparations 
containing pseudoephedrine from Bangladesh also 
resurfaced in 2011, with shipments from Bangladesh 
being stopped while transiting through Europe en route 
to Central America.  
 
 (d) Substances not under international control 
 
644. Following the decision of the Indian authorities in 
February 2011 to classify ketamine as a psychotropic 
substance under the Narcotic Drugs and Psychotropic 
Substances Act, the quantity of ketamine seized has 
increased, from 1.3 tons in 2010 to 1.5 tons in 2011; the 
quantity seized in the first half of 2012 was 350 kg.  
645. In Bhutan, abuse of solvents is a serious problem. In 
India, the Ministry of Health and Family Welfare banned 
the sale and storage of correction fluid, including nail 
polish remover, at the retail level from July 2012. 
 
 5. Abuse and treatment 
 
646. UNODC estimates that around 3.6 per cent of the 
population of South Asia abuses cannabis at least once a 
year. The corresponding estimate for opioids is 0.3 per 
cent; the prevalence of opiate abuse is estimated as being 
slightly lower, but still around 0.3 per cent. As regards 
abused pharmaceutical preparations of narcotic drugs 
and psychotropic substances, in each of the countries in 
South Asia, benzodiazepines are among the most 
commonly abused; codeine-based cough syrups are also 
commonly abused in Bangladesh and India.  
Heroin-dependent individuals in the region often use 
narcotic and psychotropic pharmaceuticals alongside 
heroin or as a substitute for heroin. Polydrug abuse is 
particularly apparent in Bangladesh, Maldives and Nepal. 
647. In Bangladesh, the most frequently abused drug is 
heroin, then codeine contained in cough syrups; the  
third most abused drug is cannabis. Recently, “yaba” has 
become one of the three main non-pharmaceutical drugs 
abused in Bangladesh, after heroin and cannabis. Drug 
abuse in Bangladesh is spreading from urban to rural 
areas, with indications that this is particularly the case for 
“yaba”. There is also evidence that drug abuse among 
street children in Bangladesh is increasing. The total 
number of people receiving drug abuse treatment in 
Bangladesh was approximately 2,500 in 2010.  
648. Drug abuse in Bhutan has historically been very 
low. However, according to the most recent estimates,  
4.2 per cent of the population aged 15 to 64 abuse 
cannabis in any given year. UNODC data on expert 
perceptions also indicated that abuse of cannabis was 
rising in 2010. According to UNODC, expert perceptions 
in 2010 indicated that cannabis was the most abused drug 
in Bhutan. Abuse of pharmaceuticals is also increasing 
and becoming serious, in particular the abuse of opioids, 
including dextropropoxyphene, and benzodiazepines, 
including nitrazepam, and decongestants containing 
adrenergic stimulants, as well as anticholinergics and 
antihistamines to a lesser extent, some of which are not 
internationally controlled.  
649. Cannabis is the most abused drug in India, followed 
by opioids. Among those treated for drug problems in 
India in 2010, 22 per cent abused cannabis, 66 per cent 
abused opioids (33 per cent heroin, 14 per cent opium 
and 19 per cent prescription opioids) and 12 per cent 
other substances. Some 200,000 people abuse drugs by 
injection in India. Commonly abused pharmaceuticals 
are codeine-based cough syrups, opioid painkillers and 
benzodiazepines, all of which are widely available 
through retail pharmacies. In February 2012, the  
All-India Institute of Medical Sciences initiated 
methadone maintenance treatment, as part of a pilot 
project, with assistance from the UNODC Regional 
Office for South Asia. The project currently provides 
treatment to about 250 injecting drug abusers at five sites 
in the country. All of the implementing sites are 
government health-care facilities. An increase in the size 
of the programme is currently under consideration.  
650. In India, a pilot study has been carried out to test 
the feasibility of using buprenorphine for treatment of 
opioid dependence in prison settings. It is a collaborative 
project between the UNODC Regional Office for South 
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Asia, the National Drug Dependence Treatment Centre of 
India and the prison service at Tihar prison. The 
feasibility of opioid substitution treatment in prison 
settings was demonstrated through this project. 
Additionally, a standard operating guideline was also 
developed for implementation of opioid substitution 
treatment in prison settings in the region. Opioid 
substitution treatment is not yet available in any other 
prisons in South Asia. 
651. Drug abuse has been rising rapidly in Maldives in 
the recent years, especially among young people. In the 
period 2011-2012, the Ministry of Health, the National 
Drug Agency and the National Human Rights 
Commission of Maldives, the National Drug Dependence 
Treatment Centre of India (part of the All-India Institute 
of Medical Sciences), UNODC, a national research 
organization in Maldives and civil society groups 
cooperated to undertake the national drug use survey of 
Maldives for the period 2011-2012. The survey found that 
the most commonly abused drugs in Maldives were, in 
order, cannabis resin, opioids and cannabis herb. The 
most commonly abused non-pharmaceutical opioid in 
Maldives is “brown sugar”, a variety of heroin. MDMA 
(“ecstasy”) has been abused in Maldives since 2011. Abuse 
of pharmaceutical preparations is also serious. Since 2011 
the abuse of nitrazepam has also been detected.  
652. In partnership with the Maldives Ministry of Health 
and Family, methadone maintenance treatment is being 
provided for more than 50 people through a centre 
operated by the Department of Drug Prevention and 
Rehabilitation Services. The Government of Maldives, in 
partnership with UNODC, also supports 14 local  
non-governmental organizations across nine atolls 
providing aftercare and support services for recovering 
drug users, their partners and families.  
653. In Nepal, it has been estimated that  
30,000-34,000 people abuse drugs by injection —  
some 0.18 per cent of the adult population. This is an 
increase from the estimated level of 28,500 people in 
2009. Most of the people who abuse drugs by injection in 
Nepal are believed to be abusing opioids such as 
buprenorphine and propoxyphene. UNODC also 
estimates that 30,000-50,000 people in Nepal abuse 
heroin, though it is not so often abused by injection.  
A study among female drug abusers in Nepal found  
that cannabis, benzodiazepines, heroin and 
dextropropoxyphene were the main substances of abuse. 
Multiple drug abuse using pharmaceutical preparations 
containing internationally controlled substances also 
occurs in the country; such preparations are also abused 
as substitutes for other drugs when these are in short 
supply or too expensive. 
654. According to UNODC data on expert perceptions 
in 2010, the most abused drug in Sri Lanka was cannabis, 
followed by opiates. According to other recent estimates, 
around 1.4 per cent of the population aged 15 to 64 abuse 
cannabis in any given year. Sri Lanka’s drug abuse register 
currently lists 245,000 people, of whom 200,000 abuse 
cannabis and the remainder heroin. The authorities do 
not currently have an estimate for the total number of 
people requiring treatment for drug abuse in Sri Lanka. 
Among those treated for drug abuse in 2010, some 70 per 
cent abused heroin, while 30 per cent abused cannabis. 
The authorities estimate that some 1,300 people received 
residential drug abuse treatment in 2011, of whom 75 per 
cent abused opioids and 30 per cent abused cannabis as 
their primary drug of abuse (with some abusing both 
drugs heavily).  
655. Sri Lanka employs a range of techniques in  
drug abuse treatment and increased its budget for  
treatment programmes in 2011, including screening and  
short-duration therapy. The authorities estimate that 
around 50 per cent of those in need of such interventions 
do receive them. The interventions are undergoing 
impact evaluations. Sri Lanka also provides residential 
and outpatient treatment facilities (the latter defined as 
facilities used without an overnight stay), detoxification, 
counselling, contingency management (psychosocial 
interventions providing incentives to abstain from drug 
abuse), rehabilitation and aftercare. Sri Lanka has a 
national treatment reporting and monitoring system that 
covers drug treatment provided by the public sector and 
by non-governmental organizations. 
 
 
  West Asia 
 
 
 1. Major developments 
 
656. West Asia continues to have the greatest share of 
global illicit opium poppy cultivation and illicit opiate 
production, primarily Afghanistan, which saw a 
significant rebound in illicit opium poppy cultivation, 
reaching 154,000 ha in 2012, 18 per cent more than the 
previous year, and representing an estimated 64 per cent 
of global cultivation. The number of provinces of 
Afghanistan cultivating illicit opium poppy remained 
unchanged, with opium poppy cultivation in excess of 
100 ha in half of the 34 provinces. However, illicit opium 
production in 2012 decreased by 36 per cent from the 
previous year, dropping to 3,700 tons, as an opium poppy 
disease and poor weather decreased yields in 2012.  
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657. After a substantial increase from 2010 to 2011, the 
value of opium produced in Afghanistan in 2012 dropped 
by half over the previous year and was estimated to be 
valued at over $700 million, which is the equivalent of  
4 per cent of the country’s gross domestic product  
in 2012. The majority of the farmers illicitly cultivating 
opium poppy who were surveyed in 2012 cited as the 
reason for cultivation the high income from opium 
poppy, which far exceeded the prices paid for alternative 
licit crops such as wheat. In addition, both the prices and 
the production of cannabis — particularly cannabis resin 
— appear to be increasing. 
658. The uncertain security situation and political 
instability prevailing across the Arab world provides 
fertile ground for illicit activities that profit both regional 
and international criminal networks, resulting in 
increasing levels of illicit trafficking in drugs and persons 
and money-laundering.  
659. With respect to drug trafficking in the Middle East, 
there is an increasing trend in both the quantity and the 
number of seizures reported. Most of the countries in the 
region are still considered to be transit areas for the 
smuggling of illicit drugs, in particular, Iraq.  
660. Traditionally, countries in the Middle East are 
affected mainly by trafficking in amphetamine-type 
stimulants, in particular, amphetamine sold as Captagon 
tablets. Judging by the significant number of seizures 
reported in the region, Saudi Arabia retains the record for 
most seizures, followed by Jordan and the Syrian Arab 
Republic. Saudi Arabia continues to be the destination of 
choice and an important market for Captagon tablets, 
although they also continue to be a problem in other 
countries of the Cooperation Council for the Arab States 
of the Gulf. However, reports indicate that Captagon 
tablets are also seized in other countries of the region, 
such as Iraq.  
661. Demand for various illicit stimulants, such as 
cocaine and methamphetamine, appears to be increasing 
in parts of West Asia. Seizures of these drugs have steadily 
increased, and abuse, for example, of methamphetamine 
in the Islamic Republic of Iran, has also been reported to 
be on the rise.  
662. The trend observed with regard to seizures of 
methamphetamine as reported by some countries in the 
Middle East, in particular Israel and Jordan, may indicate 
an increase in and spread of trafficking in 
methamphetamine in the region. Seizures of MDMA 
(“ecstasy”) have been reported by some countries in the 
region.  
663. Increased abuse of prescription drugs, in particular 
benzodiazepines such as diazepam, bromazepam and 
alprazolam, has been reported in a number of countries, 
including Jordan, Kuwait, Qatar and the United Arab 
Emirates. 
664. The number and quantities of seizures of 
counterfeit pharmaceuticals worldwide increased 
significantly in 2011, rising from 1,398 seizures of a total 
of 11.7 million tablets in 2010 to 1,861 seizures of a total 
of 26.7 million tablets in 2011. The number of reported 
cases in the Middle East also increased in 2011. Seizures 
of counterfeit medicines used for the treatment of 
insomnia (benzodiazepines) were reported in the region, 
although they did not constitute the drug group of 
greatest concern. 
665. Several West Asian countries continue to report 
large annual legitimate requirements for imports of 
precursors that can be used in the illicit manufacture of 
methamphetamine. Large-scale seizures of ephedrine 
were reported by the Islamic Republic of Iran in 2010  
and 2011, and in 2012, allegations of large-scale diversion 
of ephedrine were being investigated in Pakistan. The 
Government of Jordan has now prohibited the 
importation of P-2-P, a precursor that can be used in the 
illicit manufacture of, among other substances, 
amphetamines, which is common in the region.  
666. The third Ministerial Conference of the Paris Pact 
Partners on Combating Illicit Traffic in Opiates 
Originating in Afghanistan was held in Vienna in  
February 2012 and was attended by 500 participants from 
58 countries and 16 international organizations. 
Government Ministers and Paris Pact partners stressed the 
need to reduce opium poppy cultivation and production, 
opiate trafficking and illicit consumption. Ministers and 
other heads of delegation adopted the Vienna Declaration, 
a statement of international commitment to act in 
coordinated fashion against illicit Afghan opiates, which 
addressed four main areas of cooperation: strengthening 
regional initiatives to counter trafficking in opiates 
originating in Afghanistan, detecting and blocking 
financial flows linked to illicit opiates, preventing the 
diversion of precursor chemicals used in the 
manufacturing of illicit opiates in Afghanistan, and 
reducing drug abuse and drug dependence. 
 
 2. Regional cooperation  
 
667. In November 2011, Ministers of the Governments of 
Afghanistan, Iran (Islamic Republic of) and Pakistan held 
a meeting in Kabul to strengthen regional security 
cooperation to combat threats posed by illicit drugs amid 
concerns over the rapidly rising quantity of opium 
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production in Afghanistan and its increasing value. The 
confidence-building meeting was aimed at promoting the 
exchange of information and intelligence-led operations 
targeting major transnational trafficking networks. All 
parties have been increasing their cross-border drug 
control capacities. Future joint operations and patrols will 
likely cover key maritime drug trafficking routes. 
668. In November 2011, UNODC, together with the 
European Commission and the National Narcotics 
Control Commission of China, conducted a debriefing  
on operation Targeted Anti-trafficking Regional 
Communication, Expertise and Training (TARCET) III 
held in Beijing. Participants in the debriefing discussed 
the results of the operation to counter trafficking in 
precursors, involving Afghanistan, Iran (Islamic Republic 
of), Pakistan and all Central Asian States. Seizures in 
Afghanistan of 13 tons of acetic anhydride, 3.5 tons of 
acetic acid, 7 tons of hydrochloric acid, 2 tons of sodium 
carbonate and 1 ton of ammonium chloride during the 
operational period were reported. At the meeting, the 
Islamic Republic of Iran also reported having seized  
1.5 tons of acetic anhydride. Weaknesses in information 
exchange continue to hinder backtracking investigations 
to identify the source of diversion and intelligence-led 
operations related to precursor chemicals in Afghanistan 
and neighbouring countries, particularly as trafficking in 
chemicals is a global phenomenon. Therefore, to enhance 
intelligence-sharing, particularly among those agencies in 
a position to take action, the Board encourages all 
Member States to communicate all illicit chemical-related 
incidents through the Board’s secure online global 
communication platform: PICS. 
669. The Istanbul Conference for Afghanistan: Security 
and Cooperation in the Heart of Asia was held in 
November 2011, following preparatory meetings in Oslo 
and Kabul in October. At the Conference, the declaration 
entitled “Istanbul Process on Regional Security and 
Cooperation for a Secure and Stable Afghanistan” was 
adopted by 13 participating States in the region and 
supported by 22 other States, institutions and 
organizations present as observers. The Istanbul Process 
reaffirms general principles of regional cooperation and 
contains a list of seven specific confidence-building 
measures for consideration by the countries of the region, 
including one measure in the area of counter-narcotics.  
670. The International Conference on Afghanistan,  
held in Bonn, Germany in December 2011, marking a 
decade of partnership between Afghanistan and the  
international community, was attended by 85 States  
and 15 international organizations. Participants discussed 
issues related to future regional cooperation; governance; 
the peace process; economic and social development; 
security, including terrorism-related issues; and illicit 
drug trafficking. Afghan authorities will assume 
responsibility for the security of their country, fully 
taking over from the International Security Assistance 
Force (ISAF), at the end of 2014. The international 
community has committed to the continued support of 
Afghanistan beyond 2014. 
671. The forty-sixth session of the Subcommission on 
Illicit Drug Traffic and Related Matters in the Near and 
Middle East was held in Vienna in December 2011. It was 
attended by representatives of Azerbaijan, Egypt, India, 
Iran (Islamic Republic of), Iraq, Jordan, Lebanon, Oman, 
Pakistan, Qatar, Saudi Arabia, the Syrian Arab Republic, 
Turkey, United Arab Emirates and Yemen, along with 
numerous observers. The Subcommission discussed and 
made recommendations regarding the ongoing impact of 
illicit drug production in the Near and Middle East, 
improved coordination and models of drug demand 
reduction, developing and enacting legislation to allow 
for coordinated cross-border law enforcement activities 
such as controlled deliveries, strengthening the 
monitoring of precursor chemicals and synthetic drug 
trafficking, and supporting the implementation of 
evidence-based drug treatment throughout the region. 
672. In December 2011, UNODC launched the regional 
programme for Afghanistan and neighbouring countries, 
focusing on creating a broad international coalition to 
counter opium poppy cultivation, drug production and 
trafficking. The programme includes a comprehensive set 
of responses aimed at addressing the nexus of poverty and 
drug cultivation, curbing illicit drug demand, sharing 
intelligence and targeting high-value traffickers. 
673. A meeting organized by UNODC in Almaty in 
February 2012 provided an opportunity for the heads of 
counter-narcotics operational units from Afghanistan, 
Iran (Islamic Republic of), Kazakhstan, Kyrgyzstan, 
Pakistan, Tajikistan, Turkmenistan and Uzbekistan to 
review the current state of multilateral operations. The 
meeting, attended by senior officials from police, customs 
and drug control agencies, in addition to international 
counterparts from 30 countries, international and 
regional organizations, focused on sharing information 
on targeted transnational drug trafficking groups, 
reviewing regional cooperation efforts related to 
precursor control in Afghanistan and developing a list of 
specific drug control activities for 2012. 
674. In May 2012, the Ministerial Meeting of  
the Tripartite Initiative brought together drug  
control authorities from Afghanistan, Kyrgyzstan  
and Tajikistan to improve regional cross-border  
counter-narcotic activities. Regional partners are 
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promoting counter-narcotics cooperation by 
strengthening border controls between Afghanistan and 
Tajikistan through the provision of training and 
equipment and by making available legal, health-related 
and law enforcement expertise to Governments in  
the region. 
675. The active participation of countries in the Middle 
East in regional and subregional cooperation meetings 
under the umbrella of the Council of Arab Ministers of 
the Interior, the Cooperation Council for the Arab States 
of the Gulf and the Arab Office for Narcotic Affairs, as 
well as close cooperation between law enforcement 
agencies, including INTERPOL, the Arab Criminal Police 
Bureau and the Arab Office for Narcotic Affairs resulted 
in successful cross-border drug control operations and 
numerous controlled deliveries leading to the dismantling 
of international drug networks.  
676. The first meeting of the steering committee of  
the regional programme for the Arab States for the  
period 2011-2015 was held under the auspices of the 
League of Arab States in Cairo in May 2012. The steering 
committee consists of the League of Arab States and its 
relevant councils, UNODC and the 18 States included in 
the UNODC regional programme. The steering 
committee called upon all States concerned to strengthen 
regional cooperation on drug control, in particular in the 
light of the Arab region’s increased exposure to drug 
trafficking and organized crime in 2011, as reported by 
Member States.  
677. At the 21st INTERPOL Asian Regional Conference, 
held in Amman in September 2012, measures were 
approved by senior law enforcement officials from Asia, 
the South Pacific and the Middle East to enhance 
collective police responses and the capacity of law 
enforcement authorities to enhance regional and 
international security. Delegates from some 40 countries 
reviewed a range of law enforcement issues including 
terrorism, cybercrime, trafficking in persons, integrity in 
sports, maritime piracy, trafficking in illicit goods, 
pharmaceutical crime and environmental security.  
678. The Board takes note with satisfaction of the 
increasing number of bilateral agreements and 
memorandums of understandings signed between 
countries in the region. All countries in the region affirm 
that they are committed to regional and international 
cooperation for drug control in the Middle East. 
 
 3. National legislation, policy and action  
 
679. In 2012, the Government of Afghanistan launched 
the National Drug Demand Reduction Policy for  
the period 2012-2016, prepared by the Ministry of 
Counter-Narcotics, as the competent national authority, 
in close cooperation with the Ministry of Public Health 
and the Ministry of Labour and Social Affairs, Martyrs 
and the Disabled. The policy addresses drug  
abuse prevention and the treatment and rehabilitation  
of drug-affected persons and recommends the 
establishment of regional drug treatment centres and  
an increase in drug prevention and treatment capacity  
by up to 40 per cent over the next five years. In addition, 
drug treatment services will become part of the  
regular public health services budget in order to improve 
funding stability. 
680. In February 2012, the Government of Afghanistan 
also launched the National Alternative Livelihood Policy, 
aimed at strengthening and diversifying rural livelihoods 
by tackling the root causes and drivers of dependency on 
illicit crops. The policy has six main objectives: undertake 
comprehensive, locally-adapted and practical 
interventions focusing on rural communities affected by 
the Government’s counter-narcotics campaigns; provide 
assistance to farmers, labourers and rural communities 
that have taken the decision not to engage in the 
production of narcotics; maintain the “opium poppy-free” 
status of communities that have opted not to engage in 
the illicit cultivation and production of narcotics; reduce 
the cultivation of opium poppy and production of 
narcotics; prevent the spread of illicit opium poppy 
cultivation; and achieve a steady reduction in illicit opium 
poppy cultivation.  
681. In May 2012, the Government of Afghanistan 
launched its new Anti-Drug Trafficking Policy, which 
concentrates law enforcement resources on high-value 
drug traffickers and their organizations. The policy 
prioritizes asset forfeiture, improves existing processes for 
opium poppy eradication, enhances the capacities of 
counter-narcotics agencies, strengthens border controls, 
enhances regional cooperation and coordination among 
counter-narcotics institutions, establishes a fund to 
provide incentives to law enforcement authorities and 
seeks to improve the conditions of those incarcerated for 
drug offences. The policy’s objectives include increasing 
the drug seizure rate from the current 0.5-1.5 per cent to 
a minimum of 12 per cent and increasing the precursors 
seizure rate to between 30 and 50 per cent within  
five years. 
682. The Board continues to be concerned about the lack 
of reliable data and information being collected on the 
nature and extent of drug abuse in the Middle East, as it 
hinders the provision of adequate treatment and 
prevention programmes. In that connection, the Board 
welcomes the signing in 2011 of a five-year agreement 
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between the United Arab Emirates and UNODC to carry 
out an in-depth analysis of shortages in the availability of 
treatment for drug addiction in the country.  
683. In the area of reduction of illicit drug demand, the 
Board notes that UNODC and the Ministry of the 
Interior of the United Arab Emirates jointly established 
the rapid situation assessment and data collection 
process. The Board encourages all Governments in the 
region to start or to continue to assess the patterns of and 
trends in drug abuse in their country in order to better 
assist the authorities in addressing the drug problem, 
including the diversion of pharmaceutical preparations; 
to do so will reinforce efforts in drug demand reduction. 
In that context, the Board would like to stress  
the importance of establishing epidemiological data 
collection and improving the health-care system’s 
capabilities in the area of prevention and treatment.  
684. The Board welcomes the fact that the Jordanian law 
on drugs drafted in April 2012 recommends that  
first-time drug users be sent to a rehabilitation centre 
instead of prison.  
685. In an effort to address the challenging problem of a 
fast-developing synthetic drug market, the Government 
of Israel amended the Dangerous Drug Ordinance to 
include analogues of amphetamine, methamphetamine, 
cathinone and methcathinone. 
686. Jordan has taken measures to increase public 
awareness of dangers of drugs by involving governmental 
institutions, non-governmental organizations, correction 
and rehabilitation centres and youth clubs. Actions taken 
in 2011 included courses aimed at preventing drug abuse, 
lectures and fairs to raise awareness, and media 
programmes and press briefings.  
687. The Syrian Arab Republic established stringent 
procedures for the control of some pharmaceutical 
preparations containing trihexyphenidyl (benzhexol), 
codeine and dextropropoxyphene, which may be 
dispensed only upon receipt of a renewable prescription 
for a maximum of seven days supply at each dispensation. 
Severe penalties are established for pharmacists 
contravening those procedures, although it is unlikely 
that the law will be enforceable throughout the country 
under the current circumstances. 
 
 4. Cultivation, production, manufacture and 
trafficking  
 
 (a) Narcotic drugs  
 
688. UNODC estimates that in 2012, illicit opium poppy 
cultivation totalled 154,000 ha in Afghanistan, an increase 
of 18 per cent over 2011. That amount represents an 
estimated 64 per cent of global cultivation. An opium 
poppy disease that damaged the harvest significantly  
in 2010 reappeared again in 2012, and, along with adverse 
weather, decreased the opium yield, particularly in the 
eastern, western and southern regions of the country.  
689. Opium poppy cultivation in 2012 increased in most 
of the significant opium poppy-growing provinces and 
remained concentrated in the south, notably Helmand 
province. However, growth in cultivation in the central 
and eastern provinces was noted. Beyond Helmand and 
Kandahar, attention should be given by the Government 
to the increasing cultivation trends in Nangarhar and 
Badakhshan provinces, which previously had significant 
areas of illicit opium poppy cultivation. 
690. The number of opium poppy-free provinces 
remained unchanged in 2012, with 17 cultivating opium 
poppy in excess of 100 ha. Increases were also seen among 
the provinces with the largest areas of opium-poppy 
cultivation, with cultivation in Helmand and Farah 
increasing 19 and 58 per cent, respectively. A slight 
decrease was noted in Kandahar. However, the area under 
cultivation remained elevated, with more than 24,000 ha 
of opium poppy cultivation. 
691. Afghanistan accounted for nearly three quarters of 
estimated global opium production, even as production 
decreased to 3,700 tons in 2012, compared with  
5,800 tons in 2011. The Afghanistan: Opium Survey  
2012, a survey jointly carried out by the Ministry of 
Counter-Narcotics of Afghanistan and UNODC, revealed 
a 49-per-cent drop in the farm-gate value of opium over 
the past year, which was estimated to have had a value of 
over $700 million in 2012, equivalent to 4 per cent of the 
country’s gross domestic product.  
692. In 2012, the farm-gate price for dry opium had 
decreased to $196 per kilogram, a 19-per-cent drop  
from 2011. Even with the decrease, 64 per cent of village 
leaders surveyed in 2012 cited the high income from 
opium as the predominant reason for growing opium 
poppy. 
693. The price of illicit dry and fresh opium declined in 
2012 — but continues to far outweigh prices of licit 
agricultural products — making illicit opium poppy 
cultivation more profitable than licit crops for farmers. 
None of Afghanistan’s licit crops can match the gross 
income per hectare generated by the illicit cultivation of 
opium poppy. Additionally, UNODC production and 
price data for 2011 indicate that gross revenue generated 
from illicit cannabis cultivation surpassed that of opium 
poppy, with households, numbering 65,000, reportedly 
earning $8,100 per hectare annually from cannabis plant 
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cultivation, which is significantly greater than the 2012 
estimated per hectare earnings generated from opium 
poppy cultivation ($4,600). 
694. The Government of Afghanistan estimated that  
in 2011, the livelihoods of some 191,500 rural households 
depended on the growing of illicit drug crops, primarily 
opium poppy. Among the surveyed villages, however, only 
30 per cent had received some form of agricultural 
assistance (e.g. seeds, fertilizers and irrigation) in the 
preceding year. Without sustainable alternatives for 
households currently engaged in the illicit cultivation of 
drug crops and production of narcotics, it will be difficult 
to achieve regional security, governance, development 
and counter-narcotics objectives.  
695. Research continues to suggest that there is a strong 
correlation between security and agricultural assistance 
and the likelihood of opium poppy cultivation. Villages 
that reported good levels of security and that had received 
government-sponsored agricultural assistance in the 
previous year were significantly less likely to have grown 
opium poppy in 2012 than were villages with a low level 
of security and that had not received assistance. 
Additionally, villagers who had received materials to raise 
awareness of the problems associated with opium poppy 
were found to be significantly less likely to grow illicit 
opium poppy. The continuing decreases in the force levels 
of ISAF and the planned handover by ISAF of security 
responsibility to the Afghan Government by 2014 could 
impact on security in parts of the country, and that, 
combined with an increase in opium prices, could foster 
instability and lead to greater levels of illicit drug 
production.  
696. As of August 2012, a total of 9,672 ha of  
Governor-led eradication of fields of opium poppy 
cultivation were verified in 18 provinces of Afghanistan, 
an increase of 154 per cent over the area eradicated in the 
same period in 2011, with large increases in verifiable 
eradication noted in Helmand, Kandahar and Nangarhar 
provinces. Increases were due to pre-planting and  
pre-eradication campaigns conducted by the Ministry of 
Counter-Narcotics and to its improved coordination with 
other Government ministries. However, eradicating illicit 
opium poppy crops is not without risk to the eradication 
teams involved. Farmers’ resistance to operations took the 
form of direct attacks, mine explosions, the flooding of 
poppy fields and violent demonstrations. In 2012, as  
of June, 102 lives had been lost and 127 people had  
been injured during eradication efforts.  
697. Pakistan reports limited illicit cultivation of opium 
poppy and Government eradication efforts, with an 
estimated 362 ha of opium poppy cultivation in 2011, the 
lowest levels in a decade. Pakistan is affected far more by 
cross-border trafficking in illegal drugs and precursor 
chemicals, which have a local value estimated at between 
$910 million and $1.2 billion. Reports suggest that 40 per 
cent of heroin trafficked from Afghanistan transits 
Pakistan (the so-called southern route), 35 per cent 
transits the Islamic Republic of Iran (the Balkan route) 
and a quarter transits various Central Asian countries 
(the northern route). It appears that traffickers are 
increasingly using Central Asian railways to transport 
opiates to the Russian Federation. 
698. Turkey continues to seize significant amounts of 
opiates originating in Afghanistan and destined for 
markets in Europe, and in 2011 approximately 98 per cent 
of opiates seized by the country’s authorities were in the 
form of heroin (6.4 tons). Turkey reports that the number 
of seizures of all opioids has been in decline, with heroin 
seizures at their lowest level in the past five years and the 
number of opium seizures dropping by 80 per cent 
between 2007 and 2011. As was the case in 2010,  
no seizures of morphine base were reported in 2011. 
Decreases were attributed to lower production in 
Afghanistan, the increased use of air and sea cargo 
shipping methods and trafficking routes avoiding Turkey, 
as traffickers responded to enhanced law enforcement 
efforts in that country.  
699. Heroin seizures remain low in the Middle East, but 
the global trend in 2011 showed an increase, particularly 
in Saudi Arabia, which reported total seizures of  
111 kg, followed by Jordan and the Syrian Arab Republic 
(92 kg each) and Qatar (12 kg).  
700. In 2011, the authorities of Azerbaijan, Kazakhstan, 
Kyrgyzstan, Tajikistan, Turkmenistan and Uzbekistan 
detained a total of 15,690 people for suspected 
involvement in illicit drug offences, 22 per cent fewer 
than in 2010. Compared with 2010, opioid seizures  
in those countries declined 21 per cent in 2011, to  
4.3 tons. However, total drug seizures increased  
89 per cent, to 91.6 tons, driven by a substantial increase 
in seizures of cannabis, including cannabis resin. 
701. Three of the five countries most commonly 
reported worldwide as the origin of cannabis resin are 
located in West Asia, namely Afghanistan, Lebanon and 
Pakistan. According to UNODC, information on the 
origin of seized cannabis resin indicates that Afghanistan 
is the second most commonly identified supplier of 
cannabis resin, after Morocco. Cannabis cultivation and 
cannabis resin production may also be spreading, with 
more than half of Afghanistan’s provinces now cultivating 
cannabis plant. Cannabis plant cultivation in Afghanistan 
in 2011 covered 8,000-17,000 ha, with subsequent 
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cannabis resin production estimated at 1,000-1,900 tons. 
The demand for Afghan cannabis resin, irrespective of 
quality, also appears to have risen in recent years, with 
average farm-gate prices for the highest quality resin 
increasing from around $35 per kg in 2009 to $86 per kg 
in 2010 and $95 per kg in 2011.  
702. Illicit cultivation of cannabis plant continued in 
some areas throughout the Middle East, in particular 
Lebanon. According to officials in the Occupied 
Palestinian Territory, some illicit cultivation of cannabis 
plant, although limited, takes place in the West Bank.  
703. The volume of both cannabis resin and herbal 
cannabis intercepted in the Middle East increased  
in 2011. Most of the seizures in 2011 were reported  
by Jordan and Saudi Arabia, which seized 1.7 tons and  
23 tons, respectively. Yemen, for the second consecutive 
year, was identified as the source country. 
704. Although the number of seizures involving opium 
in the region decreased, quantities seized in Qatar in 2011 
increased significantly (to 535 kg) compared with 
previous years (less than 5 kg). Most of the seizures were 
carried out at the Doha international airport and involved 
passengers from Bangladesh, Egypt and Iran (Islamic 
Republic of). 
705. Cocaine seizures in West Asia are reported to be 
occurring with increasing frequency and to be of 
increasingly large amounts, with cocaine seizures 
increasing more than 20 times between 2001 and 2010.  
In 2011, Turkey seized a record 589 kg of cocaine — 
nearly double the amount in 2010 — and reported that 
the number of cocaine seizures had increased 
dramatically, as well as the average amount per seizure. 
Qatar, which has reported no cocaine seizures, was 
frequently identified as a transit area for cocaine 
trafficked from Brazil in 2011, often destined for 
countries in East Asia. 
706. The new trend of smuggling of cocaine observed in 
Jordan in 2010 continued in 2011. However, the quantities 
seized were less: in 2011, Jordan seized 1.4 kg of cocaine 
compared with more than 4.2 kg in 2010. Cocaine enters 
Jordan from South America via European airports, 
destined for Israel, Lebanon and other countries in the 
region.  
 
 (b) Psychotropic substances  
 
707. West Asia has experienced considerable growth in 
trafficking in and seizures of amphetamines, and, as was 
reported in the report of the Board for 2011, a particular 
concern is the rapid emergence and growth of 
methamphetamine manufacture, trafficking and abuse 
throughout the region. Significant increases were seen in 
the Islamic Republic of Iran, where the country reported 
seizing 3.9 tons of methamphetamine — nearly triple the 
previous year’s totals — placing it among the countries 
seizing the largest quantities of the substance globally. 
Iranian authorities reported dismantling several 
significant methamphetamine trafficking organizations  
in 2011. In 2010, 166 illicit clandestine methamphetamine 
laboratories were reported to have been dismantled.  
708. According to UNODC, the region accounted for 
nearly a quarter of the global amphetamine 
(amphetamine and methamphetamine) seizures. In 2010, 
large amphetamine seizures totalling 500 kg or more were 
reported in Iran (Islamic Republic of), Iraq, Jordan, Saudi 
Arabia and the Syrian Arab Republic. In 2011, customs 
authorities in Saudi Arabia reported seizures of tablets 
sold as counterfeit Captagon and amphetamine totalling 
20,585 kg — the highest amounts ever recorded — while 
Jordanian authorities reported seizures of 905 kg.  
In all cases, the drugs were en route to Saudi Arabia, with 
48 per cent originating in the Syrian Arab Republic and 
44 per cent originating in Jordan. 
709. Saudi Arabia continues to be the main country of 
destination for amphetamine sold as counterfeit 
Captagon tablets. These tablets are smuggled into the 
country through Jordan and the Syrian Arab Republic.  
In 2011, the volume of amphetamine (including 
Captagon) seized in the Middle East amounted to nearly 
22 tons, and according to the World Customs 
Organization, seizures made in Saudi Arabia constituted 
nearly 95 per cent of the total, followed by Jordan. 
According to Government sources, total seizures of 
amphetamine in Saudi Arabia amounted to 11.4 tons, 
followed by the Syrian Arab Republic (3.8 tons)  
and Jordan (1.8 tons).  
710. Jordan and the Syrian Arab Republic continue to be 
the main countries of origin of the seized amphetamine. 
Furthermore, in the light of the seizures reported in Iraq, 
the amphetamine market seems to be expanding in that 
country.  
711. According to the World Customs Organization, the 
quantity of methamphetamine seized decreased sharply 
in 2011 compared with previous years, and a total of 31 kg 
were intercepted in Saudi Arabia. On the other hand, 
MDMA (“ecstasy”) seizures in the region increased, 
according to Bahrain and Yemen. In all cases, the drug 
was found in international airports in travellers’ 
belongings. Origins cited included Iran (Islamic Republic 
of), Jordan and Thailand.  
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712. In 2010, Jordan reported for the first time the 
seizure of methamphetamine (2 kg), and seizures of the 
substance reported by Israel have increased over the past 
few years.  
713. Most countries in the region continue to report the 
abuse of prescription drugs containing psychotropic 
substances such as benzodiazepines and stimulants such 
as methylphenidate. In Israel, Ritalin (methylphenidate) 
is mainly abused among the student community.  
 
 (c) Precursors 
 
714. Most acetic anhydride reported seized was destined 
for use in Afghanistan. Based on a limited number of 
backtracking investigations, combined with an analysis of 
pre-export notification patterns, the source of diverted 
acetic anhydride in the region is best characterized as 
diversion from domestic distribution channels followed 
by subsequent smuggling into Afghanistan. The Board 
urges increased use of backtracking investigations of 
seizures of acetic anhydride and other scheduled 
chemicals, particularly those found in illicit heroin 
laboratories, to determine their source of diversion. 
Results of such investigations should be shared with the 
Board through the global Project Cohesion mechanism 
and among other relevant regional and international 
partners. 
715. Data collected by the Afghanistan Ministry of 
Counter-Narcotics and UNODC suggest that the price  
of illicit acetic anhydride, as estimated in May 2011  
($416 per litre) declined by about half by May 2012, to 
between $165 and $232 per litre, depending on the 
perceived quality of the substance. Given the inherent 
value of illicit precursor price data in understanding  
the dynamics of illicit markets, the Board recommends 
the systematic collection and monitoring of prices of 
illicit precursors by Governments, as is typically done for 
illicit drugs. 
716. The Government of Jordan informed the Board that 
the import of P-2-P had been prohibited as of May 2012. 
The country previously had the highest annual legitimate 
requirements for the substance in the world, purportedly 
for use in cleaning supplies for export to Iraq. The Board 
had repeatedly expressed concerns to the Government 
over its unusual use and the high likelihood of diversion 
into the illicit manufacture of amphetamine, the 
psychoactive ingredient found in counterfeit Captagon 
tablets seized in mass quantities throughout the region. 
Iraqi authorities no longer allow importation of  
P-2-P-based cleaning products. 
717. Several countries in West Asia continue to report 
some of the highest annual legitimate requirements for 
imports of ephedrine and pseudoephedrine, precursors 
that can be used in the illicit manufacture of 
methamphetamine. Iran (Islamic Republic of), the Syrian 
Arab Republic and Pakistan have some of the highest 
annual legitimate requirements for importation of 
pseudoephedrine of any country. Pakistan has the fourth 
highest annual legitimate requirements for ephedrine 
worldwide, and since March 2012, the alleged diversion of 
significant amounts of ephedrine have led to high-profile 
investigations in the country. In 2011, the Islamic 
Republic of Iran reported several significant seizures of 
ephedrine originating in the neighbouring countries of 
Iraq and Pakistan. The Board encourages all 
Governments to communicate all chemical-related 
incidents through PICS, the Board’s secure online global 
communication platform.  
718. The Board continues to be concerned by 
Governments in high-risk regions failing to implement 
the most fundamental tools to counter trafficking in 
chemicals. Many countries in West Asia are not registered 
with the Pre-Export Notification Online (PEN Online) 
system, which provides real-time notification of pending 
exports of chemicals that can be used in illicit drug 
production. Of equal concern is the fact that many 
countries in the region — including those registered  
with and actively using the PEN Online system — have 
not invoked article 12, paragraph 10 (a), of the  
1988 Convention, meaning that exporting countries are 
not required under international law to notify importing 
Governments of any pending precursor shipments. These 
fundamental anti-trafficking tools are provided to all 
Governments free of charge. The Board calls upon all 
Governments that have not yet done so to register  
with the PEN Online system and invoke article 12, 
paragraph 10 (a), of the 1988 Convention for all 
substances in Tables I and II without further delay. The 
international community’s development assistance efforts 
should include any technical assistance required to enable 
States effectively to take part in these Board-managed 
precursor control mechanisms.  
 
 (d) Substances not under international control 
 
719.  Substances not under international control, in 
particular khat, continue to be seized in the Middle East. 
In 2011, a total of 250 kg of khat, destined for Saudi 
Arabia, was seized, almost all by the Yemeni customs 
services. Abuse of khat is also reported in Israel.  
720. Solvent and inhalant abuse is reported in some 
countries, such as Israel and Saudi Arabia. In Saudi 
Arabia, a large proportion of patients seeking care for 
drug abuse in rehabilitation centres are being treated for 
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solvent abuse (glue and gasoline), with a reported 
growing number of school students among those patients. 
 
 5. Abuse and treatment  
 
721. Many countries of West Asia have high levels of 
opiate abuse, which can be seen in both direct and 
indirect estimates of annual prevalence of drug abuse and 
treatment admissions data, with indications that opiate 
abuse is increasing, particularly abuse of heroin. 
Prevalence of heroin abuse is particularly high in 
Afghanistan and neighbouring countries. UNODC 
estimates the prevalence of opiate abuse in Afghanistan, 
excluding abuse of opioids and pharmaceutical opioids,  
as among the highest in the world, with prevalence of 
past-year abuse at between 2.3 and 3 per cent of the 
general population aged 15-64 years.  
722. The Afghanistan Ministry of Counter-Narcotics 
reports that the number of drug abusers in the country is 
increasing, especially abusers of heroin and opium.  
From 2005 to 2009, the number of heroin abusers 
increased by 140 per cent, and the number of opium 
abusers increased by 53 per cent. The Government 
estimates that more than a third of the 940,000 drug 
abusers in Afghanistan live in Kabul province. Studies of 
drug abusers in Kabul found that the most commonly 
abused drug types are opium, cannabis oil, heroin and 
pharmaceutical preparations containing controlled 
substances. Approximately 13 per cent of those studied 
were injecting drug abusers. Drug abuse initiation was 
most commonly due to the influence of friends or done 
out of curiosity, as indicated by 54 per cent of 
respondents.  
723. Limited data are available on the prevalence of 
injecting drug use in the countries of the Middle East. 
There are estimates of 20,000 injecting drug abusers in 
Afghanistan and 2,000-4,000 injecting drug abusers in 
Lebanon. In the Islamic Republic of Iran, 18.7 per cent of 
the approximately 1.5 million drug abusers are injecting 
drug abusers, while other countries do not report data in 
that regard. 
724. The prevalence of injecting drug abuse in prison 
settings is also largely unknown, except for the Islamic 
Republic of Iran, where data indicate that 1.2 per cent of 
male prisoners are injecting drug users. There is virtually 
no data available on the prevalence of HIV among 
injecting drug abusers in prisons, apart from the Islamic 
Republic of Iran, where there is an estimated rate of  
HIV infection of 8.1 per cent among inmates who had a 
history of injecting drugs.  
725. In the Middle East, needle and syringe programmes 
are available in Iran (Islamic Republic of), Israel, Lebanon 
and Oman, as well as the Occupied Palestinian Territory, 
whereas opioid substitution therapy is available only in 
Bahrain, Iran (Islamic Republic of), Israel and Lebanon. 
Only the Islamic Republic of Iran has made available 
opioid substitution therapy in prisons and other closed 
settings. Lebanon is planning a pilot opioid substitution 
therapy programme in prisons.  
726. The Islamic Republic of Iran reports that 2.7 per 
cent of the general population have abused opiates in the 
past year. Drugs abused included opium (34 per cent of 
drug abusers), “crack” heroin (a high purity form of 
heroin) (27 per cent), heroin (19 per cent), opium residue, 
analgesics and methamphetamine (4 per cent each) and 
cannabis (2 per cent). Abuse of methamphetamine, 
although substantially lower than abuse of opiates, has 
increased, and the Government reported that in 2011, the 
national drug addiction telephone hotline received more 
than 470,000 calls, with the most common questions 
related to crystalline methamphetamine.  
727. New 2010 estimates of prevalence of drug abuse 
from Azerbaijan and Georgia showed that, since the time 
of the last survey (2-4 years ago) abuse of opioids 
(including opiates) has more than doubled in those 
countries. In Azerbaijan, past-year prevalence of opioid 
abuse for the general population aged 15-64 years 
increased from 0.2 per cent in 2008 to 1.3-1.7 per cent. 
The prevalence of past-year drug abuse in Georgia 
increased from 0.6 per cent in 2006 to 1.3-1.4 per cent.  
728. Treatment admission data for most countries of 
West Asia show elevated levels of opioid abuse, mostly in 
the form of heroin abuse. Treatment admissions data 
reported by countries showed that the proportion of 
those entering treatment primarily for opioid abuse 
ranged widely, between 31 and 99 per cent of admissions 
since 2006, with the highest proportions of opioid abuse 
(rates of 75 and 97 per cent in two countries) found in 
Central Asian countries. Most recent UNODC estimates 
suggest that drug abusers in West Asia (excluding Turkey) 
consumed an estimated 12 per cent of all heroin 
consumed worldwide.  
729. Treatment in Afghanistan is woefully limited, with 
existing drug treatment capacity equal to just 3 per cent 
of the estimated number of opiate abusers. There are  
50 drug treatment centres located throughout the country 
providing treatment and aftercare services. There are  
nine treatment centres in Kabul province, with a total of 
255 beds, of which two treatment centres are allocated for 
women and one for children; the remaining six centres 
are for men. The centres admit nearly 2,000 drug abusers 
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annually, with the average length of stay in treatment 
being just one month. Rates for successful treatment 
completion and relapse were not reported.  
730. According to the Ministry of Health of Iraq,  
the number of drug abusers entering outpatient and 
inpatient treatment countrywide has steadily increased, 
with 1,462 individuals receiving treatment in 2008,  
2,337 individuals in 2009, 5,668 individuals in 2010 and 
2,761 individuals in the first half of 2011. The highest 
number of those entering treatment are from the 
southern district of Basra, bordering the Islamic Republic 
of Iran, with trihexyphenidyl (benzhexol) being the most 
commonly reported substance of abuse. That substance is 
also found to be abused in the Syrian Arab Republic. The 
Board encourages the Governments of Afghanistan and 
Iraq, through assistance by the international community, 
to expand appropriate drug treatment services 
throughout their respective countries. 
731. The Board notes with satisfaction that some 
countries in West Asia, such as Jordan and Lebanon, took 
measures to strengthen their treatment and rehabilitation 
centres. In particular, the involvement of both the private 
and public medical care sectors in order to reach the 
maximum number of drug abusers. In Lebanon, for 
example, drug addicts are treated in hospitals and by 
some non-governmental organizations. A study cited  
by the Lebanese Ministry of Public Health on drug 
addicts treated in hospitals and by non-governmental 
organizations in 2011 showed that a total of 1,411 patients 
were receiving treatment (1,206 males and 205 females). 
Almost 22 per cent of the patients are treated for abuse of 
tranquillizers, followed by alcohol (16 per cent), cocaine, 
amphetamine, cannabis oil, heroin and codeine, in 
descending order. In addition, among the patients, there 
were 119 cases of polydrug abuse. 
 
 
 D. Europe 
 
 
 1. Major developments 
 
732. Abuse of illicit drugs in Europe has stabilized in 
recent years, although at a high level. Yet the emergence of 
new psychoactive substances, so-called “designer drugs” 
or “legal highs”, poses a major challenge, which many 
Governments are addressing by placing individual 
substances or groups of substances under national control. 
Adding to the challenge is the pattern of polydrug abuse: 
the consumption of illicit drugs in combination with other 
drugs, alcohol and non-controlled substances. In 2011, a 
significant increase in new cases of HIV infection based 
on a high HIV prevalence among injecting drug users was 
reported by Bulgaria, Greece and Romania. 
733. Bosnia and Herzegovina has become an important 
regional trafficking hub for narcotics shipments. Main 
trafficking routes pass through Bulgaria, Romania and 
the former Yugoslav Republic of Macedonia to Kosovo,33 
then through Montenegro and Serbia to Bosnia and 
Herzegovina, and from there to Croatia and Slovenia and 
Western European markets. 
734. In October 2011, the Convention of the Southeast 
European Law Enforcement Center entered into force, 
and the Southeast European Cooperative Initiative (SECI) 
Center became the Southeast European Law Enforcement 
Center (SELEC). The main objective of SELEC is to 
provide support for the competent national authorities of 
Member States and enhance coordination in preventing 
and combating organized crime in the region. SELEC 
inherits the activities of the SECI Center: 12 years of 
operational activities, joint investigations, training 
sessions and strategic analysis covering the most sensitive 
criminal areas in the South-Eastern European region. 
735. Detections of laboratories used for the illicit 
manufacture of amphetamines have increased, and the 
increased manufacturing capacity of some of these sites 
has been noted. The trend of methamphetamine 
replacing amphetamine in Northern and Western Europe 
appears to be continuing, and the quantity of 
methamphetamine seized in Northern Europe has 
increased significantly.  
 
 2. Regional cooperation 
 
736. In November 2011, a dialogue on drugs was held 
between the European Union and the Russian Federation 
in Brussels. Also in November 2011, a regional ministerial 
conference on challenges and achievements related to 
regional and transnational cooperation in the fight 
against organized crime in South-Eastern Europe was 
held in Belgrade. The conference was attended by 
ministers of internal affairs and justice and public 
prosecutors from the region, as well as representatives of 
European Union member States and members of the 
European Commission. The participants agreed on the 
necessity of creating expert teams to monitor regional 
cooperation in criminal matters and judicial cooperation. 
737. In November 2011, the regional anti-drug initiative, 
Operation Channel, carried out annually under the 
auspices of the Collective Security Treaty Organization 
(CSTO), involved competent law enforcement,  
customs authorities and financial intelligence units of 
CSTO member States. In the course of the operation, 
__________________ 
 33  All references to Kosovo in the present document should 
be understood to be in compliance with Security 
Council resolution 1244 (1999). 
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many tons of drugs and psychotropic substances were 
seized, including 11.6 tons of opium, 17.4 tons of 
cannabis herb, 3.2 tons of cannabis resin and 871 kg of 
heroin. 
738. A high-level meeting of the Pompidou Group of  
the Council of Europe in December 2011 decided to 
reinforce cooperation with the countries of Eastern and  
South-Eastern Europe, especially in the fields of 
prevention and treatment, and adopted a policy paper on 
licit and illicit drugs and a strategic document setting  
out a political agreement regarding drugs. Also in 
December 2011, the European Commission proposed the 
establishment of a European border surveillance system 
(EUROSUR) to enhance coordination among member 
States and prevent and combat serious crime, including 
drug trafficking.  
739. In December 2011, the Council of the European 
Union adopted conclusions on new psychoactive 
substances, and in June 2012 it adopted conclusions on 
the new European Union drugs strategy for the  
period 2013-2020 to address polydrug use, the rapid 
spread of new psychoactive substances, ensuring access to 
and addressing misuse of prescribed controlled 
medications, the use of the Internet in the illicit 
distribution of drugs, the diversion of precursors, the 
quality of demand reduction services and the high 
incidence of blood-borne diseases. Combating synthetic 
drugs and new psychoactive substances was identified by 
the Standing Committee on Operational Cooperation on 
Internal Security (COSI) of the European Union as one of 
the Union’s priorities in combating organized crime. The 
European Commission was in the process of carrying out 
an impact assessment on a new instrument to replace 
Council decision 2005/387/JHA on information exchange, 
risk assessment and control of new psychoactive 
substances and announced that it would propose stronger 
European Union legislation in that regard. A number of 
regional and interregional forums in 2012 have focused 
on the challenge of emerging substances of abuse. 
740. In January 2012 in Brussels, the World Customs 
Organization held the first Global Forum on Combating 
Illicit Drug Trafficking and Related Threats, with 
representatives of customs authorities from 65 countries, 
as well as international and regional organizations. The 
Forum enabled an exchange of best practices in 
combating trafficking in drugs and precursor chemicals 
and associated money-laundering and corruption. 
741. In February 2012, the seventh meeting of the 
European Union-Mexico Joint Council established by the 
Economic Partnership, Political Coordination and 
Cooperation Agreement between the European Union 
and its Member States and Mexico welcomed steps to 
reactivate the agreement on the control of precursors.  
742. In February and March 2012, the first meeting on 
drug policy cooperation in South-Eastern Europe and the 
Balkans, held in Dubrovnik, Croatia, focused on 
exchange of information and experience. The second such 
meeting, held in Zagreb in September 2012, focused on 
rehabilitation and reintegration services.  
743. In March 2012, a memorandum of understanding 
was concluded in Brussels between INCB and the World 
Customs Organization. The agreement formalized the 
long-standing cooperation between the two bodies, with a 
view to enhancing international drug control efforts 
within their respective mandates. 
744. In May 2012, within the framework of the 
Pompidou Group of the Council of Europe, an 
international conference on alcohol, drugs and 
prevention in the workplace, held in Strasbourg, France, 
adopted a frame of reference for policies for preventing 
alcohol and drug use in the workplace.  
745. In May 2012, UNODC launched a new regional 
programme for South-Eastern Europe for the  
period 2012-2015 on “Countering illicit trafficking and 
organized crime for improved governance, justice and 
security”. The programme is aimed at combating illicit 
drug trafficking via the Balkan route and related 
problems, as well as at improving intraregional 
cooperation between countries along the Balkan route 
and countries in West and Central Asia and Europe 
affected by heroin trafficking from Afghanistan. 
746. The fourteenth High-level Meeting of the 
Coordination and Cooperation Mechanism on Drugs 
between the European Union and the Community of 
Latin American and Caribbean States, held in Brussels in 
June 2012, expressed support for, inter alia, continued 
cooperation between the two regions in addressing the 
world drug problem, highlighting the need to address 
prevention, early intervention, treatment, rehabilitation, 
social reintegration and reduction of the negative health 
and social consequences of drug abuse.  
747. The third World Forum against Drugs, held in 
Stockholm in May 2012, focused on human rights, the 
right of children to be protected from illicit drugs, illicit 
drug use and trafficking problems in Latin America, as 
well as on primary prevention. A joint statement was 
signed at the Forum by the representatives of Italy, the 
Russian Federation, Sweden, the United Kingdom and the 
United States, reiterating their commitment to ensuring 
the adequate availability of narcotic drugs and 
psychotropic substances for the relief of pain, treatment 
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of illness and research; preventing and reducing the use of 
those drugs for any other purpose and reducing the 
consequences of such use; and calling for a balanced 
approach to the world drug problem, with a strengthened 
international partnership. The second Congress of the 
World Federation against Drugs, also held in Stockholm 
in May 2012, resulted in a statement highlighting the 
need to support the international drug control 
conventions and to promote policies aimed at limiting the 
harmful effects of drugs through prevention, law 
enforcement and treatment and recovery programmes.  
 
 3. National legislation, policy and action 
 
748. Many countries in the region have introduced 
legislation to address the challenges posed by the abuse of 
new psychoactive substances. In Austria in January 2012, 
legislation entered into force that brought under control 
substances or groups of substances that are not subject to 
the 1961 or 1971 conventions and that have the potential 
for psychoactive effects, are likely to be abused and pose a 
potential health threat.  
749. Cyprus introduced a generic system of classification 
in national drug control legislation in 2011. In Denmark, 
legislation entered into force in July 2012 that introduced 
the generic scheduling of drugs, including synthetic 
cannabinoids. Finland amended the 2008 Narcotics Act in 
June 2011 to enable the control of substances based on a 
risk assessment by the Finnish Medicines Agency, 
together with the police, customs authorities and the 
National Institute for Health and Welfare. In April 2012, 
Hungary created a schedule C to existing legislation, on 
which a substance can be included after a formalized 
rapid assessment has found that it affects the central 
nervous system and therefore poses as serious a threat to 
public health as the substances listed in the international 
drug conventions, and that the substance has no 
therapeutic use. Within one year of placement on the 
schedule, the risk of individual substances must be 
assessed, resulting in either full control or removal from 
the schedule; compound groups remain on the schedule 
as long as any substance in the group meets the  
above-mentioned criteria. Following the enactment of  
the revised drug law in Switzerland in July 2011, yearly 
reviews of new synthetic substances enable such 
substances to be brought under national control. 
“Temporary class drug orders” were introduced in the 
Misuse of Drugs Act 1971 of the United Kingdom as at 
November 2011, enabling the control of a new 
psychoactive substance for one year if the substance is 
misused, likely to be misused or could have harmful 
effects. In addition, a new action plan to tackle 
psychoactive substances, published in May 2012, is aimed 
at reducing the demand for such substances by providing 
information about the associated risk and harms, 
restricting supply and ensuring effective treatment and 
support for lasting recovery.  
750. Many countries in the region are also placing 
individual substances or groups of substances under 
national control. For example, mephedrone has been 
brought under control by most member States of the 
European Union, with the Czech Republic, Finland, 
Greece, Latvia, Slovenia and Spain, as well as Switzerland, 
all placing it under control in 2011, and tapentadol was 
placed under national control in Cyprus, Estonia, 
Finland, Greece, Latvia and Spain in 2011.  
751. In May 2011, the first national survey on the use of 
drugs and other addictive substances among the general 
population in Croatia was initiated. In July 2011, the 
Government of Croatia adopted amendments to the Act 
on the Suppression of Drugs Abuse (OG 84/11), thus 
enabling the introduction in the country of the unified 
prescription form used by physicians active in the 
Schengen area to prescribe medicine containing narcotic 
drugs for the personal use of travellers within that region 
for a maximum of 30 days. In October 2011, the Croatian 
Parliament adopted a new penal code, which entered into 
force on 1 January 2012. In the new penal code, the abuse 
of narcotic drugs is punished according to the provisions 
of two criminal acts covering the unauthorized 
possession and manufacture of, and trade in, drugs and 
substances banned in sports. The new penal code also 
provides for the criminalization of growing plants and 
fungi from which narcotic drugs can be obtained and of 
activities related to money-laundering. In the context of 
the process of adapting the Croatian drug demand 
reduction system to European Union standards, the 
Government in 2011 initiated the creation of a database 
for programmes on combating drug abuse in Croatia. The 
purpose of the database is to consolidate information 
about all of the demand reduction activities that are being 
implemented at all levels in Croatia. 
752. In November 2011 in Denmark, the city council of 
Copenhagen decided that it would ask the national 
Government for authorization to introduce an 
experimental scheme concerning the legalization of trade 
in and use of cannabis; however, according to information 
provided by the Government, it had not been asked for 
such an authorization and had indicated that such an 
authorization would not be granted. In July 2012, an 
amendment to the drug law was to come into effect that 
would empower the Minister of Health to license, at the 
request of municipal governments, “drug consumption 
rooms” and regulate their operation by municipal 
authorities and private organizations with operational 
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agreements with the municipal authorities. The 
Government of Denmark has been informed of the 
position of the Board that consumption rooms are in 
violation of the provisions of the international drug 
control conventions. 
753. In May 2012, a code of conduct developed by the 
Government of France and the chemical industry was 
published, with the aim of facilitating the identification 
and reporting of suspicious transactions of precursor 
chemicals.  
754. In August 2012, the National Substance Misuse 
Strategy of Ireland was published, integrating strategies 
for alcohol and drug abuse for the first time. In  
January 2012 in Latvia, new procedures came into force 
for the treatment of addiction to alcohol, narcotics, 
psychotropic substances, toxic substances and gambling, 
with redesigned rules for opioid substitution treatment 
that allow the provision of substitution treatment and for 
such treatment to be offered beyond the capital city 
provided that certain criteria are met.  
755. In December 2011, the parliament of Lithuania 
adopted a political resolution expressing grave concern 
about new psychoactive substances and calling for further 
preventive and improved control measures. Also in 
December 2011, a Government order set out conditions 
for the storage of precursor chemicals in order to comply 
with European Commission regulations.  
756. In June 2012, the Republic of Moldova became the 
thirty-seventh member of the Pompidou Group following 
the adoption of Law No. 75. Currently, the Pompidou 
Group collaborates with the Republic of Moldova in the 
fields of drug treatment in prisons, drug prevention for 
youth and the development of systems to improve drug 
detection at European airports. 
757. In January 2012, amendments to the national 
framework of the Netherlands for policy related to  
so-called “coffee shops” as contained in the Opium Act 
Instructions came into force, with the aim of reducing the 
size of such sites, facilitating control and combating drug 
tourism. Access to “coffee shops” is to be restricted to 
residents of the Netherlands aged 18 years or older who 
are members of a “coffee shop”, with membership to each 
site limited to 2,000 individuals per calendar year.  
The restrictions were applied in three southern  
states (Limburg, North Brabant and Zeeland) as from 
May 2012, and were to be implemented nationwide from 
January 2013. The amendments also increase the 
minimum distance between “coffee shops” and secondary 
schools and secondary vocational institutions. While the 
Board has taken note of this development, its position 
continues to be that such “coffee shops” are in violation of 
the provisions of the international drug control 
conventions.  
758. On 1 June 2012, measures to prohibit  
over-the-counter sales of medicines containing codeine  
or its salts became effective in the Russian Federation. 
Since 1 June 2012, the sale of such medicines by 
pharmacies is allowed only with a doctor’s prescription. 
The increased controls are a result of the fact that  
these medicines are often used for the clandestine 
manufacture of desomorphine. 
759. In November 2011, the Government of Serbia 
established within the Ministry of Health a commission 
on psychoactive controlled substances, an interministerial 
committee responsible for providing expert advice to the 
Government on issues related to psychotropic substances, 
as well as for issuing licences for forensic laboratories. 
760. In 2012, the Government of Ukraine adopted the 
National Drug Strategy through 2020. The strategy 
defines administrative, social, medical, legal, educational, 
informational and other measures aimed at preventing 
non-medical use of drugs, reducing the supply and 
demand of illegal drugs and facilitating the availability of 
drugs for medical and scientific use. 
761. In May 2012 in the United Kingdom, the National 
Institute for Health and Clinical Excellence released 
clinical guidelines for England and Wales for the 
prescribing of strong opioids for the treatment of pain for 
adults in palliative care, noting that published evidence 
suggested that pain resulting from advanced disease, 
especially cancer, remained undertreated and expressing 
the goal of helping to improve pain management and 
patient safety.  
 
 4. Cultivation, production, manufacture and 
trafficking 
 
 (a) Narcotic drugs 
 
762. The illicit cultivation of cannabis plant in Western 
and Central Europe, especially indoor cultivation and 
cultivation on a commercial scale, has continued to 
increase. The involvement of criminal groups in illicit 
cannabis cultivation, as reported by Bulgaria, Denmark, 
Germany, France, Hungary, Italy, Norway, Slovakia, 
Sweden and the United Kingdom, is a growing concern. 
In a study by EMCDDA of 30 countries in Europe,  
16 countries indicated that indoor cultivation was the 
dominant method of illicit cultivation, while the Czech 
Republic, France, Germany, Latvia, Sweden and the 
United Kingdom reported increases in indoor cultivation 
in recent years and France reported that three quarters of 
cases of illicit cultivation of cannabis plant involved 
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indoor cultivation. Hydroponic cultivation was noted by 
12 countries (Belgium, Czech Republic, Ireland, Greece, 
Hungary, Latvia, Luxembourg, Netherlands, Romania, 
Slovenia, Slovakia and the United Kingdom) and was 
reported to have increased in the Czech Republic and 
Slovakia. In the United Kingdom, detections of sites of 
illicit cultivation of cannabis have continued to increase, 
coupled with a reduction in the size and scale of 
commercial illicit cultivation sites. Similarly, in Finland, 
small-scale cultivation at the household level is 
increasing. Slovenia reported an increase in indoor 
cultivation, while at the same time it noted a decrease in 
outdoor cultivation. In Bulgaria, an increase in the indoor 
cultivation of cannabis plant was reported in 2011.  
So-called “grow shops”, retail outlets selling products for 
the indoor cultivation of plants, have been identified as a 
potential indicator of increases in illicit domestic 
production of cannabis, especially indoors. According to 
EMCDDA, the existence of such outlets in 2009 was 
reported by 15 countries in Western and Central Europe, 
seven of which noted the existence of information on 
cannabis cultivation in such outlets.  
763. Trafficking of cannabis herb continues at significant 
levels in Eastern and Central Europe. Cannabis herb is 
usually trafficked from the former Yugoslav Republic of 
Macedonia, Albania and Kosovo to Montenegro and 
southern Bosnia and Herzegovina. There is evidence that 
cannabis herb produced in the region is playing an 
increasingly important role in the supply chain of 
European cannabis markets. While Albania has reported a 
decrease in seizures of locally produced cannabis herb, 
increases in cannabis plant cultivation have been reported 
by Bulgaria and Ukraine. Seizures of cannabis resin 
imported from beyond the region continue to decline, 
and seizures of cannabis herb remain relatively stable, 
although at a significantly lower level than a decade ago. 
The number of cannabis plants seized, however, increased 
dramatically between 2004 and 2010. While there is an 
overall stable or decreasing trend in the abuse of cannabis 
in the region, 1 per cent of European adults may be using 
cannabis on a daily or almost-daily basis, and 4 per cent 
of school students aged 15 or 16 report having abused 
cannabis at least once a week, while in France and 
Monaco more than one in every five students in that age 
group reported using cannabis in the past month. 
Treatment demand owing to the abuse of cannabis is 
increasing; between 2004 and 2009, the number of people 
entering treatment for the first time whose primary drug 
of abuse was cannabis increased by 40 per cent in  
18 European countries.  
764. Ukraine has reported the eradication of large areas 
of illicit cultivation of cannabis plant close to its border 
with the Republic of Moldova, and estimated the area 
under illicit cultivation at 920 ha in 2010. Albania, 
another important producer of cannabis herb, has 
implemented law enforcement actions against cannabis 
growers and traffickers, and reported a lower estimate of 
production capacity; areas of illicit cannabis plant 
cultivation and the production of cannabis further 
decreased as a result of joint operations by national law 
enforcement institutions. During 2011, 89 cases of 
cannabis cultivation were recorded and 21,267 cannabis 
plants were destroyed. In addition, 79 people were 
arrested and placed under investigation for charges 
related to the illicit cultivation of cannabis.  
765. There were no significant drug production cases 
reported by Croatia, with only a small number of cases of 
cannabis plant cultivation and intensive indoor 
cultivation by smaller criminal groups reported. Cannabis 
available on the Croatian market originates in Albania 
and is smuggled by organized criminal groups through 
Montenegro and Bosnia and Herzegovina into Croatia 
and on to Western Europe along the Balkan route. In the 
former Yugoslav Republic of Macedonia, small-scale 
cultivation of cannabis, mainly for domestic use, is the 
only known illegal production of drugs. In the first  
six months of 2011, the Government of the former 
Yugoslav Republic of Macedonia detected 222 crimes 
committed in the area of “illegal production and trade of 
narcotic drugs”. The biggest cannabis seizure reported 
involved 105 kg smuggled from Albania into the former 
Yugoslav Republic of Macedonia on 11 June 2011.  
766. Seizures of cannabis resin in Western and Central 
Europe are continuing to decrease, with seizures of  
534 tons in Western and Central Europe in 2010, which is 
almost half the peak amount of 1,078 tons in 2004, and 
the number of seizures dropping to the lowest level since 
2003. In Spain, the country with the greatest amount of 
cannabis resin seized by customs authorities globally, 
seizures decreased in 2010 for a second consecutive year, 
to the lowest level recorded since 1997. Seizures by 
customs authorities of cannabis resin in Western Europe 
decreased from 178 tons in 2010 to 147 tons in 2011. In 
Finland, however, a record quantity of cannabis resin was 
seized in 2011; most of it was en route to the Russian 
Federation. The relative importance of Morocco as a 
source of cannabis resin for Europe, the world’s largest 
illicit market for the substance, is reportedly appearing to 
decrease, with the importance of resin from other 
countries, such as Afghanistan, India, Lebanon and 
Pakistan, appearing to increase. Nevertheless, Morocco 
was identified as the source country for almost three 
quarters of the cannabis resin seized in Western Europe 
by customs authorities in 2011. The volume of cannabis 
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resin seized by customs authorities in Eastern and Central 
European countries has also dropped significantly, 
reaching 95 kg in four seizure cases in 2011, compared 
with 814 kg in 44 seizure cases in 2010. The majority of 
the seizures were carried out on board trains coming 
from Azerbaijan, Tajikistan or Ukraine. The largest 
seizure was reported by Belarus: 131 kg of cannabis resin 
seized at the land border with Latvia. 
767. The number of seizures of cannabis herb in Western 
and Central Europe has increased since 2001, doubling 
between 2005 and 2009 and, in 2010, exceeding seizures 
of cannabis resin for the first time. The amount of 
cannabis herb seized in Western and Central Europe has 
remained at about 60 tons since 2004 (62 tons in 2010), 
half the peak level of 124 tons in 2002. Following a 
decrease in seizures by customs authorities of cannabis 
herb in Western Europe from 2009 to 2010, the total 
amount seized more than doubled from 8.8 tons in 2010 
to 17.7 tons in 2011. According to UNODC, over the 
period 2001-2010, seizures of cannabis herb by weight 
decreased in Western Europe yet increased in Northern, 
Central and Eastern Europe. The volume of cannabis herb 
interceptions made in Eastern and Central Europe in 
2011 was more than double that of 2010, totalling 2.7 tons 
in 74 seizure cases. According to the World Customs 
Organization, Albania remains an important source 
country for cannabis herb seized in Eastern and Central 
Europe, accounting for a total volume of 2,194 kg, more 
than 80 per cent of the total amount seized in 2011. 
Almost all of the seizures of cannabis herb in Eastern and 
Central Europe were made while the cannabis herb was 
being transported by road.  
768. Seizures of cannabis plants have continued to 
increase in Europe since 2004, from 1.7 million plants in 
2004 to about 30 million plants in 2010, with seizures of 
plants totalling 42 tons in 2008 and 35 tons in 2010, most 
of which was accounted for by Spain (27 tons) and 
Bulgaria (4 tons). In the United Kingdom (England and 
Wales), the number of seizures involving plants increased 
by 12 per cent, despite a decrease in the number of plants 
seized. In Germany, while seizures of cannabis resin and 
cannabis herb both decreased by almost 20 per cent from 
2010 to 2011, seizures of plants increased by almost a 
third.  
769. While the amount of cocaine seized in Western and 
Central Europe has declined in recent years, there are 
some signs of stabilization. After increasing from about 
50 tons in 2009 to about 60 tons in 2010, seizures of 
cocaine in Western and Central Europe remained at about 
half the peak amount of 120 tons in 2006. Spain 
continued to be the country reporting the largest quantity 
seized (25 tons), almost half the total for Western and 
Central Europe, followed by the Netherlands (10 tons). 
The quantity of cocaine seized by customs authorities in 
Western Europe remained relatively stable at about 34 to 
37 tons per year between 2009 and 2011, representing 
almost half of global seizures of cocaine by customs 
authorities. In Romania, the total amount of cocaine 
seized in 2011 was more than 161 kg, approximately  
63 times the quantity seized in 2010 (2.6 kg). The amount 
seized in 2011 was mainly the result of one large seizure 
(157.5 kg) made in Constanta harbour. 
770. Cocaine traffickers use ports in Croatia and Greece 
for shipments to Eastern Europe. From there, cocaine is 
moved to smaller harbours in Montenegro and Albania, 
from which it is transported by road to Kosovo and then 
Serbia before reaching Bosnia and Herzegovina and 
Western European markets. The abuse of cocaine in 
Western and Central Europe remains stable, although 
with a high annual prevalence of 1.2 per cent.  
771. Ships are still the main mode of transportation for 
cocaine trafficked to Western Europe, representing almost 
80 per cent of the quantity seized by customs authorities 
in 2011; however, seizures by customs authorities at 
airports accounted for 15 per cent of the quantity seized 
in Western Europe. Cocaine is increasingly trafficked to 
Slovenia via container from Latin America, with 
shipments also arriving at ports on the Adriatic Sea and 
then entering Slovenia via the western Balkans. Of the 
cocaine seized by customs authorities in 2011 in Western 
Europe, 80 per cent was identified as having originated in 
Bolivia (Plurinational State of), Brazil, Chile, Colombia, 
Costa Rica, the Dominican Republic, Ecuador, Panama, 
Peru and Venezuela (Bolivarian Republic of). In 2010, 
cocaine deliveries to the Russian Federation arrived 
mainly from Ecuador. This trend continued in 2011, with 
two seizures carried out at the Saint Petersburg seaport, of 
20.6 kg and 4.5 kg of cocaine arriving from Ecuador. 
Since 2009, the Caribbean region has become increasingly 
important in the trafficking of cocaine shipments 
destined for Europe. For example, the Dominican 
Republic was identified as the origin of 273 shipments, 
amounting to 3.5 tons, of cocaine seized by customs 
authorities in Western Europe in 2011. The significant 
increase, of about 50 per cent, in French seizures of 
cocaine in 2011 (almost 11 tons) compared with 2009 and 
2010 was the result of seizures in the Caribbean. In 
January 2012, 1.2 tons of cocaine destined for the 
European market were seized on two vessels off the coast 
of Martinique. 
772. Eastern Europe’s biggest drug control problem 
continues to be the illicit trafficking of heroin and opiates 
originating in Afghanistan. Turkey continues to be a main 
corridor for heroin trafficking to Europe. Heroin also 
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continues to be trafficked through Central Asia into the 
Russian Federation along the northern branch of the  
so-called “silk route” (via Kazakhstan, Kyrgyzstan, 
Tajikistan, Turkmenistan and Uzbekistan), both for 
domestic use and for trafficking onward to Western 
European countries. 
773. In 2010, about 6 tons of heroin were seized in 
Western and Central Europe, a decrease from the 
approximately 8-9 tons seized annually between 2005  
and 2009, with the highest quantities of seizures made in 
France and Italy (each approximately one ton) and with 
the decline affected by decreases in amounts seized in 
Bulgaria and the United Kingdom. Customs seizures  
of heroin in Western Europe decreased from 1.9 tons  
in 2009 to 1.0 ton in 2011. A decline in the availability of 
heroin on the illicit drug market was observed in some 
European countries between 2010 and 2011. This 
observation was supported by data from Ireland 
indicating that the prevalence of Drug Treatment Centre 
Board laboratory samples testing positive for heroin 
marker 6-acetylmorphine was at its lowest level in 
December 2010, slowly increasing at the beginning of 
2011. Samples testing positive for benzodiazepine peaked 
in December 2010, coinciding with the shortage of 
heroin, followed by an ongoing increase, indicating either 
substitution or “cutting” of heroin with benzodiazepines. 
774.  In 2010, a decrease in seizures of heroin was 
recorded in most of the countries (except the Islamic 
Republic of Iran) along the main Balkan trafficking route, 
from Afghanistan through South-Eastern Europe to 
Western and Central Europe, although large quantities of 
heroin continued to be trafficked along that route.  
In 2011, nearly two thirds of the heroin seized at the 
borders of the United Kingdom had been trafficked 
directly from Pakistan (in air freight and containers). At 
the same time, there was a reduction in the amount of 
heroin being trafficked to the United Kingdom via 
Turkey. According to the World Customs Organization, 
the decreasing trend since 2009 in the amount of heroin 
seized in Eastern and Central Europe continued; in 2011 
the total amount of heroin seized was 23 per cent of the 
amount seized in 2010. 
775. Amounts of heroin seized by customs authorities 
along the traditional Balkan route (Turkey, Romania, 
Hungary and Austria) were greater than along the 
southern Balkan route (to Italy via Albania, the former 
Yugoslav Republic of Macedonia or Greece), with the use 
of the “silk route” continuing to be significant. In 
Romania, the quantity of heroin seized decreased by 
almost 90 per cent, from 108 kg in 2010 to 12 kg in 2011. 
Bulgarian customs authorities alone made 60 per cent of 
the seizures in Eastern and Central Europe and over  
85 per cent of the total volume seized. The two largest 
seizures were made in Bulgaria, the first at the border 
with Turkey at the Kapitan Andreevo checkpoint, where 
customs authorities discovered 96 kg of heroin coming 
from Turkey. The second seizure was made at the border 
with Romania, at the Ruse checkpoint, where customs 
authorities discovered 43 kg of heroin bound for the 
Netherlands in a lorry load. Substantial seizures of heroin 
were also reported by the customs authorities of the 
former Yugoslav Republic of Macedonia, followed by 
those of Ukraine, Serbia and Albania with significantly 
smaller amounts. The Russian Federation reported  
101 seizures by customs authorities in 2011, with a total 
of 138 kg of heroin.  
776. Western Europe accounted for only a small portion 
(about 3 per cent) of the global seizures of opium by 
customs authorities in 2011; Turkey was identified as the 
source country in half of the shipments. A total of  
112 tons of opium were seized in Germany in 2011,  
an increase of over 800 per cent compared with 2010 
(12.3 tons). Buprenorphine, an opioid controlled under 
the 1971 Convention, is trafficked on a large scale from 
France to Finland, where seizures increased in 2011, while 
seizures of the substance between Finland and Estonia 
decreased. In Estonia, the trafficking of heroin and other 
opiates is reported to be in decline. In Latvia in 2011,  
two illegal laboratories for the manufacture of methadone 
were detected; the destination of the methadone 
produced was believed to be the Russian Federation.  
777. Little progress was made in the past year in tackling 
drug trafficking in Bosnia and Herzegovina, a country 
which continues to be a transit corridor for international 
trafficking of narcotics. Organized crime groups linked 
with drug trafficking continued to operate through the 
country’s territory. Local illicit drug consumption 
remained relatively low compared with other European 
countries. Bosnia and Herzegovina remains at an early 
stage in the fight against drug trafficking, as well as in 
taking effective action on reducing drug demand. 
Effective, sustainable and institutionalized mechanisms 
for cooperation and strategic coordination between 
different law enforcement agencies are still being 
developed, and the performance of law enforcement 
agencies in the fight against drug trafficking remains 
uneven. The Board urges the Government of Bosnia and 
Herzegovina to establish an office to coordinate national 
drug control activities as a matter of priority and to 
continue its efforts to strengthen drug control in both of 
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its constituent entities: the Federation of Bosnia and 
Herzegovina and the Republika Srpska. 
 
 (b) Psychotropic substances 
 
778. Customs seizures of amphetamines in Western 
Europe tripled from 615 kg in 2010 to 1,827 kg in 2011, 
although they were still lower than in 2009 (3,028 kg). 
Europe continues to account for the majority of 
laboratories seized worldwide for illicitly manufacturing 
substances in the amphetamine group; the number of 
amphetamine laboratories seized in Europe increased 
from 43 in 2009 to 62 in 2010. It has been reported that 
the capacity of amphetamine manufacture in the 
Netherlands and Belgium may have increased by a factor 
of five to six, and in Poland by 30 to 160 per cent. The 
quantity of amphetamine powder seized in Western and 
Central Europe decreased from a peak of 8 tons in 2007 
to 5 tons in 2010, with Germany accounting for almost a 
quarter of the amount seized, followed by the United 
Kingdom, the Netherlands and Poland. The number of 
amphetamine tablets seized in Western and Central 
Europe, however, doubled from 170,000 in 2008 to 
345,000 in 2010, with 96 per cent of those seizures taking 
place in Spain. Most amphetamine seized in Europe is 
manufactured in (in descending order of significance) the 
Netherlands, Poland, Belgium, Bulgaria and Turkey, and 
the Netherlands remains the main source or distribution 
country for the majority of amphetamine consignments 
seized in the Central and Eastern European region (31 kg 
out of a total of 57 kg). The volume of amphetamines 
seized in Central and Eastern European countries 
decreased significantly in 2011 compared with 2010, 
falling to 57 kg. Customs authorities in Poland  
seized a total of 49 kg, far ahead of the quantity of 
amphetamine-type stimulants seized in Ukraine (3 kg) 
and Bulgaria (2 kg). The largest seizure of amphetamines 
(31 kg) was made in Olszyna, Poland, close to the 
German border, in a private vehicle coming from the 
Netherlands. Five seizures of amphetamines, with a total 
weight of 11 kg, were made in 2011 by the customs 
authorities of Belarus and the Russian Federation. 
779. Methamphetamine has been reported as 
increasingly present in the illicit amphetamine market in 
some Nordic and Baltic countries, although amphetamine 
is far more commonly available in Europe. In Poland, 
which saw a decrease in 2011 in illicit amphetamine 
laboratories, there was some increase in the number of 
illicit methamphetamine laboratories detected; that was 
also the case in 2011 in the Czech Republic. The number 
of illicit methamphetamine laboratories seized in Europe 
decreased from 361 in 2009 to 328 in 2010. The majority 
of them (307) were seized in the Czech Republic, with an 
increase in the number of detections of such facilities in 
Austria and Bulgaria. The number of seizures and the 
quantity of methamphetamine seized in Western and 
Central Europe have continued to increase since 2001; 
there were about 7,300 seizures and 500 kg each year  
in 2009 and 2010, an increase from almost 300 kg in 2008, 
mainly owing to increases in 2009 in Sweden and Norway, 
the main countries for seizures of methamphetamine. 
Customs seizures of methamphetamine fell by more than 
50 per cent in 2011 to 64 kg, from 142 kg seized in 2010, 
after having increased significantly from 2009 (30 kg). 
Thailand continued to be the main source country for 
methamphetamine seized by customs authorities in 
Western Europe in 2011 (28 out of a total of 67 seizures). 
African countries were also significant source countries 
in that regard, although to a lesser degree than in 2010. 
Benin, Ghana, Nigeria and South Africa together 
accounted for 10 per cent of the quantity seized.  
780. After several years of decline, especially in 2009, 
MDMA (“ecstasy”) has made a possible resurgence in 
Europe since mid-2010, according to Europol. Seizures of 
“ecstasy”-group substances more than doubled, from  
595 kg in 2009 to 1.3 tons in 2010. In Romania, the 
number of tablets seized in 2011 was approximately  
2.5 times the number seized during the previous year.  
No “ecstasy” laboratories were reported to UNODC as 
having been seized in Europe in 2010, yet several were 
detected in 2011. It has been suggested that this trend is 
possibly connected to the emergence of slightly modified 
precursor chemicals that are not controlled at the 
international level. EMCDDA reports increasing 
availability of MDMA in “ecstasy” tablets, after having 
decreased in recent years, with production methods 
apparently now based increasingly on safrole or on 
chemicals such as 3,4-MDP-2-P-glycidate, which are 
structurally similar to the controlled precursors 
traditionally used in the illicit manufacture of “ecstasy”. 
 In 2010, 3 million “ecstasy” tablets were seized in 
Western and Central Europe, a 50-per-cent increase 
compared with 2009 but significantly less than the  
peak of almost 23 million tablets in 2002. France,  
the Netherlands and Spain each accounted for about one 
fifth of tablets seized, followed by Germany, Poland and 
the United Kingdom. In Germany, the amount of 
“ecstasy” tablets seized more than doubled from 2010 to 
2011. Customs seizures of MDMA (“ecstasy”) in Western 
Europe increased from 109 kg in 2009 to 206 kg in 2010 
and to 466 kg in 2011, with over half of the total amount 
seized by French customs authorities. The World Customs 
Organization reported only five seizures of “ecstasy” 
made in 2011 in Eastern and Central Europe (three by 
Poland, one by Serbia and one by Estonia), totalling  
21 kg. The Netherlands was identified as the main source 
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country for illicit shipments of “ecstasy” to other 
European countries, representing about 80 per cent of the 
total amount seized by customs authorities in 2011.  
 
 (c) Precursors 
 
781. Non-controlled substances are continuing to replace 
controlled precursor chemicals, through masking or 
substitution, although this was rare in Europe before 
2010. Europol reported several large seizures between 
2009 and 2011 of alpha-phenylacetoacetonitrile (APAAN) 
consignments and the dismantling of laboratories for the 
conversion of APAAN into 1-phenyl-2-propanone  
(P-2-P), a precursor chemical used in the illicit 
manufacture of amphetamine and methamphetamine. In 
addition to the illicit manufacture of P-2-P in Europe, 
trafficking of the substance continues.  
 
 (d) Substances not under international control 
 
782. Illicit manufacture, trafficking and abuse of new 
psychoactive substances continue to pose a serious threat 
in Western and Central Europe. In 2011, a record 49 new 
psychoactive substances were reported to the European 
Union early warning system. All of the substances 
identified were synthetic; they included 23 synthetic 
cannabinoids and 8 synthetic cathinones. Five new 
chemical families of synthetic cannabinoids were 
detected; those substances make up the largest group 
monitored through the early warning system. Seven 
substances that were medicines, metabolites or precursors 
of medicines were also identified. In 2011, public health 
warnings were issued through the European Union 
system about adverse health effects related to a number of 
substances. In the United Kingdom, 19 per cent of 
Internet test purchases of new psychoactive substances, 
sold as “plant food” or “research chemicals”, contained a 
substance under national control (20 per cent, 18 per cent 
and 22 per cent of samples contained, respectively, 
cathinones, synthetic cannabinoids or piperazines).  
783. The number of Internet-based retail sites selling 
psychoactive products and shipping to European Union 
member States increased from 170 in January 2010 to  
314 in January 2011 and 690 in January 2012. About a 
third of them were hosted on servers based in the United 
States, and a fifth of them were hosted on servers based in 
the United Kingdom. About two thirds of the sites 
identified had some type of disclaimer or product 
warning, and there was an increasing use of measures to 
restrict access to such sites and to protect the identity of 
buyers and sellers. Kratom (Mitragyna speciosa) and 
Salvia divinorum were the two most frequently identified 
products, available from 128 and 110 online sites, 
respectively. A 2011/12 study in England and Wales found 
that 0.9 per cent of adult respondents had purchased 
drugs over the Internet the most recent time they  
had taken drugs, compared with 0.7 per cent the  
previous year. 
784. Mephedrone accounts for an increasing proportion 
of the illicit drug market in some European countries. 
Although not under international control, mephedrone 
has been placed under control in most European Union 
member States, yet it continued to be offered for sale over 
the Internet, although on fewer sites and at higher prices. 
In 2010/11 in the United Kingdom, over 120 websites 
advertising mephedrone and naphyrone for sale were 
closed down; those substances had been classified 
nationally as class B drugs in 2010. In Hungary, 
mephedrone was the most frequently seized synthetic 
substance in 2010, and increasing prevalence of injection 
of mephedrone and other cathinones was reported in the 
period 2010/11. In the United Kingdom, 286 of the  
2,564 seizures made in Northern Ireland in 2010/11 were 
of mephedrone, considerably more than those of 
amphetamines (128 seizures) and “ecstasy” (150 seizures) 
and only slightly fewer than seizures of cocaine  
(304 seizures). In England and Wales in the  
period 2010/11 (both before and after the national control 
of mephedrone), annual prevalence of mephedrone abuse 
among people between the ages of 16 and 59 was 1.4 per 
cent, similar to “ecstasy” abuse and representing the 
third-most-abused drug within that age group. Among 
those aged 16-24, it was as frequently abused as cocaine 
(4.4 per cent). In 2011, there was a large increase in the 
detection of laboratories illicitly manufacturing 
mephedrone in Poland. 
785. Customs seizures of khat continued to increase  
in Western Europe, from 49 tons in 2010 to almost  
54 tons in 2011, with 95 per cent of the seizures  
in Germany (23.8 tons), Sweden (12.8 tons), Norway  
(8.3 tons) and Denmark (6.6 tons). A large increase in 
seizures of khat (1.4 tons) was reported in Malta in 2011. 
In 2012, the Government of the Netherlands placed khat 
under national control in List II of the Opium Act. 
 
 5. Abuse and treatment 
 
786. With an average annual prevalence of 5.2 per cent, 
cannabis is still the most commonly abused drug in 
Europe, followed by cocaine, amphetamine-type 
stimulants and opioids (specifically heroin). Experts in 
numerous countries in Eastern and South-Eastern Europe 
have reported an increasing trend in the abuse of 
cannabis and amphetamine-type stimulants, including 
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“ecstasy”, while the abuse of opioids and cocaine is 
reported as stable. Annual prevalence of cannabis in 
Eastern and South-Eastern Europe is estimated at 2.6 per 
cent, that of opioids at 1.2 per cent and that of opiates at 
0.8 per cent. Annual prevalence of abuse of cocaine in 
Eastern and South-Eastern Europe is estimated at 
between 0.1 and 0.3 per cent of the population, abuse of 
amphetamine-type stimulants at between 0.2 and 0.5 per 
cent and abuse of “ecstasy” between 0.5 and 0.6 per cent. 
787. In the European Union, annual prevalence of abuse 
of cannabis among adults is 6.7 per cent, ranging from  
0.3 per cent to 14.3 per cent depending on the country. 
On average, 3.6 per cent of adults in Western and Central 
Europe abused cannabis in the preceding month, with the 
highest levels reported in Spain (7.6 per cent) and Italy 
(6.9 per cent). The stable or decreasing trend in cannabis 
abuse in Western and Central Europe appears to be 
continuing in general,34 especially among young adults, 
although still at a high level, and an estimated 1 per cent 
of all European adults may be using cannabis on a daily 
or almost-daily basis. Annual prevalence of cannabis 
abuse among younger adults (15-24 years old) in Western 
and Central Europe averages 15.2 per cent, with a range 
from 0.9 per cent to 22.3 per cent. With monthly 
prevalence averaging 8 per cent, more than one in  
10 people between the ages of 15 and 24 in France  
(11.8 per cent) and Italy (11 per cent), and almost one in 
five in Spain (17.2 per cent) reported abuse of cannabis 
within the previous month. A comparison of WHO 
Health Behaviour in School-aged Children surveys  
for 2005/2006 and 2009/2010 indicates an overall stable 
or decreasing trend in most countries in Europe  
in lifetime prevalence of cannabis abuse among  
students aged 15 and 16, yet an increasing trend in  
30-day prevalence. In Switzerland, 10.4 per cent of youth 
and young adults (13-29 years old) had consumed 
cannabis in the previous six months, a decrease from  
11.1 per cent in 2007 and 13.3 per cent in 2004, while  
the prevalence of daily or almost-daily abuse remained 
stable at about 1 per cent over the period 2007-2010. 
“Youth in Europe”, a research-based drug abuse 
prevention programme initiated by European Cities 
against Drugs, published findings indicating a decrease in 
lifetime prevalence of cannabis abuse among young 
people (15-16 years of age) in Iceland, from 17 per cent  
in 1998 to 3 per cent in 2011. In Germany, annual 
prevalence of cannabis abuse among young people  
aged 12-17 years decreased from 9.2 per cent in 2001 to 
4.6 per cent in 2011, yet remained relatively constant 
among those aged 18-25 at about 13.5 per cent in 2011. 
__________________ 
 34  Poland, however, reported a large increase in cannabis 
abuse in 2010. 
788. The level of abuse of cocaine remains relatively 
stable, with an average annual prevalence in Western and 
Central Europe among adults of 1.2 per cent, and a range 
of 0.1 per cent to 2.7 per cent (2.1 per cent among people 
aged 15-34). A decrease in annual prevalence of abuse of 
cocaine among adults has been seen over the past few 
years in countries with high prevalence rates, such as 
Denmark, Ireland, Spain and the United Kingdom. In 
France, however, the annual prevalence of cocaine abuse 
among adults has continued to increase, from 0.3 per cent 
in 2000 to 0.9 per cent in 2010, while lifetime prevalence 
among 17-year-olds decreased to 3 per cent in 2011 from 
3.3 per cent in 2008, after having increased from 0.9 per 
cent in 2000.  
789. The abuse of opioids in Western and Central 
Europe is reported to be stable, at an estimated average 
annual prevalence of 0.4 per cent. Heroin abuse in  
Europe may be declining or stabilizing, while the abuse  
of synthetic and semi-synthetic opioids appears to  
be increasing in some countries. Synthetic and  
semi-synthetic opioids such as fentanyl and 
buprenorphine may be displacing heroin in some 
countries in Northern and Central Europe, notably 
Estonia and Finland. Opioids account for almost half  
of new treatment cases and cause the majority of  
drug-related deaths in the region; 5 per cent of those 
entering treatment specified opioids other than heroin as 
the primary drug of abuse. In Estonia, which according to 
EMCDDA has the highest per capita level of drug-related 
deaths in the European Union, three quarters of those 
entering treatment reported fentanyl as the primary drug 
of abuse, and in Finland more than half of those entering 
treatment cited buprenorphine as the primary drug of 
abuse. 
790. The abuse of amphetamines in Western and Central 
Europe remains stable, with an average annual prevalence 
among adults of 0.5 per cent and a range of between 0 and 
1.1 per cent. Among people aged 15-34, the average 
annual prevalence of amphetamine abuse was 1.1 per 
cent, double that of the general population. In many 
countries, especially in Northern, Central and Eastern 
Europe, amphetamine is the most abused stimulant and, 
in many of those countries, it is the second-most-abused 
illicit drug, after cannabis. Annual prevalence of 
amphetamine abuse among those aged 15-34 has 
decreased in the United Kingdom, from 6.2 per cent  
in 1998 to 1.8 per cent in 2009/10, and in Denmark,  
from 3.1 per cent in 2000 to 2 per cent in 2010. 
Methamphetamine is increasingly available in countries 
in Northern and Western Europe, with increasing  
levels of abuse reported in Germany, Norway and  
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other Scandinavian countries; in Lithuania, 
methamphetamine has become the most commonly 
abused amphetamine-type stimulant. Levels of “ecstasy” 
abuse in Europe have been stable in recent years, with an 
average annual prevalence of 0.8 per cent, yet there are 
indications of a possible resurgence.  
791. According to EMCDDA, although the levels of 
abuse of new psychoactive substances are not substantial, 
there is a potential for an increase. In Ireland in 2010/11, 
the annual prevalence of abuse of new psychoactive 
substances was 4 per cent among adults and 10 per cent 
among younger adults (aged 15-24). In Poland, annual 
prevalence among students aged 18-19 of abuse of  
so-called “legal highs” increased from 2.6 per cent in 2008 
to 7.1 per cent in 2011; monthly prevalence was 2.5 per 
cent. In the United Kingdom, there were increases in 
hospital admissions and medical appointments owing to 
new psychoactive substances, as well as reports of health 
problems caused by the regular use of such substances. 
While overall drug-related deaths in the United Kingdom 
fell by 14 per cent from 2009 to 2010, deaths caused by 
emerging substances of abuse increased significantly, 
from 6 cases in 2008 to 44 cases in 2009. In England and 
Wales in 2011/12, annual prevalence of abuse among 
adults of mephedrone was 1.1 per cent, a decrease from 
1.4 per cent the previous year. Among younger adults 
(aged 16-24), the annual prevalence was 3.3 per cent, the 
same as for “ecstasy”, which nevertheless represents a 
decrease from 4.4 per cent in 2010/11. In Italy, a large 
increase was seen in 2010 in the abuse of tranquillizers 
and sedatives, while Spain saw a large decrease in the 
abuse of tranquillizers and sedatives. In the United 
Kingdom, in Northern Ireland, the abuse of 
antidepressants increased. 
792. The European School Project on Alcohol and  
Other Drugs 2011 survey of students aged 15-16 years in 
37 countries found that lifetime prevalence of abuse of 
illicit drugs was 18 per cent in 2011, an increase from  
11 per cent in 1995 but a level that has been stable  
since 2007. Significant decreases in lifetime prevalence of 
abuse of illicit drugs were seen in Ireland, from 37 per 
cent in 1995 to 19 per cent in 2011, and in the United 
Kingdom, from 42 per cent in 1995 to 29 per cent in 2007, 
while the largest increase — a 9-per-cent increase — was 
recorded in Monaco. An age of onset of abuse of 13 years 
or younger was reported on average by 4 per cent of 
respondents for inhalants, 3 per cent for cannabis and 
between 1 and 2 per cent for non-prescription 
tranquillizers or sedatives, amphetamines or “ecstasy”. 
The survey found that 8 per cent of students in France 
had tried cannabis by the age of 13 years, and that 15 per 
cent of students in Croatia, and one in 10 students in 
Latvia and Slovenia, had used inhalants at the age of 13. 
Annual and lifetime prevalence of cannabis abuse were 
fairly stable at 13 per cent and 17 per cent, respectively. 
The largest increases in annual prevalence were seen in 
France (from 24 to 35 per cent) and Monaco (from 21 to 
33 per cent), and large increases were also seen in Poland 
(from 12 to 19 per cent) and Portugal (from 10 to 16 per 
cent). In France and Monaco, more than one in five 
students (24 per cent and 21 per cent, respectively) 
reported having used cannabis in the past 30 days, 
followed by the Czech Republic and Spain (both 15 per 
cent). Of students surveyed, 4 per cent had abused 
cannabis at least once a week during the survey period. 
The survey found that the lifetime prevalence among 
students of non-prescription use of tranquillizers or 
sedatives remained relatively stable between 1995 and 
2011, at about 7 to 8 per cent.  
793. The most frequently cited substances of abuse for 
those entering treatment in Western and Central Europe 
were opioids (48 per cent), cannabis (25 per cent), 
cocaine (15 per cent) and stimulants other than cocaine 
(6 per cent). The most frequently reported other drug of 
abuse was cannabis. Between 2004 and 2009, the number 
of people entering treatment for the first time whose 
primary drug of abuse was cannabis increased by 40 per 
cent in 18 European countries. Amphetamine was 
reported as the primary drug of abuse in 5 per  
cent of new treatment cases in Europe in 2009;  
however, amphetamine accounted for a much larger 
proportion of new treatment cases in Sweden (28 per 
cent), Poland (25 per cent) and Finland (17 per cent). 
Methamphetamine was the primary drug of abuse 
reported for almost one third of new treatment cases in 
the Czech Republic and almost two thirds of such cases in 
Slovakia, and has increased during the past decade. In 
Ireland from 2005 to 2010, the number of new treatment 
cases increased by over 50 per cent and, while the 
proportion of treatment requests involving opiates, 
mainly heroin, fell slightly in 2009/10, the number of 
cases involving cannabis as the primary drug of abuse 
increased by over 80 per cent from 2005 to 2010, with 
cannabis overtaking heroin to become the most common 
primary drug of abuse in new treatment cases in 2010. 
New substances of abuse were reported as a main 
problem substance for the first time in Ireland in 2009  
(17 cases), increasing to 213 cases in 2010, which 
exceeded the number of cases reported for 
amphetamines, “ecstasy” and inhalants combined. In the 
United Kingdom, in England, the number of  
people under the age of 18 being treated primarily for 
abuse of heroin and cocaine decreased by 33 per cent  
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and 23 per cent, respectively, between 2009/10  
and 2010/11; similarly, the number of young adults  
(aged 18-25) entering treatment because of abuse of 
heroin and/or crack cocaine fell by more than 50 per cent 
between 2005/06 and 2010/11. Nevertheless, the number 
of young people under the age of 18 being treated 
primarily for abuse of amphetamine-type stimulants 
(excluding “ecstasy”) increased by 150 per cent between 
2009/10 and 2010/11, owing to the placement of 
mephedrone under national control in 2010. Over  
half (58 per cent)35 of young people under the age  
of 18 accessing treatment in England for substance abuse, 
including alcohol abuse, cited cannabis as the primary 
drug of abuse, although there was a slight reduction in the 
number of cases compared with the previous year.  
794. In Belarus, by December 2011, 12,967 people had 
been registered on the Narcological Register as having a 
drug dependence problem. Of those, 2,574 of them were 
registered for the first time in 2011 (2,274 were registered 
in 2010). Opiates were the most abused drug among 
registered drug users in Belarus, and opiate abuse 
accounted for 62.8 per cent of newly registered persons.  
In 2011, the majority of registered drug abusers in Belarus 
used homemade opium produced either from poppy 
straw or seeds. Among those newly registered, there were 
more cases of pharmaceutical morphine misuse and fewer 
cases of heroin abuse compared with 2010. The number 
of registered persons abusing opiates increased by 6.5 per 
cent in 2011, the number of cannabinoid abusers 
increased by 8.1 per cent, and the number of persons that 
abused sedatives and tranquillizers increased by 5.7 per 
cent. In 2011, 3.6 per cent of those newly registered 
abused amphetamine, an insignificant change compared 
with the previous year. 
795. The number of drug abusers in Bosnia and 
Herzegovina appears to be increasing, especially among 
the younger population. It is estimated that there are 
7,500 injecting drug users in the country, which 
represents approximately 0.3 per cent of the population 
aged 15-64. Surveys suggest that the average age of 
injecting drug users is 30 years, about 91 per cent of them 
are male, and the vast majority inject heroin. One third of 
surveyed injecting drug users reported needle-sharing 
within the previous month. Between 30 per cent and  
70 per cent of the prison population is estimated to be 
dependent on drugs. According to local authorities, the 
market for synthetic drugs, especially “ecstasy”, is 
expanding, particularly in urban areas. 
__________________ 
 35  If alcohol is excluded, the rate of treatment for cannabis 
would be 86 per cent. 
796. The most easily available and therefore the most 
commonly abused drug in the Russian Federation is 
cannabis, which is smuggled mainly from Central Asia 
but also produced locally. In addition, the current  
drug abuse situation is characterized by large-scale  
non-medical consumption of heroin, desomorphine, 
cocaine and amphetamine-type stimulants. The Ministry 
of Health of the Russian Federation reported about half a 
million officially registered drug-dependent persons. 
Recent trends include the replacement of heroin by less 
expensive and more readily available drugs, such as 
acetylated opium (produced from poppy straw and often 
disguised as food poppy) and desomorphine derived from 
licit codeine-based medications. 
797. According to the Federal Drug Control Service, the 
number of desomorphine users in the Russian Federation 
is growing. Desomorphine consumption increased 
dramatically from the level of five years earlier: whereas 
in 2006 only just over 2 kg of the drug was consumed,  
in 2011 the figure was nearly 100 kg. The mortality rate 
from desomorphine abuse among drug addicts — mostly 
young people — is beginning to rival that from heroin.  
It is estimated that, over the past two years, between  
5,000 and 7,000 people have died from desomorphine.  
In some areas of the country, up to 90 per cent of  
people identified as drug dependant for the first time 
used desomorphine. 
798. The number of drug-induced deaths (estimated  
at 7,237) in Europe in 2010 remained stable, as did the 
number of deaths from drug overdose. Opioids were 
involved in about three quarters of drug-related deaths, 
and a substantial proportion of all drug-related deaths 
occurred in connection with the abuse of multiple 
substances, with alcohol, benzodiazepines and other 
opioids and cocaine often found in addition to heroin. 
Among Europeans aged 15-34, drug overdoses accounted 
for 4 per cent of all deaths. Decreases in drug-related 
deaths were reported in Germany, Italy and the United 
Kingdom. Some increases in drug-related deaths were 
reported in Estonia and Finland, owing in both countries 
to increases in deaths resulting from opioids and in 
Finland also to increases in deaths associated with 
amphetamine-type stimulants, tranquillizers and 
sedatives.  
799. Following significant increases in 2011 in HIV case 
reports and prevalence among injecting drug users  
in Greece and Romania, a joint enquiry by EMCDDA  
and the European Centre for Disease Prevention and 
Control found that most countries reported no change  
in the rate of newly diagnosed cases or prevalence of  
HIV among injecting drug users in 2010/11. Bulgaria, 
Greece, Italy, Lithuania, Luxembourg and Romania 
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reported slight increases, however, while other  
countries reported increases in injecting risk behaviour  
or low coverage of prevention services among injecting 
drug users. 
 
 
 E. Oceania 
 
 
 1. Major developments 
 
800. The rates of abuse and illicit manufacture of 
amphetamine-type stimulants in Oceania are still among 
the highest in the world. This trend is particularly well 
documented in Australia and New Zealand, although 
methamphetamine abuse is reported to be stable or 
declining in those countries. While domestic illicit 
manufacture in Australia and New Zealand is widespread, 
the recent crackdown on precursor chemicals used in 
domestic manufacture has caused the price of 
amphetamine-type stimulants to rise, which has in turn 
attracted the attention of foreign traffickers seeking to 
take advantage of the potential for profits. The result has 
been that incidents of seizures of methamphetamine have 
increased, owing to higher interdiction rates. However, 
the lack of information on drug control from other 
countries in the region, in particular the Pacific island 
States, many of which have not ratified any of the 
international drug control conventions, means that a 
comprehensive and effective understanding of the drug 
trafficking situation is lacking. Nevertheless, research 
indicates that methamphetamines are available and that 
there is much abuse by youth, even in fairly remote areas.  
801. Cocaine abuse is also increasing, and large seizures 
have been reported in the region, in particular in 
Australia. This trend is in keeping with indications from 
previous years that traffickers are targeting Australia and 
New Zealand as markets with high growth potential. The 
increasing prevalence of “legal highs” poses serious 
challenges for Australian health, law enforcement and 
regulatory agencies owing to the large number of 
substances available, confusion about their legal status 
and the complexity related to their manufacture and 
supply; it is also a notable trend in terms of developing 
drug abuse patterns. While cannabis is still the illicit drug 
of choice in the region, evidence suggests that new 
stimulant-type drugs are becoming more popular among 
younger age groups. 
802. The Board welcomed the decisions by the 
Governments of Nauru and Niue to accede to the United 
Nations Convention against Illicit Traffic in Narcotic 
Drugs and Psychotropic Substances of 1988 and urged 
both Governments to build on that momentum by 
acceding to the other two international drug control 
treaties. 
803. However, the fact remains that nine States in 
Oceania have yet to become parties to all three of the 
international drug control treaties, and this continues to 
be a matter of grave concern for the Board, particularly in 
the light of increased reports of trafficking in and illicit 
manufacture of drugs in the region. High prevalence rates 
for the abuse of cannabis and knowledge of illicit 
methamphetamine manufacture in Oceania make it an 
area particularly susceptible to organized crime. The 
Board continues to urge all States concerned, namely the 
Cook Islands, Kiribati, Nauru, Palau, Papua New Guinea, 
Samoa, Solomon Islands, Tuvalu and Vanuatu, to accede 
without further delay to any of the three international 
drug control treaties to which they are not yet parties. 
Those States may easily become used by traffickers who 
want to supply the Australian and New Zealand markets.  
 
 2. Regional cooperation 
 
804. A number of regional conferences have been 
organized in the region, allowing for greater coordination 
and cooperation on issues related to drug control.  
805. The 2012 meeting of the Regional Security 
Committee of the Pacific Islands Forum was held in Fiji 
in June. The meeting’s discussions focused on transborder 
issues, in particular transnational organized crime; 
border management and counter-terrorism; national and 
regional law enforcement challenges; and human security, 
human rights and governance issues. 
806. Trafficking in precursor chemicals in Oceania 
continues to be a major source of concern for officials in 
the region. As part of efforts to tackle this problem,  
a joint meeting of the Project Cohesion and Project  
Prism Task Forces was convened in Canberra from 4 to  
7 October 2011. Task Force members from Australia, 
China, Germany, India, Mexico, the Netherlands,  
the Russian Federation and the United States, as well  
as representatives of the European Commission, 
INTERPOL and the International Narcotics Control 
Board secretariat, attended the meeting. The meeting 
reviewed operations and activities conducted under the 
auspices of those two Projects, and Task Force 
representatives gave an overview of the latest trends 
observed in their regions with regard to cocaine, heroin 
and MDMA (“ecstasy”). A number of future actions  
were agreed, including an information-gathering exercise 
and improved reporting of seizures related to  
non-controlled substitutes. It was also agreed to pilot  
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the International Narcotics Control Board Precursors 
Incident Communication System.  
807. Cooperation and capacity development in terms of 
customs and law enforcement have also continued to be 
developed. The 40th annual Pacific Islands Chiefs of 
Police Conference was held in Pohnpei, Federated States 
of Micronesia, from 23 to 25 August 2011. The Chiefs of 
Police discussed how to improve coordination and the use 
of donor resources, identifying gaps in services and how 
to support and oversee the building of sustainable 
training capacities within individual Pacific police 
organizations. The Oceania Customs Organization 
secretariat held its 14th Annual Conference in Pago Pago, 
American Samoa, on 3 May 2012. Delegates from  
18 member countries and areas attended the meeting, 
namely American Samoa, Australia, the Cook Islands, the 
Federated States of Micronesia, Fiji, Kiribati, the Marshall 
Islands, Nauru, New Zealand, Norfolk Island, Niue, Palau, 
Papua New Guinea, Samoa, Solomon Islands, Tonga, 
Tuvalu and Vanuatu. Discussions focused on new 
strategic approaches, such as customs networking and the 
use of risk management techniques based on intelligence 
and information-sharing and exchange.  
808. Australia further invested significant amounts of 
resources in its Pacific Police Development Programme. 
By the end of the four-year Programme, just under  
100 million Australian dollars will have been invested in 
new skills, leadership and community training with  
the aim of improving both effectiveness and public 
confidence in police of Pacific island countries.  
The Programme gives country-specific support to the 
Cook Islands, the Federated States of Micronesia, Kiribati, 
the Marshall Islands, Niue, Palau and Tuvalu, but also 
seeks to support efforts to address Pacific-wide policing 
issues. In 2012, this has been done through a variety of 
train-the-trainer courses, conferences and workshops.  
 
 3. National legislation, policy and action 
 
809. As reported in 2011, the Government of  
Australia endorsed a national drug strategy for the  
period 2010-2015, which is based on the three pillars of 
demand reduction, supply reduction and harm reduction. 
Its aim is to build safe and healthy communities by 
minimizing alcohol-, tobacco- and other drug-related 
harm among individuals, families and communities. 
Before that, in mid-2008, the amphetamine-type 
stimulant strategy was released by the Ministerial Council 
on Drug Strategy. The Government of Australia recently 
extended the amphetamine-type stimulant strategy to 
2015, in order for it to conclude at the same time as the 
national drug strategy.  
810. As part of its national drug campaign, Australia, 
with one of the highest levels of MDMA (“ecstasy”) abuse 
in Oceania, launched an initiative in December 2011 
aimed at warning youth about the dangers of “ecstasy” 
and other illicit drugs. That awareness-raising initiative 
highlighted the risks and potential harm associated with 
taking “ecstasy” in order to reduce the high consumption 
rates among youth. In addition, the Australian 
Government provided further funding for activities of the 
National Cannabis Prevention and Information Centre, 
which seeks to prevent cannabis uptake and provide 
evidence-based information on the harms associated with 
cannabis abuse, as well as interventions for cannabis 
users.  
811. In May 2012, Australia amended the Standard for 
the Uniform Scheduling of Medicines and Poisons to 
include synthetic cannabinoids. In addition, with respect 
to Commonwealth legislation, 4-methylmethcathinone 
(4-MMC), ketamine and BZP were included and new 
thresholds for methcathinone and phenylpropanolamine 
were defined. 
812. Following a period of consultations on the review of 
the Misuse of Drugs Act 1975, the New Zealand Law 
Commission published its final report in May 2012, 
which made recommendations to the Government about 
how New Zealand drug laws could be updated. The 
review contained a number of key proposals, including a 
full-scale review of the current drug classification system 
that would be based on an assessment of a drug’s impact 
in terms of harm as well as a proposal for the 
establishment of a pilot drug court, which would allow 
the Government the opportunity to defer sentencing until 
some offenders had undergone court-imposed treatment 
for drug abuse.  
813. In 2011, the New Zealand Government presented 
legislation to make domestically produced medication 
containing pharmaceutical preparations of 
pseudoephedrine available only by prescription. In  
March 2012, under the Misuse of Drugs Act 1975, it also 
placed a 12-month ban on the supply and sale of  
a number of synthetic cannabinomimetic substances 
(AM-1248, AM-2232 and UR-144). Cannabinomimetic 
substances are those that have been incorporated into 
products traded as legal alternatives to cannabis. In 
addition, as of early April 2012, 1,3-dimethylamylamine, a 
common ingredient in “party pills” and some weight-loss 
and sports-performance supplements, was banned. 
Furthermore, pseudoephedrine and ephedrine were 
reclassified. All imports and exports of the substances 
now require a permit for each consignment, as well as the 
issuance of a pre-export notification.  
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814. In an effort to address the rapid growth in new 
psychoactive substances, which can be synthesized so as 
to be one step ahead of existing controls, new legislation 
was introduced by the Government of New Zealand in 
July 2012. The legislation prohibits the sale of all 
psychoactive substances unless approved by a regulator.  
815. After a review of the 1994 Fiji National Drug Policy, 
the Fiji Government approved the National Medicinal 
Products Policy in June 2012. The new policy will seek to 
improve the accessibility, quality and rational use of 
medicines by health professionals and consumers.  
As of 2012, Papua New Guinea has significantly increased 
the annual budget for its National Narcotics Bureau and 
other drug enforcement agencies with a view to 
education, raising awareness, treating and rehabilitating 
users and enforcing existing drug laws. In addition, a 
recommendation is being prepared, to be presented to the 
Prime Minister and the National Executive Council, to 
establish a ministerial task force that will study, among 
other things, appropriate penalties for drug crimes, the 
establishment of treatment and counselling centres and 
the possible updating of the Papua New Guinea 
Controlled Substance Bill. 
 
 4. Cultivation, production, manufacture and 
trafficking 
 
 (a) Narcotic drugs 
 
816. Cannabis remains the most prevalent illicit drug, in 
terms of abuse, production and seizures in Oceania. 
Prevalence rates in the region are estimated at between 
9.1 and 14.6 per cent, among the highest in the world, 
with Australia ranked as the region’s largest market for 
cannabis. In Australia, in the period 2010-2011, cannabis 
seizures accounted for 72 per cent of national  
seizure incidents involving illicit drugs. In that period, 
2,137 cannabis detections were made at the Australian 
border and 50,073 cannabis seizures were made, the 
largest number of seizures reported in Australia over the 
last 10 years. 
817. New Zealand also reported a high prevalence rate; 
cannabis was the most commonly abused illicit drug in 
the country, with about 1.2 million New Zealanders 
reporting having abused the drug in their lifetimes. 
However, the abuse of the drug appears to have decreased 
in the 18-24 age group in response to health concerns 
about smoking, combined with an increasing preference 
to abuse new, uncontrolled stimulants.  
818. The abuse of cannabis and cultivation of cannabis 
plant also occur at high rates in many Pacific island 
States. Concerns that profits from this “cannabis 
industry” will be reinvested in the illicit manufacture of 
methamphetamine, in addition to other drugs, have 
previously been raised by the Board. The proximity of the 
islands to major markets for illicit drugs, combined with 
the difficulty of policing the Pacific islands owing to their 
geographic situation, appeals to drug traffickers, who 
have increasingly targeted the region. While eradication 
campaigns have been reported, recent cannabis abuse is 
estimated to be as high as 40 per cent of persons surveyed 
in Palau, Solomon Islands and Vanuatu. Abuse of 
cannabis in Papua New Guinea is also significant: officials 
there have reported that cultivation of the plant is one of 
the country’s leading sources of revenue. The Marshall 
Islands reported the lowest prevalence rate of cannabis 
abuse in the Pacific islands, with 6 per cent of men and  
3 per cent of women reporting lifetime use. 
819. Although cocaine seizures in Oceania account for 
only 0.3 per cent of total world seizures, the increased 
amounts seized in 2011 suggest that the market for the 
substance in the region has expanded and that Oceania is 
increasingly being used as a smuggling route for the drug.  
820. In the period 2010-2011, the number of cocaine 
detections at the Australian border increased by two 
thirds and the total weight of substances detected 
increased by 81 per cent from the levels of the previous 
period. Six seizures accounted for 78 per cent of the total 
amount of cocaine seized, with one of those seizures 
alone accounting for 401 kg. The diversification of 
embarkation points for smuggling of cocaine into the 
country is a notable trend, with the main embarkation 
points in terms of numbers being Argentina, Panama, 
Thailand, the United Kingdom and the United States. 
However, it is worth noting that the single seizure of  
401 kg of cocaine was detected on a small craft travelling 
from Ecuador. The vast majority of detections in terms  
of numbers involve small amounts of the substance sent 
via parcel.  
821. The 16.2 kg seized in New Zealand in the first seven 
months of 2012 represent an exponential increase from 
the 615 grams seized in 2011. While New Zealand is a 
transit country for trafficking of the drug to Australia, 
evidence suggests that most of the cocaine seized was for 
domestic consumption. Most of the cocaine detected 
came directly from South America, departing in 
particular from Argentina and Chile, with internal 
concealment being the most common form of its 
transportation. However, West African drug trafficking 
networks are also involved in the trafficking of cocaine 
into the country.  
822. The prevalence of opioid abuse in Oceania is similar 
to that in many other developed countries with a 
dependable heroin supply, although abuse of the drug lags 
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substantially behind the abuse of other illicit drugs such 
as cannabis and amphetamine-type stimulants. In 
Australia, heroin abuse has remained stable since 2001, 
although the weight of national heroin seizures increased 
substantially in the period 2010-2011 to 375.7 kg, the 
largest amount seized since 2005-2006. Heroin from 
South-West Asia accounted for the most heroin in terms 
of quantity seized, whereas incidents of seizures 
originating from South-East Asia were the most frequent. 
In terms of weight, the primary embarkation points 
identified were Malaysia, Pakistan and Viet Nam, whereas 
India, Malaysia and Singapore were the countries from 
which the seized heroin most frequently departed.  
823. In New Zealand, opioids are the third most 
prevalent drugs abused. The number of persons admitted 
for drug treatment for the abuse of heroin, morphine and 
opiates (including pharmaceutical opioids) accounted  
for 44 per cent of all drug-related hospital admissions  
in 2010. The trafficking and abuse of heroin and opium 
are not widespread in New Zealand, where many opiate 
abusers use “homebake” heroin, or diverted medicines 
such as oxycodone.  
 
 (b) Psychotropic substances 
 
824. A record seizure of 558 kg of illicit drugs, of which 
306 kg was crystal methamphetamine and 252 kg was 
heroin, was seized in Sydney in July 2012. That followed 
another major seizure, in May 2011, in which the 
Australian Federal Police seized more than 230 kg of 
methamphetamine in a raid in Sydney. The seizure  
in 2012 highlights the continued and substantial  
domestic demand for amphetamines in Australia, which 
is principally serviced by domestic illicit manufacture.  
A total of 13,982 arrests related to amphetamine-type 
stimulants were made in the period 2009-2010, 
representing 16 per cent of all drug-related arrests, 
second only to cannabis-related arrests. In the  
period 2010-2011, there were 556 detections of 
amphetamine-type stimulant (excluding MDMA 
(“ecstasy”)) laboratories and 16 MDMA laboratories were 
detected, down from 17 in the period 2009-2010. 
825. Despite this substantial domestic illicit 
manufacturing presence, trafficking of amphetamine-type 
stimulants into the country still takes place. Parcels 
accounted for over 90 per cent of detections, while air 
cargo accounted for 47 per cent of total weight detection 
for amphetamine-type stimulants (excluding MDMA 
(“ecstasy”)) at the Australian border. The most popular 
embarkation points for amphetamine-type stimulants 
were Canada, China (including Hong Kong), India  
and Ireland. Seizures of “ecstasy” were also on the  
rise: 112 kg of “ecstasy”-group substances were seized in 
2010, compared with 54 kg in 2008 and 59 kg in 2009.  
826. In New Zealand, abuse of amphetamine-type 
stimulants has grown rapidly over the last two decades, 
and it remains the most commonly abused illicit  
drug after cannabis. A well-developed domestic 
amphetamine-type stimulant manufacturing capability 
has shown itself to be adaptive and responsive to demand. 
Although pseudoephedrine extraction laboratories were 
seized in New Zealand, the total number of clandestine 
laboratories detected has fallen, and a notable shift  
to rural and semi-rural locations has been seen as  
illicit manufacturers of amphetamine-type stimulants try 
to avoid being detected. However, the detection of 
polydrug manufacturing laboratories represents a new 
development in illicit drug manufacture in the country.  
827. The New Zealand Government has identified the 
reduction of the availability and abuse of 
methamphetamine as its highest law enforcement 
priority, with 12 per cent of all drug-related arrests in 
2010 involving methamphetamine. This prioritization  
has also led to methamphetamine seizures increasing  
by 45 per cent in 2010 over seizures in 2009. However, 
those seizures may also signal the increased appeal of 
selling the drug in the country, where the price of 
methamphetamine is comparatively high and profitable 
and as such has attracted attention from organized 
criminal groups from Asia, West Africa and the Islamic 
Republic of Iran. This is evidenced in part by the border 
seizure of 19.5 kg of methamphetamine in 2010, 
representing an 81 per cent increase over the amount in 
2009. As in Australia, seizures of “ecstasy”-type substances 
increased over those of previous years: the 12 kg reported 
in 2010 matched the level of seizures reported in 2004.  
 
 (c) Precursors 
 
828. As a result of legislative changes making it more 
difficult for traffickers to divert ephedrine and 
pseudoephedrine in Australia, criminal groups have 
responded by innovating and adapting the domestic 
manufacture of amphetamine-type stimulants.  
829. Australian authorities detected 702 illicit 
laboratories in the period 2010-2011, the largest  
number ever recorded. New Zealand dismantled  
130 illicit manufacturing laboratories in 2010, primarily  
for methamphetamine manufacture or the extraction  
of pseudoephedrine, a slight decrease from the  
135 laboratories dismantled in 2009. This figure also 
includes a clandestine manufacturing laboratory that was 
extracting ephedrine and pseudoephedrine from ephedra 
plant material and pharmaceutical preparations. The use 
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of ephedra by methamphetamine laboratories represents 
a small but growing trend in the manufacture of 
amphetamine-type stimulants in New Zealand, first 
identified in 2005.  
830. The extraction of ephedrine and pseudoephedrine 
from preparations, in particular from ContacNT, a 
distinct granular pharmaceutical formulation containing 
pseudoephedrine, which is sourced from China, remains 
the main method of obtaining the precursor chemicals 
needed for the manufacture of amphetamine-type 
stimulants. In 2010, New Zealand reported seizing 949 kg 
of pseudoephedrine preparations, mainly in the form of 
ContacNT, and in May 2011 alone, New Zealand seized 
almost 68 kg of ContacNT. In 2011, Australia and New 
Zealand combined accounted for the seizure of 1.7 tons of 
ephedrine and pseudoephedrine, mostly in the form of 
preparations.  
831. It is clear that the market for MDMA (“ecstasy”) in 
Australia is still attractive. In April 2011, Australian 
authorities dismantled an organized crime syndicate in 
Sydney and made the largest seizure of safrole in 
Australian history, seizing more than 2,800 litres of  
low-concentration safrole oil, misdeclared as liquid hair 
and cleaning products originating from China. The low 
safrole content corresponded to approximately 288 litres 
of pure safrole. This potentially could have led to the 
manufacture of 2.3 million “ecstasy” tablets. 
832. In 2010, Australia reported 43 cases involving 
seizures of ephedra, which can be used in the 
manufacture of methamphetamine, totalling 3 kg. Most of 
the seizures were detected in the postal system and 
originated in the United States in the form of dietary or 
weight-loss supplements, although these may not have 
been intended for use in the illicit manufacture of drugs. 
 
 (d) Substances not under international control  
 
833. In Australia, authorities are increasingly being 
challenged by the emergence of new amphetamine-type 
stimulant analogues. The analogues mimic the effects of 
MDMA (“ecstasy”) and methamphetamine and are 
designed in such a way that they circumvent national 
drug control legislation. Although present in Australia 
since early 2000, the appeal of such substances, often sold 
as “legal highs”, has evolved to such an extent that a 
separate and distinct market has been established. 
Detection of ketamine, which has a wide range of effects 
that include hallucinations, remained stable: 22 detections 
in the period 2009-2010 compared to 23 detections in the 
period 2010-2011.  
834. Other psychoactive substances, such as mephedrone 
and methylenedioxypyrovalerone, are also increasingly 
being detected. Mimicking the effects of controlled 
substances, their presence has been detected in drugs sold 
as “ecstasy”. The most prominent sources for BZP, 
mephedrone and 4-methyl-N-ethylcathinone are Ireland 
and the United Kingdom, although China has also been 
identified as a point of origin for sourcing the substances. 
The use of piperazines also continues to be reported.  
A number of laboratories in New Zealand have  
been discovered extracting large quantities of gamma-
butyrolactone from horticultural fungicides (Fandango 
and Mogul).  
 
 5. Abuse and treatment 
 
835. As noted above, cannabis remains the most abused 
drug in Oceania. A report released in 2012 estimated that 
up to 14.8 per cent of persons aged 15-64 had used 
cannabis in Oceania in 2009, making it the top region for 
abuse of the drug in the world.  
836. In New Zealand, it was estimated that in 2011,  
3.5 per cent of the population needed treatment for drug 
abuse, with 86 deaths reported as being related indirectly 
to the abuse of illicit drugs and psychotropic substances. 
Of the 9,451 persons brought into formal contact with the 
New Zealand police and justice system for drug-related 
offences, 8,085 of the cases were in connection with 
personal cannabis-related offences.  
837. Cannabis abuse in the smaller Pacific island States is 
also notable, particularly among youth. Recent results 
from the 2011 Global School-based Student Health 
Survey found lifetime use of cannabis ranging from 4 per 
cent to 14.3 per cent among students aged 13 to 15 years, 
with boys much more likely to abuse cannabis than girls. 
The figures were as follows: for the Cook Islands, 9.2 per 
cent; Kiribati, 4 per cent; Solomon Islands, 14.3 per cent; 
and Tonga, 6.5 per cent. 
838. In 2010, 2.1 per cent of the Australian population 
aged 14 years and older reported recent abuse of 
amphetamines, and 5.9 per cent of those in the 20-29 age 
group reported using the substance, making the latter the 
age group with the highest prevalence rate. Nevertheless, 
the figure reported in 2010 is the lowest since 1995. 
839. Of alleged criminals held in custody in Australia,  
21 per cent tested positive for methamphetamine. 
Compared to 2010, this represents a 6 per cent increase, 
although it is still below the highest result, recorded  
in 2003 and 2004, when 30 per cent of detainees tested 
positive. The Australian Institute of Criminology, which 
conducted the study, also reported that users thought  
the quality of the drug had significantly improved and  
its availability had increased. 
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840. After cannabis, amphetamine-type stimulants are the 
second most prevalent class of abused drug in New 
Zealand. In 2011, abuse of amphetamine-type stimulants, 
including MDMA (“ecstasy”), amphetamine and 
methamphetamine, was stable, and six deaths related to 
their abuse were reported. However, an increase in 
intravenous abuse of amphetamine and methamphetamine 
was reported over the reporting period.  
841. In the Pacific islands, considerable challenges 
remain with regard to the reporting of statistics relating 
to illicit drug use, production and trafficking. 
Nevertheless, the use of kava (Piper methysticum) and 
abuse of cannabis are considered to be widespread. 
Furthermore, the abuse of amphetamine-type stimulants 
among secondary students is reported in many Pacific 
islands: the Marshall Islands reported a prevalence  
rate of 13.1 per cent and Palau 7.1 per cent. Evidence 
exists of intravenous methamphetamine abuse in  
many Pacific island territories, and in Vanuatu, where 
methamphetamine is injected by 41 per cent of injecting 
drug users aged 15 to 24. 
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IV. Recommendations to Governments, the United Nations and other 
relevant international and regional organizations 
 
 
842. The Board monitors the implementation by 
Governments of the three international drug control 
conventions and examines the functioning of the 
international drug control system at the national and 
international levels. The Board, on the basis of its 
findings, makes recommendations to Governments, as 
well as international and regional organizations, to 
enhance the implementation of and compliance with the 
conventions. 
843. The present chapter draws attention to the key 
recommendations in connection with chapters II and III 
of this report. The recommendations concerning the issue 
of shared responsibility in international drug control are 
contained in chapter I. Specific recommendations aimed 
at improving the control of precursor chemicals are 
contained in the 2012 report of the Board on the 
implementation of article 12 of the 1988 Convention.36 
The Board urges Governments and relevant international 
and regional organizations to review and implement, as 
soon as possible, all of the recommendations made by the 
Board, as appropriate. The Board calls on Governments 
to notify the Board of actions taken to address the 
recommendations made in this report. 
 
 
 A. Recommendations to Governments 
 
 
844. The following recommendations to Governments 
are presented by subject area: treaty accession; treaty 
implementation and control measures; prevention of 
illicit drug production, manufacture, trafficking and 
abuse; and substances not under international control. 
 
 1. Treaty accession 
 
845. The 1961 Convention as amended by the  
1972 Protocol, the 1971 Convention and the  
1988 Convention form the framework of the international 
drug control system. Universal accession to the 
conventions and universal implementation by States of 
the provisions of the conventions are a fundamental 
prerequisite for effective drug control efforts worldwide 
aimed at ensuring access to narcotic drugs and 
__________________ 
 36  Precursors and Chemicals Frequently Used in the Illicit 
Manufacture of Narcotic Drugs and Psychotropic 
Substances: Report of the International Narcotics Control 
Board for 2012 on the Implementation of Article 12 of the 
United Nations Convention against Illicit Traffic in 
Narcotic Drugs and Psychotropic Substances of 1988 
(United Nations publication, Sales No. E.13.XI.4). 
psychotropic substances for medical and scientific 
purposes while preventing their diversion to illicit 
production, manufacture, trafficking and abuse. 
Recommendation 1: The Board notes that a total of  
17 States37 have not yet become parties to all of  
the international drug control treaties. In addition, 
Afghanistan and Chad have not yet acceded to the  
1972 Protocol amending the 1961 Convention. The 
Board urges those Governments to accede to all of the 
international drug control treaties as a matter of 
urgency. 
 
 2. Treaty implementation and control measures 
 
846. While universal accession to the three international 
drug control conventions is necessary, it alone is not 
sufficient to address drug-related problems. In that 
regard, universal implementation of all provisions of the 
treaties and the effective application of the necessary 
control measures by all Governments is essential.  
Recommendation 2: National legislation in some countries 
is not in line with all provisions of the international drug 
control treaties. Likewise, in some countries the lists  
of substances controlled at the national level do not 
include all substances contained in the schedules of the  
1961 Convention and the 1971 Convention or in the 
Tables of the 1988 Convention. The Board reiterates its 
call on Governments to review their laws and regulations 
to verify that they are in line with all provisions of the 
international drug control treaties and that all 
substances under international control are under 
national control in their countries. If necessary, 
Governments should amend their laws and regulations, 
as well as amend the national schedules of controlled 
substances, so as to comply with the treaties.  
Recommendation 3: Some Governments, among them 
major manufacturing countries, experience difficulties in 
reporting accurately and in a timely manner to the Board 
data on substances under international control, in 
particular after changes of staff or after the restructuring 
of the competent authorities. To avoid such difficulties, 
the Board encourages all Governments to provide for the 
training of staff to enable them to fulfil the reporting 
obligations under the international drug control 
__________________ 
 37  Bolivia (Plurinational State of ), Cook Islands, Equatorial 
Guinea, Haiti, Kiribati, Liberia, Nauru, Niue, Palau, 
Papua New Guinea, Samoa, Solomon Islands, Somalia, 
South Sudan, Timor-Leste, Tuvalu and Vanuatu. 
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conventions and to take the necessary steps to maintain 
the knowledge base of their staff at times of change. 
Recommendation 4: Many Governments are making use 
of electronic systems to collect and compile data as 
required under the conventions. The Board welcomes the 
introduction of new technologies to facilitate such work. 
The Board notes, however, that in some countries the 
quality of information collected from national 
stakeholders, including information collected using 
electronic tools, is low. The Board reminds Governments 
of their responsibility to ensure that all national 
stakeholders are fully aware of the reporting 
requirements and that any system at the national level 
for collecting data and reporting to the Board is 
designed and implemented in a way that is compatible 
with the provisions of the relevant international treaties. 
The Board invites all Governments to establish regular 
training sessions for national stakeholders on such 
systems and on the reporting requirements under the 
international drug control conventions.  
Recommendation 5: The Board notes with serious concern 
the ongoing move towards the legalization of cannabis for 
non-medical purposes in some parts of the United States 
and, in particular, the outcomes of recent ballot initiatives 
that took place in the states of Colorado and Washington 
in November 2012. The Board stresses the importance of 
universal implementation of the international drug 
control treaties by all States parties and urges the 
Government of the United States to take the necessary 
measures to ensure full compliance with the 
international drug control treaties on its entire territory. 
 
 (a) Narcotic drugs and psychotropic substances 
 
Recommendation 6: In many countries, insufficient 
control measures governing the prescribing, distribution 
and sale of prescription drugs contribute to the diversion 
of those drugs for abuse. The Board urges Governments 
concerned to adopt and implement effective control 
measures for the prescribing of medicines containing 
narcotic drugs and psychotropic substances by health-
care professionals, their distribution by wholesalers and 
their sale by pharmacies.  
Recommendation 7: The diversion from international 
trade of psychotropic substances listed in Schedules III 
and IV of the 1971 Convention may occur when import 
and export authorizations are not required for those 
substances, as is the case in some countries. The Board 
reiterates its call for all Governments that do not yet 
require import and export authorizations for all 
psychotropic substances to extend the requirement of 
import and export authorizations to all psychotropic 
substances as soon as possible. Furthermore, the Board 
encourages the countries that have introduced such 
authorization requirements for all psychotropic 
substances, but which have subsequently exempted some 
preparations from the import and export authorization 
requirements, to reconsider those exemptions, where 
appropriate. 
Recommendation 8: The Board welcomes the 
development, by UNODC with the support of the Board 
and some Governments, of an international electronic 
import and export authorization system for narcotic 
drugs and psychotropic substances, pursuant to 
Commission on Narcotic Drugs resolution 55/6. Such a 
system would assist national drug control authorities in 
their work and enhance compliance with the 
requirements set out in the international drug control 
conventions. The Board encourages Governments to 
continue to support the development and maintenance 
by UNODC of an international electronic import and 
export authorization system and to utilize that system 
without delay, once it is developed (see also 
recommendation 36 below).  
Recommendation 9: The Board notes that most actions 
taken by Governments to support rational use of 
controlled substances have focused on opioid analgesics. 
There is also a need for more targeted action to ensure 
adequate availability and rational use of psychotropic 
substances in all countries. The Board recommends that 
Governments (a) regularly collect reliable data on the 
consumption of psychotropic substances and share such 
data with the Board to allow accurate analysis of levels of 
consumption in their country; (b) identify whether there 
are other non-specific substances used in their territory 
that are not under international control and which 
might have an impact on the consumption of 
appropriate medications used to treat mental and other 
diseases commonly treated with psychotropic 
substances; (c) compare consumption levels in their 
country with those in other countries and regions with a 
view to identifying insufficient or excessive 
consumption; and (d) take the appropriate actions to 
promote the rational use of psychotropic substances in 
their countries in accordance with the recommendations 
contained in the 2010 Report of the International 
Narcotics Control Board on the Availability of 
Internationally Controlled Drugs: Ensuring Access for 
Medical and Scientific Purposes.38 
 
__________________ 
 38  United Nations publication, Sales No. E.11.XI.7. 
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 (b) Precursors  
 
Recommendation 10: The growing diversion of chemicals 
from domestic distribution channels has become the 
most common method of obtaining several precursor 
chemicals for the illicit manufacture of narcotic drugs 
and psychotropic substances. The Board urges 
Governments to review existing domestic control 
systems to identify and address any weaknesses in the 
control of domestic trade in and distribution of 
precursor chemicals. Declaration of end-use and an 
understanding of the legitimate requirements for 
precursor chemicals by registered companies are among 
the key control measures that can assist Governments in 
preventing diversions. 
Recommendation 11: Universal implementation by  
all Governments of the provisions of article 12,  
paragraph 10 (a), of the 1988 Convention would ensure a 
robust and practical global mechanism for the control of 
international trade in scheduled chemicals. The Board 
encourages Governments that have not yet invoked  
article 12, paragraph 10 (a), of the 1988 Convention to 
do so without delay, since it would oblige exporting 
countries to issue notifications of all shipments of 
precursors destined for their country.  
Recommendation 12: The Board reminds all 
Governments exporting scheduled chemicals to 
countries that have invoked article 12, paragraph 10 (a), 
of the 1988 Convention of their obligation to provide 
notification of such shipments prior to departure, and 
recommends using the PEN Online system for  
such notifications, pursuant to Security Council 
resolution 1817 (2008). 
Recommendation 13: The Board encourages all 
Governments to actively review pre-export notifications 
sent to their country and to communicate any objection 
to these in a timely manner via the PEN Online system 
in order to maintain an unbroken chain of monitoring 
trade in chemicals. 
Recommendation 14: High estimates of annual legitimate 
requirements for imports of ephedrine and 
pseudoephedrine in some countries put those countries  
at risk of being targeted by traffickers seeking to divert 
those substances for use in the illicit manufacture  
of amphetamine-type stimulants. The Board encourages 
all countries that identify the diversion of precursors for 
amphetamine-type stimulants to re-evaluate their 
requirements for those substances and to inform the 
Board without delay about any such changes. 
Recommendation 15: In 2012, the Board launched the 
Precursors Incident Communication System (PICS) to 
assist Governments in responding to rapidly changing 
trends in the diversion of chemicals used in the illicit 
manufacture of drugs. In addition to a proactive sharing 
of information on identified precursor incidents, the 
main objective of the communication system is to trigger 
and stimulate bilateral and multilateral cooperation 
among the users of the system, including launching of 
joint investigations. The objective of the system is to 
provide a universal platform for communication of 
precursor incidents in real-time and to complement the 
exchange of information on licit trade in precursors 
through PEN Online. The national competent 
authorities of all countries that have not yet done so are 
encouraged to register for use of PICS and thereby 
benefit from its use. 
 
 3. Prevention of illicit drug production, 
manufacture, trafficking and abuse 
 
847. Parties to the international drug control treaties 
have an obligation to limit to legitimate purposes the 
production, manufacture, export, import and distribution 
of, trade in and use of internationally controlled 
substances and to prevent their diversion and abuse.  
Recommendation 16: The drug control situation in 
Afghanistan continues to be of great concern. In 2012, 
illicit opium poppy cultivation in Afghanistan continued 
to increase, involving half of the country’s 34 provinces. 
The number of opium poppy-free provinces in 
Afghanistan remained at 17 in 2012. Illicit production of 
cannabis and cannabis resin has spread, with illicit 
cultivation of cannabis plant now occurring in  
21 provinces. The Government of Afghanistan has 
recently launched several drug control policy documents, 
including the National Drug Demand Reduction Policy 
for the period 2012-2016, the National Alternative 
Livelihood Policy and the Anti-Drug Trafficking Policy. 
The Board appreciates the goals set out in those policy 
documents, including the reduction of the illicit 
cultivation of opium poppy and of illicit production and 
manufacture of narcotic drugs, an increase in drug 
seizure rates and an increase in drug abuse prevention 
and treatment capacity by up to 40 per cent over the next 
five years. The Board urges the Government of 
Afghanistan to take adequate measures to implement 
those policy documents. The Board encourages all 
Governments and relevant international entities, 
including UNODC, to assist the Government of 
Afghanistan in implementing those goals. 
Recommendation 17: The Board notes with concern the 
continuous increase of the illicit opium poppy cultivation 
in the Lao People’s Democratic Republic and Myanmar. 
The Board urges the Governments of those countries to 
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take the necessary actions to curtail illicit opium poppy 
cultivation. The Board calls on the international 
community, in particular UNODC, and other countries 
of the region, to strengthen assistance to the Lao People’s 
Democratic Republic and Myanmar, including for 
alternative development programmes and illicit crop 
eradication.  
Recommendation 18: The region of South America 
continues to suffer from the illicit cultivation of coca 
bush, as well as the illicit manufacture of and trafficking 
in cocaine. The Board urges the Governments 
concerned, in particular Bolivia (Plurinational State of), 
Colombia and Peru, to further strengthen their efforts to 
eliminate the illicit cultivation of coca bush and the 
illicit manufacture of cocaine. All Governments of 
countries in the region are encouraged to take 
comprehensive steps to address trafficking in cocaine in 
a decisive manner. 
Recommendation 19: Trafficking organizations have 
continued to use submersible and semi-submersible 
vessels to minimize the risk of detection of the smuggling 
of cocaine from South America. The Board calls on the 
Governments of the countries concerned in the 
Americas to take further measures to combat this kind 
of maritime drug trafficking and to strengthen regional 
and interregional cooperation in that regard. 
Recommendation 20: The large seizures of cannabis in 
South America in recent years continue to raise concerns 
regarding the magnitude of illicit cannabis production in 
the region. The Board calls upon the Governments of the 
countries in South America to determine, to the extent 
possible and in cooperation with UNODC, the 
magnitude of and current trends in the illicit cultivation 
of cannabis plant and to further strengthen their efforts 
to combat such cultivation.  
Recommendation 21: The level of abuse of cannabis in 
Europe remains high, and the need for treatment of 
cannabis abuse has increased dramatically in many 
countries. The Board notes with concern the continuing 
increase in illicit cultivation of cannabis plant, especially 
indoors, in Western and Central Europe, as well as the 
growing involvement of criminal groups, as reported by a 
number of countries. The Board is also concerned about 
the continuing trafficking of significant quantities of 
cannabis herb in South-Eastern Europe, as well as the 
increasing illicit production of cannabis herb in the 
subregion. The Board reminds Governments of 
countries in Europe of the need to systematically address 
the illicit cultivation of cannabis, and calls on 
Governments to step up efforts to prevent the abuse of 
cannabis and reinforce efforts to meet the growing 
demand for treatment services related to cannabis abuse.  
Recommendation 22: East and South-East Asia continue 
to be an illicit manufacturing hub and a growing illicit 
market for amphetamine-type stimulants, in particular 
methamphetamine. The illicit manufacture of 
amphetamine-type stimulants has expanded from 
traditional manufacturing countries, such as China and 
Myanmar, to other countries, including Cambodia, 
Indonesia, Malaysia, the Philippines and Thailand. The 
Board urges Governments of countries in the region to 
devise and implement appropriate strategies to address 
the illicit manufacture of, trafficking in and abuse of 
amphetamine-type stimulants. 
Recommendation 23: The Board is concerned that the 
illicit manufacture of methamphetamine has taken hold 
in countries of West Africa, including Nigeria. 
Methamphetamine has been trafficked from countries of 
West Africa to East Asia, predominantly Japan and the 
Republic of Korea. The Board calls on countries in West 
Africa to take measures necessary to address this 
problem.  
Recommendation 24: The abuse of prescription drugs 
containing controlled substances continues to be a 
growing problem in all regions of the world and is posing 
serious health and social challenges in some countries. 
The Board recommends that Governments collect 
information on the nature and extent of the abuse of 
prescription drugs by including them in national drug 
abuse surveys; formulate and implement effective 
awareness-raising and prevention strategies targeting the 
general public and the health-care professions; develop 
professional guidelines and codes of conduct; enhance 
training programmes for health-care professions to 
promote rational prescribing and dispensing of 
prescription drugs; and offer treatment modalities for 
prescription drug abuse. The Board further urges all 
Governments to take measures to prevent the diversion 
and illicit manufacture of prescription drugs as an 
effective way to prevent abuse, while at the same time 
ensuring their availability for licit purposes. 
Recommendation 25: The Board remains concerned about 
the high levels of consumption of methylphenidate and 
other substances used in the treatment of Attention 
Deficit Hyperactivity Disorder (ADHD), which has led to 
the widespread diversion and abuse of pharmaceutical 
preparations containing those substances. The Board 
recommends that Governments closely monitor the 
consumption levels of all stimulants used in the 
treatment of ADHD; ensure that such substances are 
prescribed in accordance with sound medical practice 
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and in line with the rational use of psychoactive drugs 
and that patients and, in the case of children, their 
guardians are informed of the risks and consequences of 
the abuse of such substances; ensure that the control 
measures foreseen in the 1971 Convention are applied to 
those substances; and take additional measures, such as 
enforcing safety measures for storage and distribution at 
schools, as necessary, to prevent the diversion and abuse 
of preparations containing stimulants used for the 
treatment of ADHD. The Board calls on all 
Governments to inform it of any new development with 
regard to the diversion of, trafficking in and abuse of 
those substances.  
Recommendation 26: One of the factors contributing to 
the diversion of prescription drugs for abuse is that, in 
many communities, no disposal mechanisms exist for 
prescription drugs that are no longer needed for medical 
purposes. The Board wishes to remind Governments 
that the development of effective mechanisms for the 
disposal of unutilized pharmaceuticals containing 
controlled substances is an essential component of any 
effective strategy against prescription drug abuse, and 
encourages all Governments to adopt such measures. 
Recommendation 27: The increasing levels of drug abuse 
reported by many African countries might translate into a 
greater demand for treatment and rehabilitation. The 
Board notes that the national health-care systems of many 
countries in Africa are not able to adequately meet 
demand for treatment of drug abuse and rehabilitation. 
Treatment in the region — mostly in the form of 
detoxification — is provided predominantly in State 
mental health hospitals and/or psychiatric institutions. 
The number of trained personnel is insufficient, and 
there is a lack of access to and availability of drug 
dependence treatment and rehabilitation facilities for 
people in need. The Board calls on the Governments of 
African countries to improve the range of treatment 
options available to drug-dependent persons and to 
facilitate their access to quality and affordable treatment 
services by providing support for the development and 
strengthening of such services and capacity-building for 
the entities that provide such services. 
 
 4. Substances not under international control 
 
848. An increasing number of countries report problems 
with emerging substances of abuse that are not under 
international control.  
Recommendation 28: The collection of information is 
central to efforts by Governments to develop strategies 
intended to limit the risks to public health posed by the 
emergence of new psychoactive substances of abuse. 
Without comprehensive data on prevalence, populations 
specifically at risk and patterns of abuse, it is impossible 
to evaluate the extent of the abuse of new psychoactive 
substances. The Board encourages all Governments to 
establish formal mechanisms aimed at collecting 
information regarding new psychoactive substances, 
including information regarding their chemical 
composition, patterns of abuse, marketing techniques, 
trade names, distribution and diversion methods and 
countries of origin. Governments should include 
emerging psychoactive substances in their national drug 
abuse surveys and report the findings of those studies to 
INCB and WHO, as well as disseminating them to the 
public as an additional means of raising awareness. 
Recommendation 29: The operation of early warning 
systems at the national and regional levels has proven 
very useful in the timely identification of emerging 
psychoactive substances of abuse, allowing Governments 
to take swift and targeted action to address potential 
threats to public health. The Board encourages those 
Governments which have not yet done so to consider 
establishing early warning systems and to establish 
mechanisms for the sharing of information with other 
States and with multilateral stakeholders including 
WHO, INTERPOL, the World Customs Organization, 
UNODC and INCB. 
Recommendation 30: The Board notes that many 
Governments do not currently include emerging 
psychoactive substances of abuse within the scope of their 
prevention programmes. In order to raise awareness of 
the public health dangers associated with many 
emerging psychoactive substances and to dispel any 
misconception that those substances are safe since they 
are not controlled, the Board invites all Governments to 
include emerging psychoactive substances of abuse 
within the scope of all existing prevention programmes 
and, if deemed necessary, to design specific prevention 
initiatives targeting that phenomenon.  
Recommendation 31: The Board notes that the 
distribution of new psychoactive substances of abuse 
through the Internet has in many cases impeded 
Government efforts to limit the supply of those 
substances, which are readily available from online 
sources. INCB encourages Governments to monitor the 
activities of websites selling emerging psychoactive 
substances of abuse, and products containing them, 
based in their territory, as well as such websites based in 
other countries, and to share information with the 
competent authorities of those countries. In addition, 
the Board invites Governments to apply the 
recommendations contained in the Board’s Guidelines 
for Governments on Preventing the Illegal Sale of 
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Internationally Controlled Substances through the 
Internet to address the sale of new psychoactive 
substances on the Internet. 
Recommendation 32: The Board acknowledges the 
adoption by several States of “emergency scheduling” 
procedures for submitting emerging psychoactive 
substances of abuse to temporary control measures in 
cases in which there is reason to believe that those 
substances may constitute a risk to public health. The 
Board notes that these measures have been highly 
effective in ensuring that the public is not unnecessarily 
put at risk before a comprehensive evaluation of the 
substance can be undertaken by national authorities, 
and encourages States that have not yet adopted 
“emergency scheduling” measures to consider doing so. 
Recommendation 33: The utilization of plant-based 
preparations that are not under international control and 
contain natural psychoactive ingredients is part of 
traditional indigenous rituals and religious ceremonies in 
some countries. Outside of their original sociocultural 
context, the use of those plant materials has posed 
problems in some countries. INCB reiterates its 
recommendation to the Governments of countries where 
misuse of and trafficking in such plant materials may 
occur to remain vigilant and take appropriate action at 
the national level, where the situation so requires. 
Recommendation 34: The Board is concerned about the 
growing abuse in some African countries of tramadol, a 
synthetic opioid not under international control, as well 
as the increase in trafficking of tramadol preparations to 
Africa, as evidenced by recent large seizures of such 
preparations in some countries of West Africa. The Board 
notes that in response to those developments, some 
African countries have placed tramadol under national 
control. The Board calls on countries in Africa to take 
the measures necessary to address this problem and to 
furnish pertinent information on the extent and nature 
of abuse of and trafficking in tramadol to WHO and the 
Board. 
 
 
 B. Recommendations to the United 
Nations Office on Drugs and Crime 
and the World Health Organization 
 
 
849. UNODC is the principal United Nations entity 
mandated to provide technical assistance and 
coordination in drug control matters for Governments 
and other international organizations. Under the treaties, 
WHO is responsible for providing recommendations, 
based on medical and scientific assessments, regarding 
changes in the scope of control of narcotic drugs under 
the 1961 Convention and psychotropic substances under 
the 1971 Convention. 
Recommendation 35: The Board notes that UNODC is 
developing a project aimed at building national capacities 
in regulatory control of internationally controlled 
substances. As part of the project, regional workshops will 
be organized and electronic learning tools provided to 
Governments, with the aim of improving drug control 
administration at the national level. INCB welcomes this 
project and invites UNODC to implement it as soon as 
possible.  
Recommendation 36: The international electronic import 
and export authorization system for narcotic drugs and 
psychotropic substances, which is being developed by 
UNODC with the support of the Board and some 
Governments, will assist national drug control authorities 
in their work and ensure that the requirements set out in 
the international drug control conventions are complied 
with. In its resolution 55/6, the Commission on Narcotic 
Drugs invited the secretariat of the Board to administer 
such a system, in view of the core mandate of the Board 
to ensure and promote treaty compliance by 
Governments. INCB reminds the pertinent bodies of the 
United Nations that adequate resources for the 
administration of this system would need to be assured 
(see also recommendation 8 above).  
Recommendation 37: The Board notes with appreciation 
the efforts being undertaken by UNODC on the issue of 
new psychoactive substances of abuse, particularly those 
aimed at collecting information regarding these 
substances and their abuse and at disseminating that 
information to Member States. INCB encourages 
UNODC to act as a focal point on the question of new 
psychoactive substances of abuse and to gather 
information from States regarding those substances and 
measures adopted to address the problem.  
Recommendation 38: The Board notes that many States 
continue to experience obstacles to their ability to identify 
and control new psychoactive substances of abuse due to 
limited forensic capacity. INCB invites UNODC to 
continue to provide technical assistance to States, upon 
request, in order to assist them in bolstering the capacity 
of their institutions to deal with the problem of 
emerging psychoactive substances.  
Recommendation 39: Emerging psychoactive substances 
of abuse have become a problem in many countries of all 
regions. Competent authorities of those countries would 
benefit from specific advice on health aspects of this 
problem. INCB encourages WHO to examine health 
hazards of emerging psychoactive substances and to 
share its findings with the international community (see 
also recommendation 29 above). 
CHAPTER IV. RECOMMENDATIONS 
 
121 
 C. Recommendations to other relevant 
international organizations 
 
 
850. Other international organizations also assist in 
international drug control efforts. In cases where States 
require additional operational support in specific areas 
such as drug law enforcement, the Board addresses 
recommendations to the relevant international and 
regional organizations with specific competence in  
those areas, such as INTERPOL and the World  
Customs Organization. 
Recommendation 40: The Board notes that the Regional 
Action Plan to Address the Growing Problem of Illicit 
Trafficking, Organized Crime and Drug Abuse in West 
Africa of the Economic Community of West African 
States (ECOWAS) expired in 2011. The plan, adopted  
in 2008, coordinated the efforts of ECOWAS member 
States to address the growing problem of drug trafficking, 
organized crime and drug abuse in West Africa.  
INCB calls on the ECOWAS Commission and its 
member States to renew and extend the regional  
action plan as soon as possible to ensure a sustained 
political framework for addressing the world drug 
problem in the subregion. 
Recommendation 41: Emerging psychoactive substances 
of abuse have become a problem in all regions. The  
law enforcement authorities of many countries would 
benefit from specific advice on law enforcement  
aspects of this problem. INCB invites INTERPOL and the 
World Customs Organization to continue to examine 
aspects of the problem of emerging psychoactive 
substances that fall within their mandate and to share 
their findings with the international community (see 
also recommendation 29 above). 
 
(Signed) 
Raymond Yans 
President 
(Signed) 
Francisco Thoumi 
Rapporteur 
(Signed) 
Andrés Finguerut 
Secretary 
 
 
Vienna, 16 November 2012 
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Annex I 
 Regional and subregional groupings used in the report of the International 
Narcotics Control Board for 2012 
 The regional and subregional groupings used in the report of the International Narcotics Control Board  
for 2012, together with the States in each of those groupings, are listed below. 
 
Africa 
 
Algeria 
Angola 
Benin 
Botswana 
Burkina Faso 
Burundi 
Cameroon 
Cape Verde 
Central African Republic 
Chad 
Comoros 
Congo 
Côte d’Ivoire 
Democratic Republic of the Congo 
Djibouti 
Egypt 
Equatorial Guinea 
Eritrea 
Ethiopia 
Gabon 
Gambia 
Ghana 
Guinea 
Guinea-Bissau 
Kenya 
Lesotho 
Liberia 
 
Libya
Madagascar 
Malawi 
Mali 
Mauritania 
Mauritius 
Morocco 
Mozambique 
Namibia 
Niger 
Nigeria 
Rwanda 
Sao Tome and Principe 
Senegal 
Seychelles 
Sierra Leone 
Somalia 
South Africa 
South Sudan 
Sudan 
Swaziland 
Togo 
Tunisia 
Uganda 
United Republic of Tanzania 
Zambia 
Zimbabwe 
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Central America and the Caribbean 
 
Antigua and Barbuda 
Bahamas 
Barbados 
Belize 
Costa Rica 
Cuba 
Dominica 
Dominican Republic 
El Salvador 
Grenada 
 
Guatemala
Haiti 
Honduras 
Jamaica 
Nicaragua 
Panama 
Saint Kitts and Nevis 
Saint Lucia 
Saint Vincent and the Grenadines 
Trinidad and Tobago 
 
North America 
 
Canada 
Mexico 
 
United States of America 
 
 
South America 
 
Argentina 
Bolivia (Plurinational State of ) 
Brazil 
Chile 
Colombia 
Ecuador 
 
Guyana
Paraguay 
Peru 
Suriname 
Uruguay 
Venezuela (Bolivarian Republic of) 
 
East and South-East Asia 
 
Brunei Darussalam 
Cambodia 
China 
Democratic People’s Republic of  
Korea 
Indonesia 
Japan 
Lao People’s Democratic Republic 
Malaysia 
 
Mongolia
Myanmar 
Philippines 
Republic of Korea 
Singapore 
Thailand 
Timor-Leste 
Viet Nam 
 
 
South Asia 
 
Bangladesh 
Bhutan 
India 
Maldives
Nepal 
Sri Lanka
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West Asia 
 
Afghanistan
Armenia 
Azerbaijan 
Bahrain 
Georgia 
Iran (Islamic Republic of) 
Iraq 
Israel 
Jordan 
Kazakhstan 
Kuwait 
Kyrgyzstan 
Lebanon
Oman 
Pakistan 
Qatar 
Saudi Arabia 
Syrian Arab Republic 
Tajikistan 
Turkey 
Turkmenistan 
United Arab Emirates 
Uzbekistan 
Yemen
 
Europe 
 
Eastern Europe 
Belarus 
Republic of Moldova 
Russian Federation 
Ukraine
South-Eastern Europe 
Albania 
Bosnia and Herzegovina 
Bulgaria 
Croatia 
 
The former Yugoslav Republic of
Macedonia 
Montenegro 
Romania 
Serbia  
Western and Central Europe 
Andorra 
Austria 
Belgium 
Cyprus 
Czech Republic 
Denmark 
Estonia 
Finland 
France 
Germany 
Greece 
Holy See 
Hungary 
Iceland 
Ireland 
Italy 
Latvia 
Liechtenstein
Lithuania 
Luxembourg 
Malta 
Monaco 
Netherlands 
Norway 
Poland 
Portugal 
San Marino 
Slovakia 
Slovenia 
Spain 
Sweden 
Switzerland 
United Kingdom of Great Britain 
and Northern Ireland 
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Oceania 
 
Australia 
Cook Islands 
Fiji 
Kiribati 
Marshall Islands 
Micronesia (Federated States of) 
Nauru 
New Zealand 
 
Niue
Palau 
Papua New Guinea 
Samoa 
Solomon Islands 
Tonga 
Tuvalu 
Vanuatu 
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Annex II 
 
 
  Current membership of the International Narcotics Control Board 
 
 
  Hamid Ghodse 
 
 
 Born in 1938. National of the Islamic Republic of 
Iran. Professor of Psychiatry and of International Drug 
Policy, University of London (since 1987). Director, 
International Centre for Drug Policy, St. George’s 
University of London (since 2003); President, European 
Collaborating Centres for Addiction Studies (since 1992); 
Non-Executive Director, National Patient Safety Agency, 
United Kingdom (since 2001); Chairman, Civil Honours 
Committee, Royal College of Psychiatrists, United 
Kingdom (since 2006). 
 Recipient of the following degrees, qualifications and 
awards: Doctor of Medicine (M.D.), Islamic Republic of 
Iran (1965); Diploma Psychological Medicine (D.P.M.), 
United Kingdom (1974); Doctor of Philosophy (Ph.D.), 
University of London (1976); and Doctor of Science 
(D.Sc.), University of London (2002). Fellow of the Royal 
College of Psychiatrists (F.R.C.Psych.), United Kingdom 
(1985); Fellow of the Royal College of Physicians (F.R.C.P.), 
London (1992); Fellow of the Royal College of Physicians of 
Edinburgh (F.R.C.P.E.), Edinburgh (1997); Fellow of the 
Faculty of Public Health Medicine (F.F.P.H.), United 
Kingdom (1997); Fellow of the Higher Education Academy 
(F.H.E.A.), United Kingdom (2005); Honorary Fellowship, 
Faculty of Forensic and Legal Medicine (FFFLM) (2012); 
International Distinguished Fellow, American Psychiatric 
Association (APA) (2009). Honorary Fellow, Royal College 
of Psychiatrists (R.C.Psych.) (2006); Honorary Fellow, 
World Psychiatric Association (FWPA) (2008). Member of 
the World Health Organization (WHO) Expert Advisory 
Panel on Alcohol and Drug Dependence (since 1979); 
Adviser, Joint Formulary Committee, British National 
Formulary (since 1984); Honorary Consultant Psychiatrist, 
St. George’s and Springfield University Hospitals, London 
(since 1978); Honorary Consultant Public Health, 
Wandsworth Primary Care Trust, London (since 1997). 
Consultant Psychiatrist, St. Thomas’s Teaching Hospital 
and Medical School, London (1978-1987); member, 
rapporteur, chairman and convener of various WHO and 
European Community expert committees, review groups 
and other working groups on drug and alcohol 
dependence; M. S. McLeod Visiting Professor, Southern 
Australia (1990); Honorary Professor, Peking University 
(since 1997); Honorary Fellow, St. George’s, University of 
London (2011); Lifetime Achievement Award, Royal 
College of Psychiatrists (2011). 
 Author or editor of over 350 scientific books and 
papers on drug-related issues and addictions, including the 
following books: The Misuse of Psychotropic Drugs, London 
(1981); Psychoactive Drugs and Health Problems, Helsinki 
(1987); Psychoactive Drugs: Improving Prescribing Practices, 
Geneva (1988); Substance Abuse and Dependence, 
Guildford (1990); Drug Misuse and Dependence: The British 
and Dutch Response, Lancashire, United Kingdom (1990); 
Misuse of Drugs (3rd ed.), London (1997); Young People and 
Substance Misuse, London (2004); Addiction at Workplace, 
Aldershot (2005); International Drug Control into the 21st 
Century, Aldershot (2008); Ghodse’s Drugs and Addictive 
Behaviour: A Guide to Treatment (4th ed.), Cambridge 
(2010); International Perspectives on Mental Health, London 
(2011); Substance Abuse Disorders: Evidence and 
Experience, Chichester, United Kingdom (2011); Editor-in-
Chief, International Psychiatry; Honorary Editor-in-Chief, 
Chinese Journal of Drug Dependence; member of the 
Editorial Board, International Journal of Social Psychiatry; 
member of the Editorial Board, Asian Journal of Psychiatry, 
Psychiatriki Journal, Convener of WHO expert groups on 
medical education (1986), pharmacy education (1987), 
nurse education (1989) and rational prescribing of 
psychoactive drugs. Chairman, Association of Professors of 
Psychiatry of the British Isles (since 1991); Chairman, 
Association of European Professors of Psychiatry; Director, 
National Programme on Substance Abuse Deaths (since 
1997); member of the International Association of 
Epidemiology (since 1998).  
 Member of the International Narcotics Control Board 
(since 1992). Member of the Standing Committee on 
Estimates (1992). President of the Board (1993, 1994, 1997, 
1998, 2000, 2001, 2004, 2005, 2008, 2010 and 2011). 
 
 
  Wayne Hall 
 
 
 Born in 1951 in Australia. Trained as a research 
psychologist and worked as an epidemiologist. Currently 
Professor and National Health and Medical Research 
Council Australia Fellow, University of Queensland Centre 
for Clinical Research; and Visiting Professor, National 
Addiction Centre, Institute of Psychiatry, King’s College 
London (both since 2009). 
 Professor of Public Health Policy, School of 
Population Health, University of Queensland (2006-2010); 
Professor and Director, Office of Public Policy and Ethics, 
Institute for Molecular Bioscience, University of 
 ANNEX II. CURRENT MEMBERSHIP OF THE INTERNATIONAL NARCOTICS CONTROL BOARD 
 
127 
Queensland (2001-2005); Professor and Director, National 
Drug and Alcohol Research Centre, University of New 
South Wales (1994-2001). Author and co-author of over 
700 articles, chapters and reports on addiction, drug use 
epidemiology and mental health. Member, World Health 
Organization Expert Committee on Drug Dependence 
(1996), and the Australian National Council on Drugs 
(1998-2001).  
 Member of the International Narcotics Control Board 
(since 2012). Member of the Standing Committee on 
Estimates (2012). 
 
 
  David T. Johnson 
 
 
 Born in 1954. National of the United States of 
America. Consultant and retired diplomat. Bachelor’s 
degree in Economics from Emory University; graduate of 
the National Defence College of Canada. 
 United States Foreign Service officer (1977-2011). 
Assistant Secretary for the Bureau of International 
Narcotics and Law Enforcement Affairs, United States 
Department of State (2007-2011). Deputy Chief of Mission 
(2005-2007) and Chargé d’affaires, a.d., (2003-2005) United 
States Embassy, London. Afghan Coordinator for the 
United States (2002-2003). United States Ambassador to the 
Organization for Security and Cooperation in Europe 
(1998-2001). Deputy Press Secretary at the White  
House and Spokesman for the National Security Council 
(1995-1997). Deputy Spokesman at the State Department 
(1995) and Director of the State Department Press Office 
(1993-1995). United States Consul General, Vancouver 
(1990-1993). 
 Member of the International Narcotics Control Board 
(since 2012). Member of the Committee on Finance and 
Administration (2012). 
 
 
  Galina Korchagina 
 
 
 Born in 1953. National of the Russian Federation. 
Deputy Director of Research at the National Centre for 
Research on Drug Addiction, Ministry of Health and Social 
Development, Russian Federation (since 2010).  
 Leningrad Paediatrics Institute, Russian Federation 
(1976); Doctor of Medicine (2001). Doctor, boarding 
school, Gatchina, Leningrad region, (1976-1979). Head  
of the Organizational and Policy Division, Leningrad 
Regional Drug Clinic (1981-1989); Lecturer, Leningrad 
Regional Medical Academy (1981-1989); Head Doctor,  
City Drug Clinic, St. Petersburg (1989-1994); Assistant 
Lecturer (1991-1996) and Professor (2000-2001), 
Department of Social Technologies, State Institute  
for Services and Economics; Assistant Lecturer  
(1994-2000), Associate Professor (2001-2002) and Professor 
(2002-2008), Department for Research on Drug Addiction, 
St. Petersburg Medical Academy of Postgraduate Studies; 
Chief Professor and Head of the Department for Medical 
Research and Healthy Lifestyles, Herzen State Pedagogical 
University of Russia (2000-2008); Professor, Department 
for Conflict Studies, Faculty of Philosophy, St. Petersburg 
State University (2004-2008); member of numerous 
associations and societies, including: Association of 
Psychiatrists and Drug Addiction Specialists of Russia and 
St. Petersburg; Kettil Bruun Society for Social and 
Epidemiological Research on Alcohol; International 
Council on Alcohol and Addictions; International Society 
of Addiction Medicine: head of the sociology of science 
aspects of medical and biological research section of the 
Research Council on the Sociology of Science and the 
Organization of Scientific Research, St. Petersburg 
Scientific Centre of the Russian Academy of Sciences 
(2002-2008). Author of more than 100 publications, 
including more than 70 works published in the Russian 
Federation, chapters in monographs and several practical 
guides. Award for excellence in health protection, awarded 
by the Ministry of Health of the Union of Soviet Socialist 
Republics (1987). Consultant, Global Business Coalition on 
HIV/AIDS, Tuberculosis and Malaria (since 2006);  
co-trainer, WHO programme “Skills for change” (since 
1995); participant in meetings of the Commission on 
Narcotic Drugs (2002-2008); expert on the epidemiology of 
drug addiction, Pompidou Group of the Council of  
Europe (1994-2003); temporary representative, WHO 
(1992-2008). 
 Member of the International Narcotics Control Board 
(since 2010). Vice-Chair of the Standing Committee on 
Estimates (2011, 2012). 
 
 
  Marc Moinard 
 
 
 Born in 1942. National of France. Retired law officer. 
School of Political Sciences, Paris; Paris Law Faculty; 
Faculty of Arts, Poitiers. Public Prosecutor, Beuvais  
(1982-1983); Public Prosecutor, Pontoise (1990); Public 
Prosecutor, Lyon (1990-1991); Public Prosecutor, Bobigny 
(1992-1995); Public Prosecutor in the Court of Appeal, 
Bordeaux (1999-2005), introducing major reforms into the 
legal system involving: the creation of centres for legal 
advice and mediation; the provision of legal advice in 
deprived areas; the establishment of a new system of 
cooperation between the courts and the police services 
allowing for the immediate handling of criminal offences; 
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and the creation of a new category of judicial personnel — 
assistant prosecutors. 
 Senior administrative posts in the Ministry of Justice: 
Director of Record Offices (1983-1986); President of the 
teaching board, National School of Clerks to the Court; 
Director of Legal Services; member of the Board of 
Directors, French National School for the Judiciary; 
Representative of the Minister of Justice in the Supreme 
Council of Justice (1995-1996); Director, Criminal Matters 
and Pardons (1996-1998); President, French Monitoring 
Centre for Drugs and Drug Addiction; Secretary-General, 
Ministry of Justice (2005-2008); President, Law and Justice 
Mission, responsible for the reform of the judicial map; 
President, Commission on Information Technology and 
Communication; Head of the International Affairs Service, 
Ministry of Justice. Lecturer, Paris Institute of Criminology 
(1995-2005); President, Fondation d’Aguesseau, a welfare 
body. Recipient of the following awards: Commander of the 
National Order of Merit; Commander of the Legion of 
Honour.  
 Member of the International Narcotics Control Board 
(since 2010). Member of the Standing Committee on 
Estimates (2012). Member of the Committee on Finance 
and Administration (2012). 
 
 
  Jorge Montaño 
 
 
 Born in 1948. National of Mexico. Professor of 
International Organizations and Mexican Foreign Policy, 
Instituto Tecnológico Autónomo de México, private 
consultant on the enforcement of the North American Free 
Trade Agreement (NAFTA). 
 Law and Political Science, Universidad Nacional 
Autónoma de México; Master of Arts and Doctor of 
Philosophy in International Affairs, London School of 
Economics. Director General de Educación Superior — 
Secretaría de Educación Pública (1976-1979); Member of 
the Mexican Foreign Service (1979-2008); Director of 
International Agencies (1979-1982); Assistant Secretary of 
Multilateral Affairs (1982-1988); Permanent Representative 
of Mexico to the United Nations organizations (1989-1992); 
Chairman of the Group of Experts to enhance  
the efficiency of the United Nations structure for  
drug abuse control (1990); Ambassador of Mexico to the 
United States (1993-1995); member of the Multilateral 
Evaluation Mechanism on Drugs (2001-2003) of the  
Inter-American Drug Abuse Control Commission 
(CICAD). Member of the Special Advisory Board, World 
Bank (2010-2012). Author of the following publications: 
Partidos y política en América Latina; Implicaciones legales 
de la presencia de Estados Unidos en Viet Nam; Análisis del 
Sistema de Naciones Unidas; ACNUR en América Latina; 
Negociaciones del Tratado de Libre Comercio de America del 
Norte; Cooperación México-Estados Unidos en materia de 
narcotráfico; Debilidades de la certificación del Congreso de 
Estados Unidos; Retos de la frontera norte de México; Tráfico 
de armas en las fronteras mexicanas. Author of 50 articles 
published in specialized journals. Weekly contributor to the 
editorial pages of La Jornada, Reforma and El Universal. 
President and founding member of Foreign Affairs 
Latinoamérica (formerly Foreign Affairs en Español). 
Founding President, Asesoría y Análisis, S.C., Mexican 
Council on Foreign Relations (COMEXI). Recipient of 
awards from the Governments of Chile, El Salvador, Greece 
and Guatemala. Participant in many meetings of 
organizations in the United Nations system, the 
Organization of American States and the Movement of 
Non-Aligned Countries.  
 Member of the International Narcotics Control Board 
(since 2009). Member of the Committee on Finance and 
Administration (2010). Chair of the Committee on Finance 
and Administration (2012). 
 
 
  Lochan Naidoo 
 
 
 Born in 1961. National of South Africa. Family 
Practitioner, Durban, South Africa (since 1985).  
 Bachelor of Medicine and Bachelor of Surgery 
(MBChB), University of Natal, South Africa (1983). 
Professional in Residence Programme: Hanley Hazelden 
(1995); Member of the South African Medical Association 
(since 1995); Member and Vice-Chairman of the Bayport 
Independent Practitioners Association (1995-2000). 
Certified Chemical Dependency Counsellor, National 
Board of Addiction Examiners (NBAE) (1996); Member of 
the American Society of Addiction Medicine (1996-1999). 
Diploma in Business Management, South African Institute 
of Management (1997). Founding member, International 
Society of Addiction Medicine (1999); Programme 
Designer and Principal Addictions Therapist of the Jullo 
Programme, a multi-disciplinary treatment model for 
primary, secondary and tertiary prevention of addiction 
disorders and dual diagnoses (since 1994); Clinical 
Director, Serenity Addiction Treatment Unit, Merebank, 
Durban, South Africa (since 1995). Member of the 
KwaZulu-Natal Managed Care Coalition (since 1995); 
Member of the Durban South Doctors’ Guild (since 2000); 
Honorary Lecturer, Nelson R. Mandela School of Medicine, 
University of KwaZulu-Natal, South Africa (2005-2011). 
Curriculum Committee undergraduate Lifestyle Medicine, 
University of KwaZulu-Natal (2005-2011). Drafter of the 
National Detoxification Policy and Procedure for the 
Department of Health of South Africa (2006); designer of 
the Roots connect software program, an Internet-driven 
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emotional and addiction psychoeducation delivery system 
(2007); Member of the Opiate Advisory Board of South 
Africa (2006-2008); Member of the Board, Central Drug 
Authority of South Africa (2006-2010); Member of the 
Governance Committee, Central Drug Authority of South 
Africa (2006-2010). Member of the Expert Committee on 
Opiate Treatment (2007-2008); Central Drug Authority 
representative to the Western Cape Province, South Africa 
(2007-2010); established “Roots HelpPoints” for early 
intervention and primary prevention among high-risk 
individuals (2008). Co-author of “Guidelines for opiate 
treatment in South Africa”, South African Medical Journal 
(2008). Member of the Suboxone Advisory Board (2009). 
Co-author of “Suboxone update”, South African Medical 
Journal (2010); Designer of “RehabFlow” cloud computing 
software for addiction and co-morbidity management 
(2010); Management Committee Member of eThekweni 
District Mental Health and Substance Abuse Forum (2010). 
Rehabilitation and addictions trainer for health-care 
practitioners. Medical educator for undergraduate and 
postgraduate medical practitioners (since 1995); Patron of 
Andra Maha Sabha of South Africa; founder, Merebank 
West Community Coalition (1995). Trustee, Merebank 
Community Trust (2000-2005).  
 Member of the International Narcotics Control Board 
(since 2010). Member of the Standing Committee on 
Estimates (2011). Member of the Committee on Finance 
and Administration (2011). First Vice-President of the 
Board (2012). 
 
 
  Rajat Ray 
 
 
 Born in 1948. National of India. Professor and Head 
of the Department of Psychiatry and Chief, National Drug 
Dependence Treatment Centre (NDDTC), All India 
Institute of Medical Sciences (AIIMS), New Delhi. 
Graduate of Medicine (MBBS), Medical College in Calcutta 
(1971). M.D. (Psychiatry), AIIMS (1977). Member of the 
faculty, Department of Psychiatry, National Institute of 
Mental Health and Neuro Sciences, Bangalore (1979-1988). 
Author of several technical reports and articles in peer 
reviewed national and international journals. Assistant 
Editor, Addiction Biology. Member of the International 
Advisory Board, Mental Health and Substance Use: Dual 
Diagnosis and the Editorial Board, of the scientific journal 
International Drug Sciences and Drug Policy. 
 Recipient of research support from various bodies at 
the national level (such as the Ministry of Health and 
Family Welfare and the Indian Council of Medical 
Research) and the international level (such as the United 
Nations Office on Drugs and Crime (UNODC) and WHO. 
Member of a study on HIV/AIDS, a collaborative project of 
NDDTC, AIIMS and the Centre for Interdisciplinary 
Research in Immunology and Disease, University of 
California, Los Angeles (UCLA), United States of America. 
Member of the WHO Expert Advisory Panel on Drug 
Dependence and Alcohol Problems. Member of the expert 
group to discuss mental health and substance use disorder 
at the primary care level, an activity of the WHO Regional 
Office for South-East Asia. Member of the WHO expert 
group on regional technical consultation to reduce harmful 
use of alcohol. Coordinator of various activities in India on 
substance use disorder, sponsored by WHO (since 2004). 
Member of the National Drug Abuse Control Programme, 
India, and the Technical Guidelines Development Group 
on Pharmacotherapy of Opioid Dependence, a joint project 
of UNODC and WHO. Member and Chairperson of the 
Technical Resource Group on Injecting Drug Use, a project 
of the National AIDS Control Organization. Member of the 
project advisory committee on the prevention of 
transmission of HIV among drug users in South Asian 
Association for Regional Cooperation (SAARC) member 
States, a project of the UNODC Regional Office for South 
Asia. Member of the Subcommittee on Postgraduate 
Medical Education, Medical Council of India. Chairperson, 
Working Group on Classification of Substance — Related 
and Addictive Disorder, International Advisory Group for 
the Revision of ICD-10 Mental and Behavioural Disorders 
(2011); Principal investigator, WHO Project “Web-Based 
Intervention (Portal) for Alcohol and Health”, Geneva 
(since 2010); principal investigator, NDDTC, Global Fund 
to Fight AIDS, Tuberculosis and Malaria Round 9 and 
Nodal Regional Resource and Training Centre; Principal 
Coordinator, National Policy and Twelfth Five-Year Plan of 
India, covering the period 2012-2017, areas relating to 
control of alcohol and drug problems, Ministry of Social 
Justice and Empowerment, Government of India; Principal 
Investigator, opioid substitution therapy in India: issues 
and lessons learned, a joint project of NDDTC, AIIMS, the 
National AIDS Control Organisation, the government of 
Punjab and the Department for International Development 
(UK aid) — Technical Assistance Support Team, targeted 
intervention (since 2010); member of the Expert 
Committee on Psychotropic Substances and New Drugs, 
Drug Controller General of India (2011). Reviewer and 
contributor, Indian Journal of Medical Research, official 
publication of the Indian Council of Medical Research 
(since 2010). 
 Member of the International Narcotics Control Board 
(since 2010). Member (2010) and Chair (2011) of the 
Standing Committee on Estimates. Second Vice-President 
of the Board (2011). Member of the Standing Committee 
on Estimates (2012). 
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  Ahmed Kamal Eldin Samak 
 
 
 Born in 1950. National of Egypt. Graduated with a 
Law and Police Licence in 1971. Worked in the field of  
anti-narcotics for more than 35 years, until becoming the 
Minister Assistant of Police and Head of the Anti-Narcotics 
General Administration (ANGA) of Egypt. Independent 
adviser in the field of anti-narcotics and crime. First-rank 
badge of honour on the occasion of the police festival 
(1992). Contributed to several missions, such as to Jordan, 
for anti-narcotics training (1988); India, for the signing of 
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About the International Narcotics Control Board 
 
 
The International Narcotics Control Board (INCB) is an independent and quasi-judicial control organ, established by 
treaty, for monitoring the implementation of the international drug control treaties. It had predecessors under the former 
drug control treaties as far back as the time of the League of Nations. 
 
 
Composition 
 
 
 INCB consists of 13 members who are elected by the Economic and Social Council and who serve in their personal 
capacity, not as Government representatives. Three members with medical, pharmacological or pharmaceutical 
experience are elected from a list of persons nominated by the World Health Organization (WHO) and 10 members are 
elected from a list of persons nominated by Governments. Members of the Board are persons who, by their competence, 
impartiality and disinterestedness, command general confidence. The Council, in consultation with INCB, makes all 
arrangements necessary to ensure the full technical independence of the Board in carrying out its functions. INCB has a 
secretariat that assists it in the exercise of its treaty-related functions. The INCB secretariat is an administrative entity of 
the United Nations Office on Drugs and Crime, but it reports solely to the Board on matters of substance. INCB closely 
collaborates with the Office in the framework of arrangements approved by the Council in its resolution 1991/48.  
INCB also cooperates with other international bodies concerned with drug control, including not only the Council and its 
Commission on Narcotic Drugs, but also the relevant specialized agencies of the United Nations, particularly WHO. It 
also cooperates with bodies outside the United Nations system, especially the International Criminal Police Organization 
(INTERPOL) and the World Customs Organization. 
 
 
Functions 
 
 
 The functions of INCB are laid down in the following treaties: the Single Convention on Narcotic Drugs of 1961 as 
amended by the 1972 Protocol; the Convention on Psychotropic Substances of 1971; and the United Nations Convention 
against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988. Broadly speaking, INCB deals with the 
following: 
 (a) As regards the licit manufacture of, trade in and use of drugs, INCB endeavours, in cooperation with 
Governments, to ensure that adequate supplies of drugs are available for medical and scientific uses and that the diversion 
of drugs from licit sources to illicit channels does not occur. INCB also monitors Governments’ control over chemicals 
used in the illicit manufacture of drugs and assists them in preventing the diversion of those chemicals into the illicit 
traffic; 
 (b) As regards the illicit manufacture of, trafficking in and use of drugs, INCB identifies weaknesses in national 
and international control systems and contributes to correcting such situations. INCB is also responsible for assessing 
chemicals used in the illicit manufacture of drugs, in order to determine whether they should be placed under 
international control. 
 In the discharge of its responsibilities, INCB: 
 (a) Administers a system of estimates for narcotic drugs and a voluntary assessment system for psychotropic 
substances and monitors licit activities involving drugs through a statistical returns system, with a view to assisting 
Governments in achieving, inter alia, a balance between supply and demand; 
 (b)  Monitors and promotes measures taken by Governments to prevent the diversion of substances frequently 
used in the illicit manufacture of narcotic drugs and psychotropic substances and assesses such substances to determine 
whether there is a need for changes in the scope of control of Tables I and II of the 1988 Convention; 
 (c) Analyses information provided by Governments, United Nations bodies, specialized agencies or other 
competent international organizations, with a view to ensuring that the provisions of the international drug control 
treaties are adequately carried out by Governments, and recommends remedial measures; 
  
 
 
 (d) Maintains a permanent dialogue with Governments to assist them in complying with their obligations under 
the international drug control treaties and, to that end, recommends, where appropriate, technical or financial assistance 
to be provided. 
 INCB is called upon to ask for explanations in the event of apparent violations of the treaties, to propose appropriate 
remedial measures to Governments that are not fully applying the provisions of the treaties or are encountering 
difficulties in applying them and, where necessary, to assist Governments in overcoming such difficulties. If, however, 
INCB notes that the measures necessary to remedy a serious situation have not been taken, it may call the matter to the 
attention of the parties concerned, the Commission on Narcotic Drugs and the Economic and Social Council. As a last 
resort, the treaties empower INCB to recommend to parties that they stop importing drugs from a defaulting country, 
exporting drugs to it or both. In all cases, INCB acts in close cooperation with Governments. 
 INCB assists national administrations in meeting their obligations under the conventions. To that end, it proposes 
and participates in regional training seminars and programmes for drug control administrators. 
 
 
Reports 
 
 
 The international drug control treaties require INCB to prepare an annual report on its work. The annual report 
contains an analysis of the drug control situation worldwide so that Governments are kept aware of existing and potential 
situations that may endanger the objectives of the international drug control treaties. INCB draws the attention of 
Governments to gaps and weaknesses in national control and in treaty compliance; it also makes suggestions and 
recommendations for improvements at both the national and international levels. The annual report is based on 
information provided by Governments to INCB, United Nations entities and other organizations. It also uses information 
provided through other international organizations, such as INTERPOL and the World Customs Organization, as well as 
regional organizations. 
 The annual report of INCB is supplemented by detailed technical reports. They contain data on the licit movement 
of narcotic drugs and psychotropic substances required for medical and scientific purposes, together with an analysis of 
those data by INCB. Those data are required for the proper functioning of the system of control over the licit movement of 
narcotic drugs and psychotropic substances, including preventing their diversion to illicit channels. Moreover, under the 
provisions of article 12 of the 1988 Convention, INCB reports annually to the Commission on Narcotic Drugs on the 
implementation of that article. That report, which gives an account of the results of the monitoring of precursors and of 
the chemicals frequently used in the illicit manufacture of narcotic drugs and psychotropic substances, is also published as 
a supplement to the annual report. 
 Since 1992, the first chapter of the annual report has been devoted to a specific drug control issue on which INCB 
presents its conclusions and recommendations in order to contribute to policy-related discussions and decisions in 
national, regional and international drug control. The following topics were covered in past annual reports: 
 1992:  Legalization of the non-medical use of drugs 
 1993:  The importance of demand reduction 
 1994:  Evaluation of the effectiveness of the international drug control treaties 
 1995:  Giving more priority to combating money-laundering 
 1996:  Drug abuse and the criminal justice system 
 1997:  Preventing drug abuse in an environment of illicit drug promotion 
 1998:  International control of drugs: past, present and future 
 1999:  Freedom from pain and suffering 
 2000:  Overconsumption of internationally controlled drugs 
 2001: Globalization and new technologies: challenges to drug law enforcement in the twenty-first century 
 2002:  Illicit drugs and economic development 
  
 
 
 2003:  Drugs, crime and violence: the microlevel impact 
 2004:  Integration of supply and demand reduction strategies: moving beyond a balanced approach 
 2005: Alternative development and legitimate livelihoods 
 2006: Internationally controlled drugs and the unregulated market 
 2007: The principle of proportionality and drug-related offences 
 2008: The international drug control conventions: history, achievements and challenges 
 2009: Primary prevention of drug abuse 
 2010: Drugs and corruption 
 2011: Social cohesion, social disorganization and illegal drugs 
 Chapter I of the report of the International Narcotics Control Board for 2012 is entitled “Shared responsibility in 
international drug control” 
 Chapter II presents an analysis of the operation of the international drug control system based primarily on 
information that Governments are required to submit directly to INCB in accordance with the international drug control 
treaties. Its focus is on the worldwide control of all licit activities related to narcotic drugs and psychotropic substances, as 
well as chemicals used in the illicit manufacture of such drugs. 
 Chapter III presents some of the major developments in drug abuse and trafficking and measures by Governments 
to implement the international drug control treaties by addressing those problems. 
 Chapter IV presents the main recommendations addressed by INCB to Governments, the United Nations Office on 
Drugs and Crime, WHO and other relevant international and regional organizations. 
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